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Abstract
The studies comprising this thesis were conducted to examine the potential of a
range of cross-linking therapies; in particular, to investigate the effect of a novel
cross-linking therapy (involving a bacteriochlorophyll derivative and near-infra red
illumination (WST-D/NIR)) on the structure of the cornea, and to develop a trans-
epithelial riboflavin/Ultraviolet-A (UVA) corneal cross-linking protocol that was
equally effective to that of the standard protocol (SCXL), without the need for
epithelium removal. A number of laboratory techniques were used to investigate
changes in the structure of the cornea and its biochemical and biomechanical proper-
ties following cross-linking. X-ray scattering and electron microscopy data provided
evidence that treatment with WST-D/NIR resulted in no change in corneal colla-
gen organisation and confirmed its potential as an alternative to riboflavin/UVA
cross-linking for stiffening diseased or surgically weakened corneas. Enzyme diges-
tion studies and strip extensometry were performed to compare the effectiveness of
newly developed riboflavin/UVA protocols to that of the SCXL protocol in terms
of their ability to increase the enzymatic resistance and stiffness of the cornea. The
studies indicated that the intensity and distribution of cross-links formed within the
cornea vary with different protocols, and that the outcome of trans-epithelial ri-
boflavin/UVA cross-linking may be significantly enhanced through the use of higher
concentrations of riboflavin, a longer duration of iontophoresis and the use of pulsed
and higher energy dose UVA.
As the precise amount of CXL required to prevent disease progression is still
unidentified, and an effective depth of cross-linking less than that achieved with
SCXL may prove sufficient, the modified trans-epithelial protocols identified in this
thesis may be an effective means of halting keratoconus progression. Further clinical
studies, especially randomized prospective trials, are, however, required to confirm
the encouraging results of these modified procedures.
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CHAPTER 1
INTRODUCTION
1
Investigations into the effectiveness of new and existing corneal cross-linking therapies
1.1 Introduction
Each part of the eye plays a crucial role to deliver clear vision. Our window to the world is
provided by the cornea on the front surface of the eye. The cornea’s clarity and refractive
power are vital to maximize the visual potential of the eye, and any disorder that affects the
transparency or shape of the cornea will affect its performance. Therefore, the integrity
and functionality of the cornea is essential for vision. This chapter overviews the anatomy
and cell biology of the human cornea, providing an insight into the substructure and
biological features of the cornea.
1.2 Cornea: Cellular and molecular biology
The cornea is the distinctive transparent connective tissue of the outer ocular surface of
the eye that plays a vital role in the vision pathway. Along with the covering tear film, it
acts as the primary infectious barrier as well as a barrier to fluid loss from the surface of
the eye (Evans et al. 2013; Kaufman et al. 1998; Zhang et al. 2017). Corneal transparency
may alter due to any change in the anatomical and physiological structure (DelMonte
et al. 2011; Huang et al. 2001). The corneal extracellular matrix provides the mechanical
strength of the cornea, and is also crucial to the maintenance of corneal tissue hydration
and hence transparency (Kaufman et al. 1998; Meek et al. 2015). The cornea provides
a significant optical refractive element, which constitutes about two-thirds of the total
refractive power of the eye (Asgari et al. 2013; Ortiz et al. 2012), with the residual optical
power provided by the lens (Savini et al. 2013b). As the major refractive surface of the eye,
the anterior surface of the cornea provides 40 to 44 dioptres of the total refractive power
of the eye (Krachmer et al. 2011). Both the corneal anterior radius of curvature (≈ 7.8
mm) and the refractive index (1.376) (Savini et al. 2013a) generate this refractive power.
The cornea evolved as an avascular structure that dissolves oxygen supplies mostly from
the atmosphere through the superficial corneal surface and relies on the aqueous humor
for other nutritional requirements (Seal et al. 2007). The connective tissue serves not only
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as a structural support but also as the conduit of fluid and nutrients, it also houses support
cells that provide for maintenance of the matrix and overlying epithelium (Smolin et al.
2005).
1.2.1 Gross Anatomy
The eye has three primary layers: a fibrous tunic which covers the whole outer surface of
the eye and a choroid and neural retina layer, which comprise the middle and innermost
layers of all but the anterior-most portion of the eye. The cornea is positioned at the
front of the eye and constitutes one-sixth of the outer fibrous tunic, the posterior opaque
fibrous tissue of the eyeball called sclera, forms the remaining five-sixths of the outer tunic
(Ashalatha et al. 2012) (Figure 1.1).
Figure 1.1: The anatomy of the eye. The eye has three primary layers: an outer fibrous
tunic, a middle choroid, and an inner neural retina layer. Reproduced from https :
//nurseslabs.com/special − senses − anatomy − physiology/ [accessed 31 December
2017]
The normal cornea has an asymmetrical anterior and posterior viewing surface, it has
an elliptic shape on the anterior surface and a circular shape at the posterior, because of
scleralization superiorly and inferiorly (He et al. 2010). The anterior surface dimensions
of the adult human cornea are 11-12 mm horizontally by 9-11 mm vertically. The
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average diameter of the posterior surface is 11.76 mm (Lens et al. 2008). The cornea is
approximately 550 µm thick at the centre (Feizi et al. 2014), and progressively increases
in thickness toward the periphery, where it is roughly 650 µm thick (DelMonte et al. 2011;
Land 2014). The corneal curvature is not uniform, being steeper centrally and flatter at
the periphery, more so nasally than temporally (Albert et al. 2008). The central one-third
of the cornea is called the optical zone, where the surface is almost spherical. The average
radius of curvature is between 7.5 and 8.0 mm (Sideroudi et al. 2013).
1.2.2 Corneal histology
The human cornea is divided into five specialized layers: epithelium, Bowman’s layer,
stroma, Descemet’s membrane and the endothelium. The structure of the cornea and its
component layers are shown in (Figure 1.2).
Figure 1.2: (a) The structure of the cornea and its principle layers. (b) Shows epithelium,
Bowman membrane and anterior stroma. (c) Illustrations the posterior corneal stroma,
Descemet’s membrane and endothelium. Reproduced from (Ross et al. 2006).
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Epithelium
The corneal epithelium is the superficial layer of cells that is bathed by the tear film;
it thus has a smooth, wet optical refractive surface (Lens et al. 2008; Torricelli et al.
2013b). The epithelium has an extraordinary density of sensory nerve endings per unit
area, making the cornea one of the most innervated tissues in the body. This high level
or innervation results in a high pain sensitivity (Hirata et al. 2017; Lens et al. 2008)
and a rapid response to environmental harm (Holland et al. 2013). The epithelium also
facilitates the stabilizing of fluid balance within the cornea and protects against pathogen
entry (Smolin et al. 1994). Perhaps in keeping with this requirement, the epithelium has a
short life span; it is self-renewed and takes five to seven days to complete turnover under
normal conditions (McLaughlin et al. 2008). However, in response to injury, the cells are
stimulated to undergo a much more rapid regeneration and healing may occur within a day
(Lens et al. 2008).
Human epithelium is a non-keratinized stratified squamous epithelium, with a thick-
ness of 50 µm which represents 10% of total corneal thickness. It has five to seven layers
of cells, consisting of three to four superficial squamous cell layers, one to three layers
of middle or wing cell and monolayer of deep or columnar basal cells. The junctions of
these layers are slightly different and characteristic of each layer. The outer squamous
layers have tight junctions, with gap junctions in the middle and deep layers (Figure 1.3a).
Desmosomes and hemidesmosomes are present basal cell membrane along all of these
cell borders (Holland et al. 2013; Smolin et al. 2005) (Figure 1.3a).
The superficial squamous layers are flat, polygonal cells and are about 40 to 60 µm in
diameter. The membranes of these cells have surface microvilli which form microplicae.
Electron microscopy studies have shown that this superficial squamous layer has two cell
types: dark and light cells depending on the amount and pattern of microplicae. The
dark cells are larger, and the microvilli are denser (Doughty 2016). These dark cells are
older, hyper-mature and are ready to desquamate. On the other hand, the younger cells
with lower density of microvilli are the light cells (Smolin et al. 2005). The microplicae
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Figure 1.3: (a) Corneal epithelium has tight junctions in the outer squamous layers,
with gap junctions in the middle and deep layers. Desmosomes are present along all
of these cell borders. Reproduced from (Swamynathan et al. 2011) with permission
from the copyright holder, the Association for Research in Vision and Ophthalmol-
ogy (License No: 4286520001719). (b) The three layers of basement membrane are
only visible under electron microscopic examination. These layers are the lamina lu-
cida, lamina densa also known as basal lamina and lamina reticularis. adapted from:
http : //www.histology.leeds.ac.uk/tissuet ypes/connective/conbasallam.php [ac-
cessed 29 November 2017].
increase surface area by folding, which increases oxygen and nutrition taken from the tear
film (Holland et al. 2013) and increases adherence of the mucin layer of the tear film to
gylcocalyx leading to tear film stability. This filamentous gylcocalyx found on the top
of the microplicae is formed of glycolipid and glycoprotein (Holland et al. 2013; Smolin
et al. 2005).
Middle or wing cell layers are also called suprabasal epithelial cells, and are transi-
tional cells between basal and superficial that occasionally undergo cell division. These
cells migrate superficially to terminally differentiate into superficial squamous epithelial
cells (Holland et al. 2013).
The deep or basal cell layer consists of single columnar cells attached to the epithelial
basement membrane (Holland et al. 2013), which is adjacent to Bowman’s layer. The
basement membrane is observable under light microscopy but its three layers are only
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visible by electron microscopy (Torricelli et al. 2013a). These layers are the lamina lucida
(electron-lucent), lamina densa also known as basal lamina (electron-dense), and lamina
fibroreticularis (electron-lucent) (Torricelli et al. 2013a) (Figure 1.3b). In the human
cornea, new epithelial basal cells migrate from limbal stem cells into the corneal epithelium
(Chang et al. 2008). The basal cells also have mitotic activity. As the proliferation begins,
the movement of daughter cells starts in this layer, continues anteriorly as the cells change
shape to form wing cells; as they move further forward to corneal surface, the cells turn
into corneal superficial cells. The oldest epithelial cells disintegrate and dead cells are
continually being shed into the tear film in a process known as desquamation (Li et al.
2017; Smolin et al. 2005).
Bowman’s layer
Bowman’s layer is a 15 µm thick, acellular layer of connective tissue that lies under the
epithelium. Initially, it was named ‘Bowman’s membrane’ but on the basis that lamellae
insert into it from the anterior stroma and no clear interface exists between the two
regions, it is now more commonly referred to as ‘Bowman’s layer’ or the ‘anterior limiting
lamina’ (Mathew et al. 2008). The layer comprises a random array of collagen fibrils and
laminar fibres (Reinhard et al. 2010) consisting of collagen types I, III, V, VII, XII and
XVI (Torricelli et al. 2013b), which are smaller in diameter than stromal collagen fibrils
(Komai et al. 1991). Although its role is still undefined, it is thought that it protects the
stroma against micro-organisms, supports the epithelium and anchors stromal collagen
lamellae to help maintain corneal shape (Lens et al. 2008). It has also been suggested that
the layer may act as a corneal ligament to maintain corneal structure, however, the low
number of complications following removal of the layer post-excimer laser photorefractive
keratecotomy does not support this theory (Wilson et al. 2000).
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Stroma
The stroma is the core layer of the cornea and offers the majority of the structural framework
of the tissue. It is roughly 500 µm thick (DelMonte et al. 2011) and comprises about 90%
of the corneal tissue (Meek et al. 2001). The stroma contains about 78% water and type
I and type V collagen fibrils embedded in a proteoglycan-rich matrix. The anatomic and
biochemical properties of the stroma play an essential role in many characteristics of the
cornea, including its physical strength, stability of shape, and transparency. The collagen
within the stroma is contained within 200 - 250 transparent lamellae.
The lamellae in the centre of the human cornea lie in all directions within the plane
of the tissue but exhibit a predominant alignment along the superior–inferior and me-
dial–lateral meridians (Boote et al. 2004). The lamellae are narrower and more interlaced
in the anterior one-third of the stroma than those in the posterior two-thirds of the stroma
(Boote et al. 2006; Li et al. 2014). This tighter lamellar organization increases the strength
of the anterior stroma and helps to sustain the corneal curvature (Bron 2001). In ad-
dition to water, collagen and proteoglycans, the stroma also contains other components
such as glycoproteins, soluble proteins, lipid droplets, salts, keratocytes, lymphocytes,
macrophages and polymorphounclear leukocytes; however the latter three cell types only
occur in cases of inflammation (Krachmer et al. 2011).
The corneal stroma consists of a flexible collagen network, organized as fibrils within
lamellae and associated with proteoglycans. Proteoglycans are produced by stromal
keratocytes. Proteoglycans are macromolecules consisting of a protein core covalently
bound to glycosaminoglycan side chains (Figure 1.4) (Akhtar et al. 2008a; Cheng et al.
2015). Out of the three glycosaminoglycan types in the stroma, keratan sulphate is the most
abundant constituting with about 65% of the total glycosaminoglycan content in cornea.
The remaining glycosaminoglycans are dermatan sulphate (or chondroitin sulphate) and a
minor amount of heparan sulphate, of which the latter is synthesized mainly by epithelial
cells (Michelacci 2003). The core proteins of the proteoglycans are members of the family
of small leucine-rich proteoglycans (SLRPs), which comprise a common central domain
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containing about 10 leucine-rich repeats (Kao et al. 2003). Initially in the embryonic
stroma, they collect as low-sulphate glycoproteins, afterward in typical adult cornea,
glycosaminoglycans bind to form proteoglycans (Krachmer et al. 2011).
The SLRPs in the extracellular matrix of corneal stroma are: keratocan, lumican,
mimecan (also called osteoglycin) and decorin, each characterised by a different pro-
tein core. The first three are keratan sulphate-containing proteoglycans, and the last is
a dermatan sulphate-containing proteoglycan. Proteoglycans are involved in regulating
collagen fibril diameter, in the control of interfibrillar spacing and in the lamellar adhesion
properties of corneal collagens, which make proteoglycans play important role in regulat-
ing both hydration and corneal structure properties, and consequently corneal transparency
(DelMonte et al. 2011; Lewis et al. 2010; Michelacci 2003; Ruberti et al. 2011).
Figure 1.4: (a) Proteoglycans are macromolecules consist of a protein core with covalent
bond to glycosaminoglycan side chains. (b) Proteoglycans from matrix around collagen
fibrils.
The main cellular components of the corneal stroma are keratocytes, which are
quiescent fibroblasts that are scattered between the lamellae. Keratocytes are flat stromal
cells that have a spindle-shape with long extensions (Figure 1.2). Corneal connective tissue
turnover is very slow (years) and keratocytes are normally quiescent, but become activated
if the cornea is injured (West-Mays et al. 2006). Keratocytes are flat in order to minimise
the path of light through them, and are also thought to produce crystallins which serve to
minimise light scatter and help preserve corneal transparency (Gardner et al. 2015; Jester
et al. 1999). Keratocytes turn over occurs every two to three years (Krachmer et al. 2011).
Keratocytes are highest in density in the anterior stroma, lowest in the central cornea and
have an intermediate density in the posterior stroma (Berlau et al. 2002). Keratocytes
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are involved in synthesizing collagen molecules and glycosaminoglycans and producing
matrix metalloproteases (MMPs) to stabilize stroma (DelMonte et al. 2011).
Collagen is the main protein component in connective tissues and constitutes about
70% of the total dry weight of the cornea (Meek et al. 2001).The structural strength of
stromal connective tissues is provided by collagen, which exists as fibrils held together by
intermolecular covalent bonds (Meek et al. 2001). The fibrils are parallel to one another
within lamellae and are packed with a high degree of lateral order. This highly ordered,
lattice-like arrangement of collagen fibrils is essential for corneal clarity (Boote et al.
2013; Jester et al. 2001).
At least twenty-nine different types of collagen have been identified in human body
(Schegg et al. 2009), roughly fourteen of these collagens are found in the eye. Collagens
have been classified into several groups: Fibril-forming collagens (e.g. types I, II, III, V,
XI collagen), fibril-associated collagens with interrupted triple helices, known as FACIT
collagens (e.g. types IX, XII, XIV, XVI, XIX collagen) and nonfibrillar collagens (e.g.
types XIII, XVII and XXV) (Koch et al. 2001; Sandberg-Lall et al. 2000; Snellman
et al. 2000). These collagens contain triplet helix structures (Figure 1.5). The triple
helices are made of three polypeptide, so-called alpha-chains, which are wrapped around
a common axis into a right-handed superhelix, therefore, the final domains is a “rope-like
rod” (Michelacci 2003). The α - chains comprise the repetitious amino acid sequence
glycine – X – Y, where X and Y are frequently proline or hydroxyproline (Motooka et al.
2012).
The collagen in the corneal stroma is mostly type I (75%), type V (10–20%) and
type VI (17%), with minor quantity of type III which undergo a rapid increase during
wound healing and inflammation (Birk et al. 1990, 1988, 1986; Krachmer et al. 2005;
Nakamura 2003). Corneal collagen fibrils have a uniform 25 - 30 nm diameter (Smolin
et al. 1994); homogeneity of both the mean diameter and mean distance between fibrils
is responsible for cancellation of scattered light rays, permitting light to pass through
the cornea (Remington 2011). The occurrence of corneal fibrosis or edema results in
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Figure 1.5: Collagen structure. (a) Collagen twisted together into triplet helix. (b) The
staggered positioning of adjacent collagen molecules results in alternating gap and over-
lap regions along the fibril (D-period). (c) The gap and overlap regions create visible
striations in positive stained collagen. (d) An electron micrograph of collagen fibrils. Re-
produced from https://chempolymerproject.wikispaces.com/Collagen-D-apml [accessed
9 November 2017]. Copyright © 2000 Benjamin/cummings, an imprint of addison wesley
longman. Inc.
heterogeneity of this diameter or of the distance between collagen fibrils, which then
scatters the incident rays randomly and causes corneal opacity (Krachmer et al. 2011).
When collagen fibrils are stained with heavy metals, dark and light bands are visible.
These bands are further divided by cross banding which displays an extraordinarily con-
stant length or “D-period”. One dark with light band shows a D-period of ≈67 nm in moist
rat-tail tendon (Orgel et al. 2000) and ≈65 nm in physiologically hydrated cornea. The
length of the D-period varies in different collagenous tissues and under different condition
(Meek et al. 1983) (Figure 1.6). This periodic banding pattern of stained collagen fibrils
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detected in the electron microscope can be correlated with the charge distribution realised
from the amino acid sequence (Meek et al. 1979). Hodge and Petruska (1963) were the
first to find the ordered arrangement of individual collagen molecules along fibrils. The
arrangement of individual collagen molecules was organised on the same orientation and
packed together side-by-side based on a staggered arrangement of individual collagen
monomers (Chapman et al. 1990). Adjacent collagen molecules are offset by approxi-
mately a quarter length of a collagen molecule, this is called “axial stagger” arrangement
(Goodson 2013). Five different possibility of axial offset positions occurred across the
fibril as demonstrated in Figure 1.6a. This produces a regular, distinctive banding pattern
as seen on staining intensity. Negative staining depends on molecular density, the dark
band where the heavy metal stain has infiltrated regions of low packing density of collagen
in the “gap” regions and light where the stain is excluded by higher packing density in
the “overlap” regions (Meek et al. 1979). Similar banding with the same regularity and
periodicity can also be observed with “positive staining” (Meek et al. 1979) (Figure 1.6),
however, the principle of staining is more complex. With negative staining, regions of
high stain uptake exist where there is lower molecular density, i.e. it is based on physical
accessibility to the stain, whereas positive staining has an electrostatic basis (Tzaphlidou
et al. 1982). Under the electron microscope, uranyl acetate (UA) can be used for positive
staining to visualise the regions along the fibril containing comparatively high concen-
trations of acidic amino acids (aspartate and glutamate) due to binding of the positively
charged uranyl ion (Tzaphlidou et al. 1982). Because the uranyl ion is small, it tends to be
able to move further into the fibril. Therefore, staining by uranyl ions alone tends to result
in better definition of the banding pattern (Meek et al. 1983).
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Figure 1.6: (a) A diagrammatic illustration of the axial structure of D-periodic collagen
fibrils. The gap (dark) and overlap (light) areas cover a distance (D-period) of roughly
67nm in calfskin collagen. (b) Transmission electron micrograph of a negatively and
(c) positively stained calf skin collagen fibril. Negative staining depends on molecular
density, with the dark bands marking regions where the heavy metal stain has infiltrated
areas of less densely packed collagen, and the “gap” regions occurring where the stain
has been excluded by a higher packing density in the “overlap” regions. Similar banding
with the same regularity and periodicity can also be observed with “positive staining”.
There are 12 common positively-stained bands, which is shown in the white box (from
left to right) c1, b2, b1, a4, a3, a2, a1, e2, e1, d, c3, c2. Taken from (Chapman et al.
1990) and reproduced with permission from the copyright holder, Elsevier (License No:
4241941117833).
Pre-Descemet’s layer (Dua’s layer)
Recently, Dua and his colleagues proposed the present of a sixth layer within the cornea
in a region immediately above Descemet’s membrane, which measures about 6 - 15 µm
thick, and contains around 5 - 8 firmly packed mainly type I collagen lamella (Dua et al.
2013, 2014). According to Dua, this layer has few or no keratocytes, a different collagen
architecture to the rest of the stroma, and has a substantial impact in relation to corneal
surgery such as lamellar keratoplasty using air-injection techniques (Dua et al. 2013, 2014).
While there is a general agreement that this layer is biomechanically distinct from the rest
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of the cornea (Dua et al. 2016, 2015; Zaki et al. 2015), many other investigations show
scepticism that it is a distinct layer, and it is believed that it is just a specialised region
of the posterior stroma; this region is now commonly refer to as pre–Descemet’s region
(Jester et al. 2013; Lewis et al. 2016).
Descemet’s membrane
Descemet’s membrane is a homogenous layer between the stroma and endothelium. It
forms the basement membrane of the corneal endothelium and is composed of two lam-
inated structures, an anterior banded layer and a posterior non-banded layer (Reinhard
et al. 2010). The thickness of the anterior banded layer does not change, is roughly 3
- 4 µm at birth while the posterior non-banded layer grows from 3 µm at birth to 20 -
30 µm postnatal life (DelMonte et al. 2011; Reinhard et al. 2010; Smolin et al. 2005).
Descemet’s membrane contains types IV and VIII collagen, laminin entactin, perlecan
and fibronectin. Descemet’s membrane structure is a hexagonal array of collagen bundles
organized parallel to the surface of the membrane with intervals of 110 µm (Reinhard et al.
2010). Descemet’s membrane helps to preserve corneal integral structure and maintains
fluids within stroma and aqueous humour which conserves the intraocular pressure (Zavala
et al. 2013).
Endothelium
The endothelial layer of the cornea is a neural crest-derived monolayer of honeycomb-like
mosaic cells between 455,000 and 338,000 cells over an area of about 130 mm2 that serves
as a major pump to corneal deturgescence which thereby maintains corneal transparency.
At birth there are approximately 400,000 cells with a uniform thickness of about 10 µm,
with cell density ranging from 3,500 to 4,000 cells per mm2 (DelMonte et al. 2011;
McMonnies 2014; Smolin et al. 2005). In normal corneas, there is an annual reduction of
central endothelial cell density at an average rate of 0.6% (Bourne et al. 1997). Between
endothelial cells there are gap and tight junctions (Bazzoni et al. 2004; Dejana et al. 1995).
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Over time, the endothelial cells flatten and extensively adhere to each other.
During adulthood endothelial cells rarely undergo mitosis, therefore the cell density
decreases with age; fortunately, corneas may maintain their clarity with less than 1,000
cells per mm2 (John 2010). Loss of endothelial cells is compensated by a flattening and
enlargement of the remaining cells to maintain a continuous monolayer (Reinhard et al.
2010). The change in the size and shape of the endothelial cells as a result of this flattening
and enlargement, reduces the ability of the endothelium to regulate corneal hydration. This
emphasises the role of the endothelial layer as an ATP-dependent pump to transport fluid
and ions from the stroma to the aqueous humor and explains the mitocodria richness in
endothelial cells (Reinhard et al. 2010).
1.3 Corneal Diseases: Keratoconus
In 1854, Nottingham first described keratoconus in detail. Keratoconus derives from
the Greek words Kerato (cornea) and Konos (cone). Keratoconus is a bilateral corneal
disease often asymmetrical which causes corneal stroma thinning leading to deformation
of the normal corneal architecture which in turn results in corneal protrusion (Wang et al.
2010) (Figure 1.7). Keratoconus has been traditionally classified as a non-inflammatory
condition, hence there are usually no obvious sign of inflammation such as heat, redness,
swelling, and pain associated with the condition (McMonnies 2015). Recent research has
discovered several inflammatory processes that have been found in the tears of keratoconus
patients along with some inflammation relevant differences in the keratoconus cornea
(Galvis et al. 2015; Popescu et al. 2014). The location of keratoconus occurs in the central
two-thirds of the cornea, typically the cone apex is concentrated just beneath the visual
axis (Krachmer et al. 2011). Irregular astigmatism and high myopia occurs due to corneal
protrusion, affecting vision clarity (Wojcik et al. 2013).
The onset of keratoconus is typically early adolescence, because of the progressive
changes of normal cornea curvature with age. At birth, the normal cornea tends to
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be spherical, but the cornea develops with-the-rule astigmatism during childhood and
adolescence, then in middle-aged adults the cornea becomes more spherical, and with
aging, the elderly cornea progresses to against-the-rule astigmatism (Wang et al. 2010).
Keratoconus initiates in youth and progress for three or four decades in adulthood before
cessation.
Figure 1.7: Schematic representation of a normal cornea (a) and a keratoconic cornea (b).
Image reproduced from (Wojcik et al. 2013).
There are three types of cone morphology: round, oval and keratoglobus shaped cone
(Davidson et al. 2014; Perry et al. 1980). The round or “nipple-shaped” cone is the most
common cone, this cone usually lies in the infero-nasal quadrant closer to cornea centre
and has a diameter of about ≤ 5 mm. The oval or sagging cone is usually larger, has a
diameter > 5 mm, and locates in the infero-tempral area, paracentral towards the corneal
peripheral (Ertan et al. 2009). The keratoglobus cone is generalized corneal thinning, and
75% of the cornea is cone (Davidson et al. 2014).
Disease progression is the main method that ophthalmologists and optometrists use to
describe the severity of keratoconus. Table 1.1 describes the classification of keratoconus
based on disease severity.
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Table 1.1: Clinical classification of keratoconus in stages by (Krumeich et al. 2009).
Stage Characteristics
• Eccentric steepening Induced myopia and/or astigmatism of ≤ 5.0 D
Stage 1 • K-reading ≤ 48.00 D
• Vogt’s lines, typical topography
• Induced myopia and/or astigmatism > 5.0 to ≤ 8.00 D
Stage 2 • K-reading ≤ 53.00 D
• Pachymetry ≥ 400µm
• Induced myopia and/or astigmatism > 8.0 to ≤ 10.00 D
Stage 3 • K-reading > 53.00 D
• Pachymetry 200 to 400 µm
• Refraction not measurable
Stage 4 • K-reading > 55.00 D
• Pachymetry ≤ 200µm
• Central scars
Stage is determined if one of the characteristics applies.
Corneal thickness is the thinnest measured spot of the cornea.
1.3.1 Histopathology
The classic histopathological findings in keratoconus are corneal stromal thinning, Bow-
man’s layer rupture and iron deposits in the basal layer of the epithelium (Rahman et al.
2006). Depending on the severity of the disease, keratoconus has consequences in all
corneal layers.
Some have reported thinning of the central epithelium of the keratoconic cornea in
the presence of breaks in Bowman’s membrane (Barbara et al. 2011; Zhou et al. 2014),
while others showed central epithelium thickening in keratoconus (Sherwin et al. 2004;
Wang et al. 2008). This variation may indicate the variable presentation of keratoconus.
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Early degeneration of basal epithelial cells can be seen in the earliest appearances of
keratoconus (Wang et al. 2010). Moderate keratoconus usually does not demonstrate
changes in either the superficial or wing cells. However, in severe case, keratoconus
flattens the superficial epithelial cells and extraordinarily large wing cells with irregular
spaced nuclei are observed (Efron et al. 2008). In advanced cases of keratoconus, the
basal cell layer diminishes and may even disappear, and noticeable iron deposits are seen
within and between epithelial cells (Ucakhan et al. 2006).
Bowman’s layer often shows breaks filled by epithelial down-growth or collagen
eruptions of the stroma, periodic acid Schiff positive nodules and Z-shaped interruptions
caused by the separation of stromal collagen bundles and scar reticulation (Sherwin et al.
2004).
The stromal thinning observed in keratoconus corneas may be related to changes in
enzyme levels that cause increases in proteolytic enzymes, decreased concentration of pro-
tease inhibitors, which weakens and thins the cornea (Mackiewicz et al. 2006; Sawaguchi
et al. 1990, 1994). From confocal microscopy, keratoconus eyes show haziness, hyper-
reflectivity in stroma, and reduction in keratocytes density (Ku et al. 2008). Keratoconus
eyes appear to have an increase in keratocyte apoptosis and change in keratocyte morphol-
ogy especially in the anterior stroma (Alio 2016; Kim et al. 1999). Transmission electron
microscope studies showed that the number of stromal collagen lamellae in the kerato-
conus cornea is reduced compared to normal eyes, but there was no change in collagen
lamellae thickness (Takahashi et al. 1990). Examination of the collagen distribution by
x-ray studies found that the orientation of collagen fibrils within the lamellae is altered in
the keratoconus cornea, which may affect the strength of cornea and provided evidence
of lamella redistribution (Meek et al. 2005; Takahashi et al. 1990). However, there was
no distinct difference in the intrafibrillar spacing between collagen, thus, stromal thinning
is not a result of closer packing of fibrils in keratoconus (Fullwood et al. 1992). More-
over, x-ray diffraction studies have revealed that alteration in distribution of proteoglycan
molecules in the cornea of the keratoconus eye may be associated with some loss of
strength of the stroma in keratoconus (Akhtar et al. 2008b; Fullwood et al. 1992).
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In severe keratoconus cases, Descemet’s membrane breaks and aqueous humour
penetrates into the stroma, causing corneal edema, this state known as acute hydrops
(Wang et al. 2010). Acute hydrops is found in approximately only 3% of keratoconus
corneas (Al Suhaibani et al. 2007). Generally, the endothelium in keratoconic eyes
remains intact, rarely, endothelium cell elongation may occur (Weed et al. 2007a).
1.3.2 Signs and Symptoms
The earliest signs and symptoms of keratoconus are typically blurred vision and frequent
changes in vision (Lim et al. 2002). This varies from moderate astigmatism to severe vision
distortion (Rabinowitz 1998). Although keratoconus is considered a bilateral condition, it
is usually asymmetric (Burns et al. 2004). One eye can diagnose with a critical sign of the
disease while the other eye detected with a subclinical keratoconus. The reason for this
asymmetry is not well understood. In some patients there is a complaint of glare, ghost
image, tearing, itching, burning, redness, foreign-body sensation, photophobia, frequent
rubbing of the eye and rarely monocular diplopia (Rapuano 2012; Weed et al. 2007b).
Frequently, unexplained reduction of visual acuity, change of refractive error or inadequate
contact lens fitting leads to topography testing, which exposes the diagnosis. Also a split
or scissors motion on retinoscopy indicates keratoconus or high amounts of irregular
astigmatism (Rosenfield et al. 2009). On ophthalmoscopy, keratoconus may be marked
by the presence of a circular dark red-brown shadow encircled by the usual red fundus
reflex, called the oil drop sign or the Charleauc “oil droplet” sign (Abraham et al. 2013).
Distorted mires also manifests keratoconus on keratometry (Saxena 2011).
Several keratoconus signs can be detected by slit-lamp biomicroscopy. Some of these
signs are: stromal thinning, endothelium reflex, central or eccentric cone, apical stromal
scarring, Fleischer’s ring, Vogt’s striae, Munson’s sign, Rizzuti’s sign, Axenfeld sign and
acute hydrops (Saxena 2011).
Stromal thinning expands gradually from the base of the cone to apex (Sturbaum
et al. 1993). The cause of endothelium reflex is increase of corneal concavity (Abraham
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et al. 2013). In moderate keratoconus, anterior stromal scars may occur autonomously or
secondary to hard contact lens used (Wang et al. 2010). The Fleischer’s ring is the most
frequently noted slit-lamp sign of keratoconus and is observed using a cobalt blue filter as
a line or circle (Weed et al. 2007b). It occurs as a result of epithelial deposition of iron
oxide haemosiderin (a yellow-brown to olive-green pigment) in an incomplete annulus
surrounding the base of the cone as a result of corneal stretching in the advanced stage of
keratoconus and because of an irregular tear film of the cornea in this area (Wagner et al.
2007) (Figure 1.8). Fleischer’s ring may be seen prior to evidence of corneal thinning and
conical shape change. The second common sign is Vogt’s striae, which are fine vertical
lines in the Descemet’s layer and posterior stroma that temporarily disappear when a gentle
limbal pressure is applied (Sundaram et al. 2009) (Figure 1.9).
Figure 1.8: Fleischer’s ring. Reproduced from http : //lessons4medicos.blogspot .
co.uk/2009/04/corneal − pigmentation − decoded.html [accessed 9 November 2017].
In advanced disease, the Munson’s sign and Rizzuti’s sign are not uncommon in
keratoconus patients. Munson’s sign is detected when the downgaze of a keratonic eye
shows a V-shaped pattern on the lower eyelid as it passes over the protrusion corneal cone
(Grosvenor 2007) (see Figure 1.10). Rizzuti’s sign also called Benedict sign is a triangular
conical reflection of focused beam on nasal limbus, formed when lateral illumination is
shone from temporal side of the cornea (Ambrósio Jr et al. 2006) (see Figure 1.11).
Furthermore, Axenfeld sign is loss of sensitivity on the cone apex (Abraham et al. 2013).
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Figure 1.9: Vogt’s striae. Reproduced from http : //www.gpli.in f o/sym − 2004 − 03/
[accessed 9 November 2017].
Figure 1.10: Munson’s sign. Reproduced from http : //www.pinterest.com
/waterlooeyecent/keratoconus/ [accessed 9 November 2017].
Figure 1.11: Rizzuti’s sign. Reproduced from http : //www.cltoday.com
/issues/CLToday_020914.htm [accessed 9 November 2017].
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Severe keratoconus may present with accompanying corneal hydrops (Figure 1.12).
The onset of corneal hydrops is associated with acute pain, sudden blurred vision and
photophobia. The oedema usually resolves within 2 to 3 months as the endothelial cells
stretch and enlarge to block the breaks in the endothelium (Maharana et al. 2013).
Figure 1.12: Corneal acute hydrops. Reproduced from http : //www.keratoconus −
group.org.uk/expert_contributions/kp/hydrops_and_kc.html [accessed 9 Novem-
ber 2017].
1.3.3 Epidemiology
The estimation of keratoconus prevalence fluctuates extensively depending on the geo-
graphic location, and variation in diagnostic criteria. The prevalence estimation falls
between 0.4 to 230 per 100,000 cases (Bykhovskaya et al. 2016; Gokhale 2013; Gordon-
Shaag et al. 2015; Krachmer et al. 2011). Keratoconus is known to affect all races (Wagner
et al. 2007; Weed et al. 2008) but a UK-conducted study showed that the prevalence in
Asians was roughly seven times higher than Caucasians and this was attributed to the
higher incidence of consanguineous relations, particularly first-cousin marriages, in the
assessed area (Georgiou et al. 2004). In addition, ecological influences may attribute to
the wide variation in prevalence. Geographical locations with hot climates and sunshine
like Middle East and India (Assiri et al. 2005; Jonas et al. 2009), have higher prevalence
than countries with cold weather, such as, Finland, Russia and Denmark (Gorskova et al.
1998; Ihalainen 1986; Nielsen et al. 2007).
The relationship between gender and the incidence of keratoconus is still debated.
Some studies have reported no difference in keratoconus prevalence between males and
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females (Li et al. 2004) whilst other studies have found either a higher incidence in females
(Jonas et al. 2009; Krachmer et al. 1984) or males (Pearson et al. 2000; Wagner et al.
2007).
Keratoconus is commonly considered a bilateral disease. However, advances in
computer-assisted topography and pachymetry that have enhanced the ability to detect
subtle disease have led to a rise number of patients with only early changes in one eye and
no evidence of topographical change in the second eye (Lema et al. 2009).
Although numerous ocular and systemic diseases have been documented in conjunc-
tion with keratoconus, few are accepted to be associated. Factors that have been identified
as being associated with a higher incidence of keratoconus are eye rubbing, atopy, Down’s
syndrome, and mitral heart prolapse (Balasubramanian et al. 2013; Barbara et al. 2011;
Grünauer-Kloevekorn et al. 2006). However, most often keratoconus incidence is found
to be sporadic and not in combination with other diseases.
1.3.4 Aetiology and pathogenesis
Although the accurate aetiology and pathogenesis of keratoconus is still enigma, it has
been associated with genetic, mechanical, biochemical and environmental factors.
Genetic
Genetic factors are believed to play a role in the development of keratoconus with between
6% and 23% of keratoconus patients having a family history of keratoconus (Karimian
et al. 2008; Owens et al. 2003). Autosomal recessive and autosomal dominant patterns
of inheritance seems likely to occur in most keratoconus cases, which suggest a link of
genetic factors in keratoconus (Kenney et al. 2003; Mita et al. 2014; Rabinowitz et al.
1992). Studies carried out with corneal topography techniques have revealed that 50%
of keratoconus patients have one or more relatives with the condition (Gonzalez et al.
1992). Although various genetic studies have been conducted in an attempt to identity
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genetic regions (Loci) for keratoconus (Burdon et al. 2013), it is still not clear exactly
which candidate genes are associated with keratoconus. Several studies have indicated a
link between keratoconus and the visual system homeobox 1 (VSX1) gene, which plays
a significant role in ocular development, in particular cornea development (Bisceglia
et al. 2005; Heon et al. 2002; Saee-Rad et al. 2011; Tanwar et al. 2010). In contrast,
other studies have shown that there is no correlation between VSX1 and keratoconus,
representing the involvement of other genetic factors (Davidson et al. 2014; Stabuc-Silih
et al. 2010). Similarly, some studies reported that the superoxide dismutase 1 gene (SOD1)
is connected to keratoconus (Liskova et al. 2010), which is an antioxidant defender gene,
while other publications did not support this relationship (Stabuc-Silih et al. 2010; Wojcik
et al. 2013).
Mechanical
Eye rubbing, contact lens wear, oxidative damage and stromal thinning have also been
linked to keratoconus development and progression (Wojcik et al. 2013). The incidence
of eye rubbing in keratoconus patients ranges from 66% to 73%, and maybe linked
with other diseases such as atopic disease, Down’s syndrome, and Leber’s tapetoretinal
degeneration (Balasubramanian et al. 2013; Krachmer et al. 2011). An increase in tear
protease activity and inflammatory mediators in tears after eye rubbing may be involved
in keratoconus progression (Balasubramanian et al. 2013). In addition, contact lens wear
could prompt the progression of the disease in the form of corneal microtrauma. Macsai
et al., recognized that keratoconus patients undergoing long-term contact lens wear tend to
have central cones with a flatter corneal curvature than patients with no history of contact
lens wear (Macsai et al. 1990). A reduction in number of stromal lamellae in keratoconus
causes decrease in corneal rigidly compared to normal eyes (Meek et al. 2005; Sherwin
et al. 2004). Some studies showed that stromal thinning in keratoconus is contributed to
collagen degradation by proteolytic enzymes (Sherwin et al. 2002) or reduced of proteinase
inhibitors levels (Ghosh et al. 2013; Mackiewicz et al. 2006), others proposed that there is
no loss of collagen, alteration in collagens distributed of within the cornea by slip between
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the lamellae (Polack 1976). Oxidative damage has also been associated with keratoconus
progression. Keratoconic corneas have decreased levels of two enzymes that play a vital
role in reactive oxygen processes aldehyde dehydrogenase Class 3 (Gondhowiardjo et al.
1993) and superoxide dismutase enzymes (Behndig et al. 2001). The increase of oxidative
stress causes cytotoxic deposition resulted from accumulate reactive oxygen species, that
could cause damage to the corneal tissues and potentially produce keratoconus (Kenney
et al. 2003).
Biochemistry
During the last few decades, our understanding of the biochemistry of keratoconus aeti-
ology has dramatically increased. It is important to note that the results of this research
are more related to advance keratoconus. It has been shown that keratoconus is associated
with destructive enzyme activity within the cornea (Mita et al. 2014). The increased level
of proteases and other catabolic enzymes (Fukuchi et al. 1994), or decreased levels of
proteinase inhibitors could results in a degradation of extracellular matrix of the stroma
(Wojcik et al. 2014; Zhou et al. 1998). Therefore, corneal thinning occurs due to the
loss of corneal structural components (Romero-Jimenez et al. 2010). Several biochemical
theories for keratoconus development have been found differences keratoconic corneas
in collagen types XIII (Määttä et al. 2006a), XV and XVIII (Määttä et al. 2006b) when
compared to non-keratoconus corneas, and that might cause the differences in wound
healing process that are observed between normal and keratoconic corneas (Cheung et al.
2013; Croxatto et al. 2010). Moreover, the keratocytes in keratoconus eyes have four
times greater numbers of interleukin-1 receptors in contrast to normal eyes (Bureau et al.
1993). Interleukin-1 has also been suggested to induce apoptosis or controlled cell death
of the stroma keratocytes. Apoptosis has been found in stromal keratocytes of keratoconus
corneas, but not in normal corneas (Kim et al. 1999). Corneal epithelium might release
interleukin-1 in response to microtrauma occur in the association of keratoconus with eye
rubbing, contact lens wear and atopy (Wilson et al. 1996).
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Environment
Environmental factors have also been suggested to contribute to keratoconus pathology,
such as overexposure to ultraviolet rays from the sun (Assiri et al. 2005), extreme eye
rubbing (Balasubramanian et al. 2013; Shneor et al. 2013), poor contact lenses fitting
(Macsai et al. 1990), atopy and chronic eye irritation (Sugar et al. 2012). Ultraviolet
light has been observed to be associated with keratoconus. Researchers have suggested in
corneas with keratoconus there are some defects in their ability to process accumulated
reactive oxygen species (Wojcik et al. 2013). In addition, many studies demonstrated
regions with a higher load of airborne allergens have a higher prevalence of keratoconus.
Several studies showed that asthma and hay fever are evident in 23% to 30% of keratoconus
subjects, respectively (Weed et al. 2008). However, this association may be because
patients with allergic symptoms rub their eyes more frequently, which may lead to corneal
ectasia (Sugar et al. 2012).
1.3.5 Management and Treatment
Treatment opportunities for keratoconus focus on correcting the distorted vision caused
by the thinning and protrusion of the cornea.
Spectacles and contact lenses
Initially, many keratoconic patients develop myopia and simple astigmatism which can
be corrected with spectacles or soft contact lenses before signs of the disease become
evident. These patients attract the attention of the optometrist as the myopia and astig-
matism progress, showing steeper than average keratometry or topography readings. As
keratoconus progresses to an intermediate stage, the spectacles and soft contact lenses
no longer provide functional vision. Toric soft contact lenses may help with correcting
the astigmatism to some extent. When the irregularity of the astigmatism increases, rigid
gas-permeable (RGP), hard contact lenses may provide a clear vision by creating a new
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anterior refractive surface. However, the contact lens must be fitted with an awareness of
patient tolerance, and should be tailored to the individual visual requirements.
Many keratoconus patients can be effectively fitted with hard contact lenses using
either the three-point touch technique which allows a light apical corneal touch (Szczotka et
al. 2001) or with apical clearance fitting technique (McMahon et al. 2006). Other selections
of contact lens include standard biocurved hard lenses, custom-back toric lenses, piggyback
systems hybrid lenses design of combined hard lens with a soft skits scleral lenses, and
mini-scleral lenses (Lim et al. 2002). Contact lens wear does not halt the progression
of corneal ectasia and in some cases it is actually associated with the development of
keratoconus (Krachmer et al. 2011). An alternative option for managing keratoconus is
intrastromal corneal ring implants.
Intrastromal Corneal Ring implants
Intrastromal corneal ring segments are crescent-shaped/semi-circular, made of poly-
methylmethacrylate and implanted into a deep corneal stromal tunnel created by a fem-
tosecond laser. The technique reduces corneal curvature by flatting the central cornea,
reducing astigmatism and centring the cone, ensuring improved visual acuity and better
contact lens fitting (Alio et al. 2014). The safety and effectiveness of intrastromal corneal
ring implants are reinforced by many clinical studies (Özertürk et al. 2012; Pron et al.
2011; Vega-Estrada et al. 2016).
Keratoplasty
In the last decade, corneal cross-linking (CXL) treatment reduced the need to corneal
transplant performed for keratoconus. Although most patients with keratoconus do not
progress to necessitating a transplantation, keratoconus remains one of the leading causes
of cornea transplant in the developed world (Davidson et al. 2014; Gharaibeh et al.
2012; Rabinowitz 1998). In advanced keratoconus with severe ectasia and central corneal
scarring, fitting a contact lens fails to provide clear vision. As a result, about 10 -
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20% of keratoconus patients require invasive surgical intervention such as keratoplasty
(Rabinowitz 1998). Although penetrating keratoplasty for keratoconus is still vulnerable to
endothelial allograft rejection, it is still the first choice for the severe disease (Sarezky et al.
2017). There are a few different types of corneal transplant which differ in the thickness of
grafting: full-thickness penetrating keratoplasty, partial-thickness lamellar keratoplasty,
epikeratophakia and Bowman’s layer transplantation (Dijk et al. 2014). The overall risk of
graft rejection was approximately 6.8% (Dijk et al. 2014). The risk of corneal transplant
failure coupled with the limited number of donor corneas available for transplantation, has
encouraged the development treatments aimed at halting the progression of keratoconus
and reducing the number of keratoconus patients undergoing corneal transplant surgery.
Corneal collagen cross-linking with riboflavin and Ultraviolet irradiation
In 1998, Spoerl and his colleagues introduced a new approach for keratoconus treatment.
Their experimental evidence has shown that the non-toxic photosensitizer riboflavin and
ultraviolet-A (UVA) induce additional covalent bonds in the cornea by photosensitized
oxidation, which leads to strengthening of the corneal stroma (Spoerl et al. 1998). The
concept was based on a scientific suggestion that the natural cross-linking effect of glucose
increases corneal stiffness in diabetic eyes (Andreassen et al. 1988; Williamson et al. 1986).
Applying cross-linking to progressive keratoconus or postoperative refractive surgery
ectasia, where the collagen structure is disposed to enzymatic degradation and fibrillar
slippage, has been shown to adjust the biomechanical properties of the cornea (Abad
et al. 2008; Kohlhaas et al. 2006; Sandner et al. 2004; Wollensak et al. 2003a,b). The
biomechanical effect in human eyes has been reported to significantly increase corneal
rigidity by 328.9% (Wollensak 2006; Wollensak et al. 2003b). Moreover, enzymatic
degradation resistance is increased in porcine eyes, after cross-linking (Spoerl et al. 2004),
which may also contribute to biomechanical stability (Krachmer et al. 2011). Usually
the cross-linking effect is localized in the anterior 300 µm of the stroma (Kohlhaas et al.
2006). The average collagen fibril diameter in the treated cornea is significantly increased
by 12.2% in the anterior stroma while it is increased by only 4.6% in the posterior stroma
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(Wollensak et al. 2004b), further indicating that the effect is mostly in the anterior stroma.
Cross-linking the cornea using riboflavin and ultraviolet-A light has been greatly
improved in recent years through developments and modification to make it suitable for
clinical use. In 2003, the Dresden group carried out the first prospectively designed
clinical study in 23 eyes with moderate or advanced progressive keratoconus (Wollensak
et al. 2003a). It has been proven that the riboflavin/UVA cross-linking procedure prevent
further keratoconus progression, improves the corneal shape and in some cases flattens the
cone (Kohlhaas et al. 2005). Also, improvement in best spectacle corrected visual acuity
(BSCVA) was reported together with the stability of endothelial cell density (Wittig-Silva
et al. 2014). Over the past decades, the standard cross-linking (SCXL) procedure, which
involves soaking the corneal stroma with riboflavin and then photoactivating it using 370
nm UVA with an irradiance of 3 mW/cm2 for 30 minutes, has been widely utilized to
halt the progress of keratoconus and other ectasia disease. Following the implantation of
cross-linking in the Netherlands, a 25% reduction in the number of corneal transplants
required for keratoconus has been documented (Godefrooij et al. 2016). The application
of cross-linking is not limited to corneal ectasias it has also been used to successfully
treat infectious diseases; specifically, infectious keratitis (Tabibian et al. 2015). In 2000,
Schnitzler et al, announced the efficacy of SCXL in the stabilization of corneal melting
ulcers. Multiple studies have shown the efficacy of using SCXL as a first line treatment
for advanced ulcerative infectious keratitis and early-stage bacterial keratitis as it has the
ability to render certain bacteria and viruses inactive (Garg et al. 2017; Makdoumi et al.
2016; Richoz et al. 2014).
Mechanism of cross-linking
There are four key components in the process of CXL: photosensitizer (riboflavin),
UVA illumination, oxygen and tissue (Kamaev et al. 2012). Exposing cornea soaked with
riboflavin to UVA light in an oxygenated environment forms singlet oxygen species which
lead to creation of extra CXL bonds (McCall et al. 2010; Zhang et al. 2011).
Kamaev et al. (2012) investigated the photochemical kinetics of SCXL and observed
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oxygen consumption with the cornea during the CXL process. They documented that
a photochemical type II reaction was found in cornea tissue during the first 10 - 15 sec
of the UVA exposure, which is favoured at high oxygen concentration and generates
reactive oxygen species; then complete oxygen depletion takes place and photochemical
type I reaction occurred, which is favoured at low oxygen concentration and forms singlet
molecular oxygen; after 10 minutes, corneal oxygen concentration increased slowly and
the photochemical type II reaction recurred (Kamaev et al. 2012) (Figure 1.13).
Figure 1.13: The photochemical kinetics mechanism on CXL. photochemical type II
reaction was found in cornea tissue during the first 10 - 15 sec of the UVA exposure,
which is favoured at high oxygen concentration and generated reactive oxygen species;
then complete oxygen depletion occurred and photochemical type I reaction occurred,
which is favoured at low oxygen concentration and react with oxygen to form singlet
molecular oxygen; after 10 min corneal oxygen concentration has increased gradually
and photochemical type II reaction may begin to play a role once again. Image adapted
from (Kamaev et al. 2012) with permission from the copyright holder, the Association for
Research in Vision and Ophthalmology (License No: 4270240029745).
A study by Zhang et al (2011) into the nature and location of the cross-links formed
within the extracellular matrix during riboflavin/UVA cross-linking revealed that the cross-
links could occur not just between collagen molecules but also between collagens and
proteoglycan core proteins of lumican, mimecan and keratocan and between the proteo-
glycan core proteins themselves. Although cross-linking may occur within and between
proteoglycan core proteins, the covalently attached sulphated glycosaminoglycans (keratan
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sulphate and chondroitin sulphate) are not involved in the cross-linking process. Zhang
et al. (2011) have shed light on the interaction between collagen and proteoglycan core
proteins, showing that the collagen interactions are very different in keratocan and lumican
core proteins than in mimecan and decorin.
Moreover, studies using x-ray scattering techniques, enzymatic digestion and stromal
swelling behaviour revealed that it is highly unlikely that direct interfibrillar (collagen fibril
– collagen fibril) cross-linking occurs and that collagen cross-linking is likely to occur at
fibril surfaces only, within and between collagen molecules and within the proteoglycan
coating that surrounds the fibrils (Hayes et al. 2013) (Figure 1.14). The probable cross-
linking of proteoglycan and collagen molecules shown in Figure 1.14 would explain the
increased stiffness of corneas after cross-linking treatment and the increased resistance of
stromal tissue to enzymatic digestion.
Morphologically, keratocyte alteration was observed after CXL. Initially, the treat-
ment kills these cells, but the stroma is then repopulated. It has been demonstrated that
there is a significant increase in the keratocyte proliferation and moderate apoptotic cells
primarily in the anterior part of the cross-linked stroma (Mencucci et al. 2010). Fur-
thermore, it has been well-documented that the collagen fibre diameter increased after
cross-linking therapy (Mencucci et al. 2010; Rao 2013). These morphological modifica-
tions lead to an increase in biomechanical stability.
Safety
UV irradiation would be expected to damage the endothelial layer and the crystalline
lens. However, riboflavin protects the endothelial cell and the crystalline lens by absorb-
ing a high percentage of the irradiation intensity within the stromal layer. Without the
riboflavin, the cornea will absorb nearly 30% of the UVA light, and 50% would be trans-
ferred to the crystalline lens (Wollensak et al. 2004a). However, with a stromal saturation
of 0.1% riboflavin, the UVA light irradiation of 3 mW/cm2 is significantly decreased by
95% to a non-cytotoxic irradiation of 0.15 mW/cm2 at the endothelium level, which leaves
the crystalline lens intact (Spoerl et al. 2007; Wollensak et al. 2004b). Based on a calcu-
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Figure 1.14: A schematic diagram showing the likely locations of riboflavin/UVA induced
cross-links. Three collagen fibrils are shown, each with an outer coating (the limit of which
is indicated with a dashed line) composed primarily of fibril-attached proteoglycans.
The colour key and corresponding coloured lines indicate the possible location(s) of
riboflavin/UVA induced cross-links. Image adapted from (Hayes et al. 2013).
lation of endothelial toxicity Spoerl and his colleagues recommended a minimum corneal
thickness of 400 µm to ensure safety if the endothelium during CXL (Hafezi et al. 2007;
Spoerl et al. 2007; Wollensak et al. 2003c). Therefore, pachymetry should be performed
preoperatively to confirm that the corneal thickness is appropriate for the cross-linking
procedure.
Although several studies showed a significant small increase in intra-ocular pressure
(about 1.45 mmHg) post-CXL treatment, this finding is not considered a safety concern
because the IOP seems to be overestimated because of the increased corneal rigidity
following treatment (Kymionis et al. 2010; Romppainen et al. 2007).
Inclusion criteria for CXL
CXL requires a minimum corneal thickness of 400 µm after removal of the epithelium,
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and an endothelial cell count of more than 3000 cell/mm2 to minimise the risk of endothelial
dysfunction (Wollensak et al. 2003a). However, in thin keratoconus corneas a hypotonic
riboflavin solution may be used to increase the pre-operative stromal thickness and permit
CXL to be performed (Hafezi et al. 2009).
Other pre-existing conditions would affect the CXL outcomes, such as central corneal
haze (Raiskup et al. 2009), infectious eye disease (Pollhammer et al. 2009), Herpes simplex
keratitis (Eberwein et al. 2008), severe dry eye (Vinciguerra et al. 2010), and keratometry
readings more than 58 D (Koller et al. 2009).
Patients with incisional refractive surgery like radial keratotomy or astigmatic ker-
atotomy are not recommended for treatment because of the possibility of rupture of the
incisions (Elbaz et al. 2014; Fuentes-Páez et al. 2012; Mazzotta et al. 2011; Yamamoto
et al. 1999). Concomitant autoimmune diseases, collagen vascular disease, pregnant or
nursing mothers and patients younger than 4 or over 35 years old are also excluded from
the CXL procedure (Hamada et al. 2017; Vinciguerra et al. 2010).
Clinical side effects
To date, multiple clinical trials and observational studies of CXL have been performed
which show no remarkable clinical side effects or complications (Caporossi et al. 2010;
Raiskup-Wolf et al. 2008; Wittig-Silva et al. 2014; Zotta et al. 2017). After surgery a mild
corneal edema is expected with a mild cotton-like hazy appearance within the corneal
stroma. This usually settles after four to six weeks without treatment and problems (Rao
2013).
There are consequences by not following the ideal patient selection; focal corneal
edema in a small area has been documented in one case only caused by a reduction in
endothelial cell count and focal endothelial haziness. This case was found to be below
the minimal recommended thickness. Fortunately, this eye returned to normal after one
week as a result of compensation of the migration of the surrounding endothelial cells,
and there was no further sign of endothelial damage (Wollensak 2010).
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Following CXL, most cases develop temporary stromal haze in the first few months
depending on the depth of treatment into the stroma as well as the amount of keratocyte
apoptosis (Mazzotta et al. 2008). A study evaluating the natural course after CXL demon-
strated that haze peaked at 1 month, plateaued between 1 month and 3 months and gradually
cleared between 3 and 12 months (Greenstein et al. 2010). Usually this corneal haze does
not need treatment but in some cases application of low dose topical steroid eye drops is
required (Dhawan et al. 2011). It is possible that the haze formation after CXL is a result of
back-scattered and reflected light (Connon et al. 2003), corresponding to the “demarcation
line” which Seiler and Hafezi (2006) have proposed to define the depth of cross-linked
areas. At the first month, the haze was more distinct in the central anterior stroma (Rehn-
man et al. 2011). This seems to be associated with immediate loss of keratocytes in the
corneal stroma (Dhaliwal et al. 2009; Wollensak et al. 2004b). This is supported by a con-
focal microscopy study that reported immediate keratocyte apoptosis post-CXL. Activated
keratocytes repopulated at 2 months and almost complete repopulation was observed at 6
months (Mazzotta et al. 2007). It is likely that these activated keratocytes are associated
with the development of corneal haze post-CXL (Dhawan et al. 2011; Greenstein et al.
2010). Moreover, stromal swelling pressure changes, proteoglycan-collagen interactions
and glycosaminoglycan hydration may also contribute to CXL-associated corneal haze
(Dohlman et al. 1962; Michelacci 2003; Wollensak et al. 2007).
The most common clinical disadvantages of the cross-linking involving epithelial
removal is light sensitivity, risk of infection, discomfort and pain in the first few days until
the epithelial layer is completely regenerated. Several case studies have documented that
keratitis may occur post-CXL a result of the presence of an epithelial defect (Kymionis
et al. 2007; Perez-Santonja et al. 2009; Pollhammer et al. 2009; Sharma et al. 2010). This
might present during the postoperative period rather than during the operation because
CXL can kill pathogens such as bacteria and fungi on the surface of the cornea (Tabibian
et al. 2014). A delay in re-epithelisation was also reported in a few cases, which required
corticosteroid medication during the period of epithelisation and bandage soft contact lens
wear. The corneal epithelium should recovery be completed within 24 hours and the eye
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should be perfectly healthy afterward (Wang et al. 2010).
Also, it has been noted that subepithelial stromal nerve fibres disappear post-operation.
Although re-innervation is evident a month later, complete restoration of corneal sensi-
tivity of the anterior subepithelial stroma was seen six months after the procedure (Rao
2013).
Modified protocols
Several methods have been proposed to eliminate some of the limitations of the
SCXL protocol, which requires the painful removal of the corneal epithelium, a prolonged
treatment time of one hour and is deemed unsuitable for the treatment of very thin corneas.
Some of the treatment modifications currently in use are described below:
• Trans-epithelial procedures
Epithelial debridement in the SCXL procedure may cause postoperative discomfort,
potential delay in epithelial healing, infection, and stromal haze. As a result, re-
searchers are investigating modifications to overcome the need for epithelial removal
and find a way of getting riboflavin across the intact epithelium and into the corneal
stroma to enable the cross-linking process to take place. Some of them used partial
epithelial disruption (Samaras et al. 2009), enhanced riboflavin solutions (Kissner
et al. 2010; Raiskup et al. 2012), iontophoresis, and intrastromal pockets delivery
(Kanellopoulos 2009).
i) Partial epithelial disruption
Hayes et al. showed that superficial epithelial trauma and tetracaine administration
alone were not adequate to allow the penetration of riboflavin into the corneal stroma
(Hayes et al. 2008). Insufficient stromal absorption of riboflavin may impede the
efficacy of the cross-linking process. In addition, a later study using spectropho-
tometry to indirectly measure stromal riboflavin absorption found that loosening the
epithelial tight junctions with an application of 20% alcohol solution for 40 seconds
or by puncturing the epithelium in a grid pattern also resulted in inadequate pene-
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tration of riboflavin into the corneal stroma. Both studies concluded that a complete
removal of the epithelium appears to be necessary to permit adequate riboflavin
absorption (Hayes et al. 2008; Samaras et al. 2009).
ii) Enhanced riboflavin solutions
On the other hand, a recent publication using the same grid pattern to partially
disrupt corneal epithelium with an enhanced riboflavin solution, Ricrolin TE (ri-
boflavin 0.1%, 15% dextran T500) (Sooft Italia S.p.A.), containing two chemi-
cal agents, trometamol (Tris-hydroxymethyl-aminometane) and sodium ethylenedi-
aminetetraacetic acid (EDTA), to facilitate passage of riboflavin into the corneal
stroma through an intact epithelium, demonstrated significant advantages in terms
of reduced pain, faster visual recovery, avoidance of the need for therapeutic con-
tact lens, and a reduction in infection-related complications and the risk of loss of
corneal transparency due to abnormal scarring processes (Alhamad et al. 2012). An-
other research group claimed it is essential to prepare the trans-epithelial riboflavin
dextran-free as dextran is a large molecule that hinders the penetration of riboflavin
through the intact epithelium. They also showed that adding benzalkoniumchloride
(BAC) facilitates trans-epithelial riboflavin stromal absorption (Kissner et al. 2010;
Raiskup et al. 2012). Moreover, hydroxypropyl methycellulose (HPMC) is usually
used as a riboflavin vehicle (Ramselaar et al. 1988). However, further laboratory
and clinical studies are required to evaluate the efficacy of this technique and to
compare it with the standard protocol with complete epithelial debridement both
with unenhanced and enhanced riboflavin.
iii) Intrastromal pockets delivery
Recently, a novel intrastromal delivery of riboflavin was introduced (Kanellopoulos
2009; Krueger et al. 2008). The aim of this technique was to reduce the compli-
cations associated with epithelial debridement by applying the riboflavin through a
semi-intact epithelium using femtosecond laser cut of 7 mm diameter at a corneal
depth of 100 µm (Kanellopoulos 2009). The riboflavin is injected directly into
Chapter: 1 36
Investigations into the effectiveness of new and existing corneal cross-linking therapies
the corneal stroma. This facilitates the diffusion of riboflavin and re-epithelization
recovery (Kanellopoulos 2009; Krueger et al. 2008). The first clinical case of the
intrastromal pockets delivery yielded promising results (Krueger et al. 2008). A lab-
oratory study has shown that the flat cornea and decline of the keratometry readings
was achieved within the 6 month follow-up of 10 rabbit eyes, however, the cornea
was uneven in all cases (Dong et al. 2011). Other experimental investigation on
riboflavin delivery via intrastromal channels measured the biomechanical strength
of the cornea post-treatment and revealed that the corneal rigidity in the channel
technique is similar to the standard epi-off protocol (Seiler et al. 2014). Further
laboratory and clinical investigations are essential to support this mode of CXL.
iv) Iontophoresis
Another method to be considered is iontophoretic delivery of riboflavin, which is a
non-invasive delivery system designed to transfer charged molecules throughout the
tissues to enhance the penetration. The system uses a low intensity electrical current
which flows across the intact epithelium and into the corneal stroma between a
negatively charged delivery electrode (located on the cornea) and a counter electrode
positioned on the patient’s forehead used to drive the riboflavin (Figure 1.15).
Experimental studies with riboflavin delivery by iontophoresis imbibition followed
by UVA irradiation determined that less tissue damage occurred and the stroma
remodelled safely (Cantemir et al. 2017; Cassagne et al. 2016; Lombardo et al.
2014; Mastropasqua et al. 2014; Vinciguerra et al. 2014a). Clinical studies with this
technique have demonstrated equivocal results with some suggesting similar efficacy
to SCXL (epi-off-CXL) (Bikbova et al. 2014; Buzzonetti et al. 2015; Vinciguerra
et al. 2014b), and others showing less pronounced effects (Bouheraoua et al. 2014;
Franch et al. 2015; Manetti et al. 2017).
Currently, there is no transepithelial cross-linking therapy that has been shown to
consistently achieve the same clinical effectiveness as SCXL and further investi-
gations are needed to develop an equally effective method to SCXL that does not
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required epithelial removal and is more comfortable for the patients.
Figure 1.15: Delivery riboflavin into the corneal stroma by iontophoretic using low
electrical current. Image reproduced from (Meek et al. 2013).
• Accelerated cross-linking
With the aim of reducing the procedure time and thereby improving patient comfort
and surgeon throughput, researchers theorised that based on the Bunsen-Roscoe
law of reciprocity (Bunsen et al. 1862), increasing the intensity and decreasing
the time of irradiation such that the total UV dose remained the same (at 5.4
J/cm2) would achieve the same therapeutic effect as SCXL (Krueger et al. 2014;
Schumacher et al. 2011). Consequently, second-generation CXL procedures have
been developed to increase the intensity for a shorter time using same level of
radiant exposure to accelerate the treatment. This new approach method is called
accelerated cross-linking (ACXL). An in vitro study has shown the biomechanical
properties of ACXL by increasing the illuminance intensity to 10 mW/cm2 and
reducing the exposure time to 9 minutes produces an equivalent increase in corneal
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stiffness to that gained using the SCXL (Schumacher et al. 2011). Wernli et al.
observed that the biomechanical stiffness of ex vivo porcine corneas treated with
irradiances between 3 mW/cm2 and 90 mW/cm2 and illumination times ranging
from 30 minutes to 1 minute, respectively. They found up to 45 mW/cm2 increased
in intensity was equivalent to SCXL, however, no statistically significant increase
in corneal strength could be obtained at higher levels of irradiance from 50 to 90
mW/cm2, which demonstrated the failure of the Bunsen-Roscoe reciprocity law at
very high intensities (Wernli et al. 2013).
Several studies evaluated the safety of ACXL, and showed no significant change in
endothelial cell density using confocal microscopy (Akcay et al. 2017; Kymionis et
al. 2014; Touboul et al. 2012); the results contrast with other reports which showed
a significant reduction in endothelial cell density using corneal specular microscopy
(Cinar et al. 2014; Cingu et al. 2014). These differences might be due to the different
microscopies used because the specular microscopy increased scattering and limited
imaging of the corneal endothelium in the presence of the usual post-CXL corneal
edema results in a reduction of the number of cells discernible; conversely, the use
of confocal microscopy permits corneal endothelium examination in the presence
of edema and haze (Kymionis et al. 2014).
• Treatment of thin corneas using Hypo-osmolar riboflavin solution
The standard protocol of CXL requires a corneal thickness of more than 400 µm
to be treated (Kymionis et al. 2012; Spoerl et al. 2007; Wollensak et al. 2003c).
Unfortunately, many patients with progressive keratoconus have a thinner cornea.
A promising method suggested by Hafezi et al. uses hypo-osmolar riboflavin
solution that does not contain dextran which thus induces stromal swelling and
consequently increases stromal thickness (Hafezi et al. 2009). The technique safely
allows treatment of thinner corneas, but the exact biomechanical effect may be
lower because the edematous state keeps the collagen fibers apart and may reduce
the cross-linking effect (Greenstein et al. 2011; Hafezi 2011).
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Hafezi et al. applied the modified protocol to 20 keratoconus patients and found
that clinically the amount of swelling showed distinct inter-individual variation (3
minutes to 20 minutes; 36 to 105 µm) (Hafezi et al. 2009). Another study including
thirty-two eyes of 29 patients revealed that the mean corneal thickness increase was
114.8 µm and showed a stability of the corneas one year after the cross-linking
procedure (Raiskup et al. 2011). Both studies successfully halted the progression of
keratoconus in all patients. However, CXL failure using a hypo-osmolar riboflavin
solution has been reported in an extremely thin cornea, which suggests that a
minimum preoperative stromal thickness of 330 µm is required for a successful
CXL (Hafezi 2011).
• Accelerated collagen cross-linking with pulsed light (p-ACXL)
Oxygen has a crucial role for the photochemical reaction in CXL, and is thought
to be a limiting factor in the cross-linking process. Researchers found that it
is theoretically likely that increasing UVA intensity in case of ACXL will not
permit sufficient time for oxygen to diffuse and not effectively contribute in the
photochemical type I and II reactions, which reduce the performance of ACXL
(Richoz et al. 2013). Hence, pulsed light accelerated CXL (p-ACXL) of a cycle of
(1 second on/ 1 second off) was introduced.
The modifications are based primarily on current understanding of the photochemi-
cal kinetics of UVA exposure and the theoretical principles of the Bunsen–Roscoe’s
law of reciprocity (Bunsen et al. 1862), which states that a certain biological effect is
directly proportional to the total energy dose regardless of the administered regime.
Nonetheless, as has been elucidated with other photochemical reactions (Potapenko
et al. 1991), this law may only be applicable within a certain dose range and has
to be individually defined for each reaction. Recent analysis of the photochemical
kinetics observed that the UVA illumination produced a rapid depletion of oxygen in
a riboflavin saturated cornea and turning-off the UV light gives rise to replenishment
of the oxygen to its original level within 3 to 4 minutes (Figure 1.16) (Kamaev et al.
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2012). This study also showed that the oxygen concentration dropped dramatically
to zero after approximately 5 second of ACXL compared to 10-15 on SCXL (Figure
1.17). In theory, pulsing the UVA illumination during CXL treatment may start over
the photochemical reactions producing an additional oxygen concentration that al-
lows more singlet oxygen release and the formation of “molecular bridges” between
and within collagen fibres (Spoerl et al. 1998).
Figure 1.16: Turning-off the UV light gives rise to replenishment of the oxygen to its
original level within 3 to 4 minutes. Image reproduced from (Kamaev et al. 2012)
with permission from the copyright holder, the Association for Research in Vision and
Ophthalmology (License No: 4286520062380).
Several clinical investigations emphasised that the p-ACXL treatment yields a deeper
demarcation line than the SCXL protocols (Mazzotta et al. 2014; Moramarco et al.
2015; Peyman et al. 2016). The demarcation line is defined as a biomicroscopically
detectable line seen in the slit-lamp, which marks the transition zone between the
depth at which keratocytes disappear in the cross-linked anterior corneal stroma
region and the untreated posterior corneal stroma region. Although many CXL
experts use it as an indication of CXL depth, it is as yet uncertain whether the line
represents a region of wound healing or whether it truly represents the effective
depth of cross-linking (Seiler et al. 2006). This cell apoptosis causes oxidative
stress damaged and produces a toxic nitric oxide molecule (Yuksel et al. 2016). A
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Figure 1.17: The oxygen concentration dropped dramatically to zero after approximately
5 second of ACXL compared to 10-15 on SCXL. Image reproduced from (Kamaev et al.
2012) with permission from the copyright holder, the Association for Research in Vision
and Ophthalmology (License No: 4270240029745).
biochemical study advocated that the cornea treated with p-ACXL showed a less
nitric oxide levels in aqueous humor than SCXL, which means p-ACXL with 30
mW/cm2 for 3 minutes (1 sec on / 1 sec off) seems to be a safer treatment (Yuksel
et al. 2016). However, pulsed UVA light with 30 mW/cm2 for 8 min revealed an
inferior biomechanical effect than SCXL (Kling et al. 2017). Further investigation
is essential to evaluate the strength and stability of the corneas for halting the
progression of keratoconus after the p-ACXL method.
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1.4 Aims and objectives
The three main objectives of this project are to:
• Assess the effectiveness of existing epithelium-intact and trans-epithelial riboflavin/UVA
cross-linking protocols, in terms of their ability to increase the strength and enzy-
matic resistance of the cornea, and examine the impact of changes in UVA intensity,
UVA dosage, UVA delivery mode (pulsed vs continuous) and riboflavin solution.
• Develop improved methods of transepithelial cross-linking that are equally effective
to that of SCXL.
• Characterise changes in corneal ultrastructure following photodynamic cross-linking
therapy in order to gain a better understanding of the mechanism by which such
therapies stiffen the cornea.
Graphical abstract was included on Appendix I for more illustration.
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2.1 Overview
This chapter describes materials and methods that are common to many of the following
chapters. Any subtle changes to these general methods are described in the individual
chapters.
2.2 Corneal pachymetry
The corneal thickness of both in vivo and ex vivo eyes was measured using either a Pa-
chette2™ Ultrasonic Pachymeter (DGH Technology, Exton, USA) or a Tomey ultrasound
pachymeter (Tomey Corporation, Nuremberg, Germany). The pachymeter probe was
placed perpendicular to the centre of the cornea and the mean thickness (based on 8 - 25
consecutive readings) was recorded.
2.3 Enzymatic digestion resistance and dry weight mea-
surements
Three enzymes are typically part of the enzyme panel used to evaluate the efficacy of
a cross-linking procedure, these are collagenase, pepsin and trypsin (Charulatha et al.
1997). Spoerl et al. examined the resistance of corneal disks to all three enzymes and
found that SCXL significantly increased the resistance of the cornea to digestion by pepsin
and collagenase (Spoerl et al. 2004). Most recent studies have used collagenase enzyme
to investigate the biochemical resistance of the cornea following different CXL protocols
(Fadlallah et al. 2016; Kanellopoulos et al. 2016; Zhu et al. 2017). However, as it is
thought that CXL might cause the formation of cross-links not only at the collagen fibril
surface but also in the protein network surrounding the collagen (Hayes et al. 2013),
pepsin was selected in preference to collagenase for the studies presented in this thesis. As
pepsin is a non-specific enzyme it can provide a better assessment of the effectiveness of
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different cross-linking procedures in terms of their ability to increase the overall enzymatic
resistance of the tissue.
Previous enzyme digest studies have shown that changes in corneal thickness are
not a reliable indicator of the rate of enzymatic digestion due to the considerable stromal
swelling that occurs in the vertical direction within 24 hours of immersion in pepsin digest
solution (Spoerl et al. 2004). As the diameter of the anterior surface of each corneal disk is
unaffected by changes in stromal hydration (Spoerl et al. 2004), this parameter was used to
monitor the rate of enzymatic digestion. Measurements of anterior surface diameter were
made using an electronic digital caliper (Clarke International, model CM145 4500360,
Epping, Essex, England) at 24 hourly intervals until complete digestion had occurred.
Since the diameter was found to vary slightly between different meridians of an individual
specimen, the average of the major axis and minor axis diameter of each corneal disk
was recorded at each time point and statistically evaluated. The definition of ‘complete
digestion’ was the point at which the specimen could no longer be distinguished from
the surrounding pepsin solution even under microscopical examination (light microscope,
Nikon SMZ1000 type 104, Japan). Calculations based on the sample size used (usually 6
per treatment group) and the standard deviation of the diameter measurements confirmed
that the sensitivity of the technique was such that differences between groups (in terms
of the time taken for complete digestion) of less than 1 day could not be detected by this
method.
In order to further assess the effect of each treatment on enzymatic resistance, five
corneal disks from each group were removed from the pepsin digest solution midway
through the digestion process (after approximately 12 days of digestion). These samples
were then placed in a 60◦C oven until a constant dry weight was reached. Measurement
of the average corneal dry weight for each treatment group, which represents the mass of
undigested tissue, allowsmore subtle differences between treatment groups to be identified.
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2.4 Cross-linking using illumination system
2.4.1 The standard Riboflavin/UVA cross-linking protocol
The corneal epitheliumwas completely removed from enucleated porcine eyes. Riboflavin
(vitamin B2) (0.1% solution 10 mg riboflavin-5-phosphate in 10 ml dextran-T-500 20%
solution) was applied to the corneal surface 30 minutes before irradiation and at 5 minute
interval during a 30 minute exposure to UVA light (Wollensak et al. 2003). The 30
minutes exposure to 370 nm UVA light with an irradiance of 3 mW/cm2 resulted in a total
energy dose of 5.4 J/cm2. The cross-linking device (CCL-365 Vario cross-linking system,
Peschke Trade GmbH) was positioned at a working distance of 5 cm above the cornea to
allow the UVA beam to be focussed on the central 9 mm of the cornea (Figure 2.1).
Figure 2.1: Ex-vivo porcine eye was exposed to UVA irradiation using (CCL-365 Vario™
cross-linking system Peschkmed, Huenenberg, Switzerland).
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2.4.2 Modifications to the standard cross-linking protocol
In this thesis several modified cross-linking protocols were used, and these are summarised
in Table 2.1. Prior to cross-linking, riboflavin was applied to the de-epithelialised cornea
in either a drop-wise manner or via a 9 mm diameter corneal annular suction ring (Kestrel
Ophthalmics Ltd., Broadstone, Dorset, UK) (Figure 2.2). In the majority of cases, UVA
light was provided by a CCL-365 Vario™ cross-linking system (Peschkmed, Huenenberg,
Switzerland) (Figure 2.1). However, in studies involving high-intensity, pulsed UVA
light (Chapter 5), a Phoenix CXL System was used (Peschke trade GmbH, Huenenberg,
Switzerland). Further details relating to specific cross-linking techniques are provided in
the methods section of each chapter.
Figure 2.2: The application of riboflavin through a corneal annular suction rings.
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2.5 Calculation of corneal hydration
Measurement of corneal hydration was required as part of the extensometry and SAXS
studies. As collagen interfibrillar spacing (IFS) is known to be highly sensitive to the
hydration of the tissue, it is necessary to know the water content of the tissue at the time of
x-ray data collection (Meek et al. 1991). To calculate an average wet weight of the tissue
during data collection, the sample was weighed before and after data collection. Then, to
calculate the dry weight, the sample was placed in an oven at 60◦C for at least three days
until a constant dry weight was obtained. Corneal hydration (H) was calculated using the
following equation (Equation 2.1):
H = (Wettweightt−tDrytweight)
Dry∆weight
. Equationt(2.1)
where:
H = Corneal hydration
Wet weight = Original corneal weight
Dry weight = Corneal weight post-dehydration in 60◦C oven
after removal of all water content
2.6 Extensometry
2.6.1 Corneal strip preparation
Using a custom-made cutter, comprising two parallel razor blades, 5 mm-wide strips of
tissue were cut from the endothelial side along the vertical meridian (superior-inferior)
(Figure 2.3). The length of the corneal strip was 12 mm plus 2 mm of sclera on both ends.
The corneal strips were used for biomechanical testing studies immediately after being
cut.
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Figure 2.3: Cutting corneal strips for biomechanical testing. A double-blade adjustable
strip cutting tool was used to cut 5 mm wide corneal strips from the centre of each cornea.
2.6.2 Extensometer set-up
All stress–strain measurements were performed on a commercial extensometer (Lloyd
Instruments Ltd., UK) with a 20 N or 10 N load cell in Chapter 3 and 6, respectively. The
steps involved in setting up and carrying out a test are illustrated in (Figure 2.4). Each
tensile specimen was clamped to the extensometer arms using serrated grips. Prior to
clamping, a guide was used to ensure the extensometer arms were separated by precisely
6 mm, and this distance is referred to as the gauge length. Throughout the test the sample
is surrounded by a Perspex tube containing a ball of cotton wool soaked in water, in
order to maintain hydration (for details see the preliminary study of the optimal hydration
Appendix H) (Figure 2.4).
2.6.3 Biomechanical data analysis
Stress–strain measurements
Using a force of 1 N, three precondition cycles were performed to align the collagen fibrils
within the tissue. Hoeltzel et al. found that three precondition cycles were adequate to
produce constant results (Hoeltzel et al. 1992). Prior to testing, values for the speed, gauge
length, cross-sectional area and break point were entered into the system. The Nexygen 4.1
software package (Lloyd Instruments Ltd., UK) recorded values for load and extension,
and calculated the stress and percentage strain for each corneal strip tested. After the test
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Figure 2.4: Extensometer set-up. (a) The strip was positioned in the middle of the guide.
(b and c) Then, the grips were attached firmly; the grips were serrated to reduce the
possibility of strip slippage at the grip. (d - f) The guide was removed, and the holder
was placed in a plastic tube that contained a wet cotton pad underneath the specimen to
maintain hydration.
the data was exported from Nexygen 4.1, transferred to Excel and analysed in MATLAB.
In MATLAB, the cross-sectional area was calculated by inserting the corneal thick-
ness measurement and the breadth for each sample by the equation 2.2:
A = Thickness (m) × Breadth (m) T Equation (2.2)
where:
A = Area (m2)
Thickness = Corneal thickness measured by pachymetry (µm) × 106
Breadth = Width of corneal strip (mm) ×103
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The raw data were loading from the extracted Excel file for each strip, the stress and
strain values for each sample had been calculated as equation 2.3, 2.4:
σ = F (N) / A (m2) TTTT Equation (2.3)
where:
σ = Stress (N/m2 or Pa)
F = Force (N)
A = Area (m2)
ε = ∆l
l◦
= l−l◦
l◦
T Equation (2.4)
where:
ε = Strain (mm/mm), Strain (%) = (mm/mm) × 100
∆l = Change in length (mm) (Extension)
l◦ = Original length (mm) (Gauge length)
According to Schumacher et al. the stress–strain relationship of connective tissue
can be divided into the three regions: (1) an area of nonlinear elasticity, (2) a region of
linear elastic behaviour, and (3) a region where irreversible plastic deformation occurs
(Schumacher et al. 2011) (Figure 2.5). The region of low-strain nonlinear elasticity (from
2% to 8% strain) was the area of particular interest for examining the effects of various
cross-linking protocols on the biomechanical properties of the tissue as they most closely
resemble the level of strain experienced in vivo. The stress–strain curve was fitted to an
exponential function in this region (Elsheikh et al. 2008) as equation 2.5:
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σ = A(eBε -1) TTTT Equation (2.5)
where:
σ = Stress
A,B = Constants
e = Exponential
ε = Strain
Figure 2.5: Three different elasticity regions on the stress-stain curve.
In order to produce an average stress-strain curve for each treatment group, the mean
of A and B values was calculated to plot an individual curve within a particular group.
By entering corresponding known values of strain, the equations were utilized to find
unknown values of stress i.e. 0.02, 0.04 and onwards up to 0.1. The calculated estimations
of stress were then used to find the mean value of stress for a given strain within the
treatment group, and plotted against the corresponding strain values to deliver an average
stress-strain curve (see Appendix F and G). Examples of raw and fitted curves for single
Chapter: 2 55
Investigations into the effectiveness of new and existing corneal cross-linking therapies
samples are plotted in Figure 2.6. This strategy was repeated for all treatment groups and
correlation diagrams were plotted (see Appendix F and G). In this study, the region of
interest was at lower strains, near physiological levels. Consequently, the data was isolated
in the region of 0 to 0.10 (0 % - 10 %) strain (see Figure 3.8, and Figure 6.5 in Chapter 3
and 6).
Figure 2.6: Examples of raw and fitted curves for four corneal tissue strips.
Young’s modulus
Young’s modulus reflects the characteristics of a linearly elastic material experiencing
tension. Accordingly, it is a helpful property to look at when attempting to survey the
stiffness of a sample. If the material is non-linear, Young’s modulus is more accurately
referred to as the tangent modulus and is characterized as the slope of tangent in the
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stress-strain curve at any point. The modulus at a particular strain can be calculated by
finding the slope at that specific point on the curve.
Tangent modulus was calculated for 2%, 4%, 6% and 8% strain as a gradient of the
stress–strain curve as equation 2.6:
E =
∆σ
∆ε
Equation (2.6)
where:
E = Tangent modulus
∆σ = Difference between two stress points, e.g. (σ2 − σ1)
∆ε = Difference between two stress points, e.g. (ε2 − ε1)
2.7 X-ray diffraction techniques
X-ray scattering techniques can be utilised to measure structural quantitative parameters
such as collagen fibril diameter and inter-fibrillar spacing (Meek et al. 2009, 2001).
Contrary to electron microscopy, which requires extensive tissue processing preparation
that results in shrinkage of the tissue, x-ray scattering data can be obtained from full-
thickness of corneal tissue close to its natural hydration state.
All x-ray scattering data presented in this thesis were collected at the UK synchrotron
radiation source (Diamond Light Source, Didcot, UK). At the synchrotron, electrons are
accelerated to near the speed of light inside a circular storage ring which results in the
emission of radiation at all wavelengths, including intense x-rays. The light, in our case
the x-rays, generated from this process is directed into laboratories, which are commonly
referred to as ‘beam-lines’. Samples placed in the line of the x-ray beam cause the x-rays
to be scattered at various angles. Small-angle x-ray scattering beam-lines (such as I22 at
the Diamond Light Source) are set up in such a way that x-rays scattered at small-angles
(less than 2 degrees) are recorded as an x-ray scatter pattern on a detector positioned
several metres behind the specimen. In addition to the scattered x-rays, a proportion of
the incident x-rays are absorbed by the specimen itself and others pass directly through
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the sample and are absorbed by a lead backstop.
If the sample under investigation has a structure with perfect or near- perfect order,
such as a crystal, the scattered x-rays will interfere to produce diffractionmaxima known as
x-ray reflections. The directions of constructive interference are obtained fromBragg’s law
which states that, when parallel x-rays are incident on parallel lattice planes in a crystal,
each atom acts as a scattering centre and produces a secondary wave. In particular,
the angles of both incident and reflected rays (θ) will be equal from any point of these
crystal lattice planes (Figure 2.7). Constructive interference between the reflected waves
occurs when the optical path difference between waves reflected from successive planes,
which can be determined geometrically, equals an integral number of wavelengths. This
condition is described by the Bragg equation (Equation 2.7):
n λ = 2d sinθ Equation (2.7)
where:
n = an integer numbers of the order of diffraction
d = Distance between the crystal lattice planes
λ = Wavelength of an x-ray beam incident to the crystal planes
θ = Bragg angle
Less organised structures, such as the cornea, produce more diffuse and fewer in-
terference maxima than the true diffraction maxima obtained from crystals but Bragg’s
law still applies. However, wholly disorganized structure will produce diffuse scattering,
which is so-called background scatter (Meek et al. 2001).
When corneal tissue is placed in an x-ray beam, x-rays are scattered parallel to the
fibril axis of the constituent collagen to produce a meridional pattern, and at right angles
to the fibril axis to form an equatorial pattern (Figure 2.8). The cornea comprises several
hundred lamellae and collagen fibrils run in all directions, so when x-rays are passed
through different orientations of lamellae, both the meridional and equatorial patterns will
result as a series of concentric circles (Meek et al. 2001).
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Figure 2.7: Bragg’s law states that when a beam of x-rays is incident on a pair of parallel
lattice planes in a crystal, each atom acts as a scattering centre and produces a secondary
wave. For a given angle of incidence (θ), constructive interference will occur if the path
length between adjacent reflectedwaves (2dsinθ) equals an integral number of wavelengths
(nλ).
2.7.1 Small-angle x-ray scattering
Experimental set-up
Cornea can generate a series of small-angle of meridional x-ray patterns, arising from the
axial D-periodicity of collagen (65 nm in cornea – (Marchini et al. 1986)) and additional
small-angle equatorial x-ray patterns, as a result of the uniform fibril diameters and the
regular spacing of collagen fibrils. These additional equatorial peaks give the cornea a
distinctive feature compared with most other connective tissues (Boote et al. 2003; Meek
et al. 2009). SAXS data collection as elaborated here was applied in Chapter 7. The cornea
was gently thawed, and tissue samples were trephined from the centre of each cornea to
obtain a 6 mm full-tissue-thickness biopsy. Samples were immediately wrapped in a
single layer of ClingfilmT M to minimise tissue dehydration during exposure to the x-ray
beam. Samples were then positioned in a polymethyl methacrylate (Perspex; theplastic-
shop.co.uk, Coventry, UK) sample cell with transparent Mylar windows (DuPont-Teijin,
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Figure 2.8: A schematic diagram representing fibres placed vertically in an x-ray beam. X-
rays that are scattered parallel to fibril axis will produce ameridional pattern resulting from
the regular periodicity of the collagen molecular packing along the fibril axis. Meanwhile,
at right angles to the fibril axis the x-ray scatter forms an equatorial pattern resulting from
the uniform diameter and quasi-regular spacing of the collagen fibrils. Image reproduced
from (Meek et al. 2001) with permission from the copyright holder, Elsevier. (License
No: 4274230442872).
Middlesbrough, UK) (Figure 2.9). This was mounted on a Perspex cell holder in path
of the x-ray beam such that the beam was perpendicular to the plane of the cornea and
therefore passed through the whole cornea. The x-ray wavelength was λ = 0.8 nm and
the beam cross-section measured 180 × 300 µm. The specimen-to-detector distance was
set to 5.8 m to collect the SAXS signal. A lead backstop was placed between cornea and
detector at the end of camera tube to block the straight-through beam.
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Figure 2.9: Samples were mounted in an air-tight Perspex cell with transparent Mylar
windows. During the set-up procedure, green x-ray sensitive paper was used to locate the
point within the cell through which the x-ray beam passed. By placing the sensitive paper
over the sample holder, it was then possible to correctly position each sample in the cell.
Determining the x-ray beam location and sample position
Before data collection, localizing the precise position of x-ray beam with respect to the
specimen was achieved by exposing a piece of x-ray sensitive paper, which was mounted
over the front of the specimen cell, to the x-ray beam for 10 seconds. A black dot on the
green x-ray sensitive paper identified the point through which the x-ray beam had passed.
By temporarily placing the exposed sensitive paper over the sample holder it was then
possible to correctly position each sample within the cell (Figure 2.9). The cornea was
meticulously situated over the x-ray mark on the green paper to guarantee that the x-ray
beam passed through the centre of the corneal disk (epithelium facing the x-ray beam) at
the desired location according to the necessities of the investigation; the green paper was
then removed. The sample holder was mounted on a motorised stage that could be moved
in micron steps in a horizontal and vertical direction.
Initial sample alignment was determined by calibration of a microscope viewer with
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the x-ray beam position and the computerised stage. To ensure an acceptable signal-to-
noise ratio, an appropriate x-ray exposure time was required to ensure the devices were
properly aligned and that the signalwas strong enough for following analysis. Furthermore,
the initial intensity of the x-ray beam affects the exposure time used, a higher intensity
beam enabling a shorter exposure while sustaining an adequate signal-to-noise ratio. An
exposure time of 0.5 sec was set up to be the most suitable for the samples. SAXS
beamline calibration was carried out using the 58.380 Å peak associated with the first
order reflection of powdered silver behanate. The positions of the peak from the centre
of the x-ray scatter pattern differs depending on the specimen-detector distance, thus this
calibration is essential for every set of experiments conducted on the SAXS beamline.
Following data collection in Didcot, UK, the x-ray patterns were electronically analysed
in Cardiff University.
SAXS data analysis
The x-ray data were recorded in a BSL file format, which saves the single images as a
series of frames within one large file. For processing, the BSL files were converted to TIFF
format using Fit2D data analysis program (ESRF, Grenoble, France). SAXS data (in TIFF
format) were analysed using MATLAB (MathsWork, UK) with integrated SAXS4COLL
software. The SAXS4COLL software was produced by the Structural Biophysics Group
at Cardiff University to allow rapid automated analysis of data from different SAXS
beamlines (Abass et al. 2017).
A brief description of the SAXS data analysis is given below, for more detail the
reader is referred to the guidelines in Abass et al. (2017). The centre of the SAXS pattern
was determined using a diffraction pattern acquired from a calibrant of powdered silver
behanate, by selecting seven points manually around the circumference of one of the
diffraction rings (Figure 2.11a). The x and y coordinates of the centre of the pattern were
recorded. The corneal patterns were then calibrated using the 5.838 nm peak associated
with the first order reflection of powdered silver behanate. This calibrated pixel value was
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Figure 2.10: The small-angle x-ray scattering experimental set-up used to image rabbit
corneas at the Diamond synchrotron. Top: specimen cell mounted in the cell holder.
Bottom right: Side view showing path of the x-rays as they pass through the specimen.
Bottom left: View of the camera tube from the specimen (front) to the detector.
input into the calibration input box alongside the 5.838 nm first order, which was stored
and used to automatically calculate the sample collagen peak positions (Abass et al. 2017).
The interference function (IF) and the fibril transform (FT) peaks arise from the
spacing and diameter of collagen fibrils, respectively. To determine these two peaks, the
background scatter from non-collagenous components of the cornea needed to be removed
from the total intensity of the SAXS pattern from the cornea, which consists of IF, FT
and the background (Meek et al. 2001). The software allows removal of the background
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Figure 2.11: Pre-processing the data on SAXS4COLL involved centring and calibrating
the image. (a) The image was centred using the diffraction pattern acquired from powdered
silver behanate, by selecting seven points manually on the circumference of one of the
diffraction rings. (b) The patterns were then calibrated against the position of the first-
order reflection (in pixels) of a known calibrant such as silver behanate or as shown here,
hydrated rat tail tendon. Image reproduced from (Abass et al. 2017).
scatter by plotting the data logarithmically and interactively fitting a straight line below
the data as precisely as possible by selecting three points Figure 2.12.
Figure 2.12: Removing background scatter by interactively fitting a straight line below the
data as precisely as possible by selecting three points.
After background removal, the interference function (IF) could be identified as shown
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in Figure 2.13a. The position of the IF peak was located by clicking close to the peak (Fig-
ure 2.13a), then, the software detects and records the closest peakmaximum automatically.
The SAXS4COLL automatically converts the position of this peak into the interfibrillar
Bragg spacing using Bragg’s law, and calibrates the Bragg spacing (d) against the position
of the first order reflection (pixels) of the silver behenate. The Bragg spacing is determined
after first calculating the value of θ, by applying the known parameters of silver behenate
to equation 2.7: peak position = 5.838 nm, n = 1, λ = 0.8 nm.
The fibril transform (FT) is a Bessel function that contains a wide, low peak near
the third order of collagen. To calculate the average collagen fibril diameter, the screen
displays sliding bars that generate Bessel functions from cylinders (representing collagen
fibrils) - sliding the bars changes the diameter and scattering intensity of the cylinders.
By sliding the bars it was thus possible to stop at a diameter that aligned the position
and the intensity of the peak in the calculated Bessel function with the visible peak in the
x-ray pattern (Figure 2.13b). As before, the program then calibrated this peak position
and converted it to a fibril diameter in nanometres.
Figure 2.13: Detecting the collagen peaks. (a) The interfibrillar peak IF (green circle) was
located by clicking as close to the peak as possible. (b) The fibril transform (FT) contains a
wide, low peak near the third order of collagen (circled). To calculate the average collagen
fibril diameter, it was necessary to manually slide the bars to fit the calculated Bessel
function (red line) to the experimental scatter (blue line).
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2.8 General preparation for TEM analysis
Prior to transmission electron microscope (TEM) analysis, the cross-linking treatments
were carried out in our collaborator’s laboratory at the Weizmann Institute of Science in
Rehovot as had been agreed. The Methods section of Chapter 7 explains in detail how the
treatment was performed. After treatment, corneas were dissected out from the eye globes
with a 2 - 3 mm scleral rim attached to preserve specimen structure and were placed into
a fixative solution containing 2.5% glutaraldehyde and 2% paraformaldehyde (PFA) in
0.1M Sorensen phosphate buffer (pH 7.2 - 7.4) for two hours to maintain the tissue (Step
1, Figure 2.14). They were then stored in 0.2M Sodium cacodylate buffer (pH 7.4) and
transported to Cardiff University, where electron microscopy processing was performed.
The preparation of all fixative was handled according to COSHH.
2.8.1 Fixation and staining
Corneas were washed and placed in 0.1M Sorensen phosphate buffer (pH 7.2 - 7.4)
overnight at 4 ◦C. The following day, the corneal tissue was cut into segments (Step 2,
Figure 2.14). Corneal tissue was then post-fixed in 1% osmium tetroxide in 0.1M Sorensen
phosphate buffer for one hour and rinsed three times for five minutes with distilled water
(DW). Samples were then en-block stained in 0.5% aqueous uranyl acetate (UA) for a
further one hour in the dark under foil as UA is light sensitive (Step 3-4, Figure 2.14).
2.8.2 Dehydration and resin embedding
Corneal specimens were then dehydrated through an ethanol series at the following con-
centrations: 70%, 90%, 100% (2×) each for 15min (Step 5, Figure 2.14). This dehydration
step is necessary to allow for the infiltration of tissue with epoxy resin that is non-water-
soluble; this is essential for adequately sectioning the block, otherwise, polymerized blocks
have a rubber-like texture (Dykstra 2012).
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Table 2.2: Resin mixture used to embed corneal tissue.
Resin Component Volume (ml)
Araldite monomer CY212 14
DDSA hardener 16
BDMA accelerator 0.6
Following dehydration, specimens were placed into propylene oxide (2×) for 15 min
(Step 6, Figure 2.14), to remove any remaining ethanol. Specimens were then placed
in a mixture of equivalent proportions of araldite resin and propylene oxide for one
hour. This provides an intermediary step between highly volatile propylene oxide and the
viscous resin (Step 7, Figure 2.14). Finally, the corneal tissue was embedded in araldite
resin into six steps (Step 8, Figure 2.14), which comprised the following components:
Araldite monomer CY212, dodecenyl succinic anhydride (DDSA) hardener, and benzyl
dimethylamine (BDMA) accelerator in proportions according to the procedure established
in our laboratory (Table 2.2). Adding DDSA hardener and BDMA accelerator to the
Araldite monomer avoid an overly brittle block and speed the polymerization process,
respectively (Hayat 2000). The resin infiltration process was carried out over two days
with three changes of fresh resin per day at three hourly intervals - the tops were left off
the specimen vials which were placed in a rotator in a fume hood at room temperature.
Specimens were then placed into embedding moulds and orientated so that the central
cornea produced full thickness transverse cross sections of the tissue. Polymerisation
of the resin blocks was carried out at 60◦C in an oven for 24 hours (Step 9, Figure
2.14). The polymerised resin blocks were then ready for ultrathin section collection on a
Reichert-Jung Ultracut E (UCE) ultramicrotome (Optische Werke AG, Wien, Austria).
2.8.3 Sectioning and positive staining
Resin-embedded sample blocks were fixed into a UCE ultramicrotome specimen chuck.
The resin block was then carefully trimmed with a razor blade to reveal the tissue. A
small trapezoid shape block face was carefully created by removing excess resin around
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Figure 2.14: Specimen processing steps for transmission electron microscopy. The vial
tops on step 5-8 were removed.
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the tissue using a razor blade (Step 10, Figure 2.14). The block face was then polished
using the UCE by rocking the blockface back and forth over a glass knife-edge until it was
sufficiently smooth and reflective (Step 11, Figure 2.14)
Semi-thin sections (approximately 0.25 µm in thickness) were then taken using the
UCE ultramicrotome to identify the exact area for TEM ultrastructural analysis using a
glass knife made on a Leica EM KMR2 (Leica, Austria). The sections were collected
by wire loop from a small water reservoir which was attached to the glass knife. Semi-
thin sections were then transferred onto a droplet of water on a microscope slide. After
evaporating the water droplet from the slide on a hot plate, the section was stained with
a filtered solution of 1% toluidine blue on the hot plate for 1 minute, then washed with
DW to remove any excess stain. The sections were then observed under light microscopy
to identify the exact region of interest which was the full thickness of the central cornea
showing all the corneal layers.
The surface of the block was trimmed further to a smaller trapezoid containing the
exact region of interest. A diamond knife was then used to cut ultrathin ≈90 nm thick
sections on the UCE for TEM analysis. The ultramicrotomewas set to an automatic cutting
speed of 1 mm/min and a 90 nm section thickness was selected ribbons of sections with
silver and gold interference colours indicating they were ≈ 70 - 90 nm thick were collected
on the surface of the diamond knife water reservoir (Step 12, Figure 2.14). The ribbon
sections were then stretched using chloroform (Figure 2.15). This stretching is necessary
to decompress the sections after cutting on the ultramicrotome. Ultrathin sections (3 - 4)
were separated from the ribbons using an eyelash. These were then collected on either 3
mm 300 hex copper grids or on Pioloform support film 3 mm copper 2×1 mm slot grids.
Contrast enhancement with uranyl acetate and Reynolds lead citrate was carried out
for prior to transmission electron microscope imaging. These positive staining solutions
were all centrifuged at 14,500 × for 5 min and filtered with a 0.2 µm syringe filter, in
order to remove any particulates which could contaminate the sections prior to use. At
room temperature, the grids were placed sample side down onto the surface of 25 µm
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Figure 2.15: A diamond knife was used to obtain ultrathin sections on a UCE ultrami-
crotome, showing mostly silver and few golden ribbon of sections floating on the water
surface.
drops of the stain, placed on parafilm or support film over filter paper. First, samples
were stained for 20 minutes with 2% aqueous uranyl acetate, a brown opaque cover was
placed over the samples to prevent any light from reacting with the light sensitive UA
stain. Next, the samples were stained with Reynolds lead citrate for 7 minutes. NaOH
pellets were positioned around the drops to reduce carbon dioxide reacting with the lead
citrate which can form electron dense precipitate contamination on the sections. Between
the two staining steps, the grids were washed by dipping the grid 20 times each in four
cups containing filtered DW. The grids were then dried overnight on filter paper and were
then ready for TEM analysis.
2.8.4 TEM Imaging
Grids were placed into a Transmission Electron Microscope (TEM) specimen holder
which was then inserted into the TEM via the specimen port of the TEM (Figure 2.16).
Electron microscopy was carried out on a Jeol 1010 transmission electron microscope
(Jeol UK, Herts, UK), operating at 80 keV. Images were taken in Gatan imaging software
(Gatan, Inc., Abingdon, UK) in gatan (.dm3) format, then converted to TIFF (.tif) format
Chapter: 2 70
Investigations into the effectiveness of new and existing corneal cross-linking therapies
to facilitate using these images in this thesis, Image J/Fiji program, publications, and
presentations.
Figure 2.16: JEOL 1010 Transmission electron microscope. Grids were placed on speci-
men holder then into specimen port on Transmission Electron Microscope (TEM).
2.8.5 Image analysis
Sections 60 – 70 nm thick were collected as mentioned in section 8.3 to provide the
minimum interference between lamella layers for better resolution of the image. The
TEM images of a positively stained rabbit corneal collagen fibril obtained were digitised
and displayed in 2D Viewer on a PC. Micrographs from cross-linking treatments and
untreated corneas were processed with Image J/Fiji software ((Abramoff et al. 2004);
https://imagej.nih.gov/ij/ accessed 22 November 2017) for analysing the fibril diameter
and stain intensity in the anterior and posterior stroma (see Chapter 7). Image J could be
provided with Fiji script editor with many bundled plugins, which was used in the standard
scientific image analysis. The Image J/Fiji software could display, edit, analyse, process,
save and print 8-bit, 16-bit and 32-bit binary images in grey or colour images. In this study
the standard 8 bit grey images were used. The Image J/Fiji software were used to perform
basic image processing for fibril diameter analysis and to create linear profile plots of the
distribution of stain intensity along the axis of positively stained collagen fibrils from high
Chapter: 2 71
Investigations into the effectiveness of new and existing corneal cross-linking therapies
magnification micrographs (×20,000 - ×30,000).
Fibril diameter analysis
Image J/Fiji software was used to analyse the parts of the micrographs where the collagen
fibrils were cut in cross-section, to determine the fibril diameter. First, the scale bar of
the dataset was calibrated to 100 nm : 303 pixel. Next, the circular Fibril perimeters
were marked manually with a computer mouse and measured with the help of the Image
J/Fiji program. Only clearly defined borders of high contrast were marked and used in
the analysis; profiles with low contrast and blurry borders were not circled. Only fibrils
cut in cross-section were included in the analysis, with those cut at oblique angles being
omitted from the study. As a matter of interest, the oblique sections could have been
used because the shortest diameter in an ellipsoidal section is equal to the diameter of the
corresponding circular section profile (Wollensak et al. 2004), but this was not necessary
here as there were sufficient circular cross-sectioned fibrils in the micrographs analysed.
This measurement was based on subjective eye detection to distinguish between the cross-
section (circle fibrils) from the oblique angle (oval fibril) and a manual detection of the
fibrils circumference (Figure 2.17). The diameter was then calculated on an Excel sheet
directly from the circled area.
Stain intensity analysis
Using the Image J/Fiji program, the stain intensity was plotted from a longitudinal-section
of collagen fibrils. After the image was calibrated, fibrils were selected on the basis of
positive staining band clarity and least background contamination. A highlighted line
(rectangle) was drawn over several D-periods along each selected fibril (Figure 2.18a).
The stain intensity was integrated across the fibril and plotted as a function of the position
along the fibril axis using the “plot profile” function. An example of the stain distribution
from a single D-period is shown in Figure 2.18b. The stain intensity data were acquired
for the entire usable length of the fibril.
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Figure 2.17: Cross-section through the fibrils. (a) Oblique angle sections were omitted
from this study. (b) Perpendicular section to the fibrils with a circular shape in cross-
section were included in the analysis. Adapted with permission from the copyright holder,
Wolters Kluwer Health, Inc. (Wollensak et al. 2004). (License No: 4223690894294),
Date: Nov 07, 2017.
The datawere transferred to Excel spreadsheets and subdivided to a length of precisely
oneD-periodwith the same start and end positions, so that all D-period plots would include
the same number of points taking into account the direction and polarities of the fibril.
This dataset was defined as one exact D-period. The position along the axis within each
D-period of the fibril was identified by the positive staining band (e.g. c1-b2-b1-a4-a3-
a2-a1-e2-e1-d-c3-c2) (Chapman et al. 1990). In order to reduce noise, three D-period
intensity profiles were averaged from each treatment group. Any background intensity
gradient along the D-period was removed by applying a linear ramp to ensure that the
intensity value of the first data point in the averaged profile was identical to the intensity
value of the last data point. For comparison of the treatment groups, the averaged profiles
needed to be correctly aligned. This was done by moving one plot stepwise past the one
to which it was being compared until the best visual alignment of the staining bands was
achieved.
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(a)
(b)
Figure 2.18: (a) Transmission electron micrograph of a positively stained rabbit corneal
collagen fibril analysed using the Image analysis J/Fiji program. Fibrils were carefully
chosen for use on the basis of positive staining band clarity. To extract an average band
intensity distribution for each D-period, a rectangle (yellow) was drawn over several D-
periods along the length of a fibril. The integrated axial stain intensity for the chosen
region was then extracted using the “Plot Profile” function. (b) An example of the axial
stain intensity distribution along approximately one D-period of the fibril obtained from
the Image analysis J/Fiji program.
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CHAPTER 3
STANDARD VERSUS ACCELERATED RIBOFLAVIN/
ULTRAVIOLET CORNEAL CROSS-LINKING:
ENZYMATIC DIGESTION RESISTANCE AND BIOME-
CHANICAL STRENGTH.
Parts of this chapter were published as a laboratory science article in J Cataract Re-
fract Surg 2015; 41:1989–1996. Published by Elsevier Inc. on behalf of ASCRS and
ESCRS. This is an open access article under the CC BY license (http://creativecomm
ons.org/licenses/by/4.0/).
75
Investigations into the effectiveness of new and existing corneal cross-linking therapies
3.1 Introduction
The standard Dresden CXL procedure (SCXL) takes a minimum of one hour to achieve the
desired clinical effect (Spoerl et al. 1998), as it requires removal of the corneal epithelium,
a 20 - 30 minutes instillation of riboflavin eye drops (to achieve a homogeneous stromal
uptake of riboflavin (Gore et al. 2014)) and a 30 minutes exposure to 365 nm UVA
irradiation at 3 mW/cm2. Recently, in an attempt to shorten patient treatment time,
accelerated CXL protocols (ACXL) have been introduced. The concept of ACXL is based
on the Bunsen-Roscoe law of reciprocity (Bunsen et al. 1862) and assumes that increasing
UVA fluence while simultaneously reducing the exposure time (to ensure that the total
energy dose remains unchanged), will produce the same cross-linking effect as that of the
SCXL protocol (Schumacher et al. 2012; Wernli et al. 2013). Numerous clinical studies
demonstrate the safety and efficacy of the ACXL procedure in the short term, with no
reported adverse effects and a significant reduction in both topographic keratometry and
corrected distance acuity at up to 46 months follow-up (Cinar et al. 2014; Hashemi et al.
2015; Kanellopoulos 2012; Kymionis et al. 2017; Ng et al. 2016; Waszczykowska et al.
2015). However, it is unclear if the same amount of tissue is cross-linked with the ACXL
and SCXL procedures, and the long-term effects of different cross-linking protocols, in
terms of keratoconus stability, remains uncertain.
3.2 Research aim
This study was undertaken to compare the efficacy of two ACXL protocols (9 mW/cm2
for 10 minutes and 18 mW/cm2 for 5 minutes) with that of the SCXL procedure (3
mW/cm2 for 30 minutes), in terms of their ability to enhance the enzymatic resistance and
biomechanical properties of the cornea.
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3.3 Materials and methods
3.3.1 Treatment groups
The treatment and control groups described in the methods for this chapter are detailed
below and summarized in Table 3.1.
1. Untreated controls — complete removal of the corneal epithelium using a single
edged razor blade, followed by a detailed visual inspection of the tissue to confirm that
no damage had occurred to the underlying stroma. These corneas received no further
treatment.
2. Dextran-only controls — epithelial removal (as described above) followed by
application of 20% dextran T500 eye drops comprising 1g of Dextran T500 (Pharmacos-
mos, Holbaek, Denmark) dissolved in 5 ml of PBS. The solution was applied to the cornea
every 5 minutes for 30 minutes with no UVA exposure.
3. Riboflavin-only controls — epithelial removal followed by application of com-
mercial riboflavin eye drops comprising 0.1% solution riboflavin-5-phosphate in 20%
dextran T-500 solution (Mediocross D, Peschk Meditrade, Huenenberg, Switzerland).
The riboflavin eye drops were applied every 5 minutes for 30 minutes with no UVA
exposure.
4. “Standard” 3 mW/cm2 CXL protocol (SCXL 3 mW)—epithelial removal fol-
lowed by application of commercial riboflavin eye drops (Mediocross D). Riboflavin eye
drops were applied every 5 minutes for 30 minutes before exposure of the central 9 mm
region of the cornea to UVA light with a fluence of 3 mW/cm2 for 30 minutes (CCL-
365 Vario™ cross-linking system Peschkmed, Huenenberg, Switzerland). Riboflavin eye
drops were re-applied at 5 minute intervals throughout the period of irradiation.
5. Accelerated 9 mW/cm2 CXL protocol (ACXL 9 mW)—epithelial removal fol-
lowed by application of commercial riboflavin eye drops (Mediocross D) every 5 minutes
for 30 minutes, followed by a 10 minutes exposure of the central 9 mm region to UVA light
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with a fluence of 9 mW/cm2. Riboflavin eye drops were re-applied at 5 minute intervals
throughout the period of irradiation.
6. Accelerated 18 mW/cm2 CXL protocol (ACXL 18 mW) — epithelial removal
followed by application of commercial riboflavin eye drops (MediocrossD) every 5minutes
for 30 minutes, followed by a 5 minutes exposure of the central 9 mm region to UVA light
with a fluence of 18 mW/cm2.
Table 3.1: A summary of the treatment groups and their controls
3.3.2 Tissue preparation: human donor tissue
Twelve human donor corneas with intact scleral rimwere used in this study. The tissue was
obtained from NHSBT UK eye banks in accordance with the tenets of the Declaration of
Helsinki. The corneas were no longer suitable for corneal graft due to a low endothelial cell
count and to minimise the wastage of them, they were provided for experimental research.
Therefore, a small sample size was involved in this experiment. The corneas were donated
by eleven different donors (six men, five women) of average age 73 ± 6 (65 – 81) years
and stored in culture medium (Eagle’s MEM buffered with HEPES and containing 26 mM
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sodium bicarbonate, 2% fetal bovine serum, 2 mM L-glutamine, penicillin, streptomycin,
and amphotericin B) at 34◦C for approximately 1 - 5 months (2.76 ± 2.1) prior to use.
The corneo-scleral disks were assigned according to age and equally divided into four
treatment groups with no pair allocated in the same group (detailed in Section 3.3.1):
Untreated, SCXL 3 mW, ACXL 9 mW and ACXL 18 mW. The ages of the corneas in each
treatment group were as follows: Untreated (66, 78, and 80 years old), SCXL 3 mW (66,
71, and 73 years old), ACXL 9 mW (67, 74, and 81 years old) and ACXL 18 mW (65,
73, and 80 years old). To ensure corneal curvature was maintained during the respective
treatments, each cornea was centred and mounted by its scleral rim in an artificial anterior
chamber (Baron, Katena Products, Inc, Denville, New Jersey, USA) and inflated from
behind with MEM buffer (Figure 3.1). When applicable, measurements of central corneal
thickness were performed pre-and post-epithelium removal, and pre- and post-treatment,
using a Pachette2™Ultrasonic Pachymeter (DGHTechnology, Exton, USA). Immediately
after treatment each sample was wrapped tightly in catering film and stored at 5◦C until
all treatments were accomplished.
Figure 3.1: The cornea was centred in an artificial anterior chamber and mounted by its
scleral rim. MEM buffer was injected behind the cornea to preserve its curvature during
treatment.
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3.3.3 Tissue preparation: porcine abattoir tissue
One hundred and eighteen fresh whole porcine eye globes were obtained from a local
European Community licensed abattoir within 6 - 8 hours post-mortem. All corneas were
visually inspected and found to be free of damage, visual autolytic changes, haze, or
scratches. The forty eyes destined for biomechanical testing were randomly and equally
divided into five treatment groups (detailed in section 3.3.1): Untreated, Riboflavin-only,
SCXL 3mW,ACXL 9mWandACXL 18mW. The seventy-eight porcine eyes required for
enzyme digestion studies were randomly and equally divided into six treatment groups:
Untreated, Dextran only, Riboflavin only, SCXL 3 mW, ACXL 9 mW and ACXL 18
mW. When applicable, central corneal thickness measurements were performed pre- and
post-epithelium removal, and pre- and post-treatment, using a Pachette2™ Ultrasonic
Pachymeter (DGH Technology, Exton, USA). Once the treatments were achieved, the
corneas were dissected from each globe with a 2 - 5 mm scleral rim, wrapped tightly in
catering film and refrigerated at 5◦C.
3.3.4 Enzyme digestion studies: porcine and human corneas
On completion of the treatments, a disposable skin biopsy punch (Kai Europe GmbH, ref
BP-80F, Solingen, Germany) was used to trephine an 8 mm corneal disk from the centre
of each of the seventy-eight porcine and twelve human corneas prepared for enzyme
digestion studies. The corneal disks were weighed, then placed in individual plastic tubes,
each containing 5 ml of pepsin solution made up from 1 g of 600–1200 U/mg pepsin
from porcine gastric mucosa (Sigma-Aldrich, Dorset, UK) in 10 ml 0.1M HCl at pH 1.2.
The human corneal disks had five changes of fresh pepsin approximately every 40 days
during the digestion period as enzyme activity decays over time. The corneal disks (in
pepsin digest solution were then incubated in a water bath (VwB6, Leuven, Germany) at a
temperature of 23◦C. Following a preliminary study investigating the effect of temperature
on the total digestion time of cross-linked and non-cross-linked porcine corneal disks, 23◦C
was identified as the optimum temperature for detecting differences of one day or more
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between treatment groups (Appendix D).
As detailed in Chapter 2, section 2.3, the diameter of the anterior surface of eight of
the thirteen porcine corneal disks from each group, and all twelve human corneal disks,
were measured daily using digital calipers. These measurements continued until the
tissue could no longer be distinguished from the surrounding pepsin solution (even under
microscopic examination), at which point the tissue was considered to have undergone
‘total digestion’. In order to further assess the effect of each treatment on enzymatic
resistance, the remaining five porcine corneal disks from each group were removed from
the pepsin solution after 12 days of digestion and placed in a 60◦C oven until a constant
dry weight was obtained. The average corneal dry weight (which represents the mass of
undigested tissue) was calculated for each group (as described in Chapter 2).
3.3.5 Biomechanical testing studies: porcine corneas only
Within 10 minutes of treatment, a double-blade cutter was used to cut a strip of tissue
(measuring 5 mm in width) along the vertical meridian of each of the forty porcine corneas
prepared for biomechanical testing. After cutting, the corneal strip was secured within
the clamps of an enclosed sample holder and attached to the extensometer. A cotton
pad soaked in distilled water was placed within the sample enclosure directly beneath the
corneal strip to maintain the hydration of the tissue during testing. Preliminary studies
examining the effect of different sample environments on corneal hydration identified this
as the method of choice for maintaining hydration, since it resulted in a negligible 0.4%
reduction in tissue water content over a typical 35 minutes biomechanical testing period
(Appendix F). Further details relating the method of strip cutting and tensile testing are
provided in Chapter 2.
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Stress–strain measurements
Stress–strain measurements were obtained using a Lloyd extensometer (Lloyd Instruments
Ltd., UK) with a 20 Newton force cell. Initial values required to perform a stress–strain
test, were inserted as shown in (Table 3.2). Prior to testing each tissue strip, three
preconditioning cycles were performed using a force of 1 N. This was followed by a tensile
test at a velocity of 1 mm/min. During the measurement, the load, strain, extension and
stress were automatically recorded. Then in MATLAB, the stress–strain curve was fitted
to an exponential function (A and B) in low strain nonlinear elasticity region from 2% to
8% (for more information see chapter 2). The sample numbers used for each aspect of the
biomechanical testing and enzyme digestion studies are shown in Table 3.3.
Table 3.2: The values required by Nexygen 4.1 to perform a stress–strain test. The bold
row indicates parameter values that were different for each corneal strip.
3.3.6 Statistical evaluation
All data are reported as mean ± standard deviation (SD). Statistical comparisons between
means were carried out using one-way ANOVA followed by Bonferroni multiple com-
parisons between groups also using paired samples t-test. All statistical analyses were
performed with the Statistical Package for the Social Sciences (IBM SPSS Statistics 20,
New York, USA). The statistical significance of difference was taken as p ≤ 0.05.
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Table 3.3: Treatment groups and sample numbers
3.4 Results
3.4.1 Effect of CXL on corneal thickness
Measurements of central corneal thickness, recorded during the preparation of human
and porcine corneas for enzyme digestion studies, are shown in Table 3.4. As a result of
long term storage in culture medium, the pre-treatment thickness of the human corneas
far exceeded physiological levels and was also greater than that of the porcine corneas (p
< 0.0001). For each species, no statistically significant differences in corneal thickness
were observed between the groups either pre- or post-epithelial removal. However, in the
porcine corneas therewas a significant reduction in corneal thickness following administra-
tion of dextran-containing solutions in both the dextran-only group and the riboflavin-only
group (p < 0.0001). Application of the riboflavin solution (containing dextran) to the
de-epithelialised cornea resulted in a significantly greater reduction in corneal thickness
than application of the dextran-only (p < 0.001). In both porcine and human corneas, a
significant reduction in corneal thickness was also observed following CXL treatments (p
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< 0.0001). However, as the post-treatment thickness of the SCXL and ACXL irradiated
porcine corneas did not differ from that of the non-irradiated riboflavin treated porcine
corneas (p = 1.00), the corneal thinning observed after CXL may be attributed to the
application of riboflavin rather than to UVA exposure (Table 3.4). These findings were
supported by measurements recorded during the preparation of porcine corneas for biome-
chanical testing, which showed a significant decrease in tissue thickness after riboflavin
application but no further change in corneal thickness as a result of UVA irradiation (p =
1.00) (Figure 3.2).
Figure 3.2: Corneal thickness measurements recorded during the preparation of porcine
corneas for biomechanical testing. Error bars show standard deviation. Cross-linking
treatments: Standard cross-linking (SCXL 3 mW); accelerated cross-linking (ACXL 9
mW and ACXL 18 mW).
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Table 3.4: Pre- and post-treatment central Corneal Thickness measurements of human
and porcine corneas prepared for enzyme digestion studies.
3.4.2 Observations during the digestion process
In the porcine corneas, an approximately 10-fold increase in the thickness of the corneal
disk was observed in all cases within 24 hours of submersion in the pepsin digest solution.
This increase in corneal thickness occurred as a result of stromal swelling in the posterior-
anterior direction (Figure 3.3b). During swelling, the corneal disk assumed a cylindrical
shape but after one week of digestion, the anterior portion of each treated and untreated
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specimen separated from the posterior portion. Once detached, the posterior stroma was
rapidly digested (within 10 days). The anterior stromal disk persisted considerably longer
(particularly in the CXL treated corneas) and maintained its form sufficiently to obtain
reliable measurements of its changing diameter during the digestion process.
The thickness of the human corneal disks increased about 7-fold within 24 hours
of submersion in pepsin digest solution as a result of swelling in the posterior-anterior
direction (Figure 3.4). However, unlike the porcine corneas, the swollen human corneal
disks assumed a mushroom shape whereby the diameter of the posterior surface of the
cornea became notably smaller than that of the anterior. Further to this, the posterior
portion of the cornea did not separate from the anterior portion at any stage of the
digestion process.
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Figure 3.3: Porcine corneal disks at various stages of digestion. Each panel shows
photographs of untreated (U), riboflavin-only (R), SCXL 3 mW (S3), ACXL 9 mW (A9),
and ACXL 18 mW (A18) treated corneas before (a) and after 1 (b), 2 (c) and 12 (d) days
of immersion in pepsin digest solution. All corneal disks are shown to be swollen after 1
day in pepsin digest solution (b). After 2 days of digestion, the anterior curvature has been
lost in the untreated corneas but remains intact in the cross-linked corneas (c). After 12
days, all non-irradiated disks have been completely digested and only the anterior portion
of the cross-linked corneas remain.
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Figure 3.4: Human corneal disks at various stages of digestion. Each panel shows
photographs of untreated (U), SCXL 3 mW (S3), ACXL 9 mW (A9), and ACXL 18 mW
(A18) treated corneas before (a) and after 1 (b), 2 (c), 7 (d), 14 (e), 24 (f), 37 (g), 50 (h),
82 (i), 90 (j), 108 (k), 127 (l), and 141 (m) days of immersion in pepsin digest solution.
All corneal disks are shown to be swollen after 1 day in pepsin digest solution (b). After
37 days, the untreated disks have been almost completely digested and by 50 days they
have disappeared, whereas the cross-linked corneas remain intact (h). The anterior and
posterior portion of the human corneal disks did not detach, however, the posterior portion
digested earlier than anterior and showed almost a complete posterior digestion at the final
stages of the digestion process (day 37 in the untreated corneas (g) and day 127 in the
cross-linked corneas (l)).
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3.4.3 Effect of CXL on enzymatic resistance: rate of digestion and
total digestion time
Figure 3.5 shows the summed diameters of eight porcine corneal disks within each treat-
ment group as a function of incubation time in pepsin solution. Statistical analysis
revealed no significant difference in either the average porcine corneal disk diameter of
non-irradiated specimens (untreated, dextran-only and riboflavin-only) at any time point
during digestion or in the time taken for complete digestion to occur (Table 3.5). Similarly,
in the irradiated specimens, no significant differences in these parameters were detected
between porcine specimens treated with SCXL 3 mW, ACXL 9 mW or ACXL 18 mW.
The diameters of the SCXL and ACXL treated corneas were however significantly larger
than those of the non-irradiated specimens at all daily time points after day 8 (p < 0.0001)
(Figure 3.5), and the time required for complete digestion to occur was significantly longer
(p < 0.0001) (Table 3.5). By day 12, all non-irradiated porcine corneas had been com-
pletely digested but the average diameter of the CXL treated porcine eyes had decreased
by only 27.2%, 27% and 26.6%, in the SCXL 3 mW, ACXL 9 mW and ACXL 18 mW
groups respectively.
Figure 3.6 shows the summed diameters of three human corneal disks within each
treatment group as a function of incubation time in pepsin solution. Enzymatic resistance
was significantly enhanced in all of the cross-linked human corneas at all daily time points
after day 35 compared to the untreated controls (p < 0.0001). Complete digestion of all
untreated human corneas had occurred by day 46, whereas at this same time point the
average diameter of the CXL treated human eyes had decreased by only 23.2%, 22.8%
and 27.1%, in the SCXL 3 mW, ACXL 9 mW and ACXL 18 mW groups respectively.
However, the SCXL human corneal disks completed their enzymatic digestion 8 days and
10 days later than ACXL 9mWand ACXL 18mW, correspondingly. Therefore, the SCXL
protocol resulted in a greater increase in enzymatic resistance than the ACXL 9 mW and
ACXL 18 mW protocols (p < 0.0001).
The untreated human corneas took significantly longer to digest than the untreated
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porcine eyes (p < 0.0001). In human corneas, the time required for cross-linked specimens
to undergo complete digestionwas≈3.5 times longer than their untreated controls, whereas
for the porcine corneas the cross-linked specimens took only ≈2.4 times longer to digest
than the untreated controls.
Table 3.5: Time taken for the complete digestion of treated and untreated human and
porcine corneas.
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3.4.4 Effect of CXL on enzymatic resistance: residual stromal mass
at day 12
At day 12, the non-irradiated porcine corneas had undergone complete digestion, whilst
the anterior stroma of the irradiated specimens remained intact. As a result, measurements
of corneal disk dry weights at 12 days showed a statically significant difference between
the irradiated and non-irradiated specimens (p < 0.0001). Further statistical differences
were detected between the irradiated corneas treated with SCXL 3 mW, ACXL 9 mW
or ACXL 18 mW (p < 0.0001) (Figure 3.7). The SCXL 3 mW group had a statistically
higher average dry weight than the ACXL 9 mW and ACXL 18 mW groups (p < 0.0001),
and the ACXL 9 mW group had a higher dry weight than the ACXL 18 mW group (p <
0.003).
Figure 3.7: Average stromal dry weight of porcine corneal disks treated with SCXL,
ACXL 3 mW, ACXL 9 mW and ACXL 18 mW, after 12 days of digestion. Error bars
show standard deviation. Cross-linking treatments: Standard cross-linking (SCXL3mW);
accelerated cross-linking (ACXL 9 mW and ACXL 18 mW).
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3.4.5 Extensometry: stress-strain curves
Stress-strain fitted curves were plotted for all control and treatment groups and the general
trend of the curves was examined in term of stress/strain ratio (Figure 3.8). Samples
that underwent CXL treatment showed a higher average stress:strain ratio than non-cross-
linked samples (p < 0.01). Although the stress-strain curves showed a negative trend on
the curves with increasing UVA light intensity, there was no significant difference between
the treated groups. This would imply that these samples had increased in stiffness as a
result of their respective treatments to the same extent as the samples treated with the
standard procedure.
Figure 3.8: Stress-strain behaviour of cross-linked and non-cross-linked corneas. The
cross-linked corneas showed a higher stress-strain ratio than the non-cross-linked control
groups. Cross-linking treatments: Standard cross-linking with 3 mW UVA (S3), acceler-
ated cross-linking using 9 mW (A9) and 18 mW (A18) UVA. Non-cross-linked controls:
untreated (U) and riboflavin-only (R).
Tangent modulus
Bar charts depicting the average tangent modulus for each group at 2%, 4%, 6% and 8%
strain are presented in Figure 3.9 a, b, c and d, respectively. At 2% strain a significant
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difference in tangent modulus was only evident between the SCXL group and the two
controls groups (untreated and riboflavin only) (p < 0.005, p < 0.004, respectively)
(Figure 3.9 a). At 4%, 6% and 8% strain, all SCXL and ACXL treated groups had a
significantly higher tangent modulus than the non-cross-linked controls (p < 0.01) (Table
3.6 and Figure 3.9 b, c and d). At 6% strain, the average tangent modulus for the SCXL
3 mW, ACXL 9 mW and 18 mW was 4.3, 3.8 or 3.4 times higher respectively than the
non-cross-linked controls. However, no significant difference was detected between the
SCXL and ACXL groups at any of the measured levels of strain (p > 0.23) (Table 3.6 and
Figure 3.9).
Figure 3.9: Average tangent modulus of cross-linked and non-cross-linked corneas at (a)
2%, (b) 4%, (c) 6% and (d) 8% strain. Error bars show standard deviation. Cross-linking
treatments: Standard cross-linking (SCXL 3 mW), accelerated cross-linking (ACXL 9
mW and ACXL 18 mW). Non-cross-linked controls: untreated and riboflavin-only.
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Table 3.6: P-values of the tangent modulus at 2%, 4%, 6% and 8% resulting from
Bonferroni multiple comparisons between groups. Asterisks indicate where p-values
were < 0.05.
3.5 Discussion
The SCXL protocol has proven its efficacy and safety to strengthen the cornea and halt
the progression of keratoconus and other corneal ectasia diseases (Spoerl et al. 1998).
However, more recently, ACXL procedures that are based on the Bunsen-Roscoe law of
reciprocity and use higher UVA intensities, have been introduced to reduce the duration
of the CXL treatment to one-third or one-sixth of the original procedure time. Despite
the promising clinical results of ACXL treatments in the short-term, several publications
have warned that the Bunsen-Roscoe law may not be a valid application for the cornea
(Mazzotta et al. 2013; Richoz et al. 2013; Wernli et al. 2013) and a comparison of the long-
term benefits of SCXL and ACXL treatment protocols has yet to be established. In this ex
vivo study the enzymatic resistance and biomechanical properties of corneas cross-linked
with the standard 3 mW SCXL procedure were compared to those of corneas cross-linked
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using 9 mW and 18 mW ACXL procedures. In agreement to other clinical and laboratory
based studies (Greenstein et al. 2011; Hassan et al. 2014; Hayes et al. 2013) a significant
reduction in corneal thickness was detected following CXL using an isotonic riboflavin
solution; as the post-treatment thickness of the irradiated corneas did not differ from
that of the non-irradiated riboflavin treated corneas, the corneal thinning detected during
CXL and ACXL may be attributed predominantly to the application of riboflavin/dextran
solution rather than to the effect of CXL following UVA exposure. The application of
riboflavin solution (containing 20% dextran) resulted in a significantly greater reduction
in corneal thickness than application of the same concentration of dextran in the absence
of any riboflavin. This finding may be the result of riboflavin increasing the ionic strength
of the applied solution, as higher ionic strengths are known to be correlated with lower
corneal hydrations (Huang et al. 1999) and hence also, decreased corneal thickness.
This study and earlier studies have indicated that a significant stromal swelling oc-
curred (predominantly in the posterior stroma) in all corneal disks during the first 24 hours
in pepsin solution (Hayes et al. 2013; Spoerl et al. 2004). This observation can attribute
to the negatively charged glycosaminoglycans components of the proteoglycans within the
extracellular matrix, which draw the pepsin digest solution into the tissue (Klyce et al.
1988). The higher ratio of keratan sulphate to condroitin sulphate in the posterior stroma
compared to the anterior (Castoro et al. 1988) could give a reason for the occurrence of
most of the swelling in this area, since keratan sulphate has a higher water affinity than
chondroitin sulphate (Bettelheim et al. 1975). Interestingly, the separation of the cornea
into anterior and posterior stromal regions during the first week of digestion was observed
in all cross-linked and non-cross-linked porcine corneas but did not occur in any of the
human corneas. The separation could not therefore be attributed to cross-linking induced
changes within the anterior stroma. Instead this phenomenon may be due to the naturally
occurring structural differences that exist between the anterior and posterior regions of the
human and porcine cornea. This could be related to the higher interlacing of the anterior
stroma collagen bundles than the posterior stroma in human cornea (Radner et al. 1998),
whereas the porcine corneas show regular interweave of the lamellae over the stromal
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depth (Bueno et al. 2011; Tan et al. 2006). In both species, the changes in corneal hy-
dration did not affect the diameter of the anterior portion of the corneal disk and thus
formed a more reliable measure of the rate of enzymatic digestion than measurements of
corneal thickness. Calculations based on the used sample size and the standard deviation
of diameter measurements however, determined that the sensitivity of the technique was
such that differences between groups (in terms of the time taken for complete digestion) of
less than one day could not be distinguished by this method. Therefore, measurements of
corneal disk dry weight, which reflect the mass of undigested corneal tissue, were recorded
at day 12 of the digestion process, this allows finer differences in enzymatic resistance
between treatment groups to be identified. Measurements of corneal disk diameter provide
valuable information on the structural integrity of the most anterior layers of the cornea,
whilst the dry weight measurements, representing the total mass of undigested tissue,
negate the complications associated with within-sample variations in corneal thickness
and between sample differences in hydration and provide information about the effective
depth of CXL.
The results indicated an increased resistance to proteinase digestion following SCXL
that is in agreement with the findings of other investigators (Hayes et al. 2013; Kissner
et al. 2010; Spoerl et al. 2004). However, for the first time it was shown (in both
porcine and human corneas) that a similar increase in enzymatic resistance can also be
obtained using higher fluences (up to 18 mW/cm2) and shorter exposure times. Although
the diameter measurements recorded from the porcine corneas showed no difference in
enzymatic resistance between the CXL protocols used in this study, the average dry weight
of corneal tissue after 12 days of protein digestion was found to differ significantly between
groups (SCXL 3 mW > ACXL 9 mW > ACXL 18 mW). The greater enzymatic resistance
conferred by the 3 mW SCXL protocol compared to the 9 mW and 18 mW protocol was
further supported by the slower digestion rate of the SCXL treated human donor corneas
compared to the ACXL treated corneas. This postulates that protocols using a higher
fluence and shorter exposure time, result in either the most anterior layers of the corneal
stroma being cross-linked equally but the effective depth of cross-linking being decreased
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or the intensity of cross-linking ,which is known to be depth-dependent (Scarcelli et al.
2013), declining more rapidly as a function of depth. One interesting observation by
previous studies is the presence of a shallower demarcation line in ACXL compared to
SCXL (Brittingham et al. 2014; Kymionis et al. 2016; Ng et al. 2016; Touboul et al.
2012), suggesting that this may represent a reduced or shallower CXL effect. However,
this speculates that the depth of the demarcation line correlates directly with the degree
and depth of CXL and currently there is no direct evidence to support this. The so-called
stromal demarcation line, first defined by Seiler et al (2006), has been revealed to possibly
be shallower in older patients and those with more severe ectatic disease (Yam et al. 2012).
It has been shown to be thicker centrally and thinner peripherally (Kymionis et al. 2013)
and possibly related to an increased density of the extracellular matrix (Mazzotta et al.
2007). Although a deeper demarcation line has been correlated with a larger reduction
in post-CXL corneal thickness (Doors et al. 2009), its depth has not been shown to be
associated to either visual or keratometric changes at 6 months post-operatively (Yam et al.
2012). It may simply represent natural wound healing responses rather than describe the
true area between cross-linked and un-cross-linked tissue and more research is necessary
to determine the true nature of this demarcation line and its relationship to the actual
cross-linking process.
The untreated human corneas took significantly longer to digest than the untreated
porcine eyes (p < 0.0001) which may, to a small extent, be due to differences in the pH of
the pepsin digest solution used, which is known to affect the rate of digestion. However, the
greater resistance of the human corneas to enzymatic digestion is more likely the result of
the natural increase in collagen cross-linking that occurs with age, since the study utilized
relatively young pig corneas (< 1 year of age and equivalent to ≈18 human years) and
more mature human corneas (mean age of 73 years). The ex vivo studies presented in this
chapter disclose that the ACXL protocols are equivalent to the SCXL procedure in terms
of increasing the stiffness of the cornea. The results, which show that corneal stiffness
can be increased by cross-linking, are supported by other publications (Kling et al. 2010;
Kohlhaas et al. 2006; Wollensak et al. 2009, 2003). However, the 300-400% increase
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in porcine corneal stiffness observed in this study following cross-linking is higher than
that published by Wollensak et al, where the increase in stiffness was 180% (Wollensak
et al. 2003). This variance can be credited to the slight differences in the way in which
the extensometry was performed. The applied stress is very reliant on the experimental
procedure, for example, the load on the fixation clamp, the pre-stress power of themachine,
and the use of hydration control techniques (Hatami-Marbini et al. 2015). In the current
study, the gauge length between the two clamps was much smaller (5 × 6 mm) than that
utilized byWollensak et al. (5 × 14 mm), and this may influence the total energy absorbed
during the tissue tests.
In agreement with the findings presented in the current study, Wernli et al. showed
that there was no significant difference between 3 mW SCXL, 9 mW and 18 mW ACXL
treated corneas in terms of their enhanced tissue stiffness (Wernli et al. 2013). Further to
this, the stiffening effectwas still comparablewithACXLprocedures using 40mW/cm2 but
at very high irradiations of more than 45 mW/cm2, no corneal cross-linking or enhanced
strength was achieved. The failure of the Bunsen-Roscoe law of reciprocity in cases of
very high intensity and short illumination time is not yet understood, but may be related
to rapid oxygen consumption and subsequent reduced oxygen availability, which has been
shown to limit the photochemical cross-linking process (McCall et al. 2010). Oxygen and
its vital role in free radical production has been shown to be central in driving the CXL
process (McCall et al. 2010). Therefore limitation in availability, due to reduced time to
replenish suitable oxygen levels, can theoretically inhibit the photochemical cross-linking
process (McCall et al. 2010). The current study results showed a difference in enzymatic
resistance, with increasing UVA intensity up to 18 mW/cm2. Further studies with energies
of 30 mW/cm2 and above are needed to see whether the results of pepsin digestion studies
replicate those of extensometry and other mechanical methods.
The results presented here also confirm the findings of other studies which have
demonstrated the comparable stiffening effect of SCXL and 9 mW ACXL using exten-
sometry (Schumacher et al. 2011) and a variety of other biomechanical testing techniques,
such as surface wave elastometry (Rocha et al. 2008), scanning acoustic microscopy
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(Beshtawi et al. 2013) and inflation testing (Bao et al. 2018). However, contrary to this,
Hammer et al. (2014) found the stiffening effect to be greater following SCXL than 9
mW ACXL. In addition, the authors reported no significant difference between untreated
corneas and those treated with 18 mW ACXL. This finding is clearly at odds with the
results of the current study, which demonstrate a similar stiffening effect as a result of
SCXL, ACXL 9 mW and ACXL 18 mW. The difference between the two studies might be
caused by slight differences in the sample size and the methodologies used, for example,
differences in the time-delay between treatment and testing (5 minutes in the present study
versus 30 minutes in the Hammer et al. study). Certainty, the ACXL 9 mW protocol
provides cross-links to the cornea and clinical validation is required to better understand
the findings.
Further clinical studies of ACXL have been discussed in the literature. Researchers
validated the effectiveness of ACXL to halt keratoconus progression and improve vision
(Alnawaiseh et al. 2015; Kymionis et al. 2014). The equivalence of ACXL and SCXL
was pointed out in several clinical trials (Cinar et al. 2014; Kymionis et al. 2014). A
significant reduction in topographic keratometry and improvement in corrected distance
acuity, comparable to SCXL has been showed post-ACXL treatment using 9 mW/cm2
for 10 minutes at 6 months follow-up (Cinar et al. 2014). This finding was supported by
another clinical study using a similar intensity of ACXL 9 mW that found a significant
reduction in keratometry following CXL with no adverse effects in terms of endothelial
cell counts at 3 months (Kymionis et al. 2014). In addition, Touboul et al described the
superiority of ACXL over the SCXL (Touboul et al. 2012). According to Mazzotta et al
(2013) the penetration of ACXL treatment reached the depth of 200 µm in the anterior-
mid stroma, compared to 300 µm a maximum depth of SCXL. However, the most vital
biomechanical impact identified with cross-linking is located in the front 200 µm of the
cornea as reported in the literature (Kohlhaas et al. 2006), so the effect of ACXL might
be adequate in terms of biomechanical and biochemical impact (Mazzotta et al. 2013).
Clearly, further long-term clinical studies in large cohorts are required to validate the
efficacy and safety of this higher intensity procedure.
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In conclusion, this study shows that the enhanced tissue stiffness following ACXL
(with a UVA intensity of up to 18 mW/cm2), is comparable to that of SCXL. Although,
SCXL resulted in a subtly greater enhancement of enzymatic resistance than the ACXL
protocols, the minimum effective amount of cross-linking desired for ectasia stabilization
has not yet been established. Previous clinical studies demonstrated that the amount of
cross-linking produced by ACXLmay indeed be sufficient to stabilize disease progression.
The accumulating clinical and laboratory evidence demonstrating the similar efficacy of
ACXL (up to 18 mW) and SCXL, the reduced cell toxicity associated with the ACXL
technique and the clear benefits of ACXL, in terms of patient and surgeon convenience,
support its use. However, longer-term follow-up clinical studies, especially randomized
prospective trials, will be necessary to ascertain the clinical safety and efficacy of ACXL.
In addition to this, further laboratory studies are needed to determine whether even higher
UVA intensity/shorter duration cross-linking procedures can achieve the same level of
enzymatic resistance and biomechanical stiffening as that of the SCXL procedure.
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CHAPTER 4
AN INVESTIGATION INTO CORNEAL ENZYMATIC
RESISTANCE FOLLOWING STANDARD AND
TRANS-EPITHELIAL CORNEAL CROSS-LINKING
PROCEDURES.
This chapter was published as a laboratory science article in Experimental Eye Research
2016; 153:141–151. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
103
Investigations into the effectiveness of new and existing corneal cross-linking therapies
4.1 Introduction
Riboflavin is a hydrophilic molecule, with a molecular weight of 340 Dalton (Da), while,
the corneal epithelium is lipophilic, with a decreasing permeability to molecules over 180
Da (Huang et al. 1989). Hence, the removal of the epithelium from the central corneal
is essential to allow adequate stromal absorption of riboflavin prior to UVA irradiation
in the “gold-standard” CXL protocol. This requirement was supported by Spoerl et al.,
who reported no changes in corneal biomechanics when CXL was performed with the
epithelium intact (Spoerl et al. 1998). Based on this study, the epithelium was removed
in the first published clinical studies (Caporossi et al. 2006; Gkika et al. 2011; O’Brart
et al. 2011; Richoz et al. 2013; Wittig-Silva et al. 2014; Wollensak et al. 2003). However,
there are some complications associated with the epithelial debridement, including severe
ocular pain in the immediate post-operative period, delayed visual rehabilitation, the risks
of scarring and infectious and non-infectious keratitis (Evangelista et al. 2017; Koller et al.
2009).
Due to these complications, several trans-epithelial CXL techniques have been pro-
posed. The first epithelium-on CXL (epi-on-CXL) protocols included the use of multiple
topical applications of tetracaine 1% to disrupt epithelial tight junctions (Boxer Wachler
et al. 2010; Chan et al. 2007) and partial epithelial debridement in a grid pattern (Rechichi
et al. 2013). Lately, innovative development of formulations of riboflavin has been in-
troduced to facilitate epi-on-CXL (Alhamad et al. 2012; Kissner et al. 2010; Raiskup
et al. 2012). Ambiguous results were demonstrated in clinical studies with such formu-
lations, with some demonstrating similar efficacy to epithelium-off CXL (epi-off-CXL)
(Filippello et al. 2012; Magli et al. 2013), and others showing less pronounced effects
(Buzzonetti et al. 2012; Kocak et al. 2014; Koppen et al. 2012; Leccisotti et al. 2010). As
riboflavin is negatively charged at physiological pH and soluble in water, it is assumed that
iontophoresis can be used as a means of enhancing trans-epithelial absorption. In vitro
studies of CXL using iontophoresis-assisted delivery (Ion-CXL) of riboflavin 0.1% with
a current of 0.5 - 1 mA for 5 to 10 min have been encouraging, demonstrating enhanced
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trans-epithelial riboflavin absorption and increased corneal tissue strength (Cassagne et al.
2016; Lombardo et al. 2014; Mastropasqua et al. 2014a; Touboul et al. 2014; Vinciguerra
et al. 2014a). Previous clinical studies have stated cessation of progression and improve-
ments in keratometric and visual parameters (Bikbova et al. 2014; Buzzonetti et al. 2015;
Vinciguerra et al. 2014b).
Apart from the requirement to remove the epithelium, the current “gold-standard”,
epi-off-CXL protocol, involves a 30 min application of riboflavin followed by a 30 min
irradiation with 370 nm UVA light, with an intensity of 3 mW/cm2, demanding an hour
in treatment time. In an attempt to reduce treatment time, the use of accelerated CXL
(ACXL) procedures using the same energy dose but higher UVA intensities and shorter
exposure times have been studied. There are a small number of clinical studies of ACXL
protocols that are published. Improvements were recorded in corrected distance acuity
together with a reduction in topographic keratometry in those using 7 mW for 15 min or 9
mW for 10 min at up to 46 months follow-up with no complications linked with the high
fluences used (Cinar et al. 2014; Cummings et al. 2016; Kanellopoulos 2012; Kymionis
et al. 2014b; Shetty et al. 2015). As stated in the previous chapter, the 9 mWACXL for 10
min was found to be as effective as the 3 mW for 30 min, therefore, it was chosen in this
study to allow a faster throughput of samples. In recent times, it has also been confirmed
that the efficacy of ACXL may be additionally enhanced by increasing the UVA exposure
time, and the overall cumulative dosage (Aldahlawi et al. 2016; Kymionis et al. 2014a;
Sherif 2014).
4.2 Research aim
To assess the effectiveness of partially disrupted-epithelium CXL (dis-CXL) and various
epi-on-CXL protocols at enhancing corneal enzymatic resistance and compare their ef-
fectiveness to that of the standard epi-on and epi-off ACXL treatment. This study will
examine the effect of using different riboflavin formulations, modes of riboflavin delivery
and cumulative UVA energy dose on the enzymatic resistance of cross-linked corneas.
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4.3 Materials and methods
4.3.1 Specimen preparation
Fresh porcine cadaver eyes with clear corneas and intact epithelium were purchased from
a local European Community licensed abattoir. A total of one hundred and fourteen eyes
were retrieved within 6 - 8 hours of death. The study was split into two runs because of the
large number of eyes and treatment groups involved. Run 1 examined the effectiveness of
dis-CXL and epi-on-CXL protocols (including iontophoretic epi-on-CXL) at increasing
corneal enzymatic resistance to digestion with pepsin, whereas run 2 examined the effect
on enzymatic resistance of increasing the UVA dosage by 25% from 5.4 J/cm2 to 6.75
J/cm2 during iontophoretic epi-on-CXL. Additionally, the usefulness of the epi-off CXL
protocol at increasing enzymatic resistance was observed in both runs for comparative
purposes. The 11 treatment groups are described below and summarised in Table 4.1.
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Run 1:
Each treatment group consisted of six eyes.
i) Epi-off protocol (Group 1: Epi-off-ribo; Group 2: Epi-off-CXL)
Using a single-edged razor blade, complete corneal epithelial debridement was ac-
complished in groups 1 and 2. These eyes then received 0.1% riboflavin eye drops con-
taining 20% dextran T-500 solution (Mediocross D®, Peschke Meditrade, Huenenberg,
Switzerland) using corneal annular suction rings for 30 min. The central 9 mm region of
the corneas in group 2 were then exposed to 365 nm UVA light with a fluence of CXL
9 mW/cm2 for 10 min (CCL-365 Vario™ cross-linking system Peschkmed, Huenenberg,
Switzerland). The term ACXL (A9) is also described as Epi-off-CXL in this chapter and
these terms will be used interchangeably in this study. Using 5 min intervals, riboflavin
was re-applied during irradiation. Group 1 served as a non-irradiated control.
ii) Dis-epi protocol (Group 3: Dis-ribo; Group 4: Dis-CXL)
In groups 3 and 4, partial epithelial disruption was performed, by creating 64 full-
thickness epithelial punctures with a 25-gauge needle in an 8×8 grid pattern. The corneas
were then soaked in riboflavin 0.1% dextran-free solution (Vitamin B2 Streuli, Uznach,
Switzerland) using corneal annular suction rings for 30 min and rinsed with phosphate-
buffered saline (PBS) for 5 min. 9 mW UVA for 10 min was then irradiated group 4 with
PBS applied at 5 min intervals to keep the corneal surface moist. Group 3 served as a
non-irradiated control.
iii) Epi-on and high riboflavin concentration protocol (Group 5: Medio-ribo;
Group 6: Medio-CXL)
Groups 5 and 6 received 0.25% riboflavin with 1.2% hydroxypropylmethyl cellulose
(HPMC) and 0.01% BAC (Mediocross TE®, Peschketrade, Huenenberg, Switzerland)
every 5 min for 30 min. After that, they underwent a 5 min rinse with PBS. Group 6 was
then irradiated with 9 mW UVA for 10 min with PBS applied at 5 min intervals. Group 5
served as a non-irradiated control.
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iv) Epi-on, high riboflavin concentration and prolonged iontophoresis (St. Thomas-
Cardiff) protocol (Group 7: TC-ion-ribo; Group 8: TC-ion-CXL)
Groups 7 and 8 received iontophoresis assisted delivery of 0.25% riboflavinwith 1.2%
HPMC and 0.01%BAC (Mediocross TE®, Peschketrade, Huenenberg, Switzerland) using
a current of 1 mA for 5 min. corneas were then soaked with the riboflavin solution for 5
mins, prior to applying iontophoresis with a power of 0.5 mA/min for 5 min and another
5 min riboflavin soak. Ex vivo eyes were treated by the iontophoresis delivery system by
connecting the return electrode to a needle inserted into the vitreous chamber; the negative
electrode was a steel grid contained in a corneal well applicator which was adhered to the
eye by means of a vacuum well system (Figure 4.1). Riboflavin totally covered the steel
grid (negative electrode) and the power generator set to the chosen current and duration.
During the entire procedure, the steel grid remained covered with riboflavin solution. The
applicator was removed from the cornea and the corneas were washed with PBS for 5 min
after treatment. Following that, group 8 was then irradiated with 9 mW UVA for 10 min
with PBS applied at 5 min intervals. Group 7 served as a non-irradiated control.
Figure 4.1: Iontophoresis riboflavin delivery system modified for use in ex-vivo eyes.
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Run 2:
Each treatment group consisted of 11 eyes.
i) Epi-off protocol (Group 1: Epi-off-ribo; Group 2: Epi-off-CXL 5.4 J/cm2)
Similar treatment was performed in corneas as shown in groups 1 and 2 in run 1.
ii) Epi-on, high riboflavin concentration and prolonged iontophoresis/St. Thomas-
Cardiff protocol (Group 8: TC-ion-CXL 5.4 J/cm2; Group 9: TC-ion-CXL 6.75
J/cm2)
Assisted delivery of 0.25% riboflavin with 1.2% HPMC and 0.01% BAC were per-
formed in groups 8 and 9 via iontophoresis (Mediocross TE®, Peschketrade, Huenenberg,
Switzerland) using a current of 1 mA for 5 min. Subsequently, the corneas were soaked
with riboflavin solution for 5 min before receiving an additional application of iontophore-
sis with a power of 0.5 mA/min for 5 min and another 5 min riboflavin soak. After a 3
min wash with PBS, the corneas in Group 8 were irradiated with 9 mW UVA for 10 min
and those in Group 9 were irradiated with 9 mW UVA for 12 min and 30 sec. PBS drops
were applied at 5 min intervals during irradiation to avoid dehydration.
iii) Epi-on basic iontophoresis protocol (Group 10: Ion-CXL 5.4 J/cm2; Group
11: Ion-CXL 6.75 J/cm2)
According to the Sooft iontophoresis protocol, groups 10 and 11 underwent ion-
tophoresis assisted riboflavin delivery using an isotonic 0.1% riboflavin solution (Vitamin
B2) containing 1.0% HPMC dextran-free solution (Mediocross M®, Peschketrade, Hue-
nenberg, Switzerland) and a 1 mA current (Iontophoresis device, Sooft Italia S.p.A, Italy).
The corneas were washed with PBS for 3 min following treatment. Irradiation of group
10 was performed with 9 mW UVA for 10 min and group 11 was irradiated with 9 mW
UVA for 12 min and 30 sec. PBS drops were applied at 5 min intervals during irradiation
to avoid dehydration.
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4.3.2 Measurements of corneal thickness
The central corneal thickness was measured in all eyes prior to treatment, after removal of
the epithelium, post application of riboflavin and when applicable, after UVA irradiation.
Corneal thickness measurements were made using a Pachette2™ Ultrasonic Pachymetry
(DGH Technology, Exton, USA) or a Tomey ultrasound pachymeter (Tomey Corporation,
Nuremberg, Germany).
4.3.3 Measurements of enzymatic digestion
Straightway after treatment, a corneo-scleral ring was dissected from each eye, wrapped
tightly in ClingfilmTM (to prevent moisture loss) and refrigerated until all treatments were
finished. Using a disposable skin biopsy punch, an 8 mm corneal disc was trephined
from the centre of each cornea. Then, the corneal discs were submerged into individual
plastic tubes, each containing 5 ml of pepsin solution, and immersed in a water bath at
a temperature of 23◦C. The pepsin solution was made up of 1 g of > 500 U/mg pepsin
from porcine gastric mucosa (Sigma-Aldrich, Dorset, UK) in 10 ml 0.1M HCl at pH
1.2. Daily measurements of corneal disc diameter were used to assess the stability of
the most anterior layers of the cornea. An electronic digital caliper was used to acquire
the measurements, and measurements were made until the point at which the specimen
could no longer be differentiated from the surrounding pepsin solution. At this point the
tissue was considered to have undergone complete digestion. The total digestion time
(in days) was recorded for each cornea. In addition to assessing enzymatic resistance, 5
corneal discs from each of the 6 treatment groups in run 2 were removed from pepsin
digest solution after 11 days and transferred to a 60◦C oven for a minimum of one week
until a constant dry weight was measured. The dry weight of the tissue signifies the total
mass of undigested tissue and consequently can be used as an indicator of the effective
depth of cross-linking.
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4.3.4 Statistical Evaluation
One-way analysis of variance (ANOVA) test was used to statistically analyse measure-
ments of corneal thickness, complete digestion time and tissue dry weight. In order to
isolate significant interactions, post hoc Bonferroni comparisons were used. All statistical
analyses were performed with the Statistical Package for the Social Sciences (IBM SPSS
Statistics 20, New York, USA). P-value < 0.01 was considered to be significant. Data
were presented in the results as mean ± standard deviation (SD).
4.4 Results
4.4.1 Corneal thickness
The average corneal thickness pre-treatment, post-riboflavin application and post-irradiation
for each treatment group in run 1 and 2 are shown in Figure 4.2. Statistical tests discovered
a significant difference in thickness between corneas treated using the epi-off protocol and
an iso-osmolar riboflavin solution (groups 1 and 2) and the corneas in all other groups (p
< 0.007).
4.4.2 Qualitative assessment of riboflavin uptake
As shown in Figure 4.3, the distinctive yellow colouration of riboflavin wasmost obviously
noticeable in the epi-off and TC-ion treated corneas. Even if riboflavin was also seen
in corneas from other treatment groups, the colour was notably less intense. A non-
homogenous distribution of riboflavin in Ion-CXL treated corneas and a more uniform
distribution following epi-off CXL and TC-Ion-CXL were seen in photographs recorded
during the irradiation process in run 2.
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Figure 4.2: Corneal thickness measurements are shown for each group in run 1 and run
2 before treatment, after riboflavin application and where applicable, following UVA ir-
radiation. In groups 1 and 2 the corneal epithelium (measuring 90 µm in thickness) was
removed as part of the riboflavin application process.
Cross-linking treatments: (1) Epi-off-ribo (Epithelium-off non-irradiated control); (2)
Epi-off-CXL 5.4 J/cm2 (Epithelium-off standard CXL); (3) Dis-ribo (Disrupted epithe-
lium non-irradiated control); (4) Dis-CXL 5.4 J/cm2 (Disrupted epithelium CXL); (5)
Medio-ribo (Epithelium intact non-irradiated control); (6) Medio-CXL 5.4 J/cm2 (Ep-
ithelium intact high riboflavin concentration CXL); (7) TC-ion-ribo (Epithelium intact,
high riboflavin concentration and prolonged iontophoresis non-irradiated control); (8)
TC-ion-CXL 5.4 J/cm2 (Epithelium intact, high riboflavin concentration and prolonged
iontophoresis CXL); (9) TC-ion-CXL 6.75 J/cm2 (Epithelium intact, high riboflavin con-
centration, prolonged iontophoresis and high UVA energy dose CXL); (10) Ion-CXL 5.4
J/cm2 (Epithelium intact, basic iontophoresis protocol) and (11) Ion-CXL 6.75 J/cm2
(Epithelium intact, basic iontophoresis protocol with high UVA energy dose).
4.4.3 Pepsin digestion of corneal disks
The number of days required for complete tissue digestion to occur in each irradiated
and non-irradiated treatment group is shown in Table 4.2. Even though the duration of
digestion of equivalent non-irradiated (group 1) and cross-linked treatment groups (group
2) varied slightly between runs 1 and 2, the same general trends were observed in both
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Figure 4.3: Corneal disks from each group in run 1 and 2 are shown immediately post-
treatment. The characteristic yellow colour of riboflavin can be seen most clearly in the
epithelium-removed, riboflavin treated corneas (epi-off) and in the corneas that received
riboflavin via the St Thomas’s/Cardiff modified iontophoresis protocol (TC-Ion). Pho-
tographs recorded during the irradiation process show a non-homogenous distribution of
riboflavin in corneas treated with the basic iontophoresis protocol (Ion-CXL).
Cross-linking treatments: (1) Epi-off-ribo (Epithelium-off non-irradiated control); (2)
Epi-off-CXL 5.4 J/cm2 (Epithelium-off standard CXL); (3) Dis-ribo (Disrupted epithe-
lium non-irradiated control); (4) Dis-CXL 5.4 J/cm2 (Disrupted epithelium CXL); (5)
Medio-ribo (Epithelium intact non-irradiated control); (6) Medio-CXL 5.4 J/cm2 (Ep-
ithelium intact high riboflavin concentration CXL); (7) TC-ion-ribo (Epithelium intact,
high riboflavin concentration and prolonged iontophoresis non-irradiated control); (8)
TC-ion-CXL 5.4 J/cm2 (Epithelium intact, high riboflavin concentration and prolonged
iontophoresis CXL); (9) TC-ion-CXL 6.75 J/cm2 (Epithelium intact, high riboflavin con-
centration, prolonged iontophoresis and high UVA energy dose CXL); (10) Ion-CXL 5.4
J/cm2 (Epithelium intact, basic iontophoresis protocol) and (11) Ion-CXL 6.75 J/cm2
(Epithelium intact, basic iontophoresis protocol with high UVA energy dose).
runs. Therefore, the data from each run was normalised against the total digestion time of
the epi-off CXL group to permit comparison between the two runs (Figure 4.4 and 4.5).
Cumulative measurements of corneal disk diameter for each irradiated and non-
irradiated treatment group throughout the digestion process are shown in figures 4.4 and
4.5. In both runs 1 and 2, the cross-linked groups showed a significantly greater resistance
to enzymatic digestion than the non-irradiated groups (p < 0.0001). In run 1, by day 13,
complete digestion of all non-irradiated corneas had occurred (Table 4.2). At the same
time point (normalized digestion time of 0.33), the mean diameter of the epi-off-CXL,
Chapter: 4 114
Investigations into the effectiveness of new and existing corneal cross-linking therapies
dis-CXL, medio-CXL and TC-ion-CXL groups had only decreased by 39%, 62%, 74%,
and 40 %, respectively (Figure 4.4). No significant difference was found between the non-
irradiated groups in terms of either the average corneal disc diameter at any time point in
the digestion process or in the time required for complete digestion to occur (Figure 4.4).
Nevertheless, there were significant differences in the time taken for complete digestion
to occur between the cross-linked groups (Figure 4.4). The epi-off-CXL corneas (group
2) took significantly longer to digest than all other cross-linked corneas (p < 0.0001).
Although less resistant to enzyme digestion than the epi-off CXL corneas, the TC-ion-
CXL treated corneas took significantly longer to digest than corneas treated with other
dis-CXL or epi-on-CXL protocols (p < 0.0001).
In run 2, the non-irradiated corneas were completely digested by day 10 (Table 4.2)
which equates to a normalized digestion time of 0.25. At this time point, themean diameter
of corneas in the epi-off-CXL 5.4 J/cm2, TC-ion-CXL 5.4 J/cm2, TC-ion-CXL 6.75 J/cm2,
Ion-CXL 5.4 J/cm2 and Ion-CXL 6.75 J/cm2 treatment groups had only reduced by 21.4%,
16.2%, 13.4%, 26.7% and 19.4%, respectively (Figure 4.5). After 24 days of digestion
(normalised digestion time of 0.6), significant differences in the mean disk diameter in
the CXL treatment groups were seen (Figure 4.5). The epi-off-CXL group (group 2) took
longer to undergo complete digestion than all other cross-linked groups (p < 0.0001).
On the other hand, corneas treated with the prolonged, high riboflavin concentration,
iontophoresis protocol (TC-ion-CXL) were found to persist in the pepsin digest solution
for significantly longer than those treated with the basic Ion-CXL protocol (Figure 4.5).
In both the Ion-CXL and TC-ion-CXL treatment groups, a significant increase in the
time required for complete digestion to occur (p < 0.0001) was observed when the UVA
radiance was increased from 5.4 J/cm2 to 6.75 J/cm2.
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Table 4.2: Time taken for the complete tissue digestion to occur.
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4.4.4 Undigested tissue mass
In run 2, after 11 days in pepsin digest solution only the cross-linked corneas remained
(Figure 4.6). At this time point, the average stromal dry weight of the epi-off-CXL 5.4
J/cm2 treated corneas (group 2) was significantly higher than that of all other treatment
groups (groups 8, 10, 11, p < 0.0001; group 9, p < 0.001). The stromal dry weight did
not differ significantly between the Ion-CXL 5.4 J/cm2 and Ion-CXL 6.75 J/cm2 treatment
groups (p = 0.32) or between the TC-ion-CXL 5.4 J/cm2 and TC-ion-CXL 6.75 J/cm2
groups (p = 0.038). However, corneas treated with the TC-Ion-CXL 6.75 J/cm2 protocol
had a higher stromal dryweight than corneas treatedwith basic ion-CXL5.4 J/cm2 protocol
(p < 0.003).
Figure 4.6: Average stromal dry weight of corneal disks treated with Epi-off-ribo, Epi-off-
CXL, TC-ion-CXL 5.4 J/cm2, TC-ion-CXL 6.75 J/cm2, Ion-CXL 5.4 J/cm2 and Ion-CXL
6.75 J/cm2, after 11 days of digestion. Error bars show standard deviation.
Cross-linking treatments: (1) Epi-off-ribo (Epithelium-off non-irradiated control); (2) Epi-
off-CXL5.4 J/cm2 (Epithelium-off standardCXL); (8) TC-ion-CXL 5.4 J/cm2 (Epithelium
intact, high riboflavin concentration and prolonged iontophoresis CXL); (9) TC-ion-CXL
6.75 J/cm2 (Epithelium intact, high riboflavin concentration, prolonged iontophoresis and
high UVA energy dose CXL); (10) Ion-CXL 5.4 J/cm2 (Epithelium intact, basic ion-
tophoresis protocol) and (11) Ion-CXL 6.75 J/cm2 (Epithelium intact, basic iontophoresis
protocol with high UVA energy dose).
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4.5 Discussion
Achieving sufficient stromal riboflavin concentration is crucial for CXL. Riboflavin acts as
a photo-sensitizer for the production of oxygen free radicals, which drive the CXL process
(McCall et al. 2010) and consequently, insufficient stromal absorptionmay cause treatment
failure (Wollensak et al. 2009, 2003). Since riboflavin is a hydrophilic molecule that is
unable to penetrate epithelial cell membranes and tight junctions, the first riboflavin/UVA
CXL protocols required complete central corneal epithelial debridement prior to riboflavin
application (Spoerl et al. 1998; Wollensak et al. 2003). Epi-off-CXL is considered to be
the gold standard technique as supported by a number of prospective and randomized
controlled studies demonstrating its efficacy in relation to cessation of keratoconus pro-
gression and improvements in keratometric and visual parameters (Caporossi et al. 2006;
Gkika et al. 2011; O’Brart et al. 2011; Richoz et al. 2013; Wittig-Silva et al. 2014; Wol-
lensak et al. 2003). However, new techniques of epi-on-CXL have been considered to
eliminate the necessity for epithelial debridement, thus reducing post-operative pain and
possible risks of infection (Henriquez et al. 2017; Koller et al. 2009). Moreover, the use
of ACXL protocols applying the same energy dose but higher UVA intensities and shorter
exposure times to decrease the long treatment times associated with epi-off-CXL with 3
mW/cm2 UVA irradiation have been proposed (Aldahlawi et al. 2015; Elbaz et al. 2014;
Konstantopoulos et al. 2015; Shetty et al. 2015). With the aim of assessing the efficacy
of such varying CXL protocols, multiple methodologies, including extensiometry (Cas-
sagne et al. 2016; Kissner et al. 2010; Vinciguerra et al. 2014a; Wollensak et al. 2009),
shear wave elastography (Singh et al. 2017; Touboul et al. 2014), Brillouin microscopy
(Randleman et al. 2017; Scarcelli et al. 2013) and Scheimpflug air pulse tonometry (Mas-
tropasqua et al. 2014b) have been applied. However, each of these methodologies has their
imprecisions and so far, there is no approved best practice for evaluating biomechanical
changes following CXL.
Even though the precise aetiology of keratoconus is unidentified (Davidson et al.
2014), an increased activity of protease enzymes and reduced activity of protease inhibitors
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has been recognised (Spoerl et al. 2004), with the subsequent increase in stromal protein
digestion liable to be a factor in corneal thinning and secondary biomechanical instability
(Andreassen et al. 1980). An increase in resistance of stromal tissue to enzymatic digestion
following epi-off CXL with a dose response related to the intensity of UVA irradiance
was stated by Spoerl et al. (2004). Some researchers replicated this increased resistance
to protease digestion following CXL (Aldahlawi et al. 2016; Hayes et al. 2013) and it is
thought that this enhanced enzymatic resistance may be a key factor in protection against
disease advancement, in light of the known increase in proteinase activity and a reduction
in proteinase inhibitor activity in keratoconic corneas (Zhou et al. 1998). In this study,
pepsin was selected as the enzyme of choice in preference to collagenase, as it is a non-
specific endopeptidase that can break down both collagen and proteoglycan core proteins,
and both of these are thought to be sites of riboflavin/UVA induced cross-links (Hayes
et al. 2013). Due to the limited availability of human cadaver eyes and rabbit eyes in
the UK, porcine eyes were used. The reason is that they were freshly obtainable and in
the sufficiently large numbers required for this study. Nevertheless, owing to the porcine
cornea having a thicker corneal epithelium than the human cornea, the results have to be
regarded as a conservative assessment of the effectiveness of trans-epithelial CXL.
In this study, examination of the enzymatic resistance of corneas to pepsin digestion
was used to evaluate the effectiveness of epi-off-CXL, dis-CXL and epi-on-CXL. Despite
slight alterations in the rate of enzymatic digestion between similarly treated corneas in
runs 1 and 2, perhaps due to variations in the age and breed of the pig eyes in different
batches of abattoir tissue, each run exhibited an increased resistance in all of the cross-
linked groups in comparison to their non-irradiated controls. Conversely, in agreement
with the results of Wollensak et al. (2009), which stated corneal stiffness after epi-on-
CXL to be only one fifth of that seen after epi-off-CXL (indicating a reduced crosslinking
effect), our study shows enzymatic resistance to be significantly greater in epi-off-CXL
treated corneas than in dis-CXL or epi-on-CXL treated corneas. Despite the fact that dis-
CXL showed a greater resistance to digestion than the non-irradiated controls, it was not
as effective as the other epi-on-CXL protocols, maybe because of the non-homogeneous
Chapter: 4 121
Investigations into the effectiveness of new and existing corneal cross-linking therapies
uptake of riboflavin which was observed here and documented previously (Alhamad et al.
2012). This finding is supported by a recent, randomized controlled clinical study which
showed better corneal flattening with epi-off-CXL than dis-CXL, even though remarkably,
dis-CXL lead to enhancement of corrected distance visual acuity at 6 months (Razmjoo
et al. 2014).
In this study, it was demonstrated that corneas cross-linked using Mediocross TE®
(Medio-CXL protocol) showed a greater resistance to enzymatic digestion than non-
irradiated controls and dis-CXL treated corneas. However, the enhanced enzymatic
resistance achieved with Medio-CXL was established to be inferior to that of the epi-
off and ion-CXL protocols. Mediocross TE® is a hypo-osmolar riboflavin solution that
contains 0.01% BAC, a cationic surfactant that can disrupt epithelial tight junctions to
increase corneal permeability to riboflavin (Kissner et al. 2010; Raiskup et al. 2012).
Preparations with sodium chloride and BAC can facilitate riboflavin transfer through an
intact epithelium albeit with significant linked superficial epithelial damage and a lower
stromal concentration compared to that achieved with epi-off-CXL (Touboul et al. 2014;
Uematsu et al. 2007). A recent study examining the resistance of cross-linked corneas to
collagenase showed that an extended penetration time of TE-riboflavin may improve the
effect of CXL treatment and make it equivalent to SCXL (Cruzat et al. 2017). Only limited
clinical studies using enhanced riboflavin solutions with epithelial penetration enhancers
have been published and have given inconsistent results. Some have reported a similar
efficacy to epi-off-CXL (Filippello et al. 2012; Magli et al. 2013), however others have
shown high rates of treatment failure (Buzzonetti et al. 2012; Kocak et al. 2014; Koppen
et al. 2012; Leccisotti et al. 2010). Currently, published randomized, controlled trials
comparing epi-off and epi-on-CXL showed similar conclusions, with follow-up times of
up to 12 months (Nawaz et al. 2015; Rossi et al. 2015). Contrary to this, another study
involving 61 patients, showed epi-on-CXL to be safe but progression of keratoconus was
documented in 23% of cases at 12 months follow-up (Soeters et al. 2015). The last study
results are consistent with the less pronounced biomechanical alterations detected by lab-
oratory experiments after epi-on-CXL (Wollensak et al. 2009). Moreover, a prospective
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study with a follow-up of 12 months demonstrated the safety and efficacy of accelerated
epi-on CXL for halting progression of keratoconus (Aixinjueluo et al. 2017).
The use of iontophoresis has been suggested to enhance trans-epithelial riboflavin ab-
sorption because riboflavin is negatively charged at physiological pH and soluble in water.
Commercially available procedures for iontophoresis utilize 0.1% riboflavin solution and
electrical currents of 0.5 - 1 mA for 5 to 10 min (Foschini et al. 2016). On iontophoresis
procedure using 1 mA for 5 min, a reduction by two thirds in the stromal riboflavin uptake
achieved with epi-off-CXL was documented in treatment of rabbit corneas, nonetheless to
produce a similar enhancement in corneal biomechanics (Cassagne et al. 2016). Similar
findings were reported in studies on rabbit and human cadaver corneas, with improved
riboflavin penetration and increased elastometry measurements acquired with Ion-CXL
than with epi-on-CXL (using Ricrolin TE) but less than epi-off-CXL (Vinciguerra et al.
2014a); the same result was found by combining the accelerated 9 mW/cm2 for 10 min
and the iontophoresis technique on human cadaver eyes, and this revealed increased ri-
boflavin penetration and biomechanical resistance (Lanzini et al. 2016). In a human donor
eye model, a corneal stiffening effect following Ion-CXL was described by Mastropasqua
et al. (2014b) using deformation amplitude index, and inflation tests by Lombardo et al.
(2014) reported a similar effect on corneal stiffness to that with epi-off-CXL. Supersonic
shear wave elastography has confirmed these findings (Touboul et al. 2014). Moreover,
preliminary Ion-CXL clinical studies in prospective case series have stated termination
of keratoconus progression with up to 15 months follow-up and some partial progress
in keratometric and visual parameters (Bikbova et al. 2014; Buzzonetti et al. 2015; Vin-
ciguerra et al. 2014b). Nevertheless, the relative effectiveness of this technique compared
to epi-off-CXL are yet to be confirmed particularly over longer-term follow-up.
It has been established that stromal riboflavin absorption in epithelium-intact corneas
can be improved by increasing riboflavin concentration, epithelial contact time and ion-
tophoresis dosage when using spectrophotometry (Hayes et al. 2015), two-photon fluores-
cence microscopy (Gore et al. 2014) and enzymatic digestion (O’Brart et al. 2018), Based
on this work, the basic Sooft italia Ion-CXL protocol (Sooft italia S.p.A, Motegiorgio,
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Italy) was modified and the St Thomas’s/Cardiff modified iontophoresis protocol (TC-
ion-CXL) established. The TC-ion-CXL protocol uses Mediocross TE® in preference
to the Ricrolin+® solution used in the Ion-CXL protocol on the basis that the riboflavin
concentration of the former is higher (0.25%) and the use of the cationic surfactant BAC
has been shown with percutaneous treatment to have synergistic effect with iontophoresis
on the transport of anions (Fang et al. 1998). The TC-Ion-CXL protocol also includes an
extended riboflavin-epithelial contact period of 5 min after iontophoresis to permit time
for the sub-epithelial iontophoretically transported riboflavin to diffuse homogeneously
into the stroma, and involves an increased dosage of iontophoresis with a second treatment
5 min after the first. Results from this study have shown that both the basic Ion-CXL
and modified TC-ion-CXL protocols result in a greater resistance to enzymatic digestion
than all of the other dis-CXL and trans-epithelial CXL protocols examined. Furthermore,
this study has shown that the enzymatic resistance of Ion-CXL and TC-ion-CXL treated
corneas can be further improved by increasing the UVA energy dose from 5.4 J/cm2 to
6.75 J/cm2, presumably by permitting additional type I photochemical cross-linking to
happen. The enhancement in enzymatic resistance was evidenced by the Ion-CXL and
TC-ion-CXL corneas treated with a total energy dose of 6.75 J/cm2, persisting for longer
in enzyme digest solution than those that received a lower energy dose of 5.4 J/cm2. The
similarity in their dry weights after 11 days of digestion is probably clarified by the fact
that at this phase of the digestion process, the rate of digestion was alike for both the 5.4
J/cm2 and 6.75 J/cm2 treatment groups and significant differences in average corneal disk
diameter were not observed until day 24.
The enzymatic resistance accomplished with the TC-ion-CXL 6.75 J/cm2 protocol
was closest to that of the epi-off-CXL 5.4 J/cm2 protocol, signifying that this method may
be the best trans-epithelial substitute for epi-off-CXL. Its somewhat lower effectiveness
compared to epi-off-CXL, as evidenced by measurements of corneal disk diameter and
tissue dryweight, may be due to a reduced riboflavin stromal absorption or an accumulation
of riboflavin inside the epithelium, which would have the effect of absorbing UVA and
shielding the underlying stroma. However, the latter explanation is doubtful as a 3 min
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PBS wash of the ocular surface was done before UVA exposure which has been shown by
others to successfully remove riboflavin from the epithelium (Gore et al. 2015). Another
explanation is that the wash-out period may have been too long and resulted in some
loss of riboflavin from the anterior stroma. It is worth stating that excess wash-out
could also explain the reduced amount of cross-linking and hence, epithelium riboflavin
wash-out times require further optimisation, especially as the human corneal epithelium
is thinner and therefore, 3 minutes may wash-out a lot more riboflavin from the human
anterior stroma than the porcine anterior stroma. No longer than 1-2 min PBS rinse
is highly recommended (E. Spoerl, personal communication, International CXL Experts
meeting 2014 in Zurich). One more likely reason of the reduced efficacy could be the
oxygen consumption by the epithelium itself (Harvitt et al. 1998), which might lessen
the amount of oxygen available to the stroma to drive the CXL process (Friedman et al.
2017; McCall et al. 2010). Additional manipulation of the UVA dosage can overcome
such complications, regarding its intensity and duration and/or by increasing oxygen
accessibility and necessitate further exploration. Another additional explanation may be
the restriction of our porcine model. Due to the porcine cornea having a much thicker
corneal epithelium than the human cornea (90 µm and 50 µm, respectively), the results
of this study must be observed as a conservative assessment of the efficiency of trans-
epithelial CXL. Regrettably, human donor corneas are inappropriate for investigating the
effects of CXL on enzymatic resistance as a result of the fact that donors are usually over
60 years old, and the naturally occurring cross-links which increase with age, may disguise
the effects of the CXL treatment under investigation. Nevertheless, it would be interesting
to replicate our methodology in the rabbit model which has a thinner epithelium (40 µm)
and is closer in thickness to that of the human cornea. Such a study would supplement
our present conclusions by providing a more generous approximation of the usefulness of
trans-epithelial cross-linking.
The present study demonstrated the St Thomas’/Cardiff modified iontophoresis pro-
tocol (TC-ion-CXL) to be more effective than other trans-epithelial CXL protocols at
increasing the enzymatic resistance of the cornea, backing the concept that iontophoresis-
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assisted CXL may, with modifications in terms of riboflavin concentration, duration of
iontophoretic treatment, riboflavin soak-time and UVA energy dose, be an effective tech-
nique to inhibit the development of keratoconus and avoid the postoperative pain related
with epithelial debridement. This technique is predicted to be particularly suitable for
eyes that are not suitable for treatment with epi-off-CXL due to minimum corneal thick-
ness values less than 400 µm. Additional laboratory studies to enhance this protocol and
randomized, prospective clinical studies to compare its effectiveness with epi-off CXL
are required and are presently being commenced (D. O’Brart, personal communication,
International Standard Randomized Controlled Trials Number: 04451470).
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CHAPTER 5
AN EX VIVO INVESTIGATION INTO THE EFFECT OF
ACCELERATED CROSS-LINKING USING PULSED AND
CONTINUOUSUVAIRRADIATIONMODESONCORNEAL
ENZYMATIC RESISTANCE.
This chapter was published as a laboratory science article in Invest Ophthalmol Vis Sci.
2016; 57:1547–1552. DOI:10.1167/iovs.15-18769. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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5.1 Introduction
The exact photochemical mechanism involved in riboflavin/UVA CXL is at present uncer-
tain. Interestingly, however, it has been shown that oxygen is crucial to drive the process
and in the absence of oxygen, CXL is impaired (McCall et al. 2010). Not only is oxygen
an integral part of the equation, it has also been suggested that higher UVA intensity
or so-called ‘accelerated’ CXL (ACXL) protocols cause a more rapid oxygen depletion
thereby reducing efficacy (Brittingham et al. 2014; Touboul et al. 2012). However, it has
been shown that when UV irradiation is ceased, oxygen can be restored to its normal level
within 3 to 4 minutes (Kamaev et al. 2012). On this basis, it has been advocated that by
pulsing the UV light throughout the procedure, oxygen levels may continue to be replen-
ished, so that the CXL process is no longer impaired (Krueger et al. 2014; Mazzotta et al.
2014). Additionally, it has also been postulated that the efficacy of accelerated protocols
may be improved by increasing the exposure time by 30 to 40% (Kymionis et al. 2014;
Sherif 2014).
5.2 Research aim
In order to further investigate these issues and compare the efficacy of accelerated CXL,
extended accelerated CXL and pulsed CXL protocols with the ‘gold standard’ SCXL
protocol, the rate of enzymatic digestion after each CXL protocol was examined in an
ex-vivo porcine model.
5.3 Methods
5.3.1 Tissue Preparation and CXL Treatments
A total of 66 enucleated porcine eyes, obtained from a local European Community licensed
abattoir, were used within 6 hours of death. All have intact corneal epithelium and
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transparent cornea. After a complete debridement of the corneal epithelium using a
single-edged razor blade, the eyes were randomly and equally divided into the 6 groups;
groups 1 and 2 served as controls. With the exception of group 1, which received no
treatment, for the rest of the 5 groups (2, 3, 4, 5 and 6), 0.1% riboflavin solution containing
20% dextran T-500 (Mediocross D®, Peschke Meditrade, Huenenberg, Switzerland) was
applied to the anterior corneal surface for 30 minutes, using an annular suction ring (for
detail see Chapter 2). Groups 3, 4, 5 and 6 were then irradiated in the manner described in
Table 5.1, with Group 3 undergoing the SCXL protocol, Group 4 receiving a 30 mWUVA
for 3 min ACXL protocol (with the same total energy dose as that of the SCXL group) and
Groups 5 and 6 receiving a high total energy dose protocol (HCXL) comprising 30 mW
UVA for 4 min (corresponding to a 25 % increase in the total energy dose compared to the
SCXL protocol). In the case of Group 6 only, the UVA light was pulsed during exposure
in a cycle of 10-s on and 10-s off.
All of the irradiation protocols were performed using the Phoenix CXL System
(Peschke trade GmbH, Huenenberg, Switzerland) with a wavelength of 365 nm, a 50 mm
working distance and a 9 mm aperture (Figure 5.1). Measurement of the central corneal
thickness was via ultrasound pachymetry (DGH Pachmate 55; DGH Technologies, Exton,
PA, USA) (for more details please refer to Chapter 2) pre-treatment (after epithelial
debridement), post-riboflavin application and post-UVA exposure.
Following treatment, an 8 mm full-tissue-thickness biopsy was trephined from the
centre of each cornea. The corneal disks were placed in individual sealed tubes containing
5ml of pepsin digest solution (1 g of 600 to1200 U/mg pepsin from porcine gastric mucosa
(Sigma-Aldrich, Dorset, UK) in 10 ml 0.1 M HCl at pH 1.2) and incubated in a water bath
at 23◦C. 5 corneal disks from each group were removed from the pepsin digest solution
after 13 days and placed in a 60◦C oven until a constant dry weight was obtained. The
measurement and calculation used in this chapter were the same as mentioned previously
in Chapter 3.
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Table 5.1: Irradiation protocols of the six groups of porcine eyes
5.3.2 Data analysis
Data are shown as mean measurements (± SD) for corneal thickness, dry weight and
complete digestion time. Corneal disk diameter is presented as a daily cumulative mea-
surement for each treatment group. Statistical analysis was performed using a one-way
ANOVA and Bonferroni multiple comparisons in a depth-wise manner. All statistical
analyses were performed with the Statistical Package for the Social Sciences (SPSS Statis-
tics 20; IBM, Armonk, NY, USA), whereby a probability value of p < 0.05 was considered
significant.
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Figure 5.1: The Phoenix CXL System (Peschke trade GmbH, Huenenberg, Switzerland)
with a wavelength of 365 nm, a 50 mm working distance and a 9 mm aperture.
5.4 Results
5.4.1 Corneal Thickness
The average stromal thickness at each stage of treatment is shown in Figure 5.2. The
average stromal thickness did not differ significantly between groups before treatment.
However, a significant decrease in stromal thickness (p < 0.0001) was noted after 30-
minute application of riboflavin-dextran solution (group 2–6). The subsequent irradiation
of corneas in groups 3 to 6 produced no further changes in corneal thickness and the final
stromal thickness did not differ significantly between any of the CXL groups.
5.4.2 Time Taken for Complete Digestion
Figure 5.3 shows photographs of a representative corneal disk from each treatment group
prior to immersion in pepsin digest solution (day 0) and 1 and 2 days after digestion. As
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Figure 5.2: Average corneal thickness measured before, during and after treatment. Error
bars show standard deviation.
Cross-linking treatments: SCXL 3 mW (5.4 J/cm2) (standard cross-linking); ACXL 30
mW (5.4 J/cm2) (accelerated cross-linking); HCXL 30 mW (7.2 J/cm2) (accelerated, and
high energy UVA cross-linking) and p-HCXL 30 mW (7.2 J/cm2) (pulsed, accelerated and
high energy UVA cross-linking).
shown in previous experiments, within 1 day of submersion in pepsin solution, stromal
swelling, in a posterior-anterior direction was observed in all corneal disks (Figure 5.3).
After 2 days of digestion, a loss of structural integrity was seen in the untreated corneas
but the cross-linked corneas remained intact (Figure 5.3).
The cross-linked corneas (groups 3–6) took significantly longer to digest than the
non-irradiated specimens (groups 1 and 2) (p < 0.0001; Figure 5.4). Complete digestion
of non-irradiated corneas was noted after 13 days.
Corneas cross-linkedwith higher energy dose treatments (7.2 J/cm2) using continuous
(group 5) or pulsed light (group 6) took significantly longer to digest than corneas cross-
linked using lower (5.4 J/cm2) energy dose treatments (groups 3 and 4; p < 0.0001). A
direct comparison between treatments using the same energy dose revealed that corneas
cross-linked using the SCXL 3 mW (5.4 J/cm2) procedure took longer to digest than
corneas cross-linked using the ACXL 30 mW (5.4 J/cm2) procedure (p < 0.0001), and
corneas cross-linked using the pulsed irradiation p-HCXL 30 mW (7.2 J/cm2) procedure
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Figure 5.3: Photographs of a representative corneal disk from each treatment group prior
to immersion in pepsin digest solution (day 0) and 1 and 2 days after digestion.
Cross-linking treatments: SCXL 3 mW (5.4 J/cm2) (standard cross-linking); ACXL 30
mW (5.4 J/cm2) (accelerated cross-linking); HCXL 30 mW (7.2 J/cm2) (accelerated, and
high energy UVA cross-linking) and p-HCXL 30 mW (7.2 J/cm2) (pulsed, accelerated and
high energy UVA cross-linking).
took significantly longer to digest than those treated with the continuous irradiation HCXL
30 mW (7.2 J/cm2) procedure (p < 0.0001). The summed diameter of all corneal disks (n
= 6) within each cross-linked and non-cross-linked treatment group is shown as a function
of time in pepsin digest solution (Figure 5.4). In addition, the average time (± SD) required
for complete digestion of each treatment group has been added to the time-line.
Chapter: 5 133
Investigations into the effectiveness of new and existing corneal cross-linking therapies
Fi
gu
re
5.
4:
T
he
di
ge
st
io
n
ra
te
of
co
rn
ea
l
di
sk
s
tr
ea
te
d
w
ith
co
nt
ro
l
un
tr
ea
te
d,
ri
bo
fla
vi
n-
on
ly
,
SC
X
L
,A
C
X
L
,H
C
X
L
an
d
p-
H
C
X
L
.T
he
su
m
m
ed
di
am
et
er
of
al
lc
or
ne
al
di
sk
s
(n
=
6)
w
ith
in
ea
ch
cr
os
s-
lin
ke
d
an
d
no
n-
cr
os
s-
lin
ke
d
tr
ea
tm
en
tg
ro
up
is
sh
ow
n
as
a
fu
nc
tio
n
of
tim
e
in
pe
ps
in
di
ge
st
so
lu
tio
n)
no
rm
al
is
ed
ag
ai
ns
tt
he
st
an
da
rd
SC
X
L
.
C
ro
ss
-l
in
ki
ng
tr
ea
tm
en
ts
:
SC
X
L
3
m
W
(5
.4
J/
cm
2
)
(s
ta
nd
ar
d
cr
os
s-
lin
ki
ng
);
A
C
X
L
30
m
W
(5
.4
J/
cm
2
)
(a
cc
el
er
at
ed
cr
os
s-
lin
ki
ng
);
H
C
X
L
30
m
W
(7
.2
J/
cm
2
)
(a
cc
el
er
at
ed
,
an
d
hi
gh
en
er
gy
U
V
A
cr
os
s-
lin
ki
ng
)
an
d
p-
H
C
X
L
30
m
W
(7
.2
J/
cm
2
)
(p
ul
se
d,
ac
ce
le
ra
te
d
an
d
hi
gh
en
er
gy
U
V
A
cr
os
s-
lin
ki
ng
).
Chapter: 5 134
Investigations into the effectiveness of new and existing corneal cross-linking therapies
5.4.3 Undigested Tissue Mass
Thirteen days following submersion in pepsin digest solution, only the CXL-treated
corneas remained (Figure 5.5); corresponds to approximately 0.43 normalized diges-
tion time against the SCXL (Figure 5.4). At this time point, the average corneal disk dry
weight of the SCXL (5.4 J/cm2) treated corneas was significantly higher than that of the
ACXL 30 mW (5.4 J/cm2) (p < 0.0001), HCXL 30 mW (7.2 J/cm2) (p < 0.001) and p-
HCXL 30 mW (7.2 J/cm2) treated corneas (p < 0.05). Interestingly, there is no significant
difference in stromal dry weight between the two higher energy treatment groups which
used continuous (HCXL 30 mW (7.2 J/cm2)) and pulsed (p-HCXL 30 mW (7.2 J/cm2))
irradiation. The corneas treated with p-HCXL 30 mW (7.2 J/cm2) had a higher stromal
dry weight than the corneas treated with ACXL 30 mW (5.4 J/cm2) (p < 0.0001).
Figure 5.5: Average stromal dry weight of corneal disks treated with control untreated,
riboflavin-only, SCXL, ACXL, HCXL and p-HCXL, after 13 days of digestion. Error bars
show standard deviation.
Cross-linking treatments: SCXL 3 mW (5.4 J/cm2) (standard cross-linking); ACXL 30
mW (5.4 J/cm2) (accelerated cross-linking); HCXL 30 mW (7.2 J/cm2) (accelerated, and
high energy UVA cross-linking) and p-HCXL 30 mW (7.2 J/cm2) (pulsed, accelerated and
high energy UVA cross-linking).
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5.5 Discussion
Oxygen is crucial to drive the riboflavin/UVA CXL process; in its absence cross-link
formation is impaired (McCall et al. 2010). Reduced efficacy with ACXL protocols has
been postulated to be due to more rapid oxygen depletion compared to the more prolonged
but less intense UVA exposure in SCXL (Brittingham et al. 2014; Touboul et al. 2012).
The actual photochemical mechanisms involved in riboflavin/UVA CXL are uncertain.
It has been propounded that under aerobic conditions with a brief type II photochemical
reaction, sensitised photooxidation of stromal proteins occurs, mainly by their reactionwith
photochemically generated reactive oxygen species (Kamaev et al. 2012). After the initial
15 seconds of exposure to UVA, when oxygen becomes depleted, a type I photosensitizing
mechanism may then predominate, subsequently producing radical ions that can induce
covalent CXL of stromal macromolecules (Friedman et al. 2017; Kamaev et al. 2012).
In SCXL, where UVA exposure occurs over 30 minutes, the oxygen concentration in the
cornea may slowly increase during the later stages of the treatment to a level at which a
type-II mechanism may once again begin (Kamaev et al. 2012). On the basis that oxygen
can be restored to its normal tissue levels within 3 to 4 minutes of cessation of UVA
radiation (Kamaev et al. 2012). If this is so, then pulsing the UV light could potentially
help replenish oxygen levels, so that the CXL process is no longer impaired (Krueger et al.
2014; Mazzotta et al. 2014).
The other method found to improve efficacy of the accelerated CXL protocol is
increasing UVA exposure time, and ultimately the overall cumulative dosage, by 30 to
40% (Kymionis et al. 2014; Sherif 2014). In the present study, the aim was to investigate
the porcine corneal resistance to enzymatic (pepsin) digestion, utilising a number of these
newer commercially available extended and pulsed accelerated protocols.
All the eyes treated in this study received an application of an iso-osmolar riboflavin
solution (containing 20% dextran) to the deepithelialised corneal surface. Consistent with
earlier studies (Hassan et al. 2014; Hayes et al. 2013), a decrease in corneal thickness was
noted. This can be ascribed to the dehydration effect of the dextran and, possibly, to the
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existence of riboflavin (Aldahlawi et al. 2015), which has the effect of enhancing the ionic
strength of the applied solution and likely cause further reduction of the cornea hydration
(Huang et al. 1999).
Corneal thickness measurements were considered to be an unreliable measure of the
rate of enzymatic digestion due to treatment-induced variations in corneal thickness and
the swelling of the trephined corneal disks (in the posterior-anterior direction) during the
first 24 hours of immersion in pepsin digest solution (Aldahlawi et al. 2015). As such,
in this current study, daily measurement of the diameter of the anterior corneal surface
and the dry weight of the undigested tissue after 13 days of digestion was taken. These
measurements provided a more reliable assessment of both the structural integrity of the
anterior corneal stroma and the effective depth of CXL following each treatment variation.
Corneas treated with ACXL 30 mW (5.4 J/cm2) had a lower residual mass after 13
days of digestion, and took less time to undergo complete digestion than SCXL-treated
corneas. This may be due to a reduced CXL effect and a failure of the Bunsen-Roscoe
law of reciprocity at higher UVA intensities. This idea is supported by the findings of
biomechanical studies that report a reduced corneal stiffening effect with increasing UVA
intensity up to 18 mW (Hammer et al. 2014), and a sudden decrease in efficacy with very
high intensities greater than 45 mW/cm2 (Wernli et al. 2013). It is thought that the failure
of the Brunsen-Roscoe law in cases of very high intensity and short illumination time,
may be attributed to inhibition of the CXL process due to a lack of oxygen (McCall et al.
2010) and on this basis the concept of p-HCXL was introduced. However, recent studies
comparing the biomechanical changes after p-HCXL and SCXL have reported a reduced
corneal stiffening effect with p-HCXL (30 mW/cm2 for 8 min) compared to SCXL 3 mW
(5.4 J/cm2) (Kling et al. 2017), whereas, another study using uniaxial strip extensiometry
demonstrated an equal increase in the stiffening effect following cross-linking with a
45 mW pulsed UVA illumination compared to cross-linking with a 45 mW continuous
UVA illumination (Zhang et al. 2017). These findings, along with our results of increased
residual mass in p-HCXL treated eyes, lends support to this hypothesis; oxygen availability
is greater than in non-pulsed HCXL treatments. It seems that some oxygen replenishment
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occurred after each pulse. A longer pulse duration (in excess of 10 s) might be a means of
enhancing the cross-linking process further.
The enhanced enzymatic resistance observed with increased exposure time of the
cornea to 30 mW UVA from 3 to 4 minutes may be due to the increase in the total energy
dose from 5.4 to 7.2 J/cm2, which allowed additional type I photochemical CXL to take
place. It is improbable that the increased CXL effect is due to the extended treatment
providing additional time for the oxygen levels to be replenished to a level at which the
type II CXL reaction could be restarted as, even when SCXL is performed, the oxygen
concentration is thought only to reach adequate levels in the latter half of the 30-minute
protocol (Kamaev et al. 2012).
Although the dry weight of the SCXL-treated corneas was higher when measured
midway through the digestion process, corneas treated with HCXL and p-HCXL and a
total energy dose of 7.2 J/cm2 were found to persist for longer in enzyme digest solution
than SCXL (5.4 J/cm2) treated corneas. This suggests that differences in the distribution
of CXL may occur within the tissue. It can be theorised that CXL using a higher UVA
intensity and a greater total energy dose results in superior CXL strength within the most
anterior stromal layers and/or the mid-corneal region, leading to longer overall digestion
times. However, the depth of CXL may be shallower or there may be a more rapid
decrease in the intensity of CXL as a function of depth, compared to SCXL, resulting in
a reduced overall mass of cross-linked tissue. It is of interest that Brillouin microscopy
studies of SCXL-treated corneas have shown that the intensity of CXL is depth-dependent,
with the anterior stroma contributing the most to the increase in mechanical stiffness, and
examination of the effect of varying UVA exposure time (0–30 minutes) has shown a
dose-dependent tissue stiffening in the anterior third of the cornea (Scarcelli et al. 2013).
The clinical importance of these findings is ambiguous, as the exact amount and
location of cross-linked tissue necessary to prevent keratoconic progression has yet to
be determined. Clinical studies comparing CXL with accelerated pulsed or continuous
UVA CXL protocols are limited and somewhat conflicting. In a clinical study by Tomita
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et al comparing the outcomes of SCXL to an ACXL procedure using a UVA exposure
of 30 mW/cm2 for 3 minutes, there was no notable difference in either the visual and
topographic indices or the depth of the demarcation line at 6 months (Tomita et al. 2014);
however, in a randomized clinical study involving 138 eyes, Shetty et al. reported poorer
refractive and tomographic outcomes at 12 months follow-up in the patients treated with a
30 mW/cm2 for 3 minutes ACXL procedure compared to those treated with SCXL (Shetty
et al. 2015). A 1-year follow-up of 20 patients treated with either pulsed or continuous
light HCXL 30 mW (7.2 J/cm2) showed keratoconus stability in both groups, although
better functional outcomes and a deeper demarcation line were noted for the pulsed light
treatment (Mazzotta et al. 2014) and a 2-year prospective study of 132 eyes showed same
results with ACXL pulsed 15 mW/cm2 for 12 min and a total dose of 5.4 J/cm2 (Mazzotta
et al. 2017). Similarly, in a retrospective study of 60 patients treated with HCXL 30 mW
(7.2 J/cm2), the demarcation line was found to be deeper in patients treated with pulsed
rather than continuous light (Moramarco et al. 2015). Peyman et al. (2016) reported also
similar results in a clinical study of 70 eyes. However, in a comparative clinical study
by Jiang et al. (2017) between pulsed HCXL 30 mW (7.2 J/cm2) to SCXL, there was
statistically greater reduction in maximum and mean keratometry and deeper demarcation
lines in SCXL treated eyes. This result endorsed our finding that a higher undigested
corneal mass was found in SCXL than p-HCXL 30 mW (7.2 J/cm2). Clearly further,
prolonged clinical studies are needed to compare the outcomes of p-HCXL with SCXL,
both of which appear on the basis of this study to offer the best outcomes in terms of
resistance to enzyme digestion.
In conclusion, differences in the enzymatic resistance of SCXL, ACXL and HCXL
corneas indicate that the intensity and distribution of cross-links differs as a result of
the treatment protocol employed. Although the use of an accelerated protocol with a
higher energy dose and pulsed UVA (p-HCXL) appears to offer the best results in terms
of increased enzymatic resistance, the exact amount of cross-linking needed to prevent
disease progression is not yet known.
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6.6 Introduction
Whilst the clinical outcomes of the SCXL procedure have been very positive, there are
number of drawbacks to this treatment, such as the prolonged procedure time (which
lasts over an hour) and the postoperative pain/risk of infection associated with debriding
the epithelium. These factors have led to an interest in modifying CXL protocols, to
overcome these problems. These modiﬁcations include (1) reducing the irradiation time,
whilst simultaneously increasing the UVA irradiance, to deliver the same (ACXL) or
higher (HCXL) energy dose to that of the SCXL technique but over a shorter time-frame
(Cinar et al. 2014; Elbaz et al. 2014), (2) pulsed UVA delivery techniques to increase
oxygen availability during ACXL and HCXL (Mazzotta et al. 2014; Mencucci et al. 2015)
and (3) non-removal of the epithelium and the application of riboﬂavin solutions with
permeation enhancers, either in isolation or in combination with iontophoretic delivery
techniques to enhance stromal penetration (Arboleda et al. 2014; Bouheraoua et al. 2014).
As described in Chapters 3, 4 and 5, each of these modiﬁcations on their own has had
varied success to improve the resistance of the cornea to enzymatic digestion.
In vitro studies examining the eﬀectiveness of the basic iontophoresis-assisted,
epithelium-on cross-linking protocol, which uses a dextran-free riboﬂavin solution and
a current intensity of 1 mA for 5 min, have been encouraging in that they appear to en-
hance the penetration of riboﬂavin across the epithelium (Cassagne et al. 2016). However,
the stromal riboﬂavin concentration remains less than that achieved with epithelium-oﬀ
riboﬂavin application (Cassagne et al. 2016). Clinical studies of iontophoresis-assisted
cross-linking have shown a cessation of disease progression and improvements in visual
parameters in many cases, but the outcomes appear to be inferior to those of SCXL,
and the long-term eﬃcacy of the technique is unknown (Mastropasqua et al. 2014a). As
demonstrated in Chapter 4, corneal resistance to enzyme digestion can be improved by
increasing both the concentration of riboﬂavin and the duration of iontophoresis and fur-
ther gains may be achieved through the use of pulsed UVA light and HCXL treatments
involving exposure to higher UVA energy doses (Chapter 5). In this study several of
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these modiﬁcations have been combined in an attempt to ﬁnd a method of trans-epithelial
cross-linking that is equally eﬀective as SCXL but oﬀers the promise of increased patient
comfort and a shorter treatment time.
6.7 Research aim
The aim of this study was to compare the eﬃcacy of the gold-standard SCXL protocol
to that of a novel epithelium-on CXL protocol that involves the iontophoretic delivery of
a high concentration riboﬂavin solution and exposure to high-energy, pulsed UVA. The
eﬃcacy of each protocol is assessed in terms of their ability to enhance the stiﬀness and
enzymatic resistance of the cornea.
6.8 Methods
6.8.1 Sample preparation
Sixty-three fresh porcine eyes, all with transparent corneas and an intact corneal epithe-
lium, were obtained from a local European Community licensed abattoir and used within
6 hours of death. The eyes were divided into the ﬁve treatment groups described below
and summarised on Table 6.3.
1. Untreated corneas:
The corneal epithelium was removed from 6 eyes. These corneas received no further
treatment (no eye drops or UVA exposure).
2. Riboﬂavin only:
The corneal epithelium was removed from 6 eyes and a 0.1% iso-osmolar riboﬂavin
solution containing 20%dextran T-500 (MediocrossD®, PeschkeMeditrade, Huenenberg,
Switzerland) was applied to the anterior corneal surface for 30 min.
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3. Standard epi-oﬀ, low UVA intensity CXL protocol (SCXL 5.4 J/cm2):
The corneal epithelium was removed from 17 eyes and a 0.1% iso-osmolar riboﬂavin
solution containing 20% dextran T-500 was applied to the anterior corneal surface for 30
min. The cornea was then exposed to 3mW UVA for 30 min (total energy dose of 5.4
J/cm2), during which time riboﬂavin was re-applied at 5 min intervals. Total treatment
time: 60 min.
4. Epi-oﬀ, medium UVA intensity, high energy, pulsed CXL protocol (p-HCXL
7.56 J/cm2):
The corneal epithelium was removed from 17 eyes and a 0.1% iso-osmolar riboﬂavin
solution containing 20% dextran T-500 was applied to the anterior corneal surface for 30
minutes. The cornea was then exposed to 9 mW UVA for a period of 14 min with regular
stops of 15 sec every 1 min (total energy 7.56 J/cm2). Riboﬂavin was re-applied every 5
min throughout the course of the treatment. Total treatment time: 47.5 min.
5. Modiﬁed trans-epithelial iontophoresis CXLprotocol usingmedium intensity,
high energy, pulsed UVA (p-TC-ion-HCXL 7.56 J/cm2):
Seventeen corneas (with their epithelium intact) had a prolonged iontophoresis (St.
Thomas-Cardiﬀ) protocol similar to Chapter 4, which received an iontophoresis assisted
delivery of a 0.25% hypo-osmolar riboﬂavin solution containing 1.2% HPMC and 0.01%
BAC (Mediocross TE®, Peschketrade, Huenenberg, Switzerland) using a current of 1
mA for 5 min. After this initial application, the corneas were soaked with this riboﬂavin
solution for 5 min. Following this period of soakage, the corneas received a second
iontophoresis assisted delivery of fresh 0.25% hypo-osmolar riboﬂavin solution using a
current of 1 mA for 5 min and a further 5 min of riboﬂavin soakage. The corneas were
then washed with PBS for 1 min to remove riboﬂavin trapped within the epithelium and
irradiated with 9 mW UVA for 14 min with a 15 sec break from irradiation every 1
min (total energy 7.56 J/cm2). PBS was applied at 5 min intervals throughout to keep
the corneal surface moist. Following treatment, the corneal epithelium was debrided to
ensure consistency with the other groups. Total treatment time: 38.5 min.
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All of the irradiation protocols were performed using 370 nmUVA light delivered via
a CCL-365 vario™ cross-linking system (Peschkmed, Huenenberg, Switzerland), with a
50 mm working distance and a 9 mm aperture.
6.8.2 Pachymetry
Central corneal thickness was measured using ultrasound pachymetry (DGH Pachmate
55; DGH Technologies, Exton, PA), at the following experimental stages: immediately
pre-treatment (epithelium intact); pre-treatment (epithelium removed) (if applicable); post-
riboﬂavin application and post-UVA exposure (if applicable).
6.8.3 Enzymatic digestion
In this study, 6 riboﬂavin-only treated corneas and 11 corneas from each of the CXL
treatment groups were examined. An 8 mm full-tissue-thickness biopsy was trephined
from the centre of each cornea. The corneal disks were placed in individual sealed
tubes containing 5 ml of pepsin digest solution (1 g of ≥ 500 U/mg pepsin from porcine
gastric mucosa (Sigma-Aldrich, Dorset, UK) in 10 ml 0.1M HCl at pH 1.2) and incubated
in a water bath at 23◦C. Using electronic digital callipers, the diameter of the anterior
surface of each corneal disk was recorded daily. Measurements were continued until the
tissue could no longer be distinguished from the surrounding pepsin solution (even under
microscopical examination) and was considered to have undergone ‘complete digestion’.
The digestion time for each group was normalised against the total digestion time of the
SCXL treatment group.
To further assess the eﬀect of each treatment on enzymatic resistance, 5 corneal disks
from each group were removed from the pepsin digest solution after 12 days and placed
in a 60◦C oven until a constant dry weight was obtained. The average corneal dry weight
was then calculated for each group.
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6.8.4 Biomechanical test
In this study, 6 untreated corneas and 6 corneas from each of the three CXL treated groups
were examined. The corneal strip preparation, extensometer set-up and the biomechanical
data analysis were exactly the same as described in Chapter 2 and used in Chapter 3 apart
from the use of a 10 N load cell and the speed of the tensile test was reduced to 0.1 mm/min
to allow the collection of more data points. The testing parameters are summarized in
Table 6.4.
Table 6.4: The values required by Nexygen 4.1 to perform a stress–strain test.
6.8.5 Data analysis
All data are presented as mean ± SD. Measurements were taken of corneal thickness, dry
weight and complete digestion time for the enzymatic digestion experiment. Measurements
of corneal disk diameter are presented as the daily cumulative measurement of six samples
from each treatment group. For the biomechanical test, measurements were taken of
corneal thickness, while specimen strain and force were measured by the extensometry
system. The tangent modulus and ﬁtting parameters A, B and AB were calculated from
force-extension data (for details see Chapter 2). Statistical analysis for each experiment
was performed using a one-way ANOVA and Bonferroni multiple comparisons in a depth-
wise manner. All statistical analyses were performed with the Statistical Package for the
Social Sciences (IBM SPSS Statistics 20, New York, USA). The statistical signiﬁcance of
diﬀerence was taken as p ≤ 0.05.
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6.9 Results
6.9.1 Corneal Pachymetry
Figure 6.7 shows the average corneal thickness measurements recorded for each group dur-
ing the preparation of the tissue for the enzymatic digestion study (Figure 6.7a) and the ex-
tensiometry study (Figure 6.7b). Note that in the p-TC-ion-HCXL (7.56 J/cm2) group, the
epithelium, which constitutes≈75 μm of the total corneal thickness, remained intact during
CXL treatment. A signiﬁcant reduction in corneal thickness occurred immediately after
the application of riboﬂavin-dextran solution (for 30min) to the de-epithelized corneas (all
p-values were < 0.0001). The application of hypo-osmolar riboﬂavin (riboﬂavin-dextran
free) via the iontophoresis device did not signiﬁcantly change the corneal thickness from
the original thickness (p = 1.00). The diﬀerences in corneal thickness between the un-
treated group and both the SCXL (5.4 J/cm2) and the p-HCXL (7.56 J/cm2) groups (p <
0.0001) are highlighted in Figure 6.7. Further diﬀerences were observed between the epi-
on, p-TC-ion-HCXL group and both the epi-oﬀ, SCXL (5.4 J/cm2) group and the p-HCXL
(7.56 J/cm2) group (p < 0.0001). The treatment-induced changes in corneal thickness may
be attributed to both epithelium debridement (which accounts for ≈100 μm) and the ap-
plication of a riboﬂavin-dextran solution (p < 0.0001). As no signiﬁcant diﬀerence in
corneal thickness was evident between the two epi-oﬀ groups that were treated with the
same iso-osmolar riboﬂavin solution, it seems that the mode of UVA delivery (continuous
or pulsed) has no inﬂuence on corneal thickness (p = 1.00). Furthermore, the extent of
corneal thinning following UVA exposure did not diﬀer signiﬁcantly from that associated
with riboﬂavin-dextran application alone (p = 0.653), suggesting that thinning observed
after epi-oﬀ CXL is solely due to the application of an iso-osmolar solution.
Chapter: 6 147
Investigations into the eﬀectiveness of new and existing corneal cross-linking therapies
Figure 6.7: Average corneal thickness measurements recorded for each group used in the
enzyme digest study (a) and the extensometry study (b). Measurements were recorded
at various stages of sample preparation: pre-treatment (epithelium intact), pre-treatment
(epithelium removed), post-riboﬂavin application and post-UVA irradiation. Note that
in group 5 (p-TC-ion-HCXL 7.56 J/cm2) alone, the epithelium, which constitutes ≈75
microns of the total corneal thickness, remained intact during CXL treatment. Error bars
show standard deviation.
Cross-linking treatments: SCXL (5.4 J/cm2) (standard cross-linking); p-HCXL (7.56
J/cm2) (pulsed, high intensity and high energy UVA cross-linking) and p-TC-ion-HCXL
(7.56 J/cm2) (pulsed, high intensity and high energy UVA cross-linking with iontophoretic
riboﬂavin delivery).
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6.9.2 Enzymatic digestion study: Riboﬂavin uptake
Photographic images of the corneal disks taken immediately after treatment (and after
post-treatment epithelial removal in the case of p-TC-ion-HCXL) (7.56 J/cm2), showed the
distinctive yellow colouration of riboﬂavin within the stroma of all corneas and illustrated
the successful trans-epithelial delivery of riboﬂavin in the p-TC-ion-HCXL (7.56 J/cm2)
treatment group (Figure 6.8).
Figure 6.8: Corneal disks from each group are shown immediately after treatment (and
prior to enzyme digestion). In each case the epithelium has been removed (either pre- or
post- treatment) and the characteristic yellow colour of riboﬂavin can be seen within the
corneal stroma.
Cross-linking treatments: Cross-linking treatments: SCXL (5.4 J/cm2) (standard cross-
linking); p-HCXL (7.56 J/cm2) (pulsed, high intensity and high energyUVAcross-linking)
and p-TC-ion-HCXL (7.56 J/cm2) (pulsed, high intensity and high energy UVA cross-
linking with iontophoretic riboﬂavin delivery).
6.9.3 Corneal disk diameter measurements during enzymatic diges-
tion
As mentioned earlier (Chapters 3, 4 and 5), posterior-anterior stromal swelling was ob-
served in all samples after 24 hours of pepsin submersion. After one week of digestion the
anterior and posterior regions were separated, and the posterior was completely digested
by 10 days. The anterior portion of the corneal disks persisted beyond this time point and
diminished gradually allowing daily measurements of corneal disk diameter (Figure 6.9).
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There was a signiﬁcantly longer duration required for complete digestion of the CXL
treated corneal disks than that required for the riboﬂavin-only control specimens (p <
0.0001) (Figure 6.9, Table 6.5). The corneas in the high energy CXL treatment groups
(p-HCXL 7.56 J/cm2 and p-TC-ion-HCXL 7.56 J/cm2) took signiﬁcantly longer to digest
than those treated with SCXL (p < 0.0001), and the p-HCXL 7.56 J/cm2 treated corneas
took signiﬁcantly longer to digest than that the p-TC-ion-HCXL 7.56 J/cm2 treated corneas
(p < 0.0001) (Figure 6.9, Table 6.5).
Table 6.5: Average time in days taken for complete digest to occur in all groups ± SD.
6.9.4 Dry weights at day 12 of digestion (5 samples/group)
At day 12 (which corresponds to a normalised digestion time of 0.26), all of the CXL-
treated corneas were still present but the riboﬂavin-only treated corneas had undergone
complete digestion. No signiﬁcant diﬀerences were found between the average stromal
dry weights of the CXL treated groups (p = 1.0), however a large variability in stromal
mass dry weight was observed within each group (Figure 6.10).
6.9.5 Stress-strain measurements
The averaged stress–strain ﬁtted curves for each group show the typical nonlinear behaviour
of a biological tissue (Figure 6.11). The stress-strain ﬁtted data for the untreated group
were found to be signiﬁcantly lower than those for the SCXL (5.4 J/cm2) group (p <
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Figure 6.10: Average stromal dry weight of corneal disks treated with SCXL, p-HCXL
and p-TC-ion-HCXL, after 12 days of digestion. Error bars show standard deviation.
Cross-linking treatments: SCXL (5.4 J/cm2) (standard cross-linking); p-HCXL (7.56
J/cm2) (pulsed, high intensity and high energy UVA cross-linking) and p-TC-ion-HCXL
(7.56 J/cm2) (pulsed, high intensity and high energy UVA cross-linking with iontophoretic
riboﬂavin delivery).
0.005). However, the stress–strain ﬁtted data did not reveal any signiﬁcant diﬀerences
between the p-HCXL (7.56 J/cm2), p-TC-ion-HCXL (7.56 J/cm2) and the untreated group
(p = 1.00).
6.9.6 Tangent modulus (6 per group)
The average tangent modulus values were obtained by a nonlinear ﬁt of each stress-
strain curve for the four groups. Figure 6.12 shows the average of the tangent modulus
and standard deviation for each group at 2%, 4%, 6%, 8% and 10% strains. The chart
shows that the SCXL protocol yielded the largest increases in tangent modulus and had
a signiﬁcantly higher tangent modulus that that of the untreated corneas at all strains
(p < 0.04) (Table 6.6). However, despite general trends for the tangent modulus to be
higher in the p-HCXL (7.56 J/cm2) and p-TC-ion-HCXL (7.56 J/cm2) groups than in the
untreated group but lower than that of the SCXL group, no signiﬁcant diﬀerence was
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Figure 6.11: Comparison between stress-strain behaviors of untreated, SCXL, p-HCXL
and p-TC-ion-HCXL treated corneas.
Cross-linking treatments: SCXL (5.4 J/cm2) (standard cross-linking); p-HCXL (7.56
J/cm2) (pulsed, high intensity and high energy UVA cross-linking) and p-TC-ion-HCXL
(7.56 J/cm2) (pulsed, high intensity and high energy UVA cross-linking with iontophoretic
riboﬂavin delivery).
detected at 2 - 8% strain. The average tangent modulus at 6% strain was 0.3 × 106 Pa
for the untreated group, 3.3 × 106 for SCXL, 0.9 × 106 Pa for p-HCXL (7.56 J/cm2), and
1.1 × 106 Pa for p-TC-ion-HCXL (7.56 J/cm2), thus the stiﬀness (relative to the untreated
cornea) increased by a factor of 9.9, 2.8 and 3.1 for the cross-linked groups, respectively.
The ’stiﬀening factor’ decreased slightly with increasing strain from 8% to 10%. For
the SCXL at 8% strain, the stiﬀness of the cornea was 7.6 times greater than that of the
untreated corneas, and at 10% strain, the SCXL treated corneas were 6.9 times stiﬀer than
the untreated corneas. Simultaneously, the stiﬀness increased by a factor of 2.3 at 8%
strain and 1.3 at 10% strain for the p-HCXL (7.56 J/cm2) group. Meanwhile, the stiﬀness
for epi-on p-TC-ion-HCXL (7.56 J/cm2) treated group raised by the factor of 3.0 at 8%
strain and 2.9 at 10% strain. Only at 10% strain was the tangent modulus for the SCXL
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group signiﬁcantly higher than the p-HCXL (7.56 J/cm2) epi-oﬀ treated group (p = 0.025)
(Table 6.6).
Figure 6.12: Tangent modulus for each treatment group at 2%, 4%, 6%, 8% and 10%
strain.
Cross-linking treatments: SCXL (5.4 J/cm2) (standard cross-linking); p-HCXL (7.56
J/cm2) (pulsed, high intensity and high energy UVA cross-linking) and p-TC-ion-HCXL
(7.56 J/cm2) (pulsed, high intensity and high energy UVA cross-linking with iontophoretic
riboﬂavin delivery).
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Table 6.6: P-values of the tangent modulus at 2%, 4%, 6%, 8% and 10% resulting from
Bonferroni multiple comparisons between groups. Asterisks indicate where p-values were
< 0.05.
6.10 Discussion
Based on evidence from previous studies that iontophoresis delivery techniques using a
5 min riboﬂavin soak time result in only superﬁcial stromal riboﬂavin penetration and
minimal cross-linking of the tissue (Aldahlawi et al. 2016a; Vinciguerra et al. 2014a), a
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modiﬁcation to the protocol was introduced in this study which aimed to enhance stromal
riboﬂavin penetration (and ultimately the amount of cross-linking). In the modiﬁed p-TC-
ion-HCXL (7.56 J/cm2) protocol the riboﬂavin soak time was extended from 5 min to 20
min to allow more time for riboﬂavin diﬀusion. Further to this, a higher concentration
riboﬂavin solution containing BAC was used to help facilitate stromal delivery across the
intact epithelium and enhance the cross-linking process. Suﬃcient riboﬂavin penetration
is a key step in the cross-linking process (Mastropasqua et al. 2014a,b) as the presence of
the photosensitiser in the corneal stroma is essential to trigger cross-link formation during
UVA irradiation. Riboﬂavin also allows approximately 95% of the UV light to be absorbed
in the cornea, thus protecting the internal ocular structures such as the endothelium, lens,
and retina from the UV light (Raiskup et al. 2013; Spoerl et al. 2007; Wollensak et al.
2003b,c).
In this study the eﬀectiveness of a range of epi-oﬀ protocols and a novel modiﬁed
epi-on iontophoretic delivery cross-linking protocol were investigated in terms of their
ability to increase both enzymatic resistance and corneal stiﬀness, thereby providing a
more accurate assessment of the eﬀectiveness of each CXL protocol. In order to ensure
a fair comparison between the epi-on (p-TC-ion-HCXL (7.56 J/cm2)) and epi-oﬀ treated
corneas, the epithelium was removed from the p-TC-ion-HCXL (7.56 J/cm2) treated
corneas immediately prior to commencing the enzyme digest and biomechanical testing
procedures. By doing so, any eﬀects that the presence or absence of an intact epithelium
might have had on the biomechanical and biochemical properties of the cornea were
removed; this allowed the eﬀect of each treatment on the properties of the corneal stroma
to be isolated and compared between groups.
Consistent with previous experimental and clinical studies, a signiﬁcant drop in
corneal thickness was recorded during epi-oﬀ protocols, which was due to a combination
of epithelial removal and application of an iso-osmolar riboﬂavin solution (containing
dextran) (Aldahlawi et al. 2015, 2016a,b; Greenstein et al. 2011; Hassan et al. 2014;
Hayes et al. 2013). The corneal thinning can be attributed primarily to the deturgescent
eﬀect of the dextran but also, possibly, to the presence of riboﬂavin (Aldahlawi et al. 2015),
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which has the eﬀect of increasing the ionic strength of the applied solution and creating
an osmotic imbalance that draws water out of the cornea (Huang et al. 1999). The ﬁnding
that application of a dextran-free, hypo-osmolar riboﬂavin solution to epithelium-intact
corneas did not result in any change in corneal thickness, is at odds with clinical studies
which have shown that the trans-epithelial delivery of hypo-osmolar riboﬂavin solutions
increases the corneal thickness by≈66 μm (Hafezi 2011; Hafezi et al. 2009; Kymionis et al.
2012; Zhang et al. 2012). This diﬀerence is most likely due to the structural diﬀerences
that exist between human and porcine corneas, in terms of the thickness of the epithelium
(Sanchez et al. 2011). However, despite the porcine corneal epithelium presenting a
greater barrier to riboﬂavin penetration than the human cornea, spectrophotometry studies
have shown that the modiﬁed iontophoresis delivery protocol results in signiﬁcant stromal
riboﬂavin penetration (Hayes et al. 2015). The current study supports this ﬁnding, as visual
observation of the treated corneas following epithelium removal, revealed the presence of
riboﬂavin within the stroma of all epi-on and epi-oﬀ treated porcine corneas (Figure 6.8).
Consistent with other studies, the mode of delivery of UVA (continuous or pulsed) during
accelerated CXL had no eﬀect on corneal thickness (Chen et al. 2015; Sherif et al. 2016).
As shown in Chapter 4, the eﬀectiveness of iontophoretic cross-linking (measured
in terms of corneal enzymatic resistance post-treatment), can be enhanced by increasing
the riboﬂavin concentration, increasing the duration of the iontophoresis assisted delivery
of riboﬂavin and increasing the riboﬂavin soakage time. However, despite these mod-
iﬁcations, the protocol was found to remain inferior to the SCXL (5.4 J/cm2) protocol
(Aldahlawi et al. 2016a). The current study showed that the further development of the
iontophoresis protocol to include the use of pulsed UVA light and a higher energy dose
(TC-ion-p-HCXL (7.56 J/cm2)), resulted in an enhanced corneal enzymatic resistance
that was superior to that achievable with the SCXL (5.4 J/cm2) protocol. However, the
epi-oﬀ p-HCXL (7.56 J/cm2) protocol was found to be even more eﬀective than the epi-on
TC-ion-p-HCXL (7.56 J/cm2) at increasing the enzymatic resistance of the cornea. The
enhanced eﬃcacy of the epi-oﬀ p-HCXL (7.56 J/cm2) protocol compared to that of the
epi-on TC-ion-p-HCXL (7.56 J/cm2) protocol may be due to the greater stromal riboﬂavin
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uptake in the epi-oﬀ treated corneas, which has been previously demonstrated by spec-
trophotometry (Hayes et al. 2015). It may also be due to some UVA being absorbed by
the intact epithelium in the TC-ion-p-HCXL (7.56 J/cm2) group and thus reducing the
amount available for stromal cross-linking.
In the enzyme digest study, measurement of the average dry weight of the tissue
during the digestion process (which represents the undigested tissue mass), somewhat
surprisingly, showed no signiﬁcant diﬀerence between the cross-linked groups, suggesting
an equal proportion of the full-tissue thickness was cross-linked in each case. This appears
at ﬁrst glance to contradict the ﬁndings presented in Chapter 5, which showed a signiﬁcant
diﬀerence between the dry weights in the SCXL (5.4 J/cm2) and p-HCXL (7.2 J/cm2)
treatment groups. However, this may be explained by the dry weights in each study
being obtained at slightly diﬀerent stages in the digestion process. Both studies employed
the same methological process, with dry weights being obtained on the day following
the complete digestion of the untreated corneas; in the present study this led to the dry
weights of the CXL-treated corneas being recorded at day 12 of 45, which equates to a
normalised digestion time of 0.26, whereas in Chapter 5 the dry weights were obtained at
day 13 of 30, which equates to a much later normalised digestion time of 0.4. It is possible
therefore that in the current study, diﬀerences between the CXL groups were regrettably
not detected due to the dry weights being obtained too early in the digestion process.
Another possible interpretation is that the slight diﬀerence in the energy dose used in the
p-HCXL treatments described in this chapter and Chapter 5 (7.2 J/cm2 and 7.56 J/cm2
respectively), may have resulted in a diﬀerent depth of CXL formation. Although, there is
no way at present to visualise the precise depth of cross-linking, clinical evidence shows
the appearance of a demarcation line at ≈ 2 weeks post-treatment which some believe may
represent the transition between cross-linked and non-cross-linked tissue (Spadea et al.
2016). It has been shown clinically that an increase in the UVA energy dose results in a
deeper demarcation line (Kymionis et al. 2016; Mazzotta et al. 2008), which may indicate
a deeper level of cross-linking Moreover, clinical evidence indicates that p-HCXL (7.2
J/cm2) forms a deeper demarcation line than continuous HCXL (7.2 J/cm2) (Peyman et al.
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2016). Here, the dry weight of the SCXL treated corneas was equal to that of the p-HCXL
(7.56 J/cm2) and TC-ion-p-HCXL (7.56 J/cm2) treated corneas.
As the chemical bonds formed during collagen cross-linking cannot be directly vi-
sualized by staining methods, improvements in corneal biomechanical properties, such
as increased tissue rigidity, are frequently used as positive indicators of cross-linking ef-
fectiveness (Hammer et al. 2014; Kohlhaas et al. 2006; Schumacher et al. 2011; Studer
et al. 2010; Wollensak et al. 2003b). However, most of these studies measure the changes
in corneal stiﬀness following CXL as a bulk of the biomechanical properties of corneal
tissue (Beshtawi et al. 2013), even though the SCXL stiﬀening eﬀect is concentrated in
the anterior 200 - 300 μm of the cornea and the eﬀective depth of CXL may diﬀer be-
tween treatment protocols (Kohlhaas et al. 2006). In the current study, examination of
corneal biomechanical properties demonstrated that the tangent modulus at 8% applied
strain was signiﬁcantly higher in the SCXL treated corneas than in the untreated control
group. Although the tangent modulus increased by factors of 7.6, 2.3 and 3.0 for the
SCXL, p-HCXL (7.56 J/cm2), and epi-on p-TC-ion-HCXL (7.56 J/cm2) treated groups,
the two latter groups did not signiﬁcantly diﬀer from either the untreated corneas or the
SCXL treated corneas. This may be due to the within-group variability associated with
the biomechanical testing technique and diﬀerences in the intensity and eﬀective depth of
cross-linking between protocols. For example, based on the results of the enzyme diges-
tion studies, the HCXL (7.56 J/cm2), and epi-on p-TC-ion-HCXL (7.56 J/cm2) protocols
appear to result in an enhanced cross-linking of the most superﬁcial stromal layers but may
show a more rapid decrease in cross-linking intensity with depth compared to the SCXL
protocol. As the extensometry technique provides a measurement of the overall stiﬀness
of full-thickness tissue strips, highly localised anterior-posterior diﬀerences may therefore
not be detected. Indeed, evaluation of anterior and posterior corneal stromal elasticity
after corneal collagen cross-linking (CXL) treatment in human cadaver eyes using atomic
force microscopy through indentation, has shown that stiﬀness of the anterior corneal
stroma increases signiﬁcantly after SCXL, while the posterior stroma remains unaﬀected
(Dias et al. 2013).
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Some of the extensometry outcomes showed a large amount of variabilitywhichmight
be caused by other limitations of the technique. Past examinations have underlined the
limitations of corneal strip extensometry measurements to evaluate biomechanical prop-
erties (Elsheikh et al. 2005). These limitations include: the initial straightening of strips
that natively followed corneal curvature; cutting signiﬁcant quantities of collagen during
the strip preparation process; and ignoring the meridional diﬀerences. Strip extensometry
is inherently uniaxial while the native cornea experiences planar forces. Using an inﬂation
technique would overcome to some extent the uniaxial limitation, by reﬂecting the native
mechanical environment of an eyeball where the cornea is intact and loading of posterior
pressure could simulate the intraocular pressure. Nevertheless, this technique has its own
drawback of producing less accurate measurements of CXL stiﬀness as only 8 mm of the
central cornea is cross-linked and increasing the intraocular pressure could inﬂuence the
biomechanics measurement. Uniaxial extensometry, despite its many drawbacks, is still
the most widely used technique to measure the biomechanical properties of biological
tissues, but the results need to be interpreted with great caution. It is possible that other
mechanical testing techniques, such as atomic force microscopy or interferometry, may
therefore be more suitable than extensometry for identifying diﬀerences between CXL
protocols.
There are number of factors to consider when using porcine eyes as a model for
humans, particularly for trans-epithelial CXL studies. Although it is commonly agreed
that the porcine cornea is a suitable model for the human cornea in terms of its mechanical
properties (Elsheikh et al. 2008), corneal strip extensometry experiments on human and
porcine cross-linked corneas have revealed a superior CXL-induced stiﬀening eﬀect in
human corneas compared to porcine corneas (Elsheikh et al. 2008; Wollensak et al. 2003b;
Zeng et al. 2001). This is likely due to diﬀerences in the proportion of the tissue that
is cross-linked, since cross-linking following SCXL is limited to the anterior 200 - 300
μm of the cornea (Kohlhaas et al. 2006). Based on the typical values of porcine and
human corneal thickness, this represents 35% of the total porcine corneal thickness being
cross-linked and 54% in humans (Wollensak et al. 2003b). This diﬀerence will be even
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more pronounced when comparing porcine corneas with keratoconic corneas, which are
signiﬁcantly thinner than their healthy counterparts (Schlatter et al. 2015). Biomechanical
evaluation in rabbit studies demonstrated a corneal stiﬀening eﬀect following standard
iontophoresis CXL (Touboul et al. 2014; Vinciguerra et al. 2009, 2014a) and standard
iontophoresis CXL with pulsed UVA irradiation of total energy of 7.2 J/cm2 (Park et al.
2017) but less than the SCXL. The porcine epithelium is much thicker (100 μm) than
human (50 μm) (Sanchez et al. 2011), however, it would be interesting to repeat these
treatments in the rabbit model which has a slightly thinner epithelium (40 μm) (Li et al.
1997) but closer in thickness to that of the human cornea. Such a study could complement
the current results which may allow a more liberal estimate of the eﬀectiveness of trans-
epithelial cross-linking.
In conclusion, the results indicated that the outcome of the trans-epithelial corneal
cross-linking could be improved by the use of higher concentration of riboﬂavin, a longer
duration of iontophoresis and riboﬂavin soak time and an increase in the total UVA energy
dose. Based on the experimental ﬁndings presented in this study, the St Thomas’s/Cardiﬀ
modiﬁed iontophoresis protocol (p-TC-ion-HCXL (7.56 J/cm2)) may be a promising, less
painful but equally eﬀective alternative to SCXL.As the amount of cross-linking of stromal
tissue required to stabilize the progression of an ectatic disorder is not yet deﬁned further
clinical studies, especially randomized prospective trails, will be necessary to complete
the evaluation of this modiﬁed cross-linking technique. Meanwhile, the long-term clinical
validity of the SCXL protocol remains the gold standard approach.
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7.1 Introduction
Although conventional CXL (riboﬂavin/UVA) therapy has proved to be a highly eﬀective
treatment for stabilising keratoconus progression, it requires a minimum corneal thickness
of 400 μm after epithelial removal and before riboﬂavin instillation to ensure the safety
of the endothelial cell layer, lens and retina (Spoerl et al. 2007; Wollensak et al. 2003).
As a result, very thin keratoconus corneas are not eligible for treatment. Although CXL
treatment has a relatively low failure rate (approximately 7.6%) and a complication rate
of only 2.8% (Koller et al. 2009), there have been sporadic reports of side-eﬀects such as
corneal haze, keratitis and corneal scarring (O’Brart 2014).
To avoid the hazard of corneal endothelial degeneration byUVA, a group of specialists
at the Weizmann Institute of Science examined the capability of integrated chemical
derivatives of photosynthetic pigments (chlorophylls and bacteriochlorophylls) as a means
of stiﬀening corneas of all thicknesses (Marcovich et al. 2012). The direct application
of Bacteriochlorophyll Derivative (Bchl-Ds) or (WST11) to connective tissue followed by
non-hazardous spectrum, near infrared (NIR, 755 nm) illumination is expected to initiate
collagen cross-linking by the generated oxygen radicals (Hamblin et al. 2013). One role of
these photogenerated radicals is thought to be in promoting protein cross-linking (Liu et al.
2004). WST11, or palladium bacteriochlorin 130-(2-sulfoethyl) amide dipotassium salt, is
a water-soluble synthesized chemical derivative of a photosynthetic pigment that generates
oxygen radicals (O2− and OH) after illumination with non-hazardous NIR (Ashur et al.
2009; Mazor et al. 2005). To avoid endothelium damage, Marcovich et al. mixed the
WST11 with high molecular weight dextran T500 (WST-D). This treatment limited the
stiﬀening to the anterior part of the cornea and noticeably decreased post treatment oedema
and promoted faster epithelial healing. Histology post WST-D/NIR showed a reduction in
keratocyte population in the anterior corneawith no damage to the endothelium (Marcovich
et al. 2012). WST-D/NIR treatment also produced biomechanical improvements, which
was signiﬁcantly increase the corneal stiﬀening at irradiation of 10 mW/cm2 at diﬀerent
exposure time for 1, 5 and 30minutes (Brekelmans et al. 2017). Marcovich et al. found that
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saturation of the corneal stroma with palladium bacteriochlorin 130-(2-sulfoethyl) amide
dipotassium salt (Brandis et al. 2005) in 20% dextran T-500 (WST-D) and subsequent
exposure to near infra-red light (NIR) at 755 nm, resulted in a 174% increase in rabbit
corneal stiﬀness with minimal side eﬀects (Marcovich et al. 2012) .
Utilizing both x-ray scattering and electron microscopy, this study analyses the struc-
ture of rabbit corneas immediately after treatment with WST-D/NIR and following 30 days
of recovery to gain a better understanding of the means by which the corneal stiﬀening
is accomplished. Electron microscopy images give data at a highly-localised level and
can enable changes in cell morphology, collagen organisation and collagen D-periodicity
to be identiﬁed, while small-angle x-ray scattering (SAXS) patterns provide quantitative
information about ﬁbril diameter and ﬁbril separation distance as an average throughout
the thickness of the cornea, and are thus highly representative of the tissue as a whole
(Meek et al. 2001).
7.2 Research aim
The purpose of the current study was to present the ﬁrst evaluation of ultrastructural
changes in the stromal matrix following in vivo treatment with bacteriochlorophyll deriva-
tive WST-D and near infrared light (WST-D/NIR).
7.3 Methods
7.3.1 Study 1. X-ray scattering studies
Tissue preparation for x-ray scattering studies
At the Weizmann Institute of Science (Rehovot), our collaborators performed unilateral
WST-D/NIR treatment on 6 live New Zealand White rabbits (Table 7.1). In each case, the
contralateral eyes acted as untreated controls. At all times, the animals were treated in
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accordance with the Association for Research in Vision and Ophthalmology Statement for
the Use of Animals in Ophthalmic and Vision Research. The animals were anaesthetised
using intramuscular (IM) injection of 35mg/kg ketamine (Rhone Merieux, Lyon, France)
and 5mg/kg xylazine (Vitamed, Benyamina). In the case of the treated eye, the corneal
epithelium was removed and WST-D (containing 20% dextran T-500) was applied to
the corneal stroma for 20 minutes by means of 12 mm diameter eye cap. Following
saturation of the corneal stroma, the tissue was exposed to NIR (755 nm, 10 mW/cm2) for
a period of 30 minutes (Figure 7.1a). To prevent exposure of the limbal stem cells, the
illuminated area was restricted by an aluminium foil mask with an 8 mm diameter central
opening. An ophthalmic steroid and antibiotic ointment containing dexamethasone 0.1%,
neomycine and polymixin B (Maxitrol®, Alcon, Belgium) was applied to the treated
eyes once daily until full and conﬁrmed re-epithelialization had occurred. The health
and thickness of the cornea were documented at regular intervals throughout the healing
process. A portable slit-lamp was used to evaluate the health of the eyes (Model 510L w/
blue ﬁlter, Eidolon Optical LLC, Massechusetts, USA), ﬂuorescein staining was used to
follow the re-epithelialization (BioGlo, HUB Pharmaceuticals, CA, USA) and ultrasound
pachymetry was utilized to measure the corneal thickness (Cornea-Gage Plus, Sonogage
Inc., Cleveland, USA). Twenty-eight days after the treatment the rabbits were sacriﬁced
and corneo-scleral disks were removed, placed in storage medium and transported to
the Diamond Light Source (Didcot, UK) for examination on the SAXS beamline (I22).
The corneo-scleral discs destined for SAXS studies were stored in Minimum Essential
Medium Eagle (MEM) buﬀer with 6% dextran. This was necessary to preserve them
during transportation from Rehovot to Cardiﬀ. The sacriﬁce of the animals was scheduled
to coincide with the allocated beam time at the synchrotron such that the specimens were
only stored in the medium for two days.
A further twelve pairs of rabbit eyes were obtained from an abattoir and treated ex
vivo within two hours of death (Figure 7.1b). As for the in vivo treated eyes, one eye
from each pair underwent corneal de-epithelialisation and treatment with WST-D/NIR,
whilst the contralateral eye served as an untreated control. After treatment, each cornea
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(with a 2 mm scleral rim) was wrapped in polyvinyl chloride to prevent moisture loss,
kept in the dark, and transferred to -80◦C storage. The specimens remained frozen during
transportation to the Diamond Light Source andweremaintained in this state until required
for SAXS data collection.
(a) in vitro (b) in vivo
Figure 7.1: Experimental setup for in vitro (a) and in vivo (b) WST-D/NIR treatment of
rabbit eyes. Image provided courtesy of Jurriaan Brekelmans, with permission from the
Weizmann Institute of Science (2017)
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Small-angle x-ray scattering data collection and analysis
Thirty minutes before data collection, each ex vivo treated (n = 12) and untreated (n =
12) corneo-scleral disk (wrapped in ClingﬁlmTM) was thawed at room temperature. It is
noteworthy that freezing and thawing (and the consequent formation of ice crystals) does
not aﬀect the collagen parameters measured by SAXS (Fullwood et al. 1994). Immediately
before data collection, a 6 mm disk was then trephined from the centre of each cornea and
weighed to obtain a ‘wet weight’ before data collection (Figure 7.2). The same process
was repeated for the 6 pairs of in vivo prepared corneas. After weighing, each corneal
disk was rewrapped in a single layer of ClingﬁlmTM and mounted in a sealed polymethyl
methacrylate chamber (Perspex; theplasticshop.co.uk, Coventry, UK) with polyester ﬁlm
windows (Mylar; DuPont-Teijin, Middlesbrough, UK) (Figure 7.2). A single x-ray scatter
pattern was obtained from the centre of each corneal disk using a 0.5 sec exposure to a 180
× 300 μm x-ray beam (λ = 0.8 nm) and recorded on a detector positioned 5.8 m behind
the sample.
Following data collection, the corneal disks were placed in a 60◦C oven for approxi-
mately one week until a constant ‘dry weight’ was reached. The hydration of each corneal
disk was then calculated using the following equation: Hydration = (wet weight-dry
weight)/dry weight (Chapter 2, Equation 2.1).
In the case of 8 ex vivo corneal disks, an additional wet weight measurement was
recorded immediately following data collection to assess the extent of drying that occurred
during the data collection process. As collagen interﬁbrillar spacing is particularly sensi-
tive to changes in corneal hydration (Meek et al. 1991) such information is necessary to
distinguish between hydration and treatment induced changes in corneal ultrastructure.
As described in detail in Chapter 2, the small-angle x-ray scatter patterns were
calibrated against the 5.838 nm peak associated with the ﬁrst order reﬂection of powdered
silver behanate, thus allowing average measurements of collagen D-period, ﬁbril diameter
and interﬁbrillar spacing to be ascertained for each specimen examined.
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(a) (b) (c)
Figure 7.2: Preparation of corneal tissue for x-ray scattering data collection. A 6 mm
disk was trephined from the centre of the cornea (a) and weighed (b). The corneal disk
was then wrapped in a single layer of ClingﬁlmTM and mounted in a sealed polymethyl
methacrylate chamber with polyester ﬁlm windows (c). X-ray sensitive paper (green) was
used to determine the exact position of the x-ray beam with respect to the sample chamber
and allow accurate positioning of the sample to ensure that the x-ray beam passed through
the centre of the corneal disk (c).
7.3.2 Study 2. Electron microscopy studies
Tissue preparation for electron microscopy studies
Four 20-week-old (3-3.5 Kg) female, New Zealand White rabbits were anesthetized as
described previously. The left eye of each rabbit underwent corneal de-epithelialisation.
In two rabbits, corneal de-epithelialisation was followed by WST-D/NIR cross-linking
(as described previously for x-ray scattering tissue preparation) whilst in the remaining
two rabbits the de-epithelialised cornea underwent riboﬂavin/UVA cross-linking, involv-
ing a 30 minutes pre-treatment with a commercial riboﬂavin solution (containing 0.1%
riboﬂavin and 20% dextran (Mediocross, Germany) followed by a 30 minutes UVA il-
lumination with a 365 nm diode at 3 mW/cm2. The WST-D/NIR and riboﬂavin/UVA
crosslinked eyes were treated with Maxitrol (steroid and antibiotic) ointment daily for 2
weeks until the corneal erosion had fully healed. The right eye in each rabbit served as
an untreated control (Table 1). Pachymetry was measured immediately before corneal
de-epithelialisation and again after treatment. One month post-treatment the rabbit eyes
were enucleated, and the cornea-scleral rims dissected and ﬁxed in 2.5% glutaraldehyde
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and 2% paraformaldehyde (PFA) in 0.1 M Sorensen phosphate buﬀer for two hours. The
specimens were then stored in 0.2M Sodium cacodylate buﬀer (pH 7.4) until they were
required for transmission electron microscopy processing.
Electron microscopy data collection and analysis
Corneas were washed twice in 0.1 M Sorensen phosphate buﬀer (pH 7.2 - 7.4) for 2 - 3
hours on a rotator and stored overnight in 0.1 M Sorensen phosphate buﬀer at 4ºC. Spec-
imens were prepared for transmission electron microscopy by the following conventional
processing schedule. Full-thickness corneas were cut into quarters then into 12 pieces (pie
segments), such that the narrowest point indicated the corneal centre to aid in orientation
for ultramicrotomy. These corneal specimens were post ﬁxed in 1% osmium tetroxide in
cacodylate buﬀer for 1 hour and then washed in distilled water. The specimens were then
placed in 1% aqueous uranyl acetate for 1 hour followed by washing in distilled water.
Specimens were dehydrated through a graded series of ethanol washes from 70% to 100%
ethanol in four steps over the course of one hour. The samples were then inﬁltrated with
propylene oxide with two changes at 15 min intervals, then into a 1:1 mixture of propylene
oxide and Araldite resin for one hour before pure resin inﬁltration. Six changes of Araldite
CY212 resin, for about two hours each, were performed, (see Chapter 2, section 2.8.2).
The corneal specimens were then embedded into moulds such that the centre of the cornea
was at the block edge. This guaranteed that sectioning the block face would produce full
thickness (epithelium through endothelium) sections at the centre of the cornea. Blocks
were polymerized at 60◦C in epoxy resin over two days (Araldite CY212 resin, TAABLab-
oratories, England, UK). A Leica UC6 ultramicrotome was used to cut 2 μm-thick with a
glass knife, semithin sections which were then stained with toluidine blue to identify areas
of interest by light microscopy. Ultrathin sections (90 - 100 nm thick) were then cut with
a diamond knife from the regions of interest, collected on either copper mesh or slot grids
(3.05 mm in diameter) and stained with uranyl acetate and lead citrate for examination in a
JEM 1010 transmission electron microscope operating at 80 keV (Jeol (UK) Ltd, Welwyn
Garden City, UK) (for more details see Chapter 2, section 2.8.4). Transmission electron
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microscopy images were collected from the anterior and posterior regions of each cornea.
Analysis of these images in Image J/Fiji enabled the average diameter of approximately
210 ﬁbrils to be calculated for each region (Abramoﬀ et al. 2004) (for detail see Chapter
2, section 2.8.5).
Positive staining analysis of ﬁbrils
To avoid overlapping from diﬀerent collagen ﬁbrils layers and provide banding patterns
that do not cross on top of each other, ultrathin sections with 60 - 70 nm thick (silver
interference color) were cut with a diamond knife and supported on copper grids (see
Chapter 2, section 2.8.3). The sections were then positively stained with uranyl acetate
and lead citrate for examination in a JEM 1010 transmission electron microscope (Jeol
(UK) Ltd, Welwyn Garden City, UK). Longitudinal sections (i.e., parallel to the ﬁber axis)
were captured from the anterior and posterior regions of each cornea with a × 30,000
magniﬁcation. Data was extracted from photographs in .dm3 format to produce band
intensity plots for all feasible D-periods along each selected ﬁbril.
Transmission electronmicrographs of positively stained rabbit corneal collagen ﬁbrils
were analysed using Image analysis J/Fiji. For positive staining analysis, ﬁbrils with clear
banding were chosen carefully. The positive staining banding pattern was described earlier
(Chapter 1, section 1.2.2). The objective here was to obtain a typical stain intensity proﬁle
from a given treatment such that direct comparisons could be made between specimens
to look for any changes in stain binding caused by the presence of cross-links. To extract
typical band intensity data for each D-period, a rectangle was drawn over a selected region
along the ﬁbril containing several well-stained D-periods. The dataset for the chosen
region was then extracted using the “Plot Proﬁle” function as described in Chapter 2
section 2.8.5.
In this study, only three D-periods were matched and averaged to evaluate the
positively-stained banding pattern because of the high noise level in the staining pat-
terns. The signal-to-noise ratio initially reduced, but then increased when further scans
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were added, due to the diﬃculty in obtaining precise axial alignment of the scans to be
averaged.
7.3.3 Statistical analysis
In the x-ray scattering studies, statistical diﬀerences between paired samples (treated and
untreated fellow eyes) and between measurements recorded from the same samples at
multiple time points (e.g. pachymetry measurements) were evaluated by means of a
paired Student t-test. A diﬀerence between any pair of means of greater than or equal
to the least signiﬁcant diﬀerence at p<0.05 was considered to be statistically signiﬁcant.
Values presented in the results are means ± standard deviation (SD).
Statistical analyses for the electron microscopy studies were completed using one-
way ANOVA followed by Sidak post hoc test and/or Bonferroni post hoc test. The data
were shown as mean ± standard deviation. All statistical analyses were achieved with the
Statistical Package for the Social Sciences (SPSS Statistics 20; IBM, Armonk, NY, USA).
A probability value of P < 0.05 was considered signiﬁcant.
7.4 Results
7.4.1 Clinical observations and pachymetry
A signiﬁcant decline in corneal thickness was observed following epithelial debridement
and WST-D/NIR treatment in the ex vivo treated corneas (p < 0.0006) (Table 7.2, Figure
7.3). A slight green discolouration and loss of corneal transparencywere seen immediately
following WST-D/NIR treatment (Figure 7.4). The greenish discolouration disappeared
within 1-2 days in all corneas. Corneal transparency was restored within 4 - 6 days. A
5 mm epithelial erosion was evident at 3 days post-treatment but within 6 - 8 days of
treatment, the epithelium had fully recovered (Figure 7.5). At the time of enucleation (30
days post-treatment) the thickness of each in vivo treated WST-D/NIR and riboﬂavin/UVA
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treated cornea did not diﬀer signiﬁcantly from their pre-treatment values (p = 0.7 and p =
0.3), respectively (Table 7.2).
Table 7.2: Thickness measurements (μm) of in vivo and ex vivo treated and untreated
corneas.
?????????
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Figure 7.3: Average corneal thickness pre-treatment, immediately post-WST-D/INR treat-
ment (ex vivo) and 30 day post-WST-D/INR treatment and during healing (in vivo) for
SAXS study
Figure 7.4: Corneal disks trephined immediately after the treatments. From left to right
WST-D/NIR (grey-green), and untreated (clear) disks. Image provided courtesy of Jurriaan
Brekelmans, with permission from the Weizmann Institute of Science (2017).
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Figure 7.5: Photos of rabbit corneas post WST-D/NIR treatment at 3 day, 7 days and 20
days. After 3 days there was a 5 mm erosion that healed one week postoperatively. After
20 days the cornea was healthy.
7.4.2 Corneal hydration
Wet weight measurements recorded from 8 of the 12 pairs of ex vivo corneal disks before
and after SAXS revealed no signiﬁcant change in corneal hydration during data collection
(Figure 7.6). Within both the in vivo and ex vivo groups, the hydration of the WST-D/NIR
treated and untreated corneas did not diﬀer signiﬁcantly from each other.
Figure 7.6: Corneal hydration before, after and during x-ray data collection.
7.4.3 Collagen interﬁbrillar spacing, ﬁbril diameter andD-periodicity
Table 7.3 shows the average collagen interﬁbrillar spacing, ﬁbril diameter andD-periodicity
for each treated and untreated cornea. No signiﬁcant diﬀerence in these collagen param-
eters were detected between the WST-D/NIR treated corneas and their fellow untreated
corneas.
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Table 7.3: Average collagen interﬁbrillar spacing, ﬁbril diameter and D-periodicity in
WST-D/NIR treated and untreated corneas.
7.4.4 Electron microscopy
Electron microscopy images obtained from the anterior and posterior stromal regions of
pairedWST-D/NIR treated and untreated corneas and riboﬂavin/UVA treated and untreated
corneas showed no obvious diﬀerences in the packing arrangement of stromal collagen
(Figure 7.7). Measurements of average ﬁbril diameter (Figure 7.8) showed the collagen
ﬁbrils to be signiﬁcantly narrower in the posterior stroma compared to the anterior stroma
in all corneas regardless of treatment (p < 0.0001). Although statistical analysis of ﬁbril
diameter measurements between individual rabbits was not possible due to the small
sample size, pair-wise comparisons of ﬁbril diameter measurements recorded from the
treated and untreated cornea of the same animals revealed a small increase (2.3%) but
signiﬁcant diﬀerence in ﬁbril size between the WST-D/NIR treated cornea and untreated
cornea in the anterior stroma (p < 0.0001) but no diﬀerence in the posterior stroma (p
= 0.22). However, the average diameter of ﬁbrils was found to be approximately 20%
wider in the anterior stroma and 18% larger in the posterior of the riboﬂavin/UVA treated
corneas when compared with their paired untreated corneas (Table 7.4).
Fibril diameter measurements of untreated and WST-D/NIR treated corneas calcu-
lated from electron microscopy images (Figure 7.7) were found to be approximately 30%
smaller than those calculated from x-ray scatter patterns (Table 7.3), whereas electron
microscopy-derived measurements of ﬁbril diameter in the riboﬂavin/ UVA cornea were
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found to be only 20% lower than our previously reported x-ray scattering measurements
from similarly treated rabbit corneas (Hayes et al. 2013).
Table 7.4: Measurements of ﬁbril diameter (in nm)made from electronmicroscopy images
of a WST-D/NIR treated cornea, a riboﬂavin/UVA treated cornea and their contralateral
untreated corneas.
Table 7.5: Measurements (in nm) of the positively stained banding pattern made from
electron microscopy images of a WST-D/NIR treated cornea, a riboﬂavin/UVA treated
cornea and their contralateral untreated corneas. (Those indicated in bold show statistical
signiﬁcant results).
Forty D-periods measured from the stain density pattern along the rabbit corneal
collagen ﬁbril showed no signiﬁcant diﬀerence between the riboﬂavin/ UVA treated and
untreated corneas. However, the length of the D-period was signiﬁcantly higher in the
anterior stroma of WST-D/NIR treated corneas compared to their contralateral untreated
corneas (p < 0.03. shown in bold) (Table 7.5 and Figure 7.9).
The axial stain intensity proﬁles for untreated and WST-D/NIR treated cornea are
shown in (Figure 7.10). Each plot represents the average ± standard deviation of three
D-period band intensity traces from a single ﬁbril from one rabbit. The positive staining
locations are indicated (Figure 7.10). Only six staining bands were identiﬁed in this study
(b1-b2-c2-d-e-a). In the WST-D/NIR treatment, the trace shapes appear to be diﬀerent to
the corresponding untreated control traces, showing a diﬀerent pattern of positive staining
in various locations.
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Figure 7.7: Transmission electron microscopy images obtained from the anterior and
posterior stroma of paired WST-D/NIR treated and untreated corneas and riboﬂavin/UVA
treated and untreated cornea. Magniﬁcation ×20,000, and Scale bar = 100 nm
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Figure 7.8: Histogram of ﬁbril diameter distribution made from electron microscopy
images of a WST-D/NIR treated cornea, a riboﬂavin/UVA treated cornea and their con-
tralateral untreated corneas.
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Figure 7.9: Electron micrograph of Rabbit collagen ﬁbrils longitudinal sections. Each
ﬁbril consists of regular alternating dark and light bands that are further divided by cross-
striations. ×30,000, Scale bar is 200 nm
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Figure 7.10: The average of three D-period from the ﬁbril positive staining pattern of
rabbit corneal collagen. One D-period is shown in (a.) untreated and (b.) treated with
WST-D/NIR. Only the main six bands were identiﬁed in this study (b1-b2-c2-d-e-a). (c.)
Superimposition the two averages of the untreated and treated traces. Error bar represents
± standard deviation.
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Morphology post cross-linking
Further electronmicroscopical examination of the tissue conﬁrmed that complete regrowth
of the epithelium had occurred within one month of treatment (Figure 7.11) and that
normal squamous cell, wing cell and basal cell proliferation had occurred in all treated
corneas. However, in the WST-D/NIR treated corneas a double basal lamina (black and
white arrowheads), fewer and more irregular basal epithelial cell hemidesmosomes than
normal (red arrows) (Figure 7.11b and f) (for more detail see Chapter1). Bowman’s layer
in the WST-D/NIR and riboﬂavin/UVA treated corneas appeared normal (Figure 7.12b
and d) with a felt-like composite of randomly oriented, striated collagen ﬁbrils scattered
throughout an amorphous matrix.
Within the corneal stroma, keratocytes were seen to maintain their dendritic mor-
phology and their quiescent condition in untreated corneas. However, at one month
post-treatment, there was an evident reduction in the number of keratocytes in the treated
corneas compared to control corneas due to keratocytes apoptosis, which occurs in re-
sponse to epithelial debridement (Wilson et al. 1996) and cross-linking treatment (Mar-
covich et al. 2012; Wollensak et al. 2004a,b). In the anterior stroma of WST-D/NIR
corneas, activated keratocytes of an increased size, with a larger number of organelles and
an altered morphology were observed (Figure 7.12c). Moreover, intra-cytoplasmic de-
posits of lipid material with vacuoles could be seen in the anterior stroma of WST-D/NIR
corneas with few ﬂat keratocytes (Appendix H). The posteriorWST-D/NIR stroma had ﬂat
quiescent keratocytes (Figure 7.12d). However, in the anterior stroma of riboﬂavin/UVA
corneas, keratocytes were ﬂattened (Figure 7.12j). Meanwhile, the posterior stroma of
riboﬂavin/UVA corneas showed some active keratocytes (Figure 7.12h) with some ﬂat
keratocytes (Appendix H).
Both control and treated corneas revealed well delineated lamellae with normal
collagen matrix. High-magniﬁcation transmission electron microscopy images of the
lamellae are shown in (Figure 7.12). The ﬁbril diameter (Figure 7.7), and characteristic
D-banding patterns of collagen ﬁbril were observed in (Figure 7.9) and analysed Table
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7.4 and 7.5, respectively. Descemet’s membrane was a normal thin, unbanded zone in the
groups. The corneal endothelium showed intact regular morphology in all corneas (Figure
7.13).
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Figure 7.11: Electron microscopy images showing the corneal epithelium (EP) of WST-D
(b) and riboﬂavin/UVA treated (d) and untreated rabbit corneas (a and c) after one month
of healing. Complete re-growth of the corneal epithelium was evident at one month
post-treatment. However, it should be noticed that the WST-D/NIR treated corneas have
double basal lamina and irregular epithelial basal cell hemidesmosome (red arrow). (e)
untreated rabbit cornea at higher magniﬁcation (×10K) showing normal basal lamina
(white arrowheads) and regular epithelial basal cell hemidesmosome (red arrow). (f)
At higher magniﬁcation (×10K) it is evident that in the WST-D/NIR treated cornea,
the epithelium is attached to Basement membrane (black arrowheads) which shows basal
lamina (white arrowheads) that is one of Basement membrane three layers. The Bowman’s
layer (BL) is the felt-like composite of randomly oriented, striated collagen ﬁbrils scattered
throughout an amorphous matrix. The scale bar for (a, b, c and d) is 2 μm (×2000), and
the scale bar for (e and f) is 100 nm with higher magniﬁcation(×10K).
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Figure 7.12: High-magniﬁcation transmission electron microscopy images of the lamellae
(layers of collagen ﬁbrils) for all groups. Corneal stroma keratocytes appear normal in
the untreated corneas (a, b, e, and f), however, the WST-D/NIR corneas show activated
keratocytes in the anterior stroma (c) and ﬂat keratocytes in the posterior stroma (d).
Meanwhile, in the anterior stroma of riboﬂavin/UVA corneas, keratocytes were ﬂattened
(j), whereas, in the posterior stroma of riboﬂavin/UVA corneas there were some active
keratocytes with some ﬂat keratocytes (h). Scale bar is 1μm.
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Figure 7.13: The endothelial surface of the cornea (E) was intact with regular morphology
in all groups. Moreover, Descemet’s membrane (DM)was seen as a normal thin, unbanded
zone in all groups. ×6000. The scale bar is 1μm.
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7.5 Discussion
As with riboﬂavin/UVA cross-linking, WST-D/NIR cross-linking has been shown to im-
prove corneal rigidity (Marcovich et al. 2012). However, the process by which these
cross-linking treatments modify the biomechanical properties of the cornea is not yet
completely understood. In a prior examination looking at the structure and hydrodynamic
conduct of riboﬂavin/UVA treated corneas, an improvement in enzymatic resistance was
evident following treatment, however, the swelling behaviour of the stroma showed no
change. Also, no change was found in the size of the collagen ﬁbrils and their organisa-
tion. These discoveries indicated that the cross-links are in all probability formed within
and between collagen molecules at the surface of the ﬁbrils and inside the proteoglycan
rich coating surrounding them (Hayes et al. 2013). This investigation has utilized some
of the same test strategies to further understand the mechanism by which WST-D/NIR
treatment stiﬀens the cornea.
In the ﬁrst investigation examining the eﬀects of WST-D/NIR treatment on rabbit
corneas, Marcovich et al. (2012) noted that corneal oedema occurred immediately fol-
lowing treatment leading to corneal haze. However, the oedema in the majority of the
cases resolved within four days (Marcovich et al. 2012). The reason for this oedema is
not known, yet as shown by Marcovich et al. (2012) and later conﬁrmed in this study, the
endothelium is unaﬀected by the treatment, thus it is improbable that the oedema is caused
by changes in endothelial transport properties. Previous examinations on rabbit corneas
have demonstrated that epithelial removal leads to apoptosis of anterior stromal kerato-
cytes (Dohlman et al. 1968) and it has been suggested that proteolysis might discharge
hyperosmotic products from these keratocytes as they experience apoptosis (Wilson et al.
1996). Such a system may explain the swelling seen in the epithelium-debrided, WST-
D/NIR cross-linked corneas, as critical keratocyte apoptosis has been seen histologically
in the anterior stroma two days after treatment (Marcovich et al. 2012). Our electron mi-
croscope images taken one month after WST-D/NIR treatment showed a fully recovered
epithelium with active stromal keratocytes in the anterior stroma and ﬂat keratocytes in
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the posterior stroma. The stroma was repopulated with keratocytes, which appeared as
activated ﬁbroblasts, several days after surgery. A few days after cross-linking treatment,
this study observed the same series of phenotypic changes in stromal keratocytes reported
previously (Marcovich et al. 2012), including ﬂatting of cells and darkening of the cell
nuclei. The presence of these activated ﬁbroblasts is expected to lead to increased light
scatter (Gardner et al. 2015) and is assumed to cause a number of visual disturbances
experienced post-treatment, e.g. haze, haloes and starbursts (Jester 2008). It has been
clinically documented that these complications will fade and disappear with time as eyes
make a full recovery, commonly after six months to one year (Greenstein et al. 2012;
Wisse et al. 2016).
In all in vivo treated rabbits, the corneal epithelium was completely cured by eight
days, corneal thickness had come back to pre-treatment levels by day ten and, the hydration
of the treated corneas was equivalent to that of the untreated controls. As the ex vivo WST-
D/NIR-treated corneas were also found to have a comparable hydration to the ex vivo
untreated corneas at the time of information gathering, this indicates that the decline in
corneal thickness seen post treatment can be attributed to epithelial debridement and not
to a reduction in stromal hydration caused by the presence of dextran within the WST-D
solution.
Transmission electron microscopy has demonstrated defects in the normal regener-
ation of epithelial basement membrane in rabbit corneas one month after WST-D/NIR
treatment. This defect might be a duplication of the basement membrane, which is grow-
ing and slowly remodelling to go back to a normal state (Ljubimov et al. 2015). Previous
studies have advocated that the structural integrity of the regenerated epithelial basement
membrane plays a vital role in deciding if a speciﬁc cornea forms haze by restricting
the entrance of epithelium-derived growth factors, for example, transforming growth fac-
tor beta, to the stroma that modulate myoﬁbroblast development from precursor cells
and block myoﬁbroblast apoptosis (Hynes 2009; Torricelli et al. 2013). Moreover, one
month after WST-D/NIR treatment the corneal epithelium seems to have a reduction in
the hemidesmosome-stable adhesion complex or the anchoring complex. The corneal
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basal epithelial cells contain small stud-like structures called hemidesmosomes at their
basal cell membrane (Xu et al. 2010), with which they ﬁrmly attach themselves to the
underlying extracellular matrix - in the case of the cornea, the basement membrane and
underlying stroma, including Bowman’s layer in humans and some other species (Gipson
et al. 1987). The combined hemidesmosomes, anchoring ﬁbril, and anchoring ﬁlament
complex is referred to as the hemidesmosome-stable adhesion complex or the anchoring
complex (Torricelli et al., 2013). Permanent anchoring units are not formed until the
wound defect is completely covered (Dua et al. 1994) and the development of strong per-
manent adhesions occurs within 6 weeks in the case of a defective basement membrane
(Dua et al. 1994; Khodadoust et al. 1968). This suggests that the WST-D/INR-treated
cornea is still in the process of healing, and shows a slower healing response than the
riboﬂavin/UVA-treated cornea. Therefore, it is worth evaluating the ex vivo WST-D/IR
cross linking after 6 months of treatment. Another explanation for this defect on the
epithelium could be epithelium thermal injury from the IR exposure. Marcovich and his
colleagues (2012) evaluated the eﬃcacy and the safety of WST-D cross linking at a non-
hazardous wavelength, (NIR, 755 nm) for 30 minutes, which is a shorter wavelength than
the recommendation on the International Commission on NonIonizing Radiation Protec-
tion (ICNIRP) (Ziegelberger 2013). The (ICNIRP) recommended that to avoid the thermal
injury of the cornea and lens, IR exposure (770 nm) should be limited to 10 mW/cm2 for
lengthy exposures longer than 16 minutes (Ziegelberger 2013). A further investigation of
the safety of the IR exposure with a shorter duration is highly recommended before the
technique is used in the clinic.
At the point when inspected by electron microscopy, the normal width of the collagen
ﬁbrils in the untreated corneaswas observed to be consistently greater in the anterior stroma
than the deep stroma. Despite the fact that the current study was not able to statistically
compare the measurements from the two regions due to the small sample size (two corneas
only), the ﬁnding is consistent with that of other electron microscopy studies that have
reported a non-signiﬁcant trend for ﬁbrils to be wider in the anterior stroma of the rabbit
cornea compared with the deep stroma (Freund et al. 1995; Wollensak et al. 2004c). X-
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ray scattering investigations of cow corneas have additionally demonstrated a comparable
propensity for wider ﬁbrils in the anterior stroma (Ho et al. 2014), yet the situation appears
to be diﬀerent in human corneas, in which the ﬁbril distance remains basically consistent
throughout the cornea (Akhtar et al. 2008; Freund et al. 1995; Quantock et al. 2007).
X-ray scattering measurements of collagen ﬁbril diameter in untreated rabbit corneas
were similar to those reported in earlier studies using the same technique (Hayes et al.
2013; Meek et al. 1993), but the values were ≈ 30% greater than electron microscopy
estimations of ﬁbril diameter in the anterior and deep stroma. This diﬀerence in measured
ﬁbril diameter is caused by the hydration of the tissue at the time of examination, with x-
ray scattering estimations being made at physiological hydration and electron microscopy
estimations being made after signiﬁcant tissue preparation that involves drying the tissue
to below the critical point of hydration (H < 1) when water is lost from the interﬁbrillar
space as well as from the ﬁbrils themselves (Fratzl et al. 1993; Fullwood et al. 1993; Hayes
et al. 2017). In view of the model proposed by Fratzl and Daxer (1993) in which collagen
ﬁbrils of a uniform diameter are encompassed by an external proteoglycan rich covering,
the measurement of which is dictated by water content, it has been suggested that the
reduction in ﬁbril diameter seen following electron microscopy might be partly because
of shrinkage of this external covering as opposed to shrinkage of the ﬁbril itself (Hayes
et al. 2013). As recorded here and elsewhere (Wollensak et al. 2004c), riboﬂavin/UVA
cross-linking showed that the presence of ﬁbrils that are up to 20% wider than those
examined in untreated corneas when observed by electron microscopy; in any case, when
analyzed at physiological hydration by x-ray scattering, no distinction in intermolecular
spacing or ﬁbril diameter was seen between the treated and untreated corneas (Hayes et al.
2013).
In riboﬂavin/UVA cross-linked corneas it has been theorized that extra cross-links are
formed at the surface of the ﬁbril and within the external coating of the ﬁbril and restrict
the amount by which the ﬁbrils and their coating shrink during electron microscopy
preparative techniques. Such a model would clarify the absence of any obvious distinction
in collagen ﬁbril diameter between treated and untreated corneaswhenmeasured at close to
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physiological hydration using x-ray scattering procedures and clariﬁeswhy riboﬂavin/UVA
cross-linked corneas seem to have wider ﬁbrils when inspected in a dehydrated state
by electron microscopy. This idea is upheld by the present results which demonstrate
that electron microscopy estimations of collagen ﬁbril diameter in the superﬁcial and
deep stroma of a riboﬂavin/UVA cross-linked rabbit cornea were only decreased by 20%
compared with those acquired x-ray scattering (Hayes et al. 2013), meanwhile the ﬁbrils
of the untreated cornea seemed to be 30% smaller.
In the WST-D/NIR treated and untreated corneas, the ﬁbril diameter estimations
resulting from low-angle x-ray scattering and electron microscopy were not entirely in
agreement, with low-angle x-ray scattering demonstrating no diﬀerence in ﬁbril diameter
following cross-linking treatment; this ﬁnding was additionally reinforced by high-angle
x-ray scattering information which no changes in collagen intermolecular spacing because
of the treatment (Hayes et al., in press). However, electron microscopy has the advantage
that individual regions can be examined separately, and it showed a slight increase in the
anterior region (only 2.3%) in the WST-D/NIR treated cornea compared to the untreated
corneawhichwasmuch less than the 20% seen using riboﬂavin/UVA.These results suggest
that either the cross-links formed by WST-D/NIR treatment are not adequate in number or
quality to oppose the shrinkage that happens during electron microscopy preparation or
diﬀerent cross-linking mechanisms are involved. Additional proof for a distinction in the
mechanism by which the cornea has become rigid after riboﬂavin/UVA and WST-D/NIR
treatments (Brekelmans et al. 2017) has been given by ﬂuorescence spectroscopy, which
has demonstrated that the dityrosine bond ﬂuorescence at 405 nm, which is viewed as
an impression of riboﬂavin/UVA cross-linked corneas, is absent from those treated with
WST-D/NIR (Marcovich et al. 2012).
An attempt was made here to investigate the location of WST-D/NIR cross-links by
seeing if they aﬀect the charged amino acids along the surface of collagen ﬁbrils. Although
the results suggested possible changes, the noise levels were very high. This is a well-
known problem with positive staining of thin collagen ﬁbrils. Therefore, a decision was
made to discontinue this line of investigation and suggest that rat tail tendon or calf-skin,
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with much wider collagen ﬁbrils, would be a better model to unambiguously examine
changes in the positive stain bands caused by cross-linking.
As indicated beforehand for human (Hayes et al. 2011), rabbit and porcine corneas
cross-linkedwith riboﬂavin andUVA (Hayes et al. 2013), small-angle x-ray scattering from
WST-D/NIR-treated rabbit corneas likewise showed no treatment-instigated diﬀerence the
collagen D-periodicity. This shows that, in the tissue as a whole, neither the axial stagger
nor the tilt of the molecules is inﬂuenced by either type of cross-linking. Nevertheless,
it has been demonstrated that cross-linking with a strong ﬁxative such as glutaraldehyde
only yields a 0.8% decrease in the collagen D-period (Fullwood et al. 1993). As neither
riboﬂavin/UVA nor WST-D/NIR cross-linking aﬀect the full-thickness of the tissue it
is conceivable that limited changes in collagen D-periodicity might be clouded by the
averaging mechanism of the x-ray scatter procedure and discovery of changes in D-
periodicity of under 0.8% are beyond the sensitivity of our experiment. This might
explain the results of the WST-D/NIR cross-linking using electron microscopy, where the
D-period did show a signiﬁcant increase in the anterior stroma. This implies that the axial
stagger and/or the tilt of the molecules might be aﬀected by WST-D/NIR cross-linking.
Further investigations should take place to conﬁrm this ﬁnding.
In conclusion, this investigation suggests that themolecular cross-linkingmechanisms
involved in WST-D/NIR treatment diﬀer from those of riboﬂavin/UVA cross-linking, al-
though it is still not know where the cross-links occur. This study has also provided evi-
dence that the healing of the anterior stroma is slower with WST-D/NIR cross-linking than
with conventional riboﬂavin/UVA cross-linking. The absence of signiﬁcant alterations
in collagen structural parameters following treatment supports the idea that WST-D/NIR
treatment is a suitable method for safely strengthening diseased or surgically weakened
corneas, although longer term studies are needed to ascertain that complete healing takes
place.
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8.6 Concluding discussion
The SCXL method of riboﬂavin/UVA cross-linking, has become a ubiquitous treatment
for halting the progression of keratoconus and other corneal ectasia conditions, and has
become a useful tool in the management of infectious keratitis. The eﬀectiveness of the
treatment lies in its ability to induce additional cross-link formation within the corneal
stroma, thereby enhancing the stiﬀness of the cornea and its resistance to enzymatic
digestion. In recent years, many attempts have been made to modify the SCXL protocol to
produce ‘accelerated’ and ‘trans-epithelial’ CXL protocols that reduce patient treatment
time (by increasing UVA intensity and reducing the exposure time), and increase patient
comfort (by allowing the corneal epithelium to remain intact). Alongside this has been the
development of alternative cross-linking protocols that employ diﬀerent photosensitisers
and wavelengths, such as WST-D/NIR therapy. Unlike SCXL, which has undergone
extensive testing and is now in widespread clinical use, WST-D/NIR therapy remains in
its infancy and further laboratory studies are needed to assess its safety and eﬃcacy prior
to commencing clinical trials. The studies detailed in this thesis aimed to (1) compare
the eﬀectiveness of a range of new and existing epithelium -on and -oﬀ riboﬂavin/UVA
cross-linking protocols in terms of their ability to increase the enzymatic resistance and
stiﬀness of the corneal stroma, (2) develop a trans-epithelial method of cross-linking that
produces outcomes equivalent to those of SCXL, and (3) assess the eﬀect of WST-D
cross-linking therapy on the organisation of collagen within the corneal stroma as primary
step to assessing its clinical potential.
Studies examining the use of higherUVA intensity/shorter durationACXLprocedures
showed that the increase in corneal enzymatic resistance and tissue stiﬀness following
cross-linking with 9 mW/cm2 UVA for 10 minutes or 18 mW/cm2 UVA for 5 minutes, was
very similar to that achieved with the SCXL protocol. However, the enzyme digestion data
indicated that although the ACXL and SCXL procedures produced comparable cross-
linking within the most anterior stroma, the eﬀective depth of cross-linking may be
slightly less with the 9 mW and 18 mW ACXL protocols than that achieved with SCXL.
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When ACXL procedures involving higher intensity of UVA were used (30 mW/cm2 for
3 minutes), the enzymatic resistance of the cornea was signiﬁcantly less than that of the
SCXL treated corneas, indicating a failure of the Bunsen-Roscoe law of reciprocity at
very high UVA intensities. This supports the ﬁnding of biomechanical studies of ACXL
that reported a decrease in eﬃcacy with higher intensities (Hammer et al. 2014; Wernli
et al. 2013). These results agree with clinical ﬁndings of a more superﬁcial demarcation
line after ACXL using 9 mW for 10 min (Kymionis et al. 2014a) or 30 mW for 3 min
(Shetty et al. 2015) compared to SCXL. The safety of 9 mW, 18 mW and 30 mW ACXL
in terms of stromal keratocytes and the endothelium have been established in previous
studies (Kymionis et al. 2014b; Tomita et al. 2014) and the current ﬁndings reinforce the
potential for ACXL use in the clinical setting as a means of reducing patient treatment
time. This is in agreement with clinical studies of ACXL using 9 mW for 10 min that
reported the stabilization of progressive keratoconus up to 18 month (Cinar et al. 2014;
Elbaz et al. 2014; Males et al. 2017; Shetty et al. 2015).
Further studies examining the eﬀect of continuous or pulsedmodes ofUVA irradiation
during a high intensity, high energy procedure involving exposure to 30 mW/cm2 UVA for
4 minutes, showed that an increase in the UVA energy dose to a level approximately 33%
above that used in the SCXL procedure (from 5.4 to 7.2 J/cm2) and the use of a pulsed
UVA delivery mode, resulted in improved corneal enzymatic resistance. It was found that
corneas treated with p-HCXL7.2 J/cm2 persisted for signiﬁcantly longer in enzyme digest
solution than SCXL treated corneas and the dry weight measurements at day 12 were
equal to those of SCXL treated corneas. It seems that pulsing light treatment may help to
overcome the rapid oxygen depletion that occurs in very high intensity ACXL treatments
and result in deeper CXL formation. The suggestion that changes in the UVA intensity,
energy dose and UVA delivery mode may alter the distribution of cross-linking within the
cornea is supported by the ﬁndings of clinical studies that show how a pulsed, high intensity
UVA CXL protocol induces a deeper stromal demarcation line than can be achieved using
a continuous mode of UVA exposure at the same intensity and cumulative energy dose
(Mazzotta et al. 2014; Peyman et al. 2016). Although the use of an accelerated protocol
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with a higher energy dose and pulsed UVA (p-HCXL) seems to oﬀer the best results in
terms of increased enzymatic resistance, the exact amount of cross-linking required to halt
disease progression is not yet deﬁned. This highlights the importance of future studies
aimed at understanding how much CXL is actually needed to prevent disease progression.
The examination of a range of transepithelial cross-linking protocols that involve
treatment modiﬁcations such as partial epithelial disruption, the application of high con-
centration riboﬂavin solutions with added permeation enhancers or iontophoresis-assisted
riboﬂavin delivery, revealed that a prolonged iontophoresis protocol was more eﬀective
than any other transepithelial cross-linking protocol at increasing the enzymatic resistance
of the cornea. Although the eﬀect remained inferior to that achieved with the conventional
epithelium-oﬀ SCXL protocol, the study showed that by increasing the concentration of
riboﬂavin, adding 0.1%BAC to the riboﬂavin solution and using an extended period of ion-
tophoresis delivery with suﬃcient time for riboﬂavin soakage, improved the performance
of trans-epithelial cross-linking. Furthermore, it was found that a 20% increase in the total
UVA energy dose (from 5.4 J/cm2 to 6.75 J/cm2) signiﬁcantly enhanced the outcome of
the treatment in terms of increasing the resistance of the cornea to enzymatic digestion.
Additionally, the transepithelial cross-linking protocols with high riboﬂavin concentration,
permeation enhancers, longer duration iontophoresis and soakage time could be further
enhanced by pulsed modes of UVA irradiation during high intensity and high energy pro-
cedures involving exposure to 9 mW/cm2 UVA for 14 minutes (7.56 J/cm2), results in a
treatment that is comparable/exceeds the eﬀectiveness of SCXL in terms of increasing its
resistance to enzyme digestion. Our ﬁnding is supported by previous studies demonstrated
that the standard transepithelial CXL produced less keratocyte apoptosis and risk of en-
dothelium damaged than standard CXL (Armstrong et al. 2013; Stojanovic et al. 2012).
The use of the optimised St Thomas’/Cardiﬀ transepithelial cross-linking protocol has the
potential to prevent progression of keratoconus whilst also improving patient comfort by
avoiding the need for epithelial removal prior to treatment. In light of these promising
results, further randomized comparative clinical studies are essential to assess the clinical
outcomes of this new protocol and compare its eﬀectiveness to that of the SCXL protocol.
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Limitations of this study include the use of porcine cornea for examining the eﬀectiveness
of trans-epithelial cross-linking protocols, as the porcine epithelium is much thicker than
human epithelium. It would be motivating to repeat our methodology in rabbit model
(thin epithelium) to complement our current results.
The main limitation of using human corneas in this study was that the donor corneas
available for research are of very limited availability and are typically over 60 years
of age and have undergone a signiﬁcant amount of natural, age-related cross-linking.
Ideally, younger human corneas would be used (within the same age range of keratoconic
patients (18-35 years) undergoing collagen cross-linking) to obtainmore clinically relevant
information about the eﬀectiveness of each cross-linking protocol.
The evaluation of the eﬃcacy ofWST-D/NIR cross-linking on the stromal architecture
of the rabbit cornea showed a slower healing processing of epithelium and anterior stromal
in WST-D/NIR treatment compared to standard riboﬂavin/UVA treatment. However, x-
ray scattering revealed that there was no alteration in collagen parameter measurements
as a result of the treatment in either the immediate post-treatment period or after 30
days of healing. The fact that there were no structural abnormalities, coupled with the
previous published data showing its eﬀectiveness at increasing the stiﬀness of the cornea
and its safety, suggest that WST-D/NIR treatment may be a promising alternative to
riboﬂavin/UVA CXL for the treatment of corneal ectasia. However, further research is
needed to understand the mechanism of the cross-linking process and longer term in vivo
healing investigations are needed to determine the complete healing process following
WST-D/NIR therapy.
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8.7 Future work
8.7.1 Assessment of biomechanical stiﬀness of transepithelial mod-
iﬁed iontophoresis protocol using interferometry or Brillouin
microscopy
As mentioned earlier, stress-strain extensometry measurements of corneal stiﬀness after
the various CXL protocols may be complicated by diﬀerences in the eﬀective depth
of cross-linking and the uncertain contribution of the cross-linked and non-cross-linked
regions to the overall measurement. Future studies using this technique could be improved
by using a femtosecond laser or microkeratome to isolate strips of anterior stromal tissue
for tensile testing. In addition to this, radial shearing interferometry could be carried out to
evaluate the eﬀect of the optimised St Thomas’s/Cardiﬀ iontophoresis protocol on corneal
biomechanics and compare it to the outcomes of the SCXL protocol. Interferometry
techniques might be sensitive enough to detect diﬀerences in surface stiﬀness between
diﬀerent types of cross-linking protocols (Cartwright et al. 2012). A novel alternative
technique that would be useful to investigate this CXL technique is three-dimensional
mapping of biomechanics properties in high spatial resolution using Brillouin microscopy.
Brillouin microscopy can be performed in in vivo human eyes and oﬀers a noncontact
macromolecular measurement of CXL-induced biomechanical changes (Scarcelli et al.
2013). This technique could be useful to compare diﬀerent CXL treatment to better
account for additional morphological changes found in keratoconus eyes.
8.7.2 Evaluating the ﬁbril diameter ultrastructure following standard
CXL using high pressure freezing structure
Transmission electron microscope studies presented in this thesis and elsewhere (Wollen-
sak et al. 2004c) have revealed a 12 - 20% increase in collagen ﬁbril diameters within the
anterior 200 μm region post-SCXL. However, when examined at physiological hydration
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using x-ray scattering no diﬀerence in ﬁbril diameter was detected following treatment
(Hayes et al. 2013). It is promoted that a possible explanation for this discrepancy is
that rather than the ﬁbrils increasing in size as a result of the treatment, the cross-linked
ﬁbrils might be more resistant to dehydration during electron microscopy tissue process-
ing (Hayes et al. 2013). Further investigation could be possible to verify or reject this
hypothesis by processing cross-linked and non-cross-linked tissue for electron microscopy
using a non-traditional, high-pressure freezing technique that avoids tissue dehydration
and preserves the structure of the tissue in its native state. Comparison of ﬁbril diameter
measurements obtained from tissue processed using the high-pressure freezing technique
with those obtained following conventional electron microscopy processing should result
in an enhanced understanding of the location of the cross-links and their eﬀect on the
cornea.
8.7.3 Localising the CXL formation and characterising the eﬀect of
corneal cross linking on the proteoglycan core protein
To date, little is known about the speciﬁc location of the cross-links that are formed
following standard CXL protocol but it has been proposed that the cross-links form not
only on the surface of the collagen ﬁbrils but also in the protein network surrounding
the collagen (Hayes et al. 2013). To further understanding of the role of proteoglycans
in the cross-linking process it would be of beneﬁt to conduct an electron microscopical
examination of cross-linked and non-cross-linked tissue that have been treated with a range
of mild and harsh proteoglycan extraction methods. It is known that when the cornea is
placed in distilled water or salt solutions many proteoglycans are lost from the cornea, and
so if in the CXL treated corneas additional cross-links are formed between collagen ﬁbrils
and the proteoglycans then it would be expected that these corneas would show a greater
presence of proteoglycans than in the untreated corneas. Despite major advances in this
ﬁeld, much work is therefore still needed to both understand the current CXL methods and
to improve the treatment.
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against enzymatic digestion
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Keith M. Meek, DScAutho
access
.0/).PURPOSE: To examine the effect of standard and accelerated corneal collagen crosslinking (CXL)
on corneal enzymatic resistance.
SETTING: School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom.
DESIGN: Experimental study.
METHODS: Sixty-six enucleated porcine eyes (with corneal epithelium removed) were assigned to
6 groups. Group 1 remained untreated, group 2 received dextran eyedrops, and groups 3 to 6
received riboflavin/dextran eyedrops. Group 4 had standard CXL (3 mW/cm2 ultraviolet-A for
30 minutes), whereas groups 5 and 6 received accelerated CXL (9 mW/cm2 for 10 minutes and
18 mW/cm2 for 5 minutes, respectively). Trephined central 8.0 mm buttons from each cornea
underwent pepsin digestion. Corneal diameter was measured daily, and the dry weight of 5
samples from each group was recorded after 12 days of digestion.
RESULTS: All CXL groups (4 to 6) took longer to digest and had a greater dry weight at 12 days
(P < .0001) than the nonirradiated groups (1 to 3) (P < .0001). The time taken for complete digestion
to occur did not differ between the standard and accelerated CXL groups, but the dry weights at
12 days showed significant differences between treatments: standard CXL 3 mW > accelerated
CXL 9 mW > accelerated CXL 18 mW (P < .0001).
CONCLUSIONS: Standard and accelerated CXL both increased corneal enzymatic resistance; how-
ever, the amount of CXL might be less when accelerated CXL is used. The precise amount of CXL
needed to prevent disease progression is not yet known.
Financial Disclosure: No author has a financial or proprietary interest in any material or method
mentioned.
J Cataract Refract Surg 2015; 41:1989–1996 Q 2015 The Authors. Published by Elsevier Inc.
on behalf of ASCRS and ESCRS. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Riboflavin–ultraviolet-A (UVA) corneal collagen
crosslinking (CXL) is the first treatment modality
shown to halt the progression of keratoconus1–4 and
other corneal ectatic disorders.4–6 The standard treat-
ment protocol, which was first tested clinically by
Wollensak et al.,1 involves the debridement of the cen-
tral 7.0 mm of the cornea, followed by the application
of riboflavin and a 30-minute exposure to 370 nm
UVA at an energy of 3 mW/cm2. At this fluence, thers. Published by Elsevier Inc. on behalf of ASCRS and ESCRS. This
article under the CC BY license (http://creativecommons.org/procedure appears to be safe in terms of endothelial
toxicity, provided the stromal corneal thickness is
greater than 400 mm.7 In addition, beneficial clinical out-
comes in terms of cessation of disease progression and
improvements in visual and topographic parameters
are consistently achieved,1–6,8 with reported follow-
up of 4 to 6 years.9 However, the UVA exposure
time required to achieve the wanted clinical effect,10
coupled with the need to instill riboflavin eyedropshttp://dx.doi.org/10.1016/j.jcrs.2015.10.004 1989
0886-3350
1990 LABORATORY SCIENCE: CORNEAL RESISTANCE TO ENZYMATIC DIGESTION AFTER CXLfor at least 20 to 30 minutes before irradiation
(to achieve a homogeneous stromal uptake of ribo-
flavin11), results in operative times in excess of 1 hour.
Recently, in an attempt to reduce patient treatment
time, accelerated CXL protocols using higher fluences
and shorter exposure times have been postulated. The
envisaged safe and effective use of accelerated CXL is
based on the Bunsen-Roscoe law of reciprocity,12
which predicts that the same subthreshold total cyto-
toxic corneal endothelial UVA dosage can be adminis-
tered by increasing UVA fluencewhile simultaneously
reducing exposure time. At present, published clinical
studies of patients treatedwith accelerated CXL proto-
cols are few; however, they report no adverse effects
associatedwith accelerated treatment and a significant
reduction in both topographic keratometry and
corrected distance visual acuity at up to 46 months
of follow-up.13,14
Spoerl et al.15 demonstrated an increased resistance
of the corneal stroma to enzymatic digestion after stan-
dard CXL, and this has since been replicated by
others.16,17 Because increased activity of proteinase en-
zymes and reduced activity of proteinase inhibitors
have been identified in keratoconic corneas,18,19 this
increased resistance to proteinase digestion is liable
to be an important factor in the protection against
ectatic progression.15,17 Therefore, to complement
previously published studies focusing solely on the
biomechanical changes in the cornea after CXL,20,21
this study investigated the efficacy of standard and
accelerated CXL protocols in terms of their ability to
increase the resistance of the cornea against enzymatic
digestion. Our previous studies have indicated that
riboflavin–UVA causes the formation of crosslinks
not only at the collagen fibril surface but also in the
protein network surrounding the collagen.16 For this
reason, pepsin was selected for this particular studySubmitted: February 10, 2015.
Final revision submitted: April 10, 2015.
Accepted: April 27, 2015.
From the Structural Biophysics Research Group (Aldahlawi, Hayes,
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Department of Ophthalmology, St Thomas Hospital, London,
United Kingdom.
Supported by the Medical Research Council, London, United
Kingdom (programme grant 503626), and King Saud University,
Riyadh, Saudi Arabia (R1269). Veni Vidi, Halifax, United Kingdom,
provided the riboflavin for this study.
Corresponding author: Keith M. Meek, DSc, School of Optometry
and Vision Sciences, Cardiff University, Maindy Road, Cathays, Car-
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J CATARACT REFRACT SURG - Vbecause it is a nonspecific endopeptidase that can break
down collagens and proteoglycan core proteins.
MATERIALS AND METHODS
Sixty-six porcine eyes with clear intact corneas were ob-
tained from a local European Community–licensed abattoir
within 6 to 8 hours postmortem. By using a single-edged ra-
zor blade, the entire corneal epithelium was carefully
removed from each eye. A detailed visual inspection was
performed to confirm that the debridement technique had
resulted in complete removal of the epithelium without
damage to the underlying stroma. The central corneal thick-
ness (CCT) of each eye was measured before and after
epithelial debridement using a Pachette2 ultrasonic pachy-
meter (DGH Technology, Inc.). The 66 eyes were randomly
and equally divided into the 6 treatment groups:
Group 1: Untreated controls receiving no eyedrops and
no UVA exposure.
Group 2: Dextran-only controls receiving 20% dextran
T500 eyedrops (Pharmacosmos A/S) every 5 minutes
for 30 minutes and no UVA exposure.
Group 3: Riboflavin-only controls receiving riboflavin
eyedrops (0.1% solution riboflavin-5-phosphate in
20% dextran T-500 solution, Mediocross D, Peschke
Meditrade GmbH) every 5 minutes for 30 minutes
and no UVA exposure.
Group 4: “Standard” 3 mW/cm2 CXL protocol (standard
CXL 3 mW) receiving riboflavin 0.1% eyedrops in 20%
dextran T-500 every 5 minutes for 30 minutes before
exposure of the central 9.0 mm region of the cornea to
UVA light with a fluence of 3 mW/cm2 for 30 minutes
(CCL-365 Vario crosslinking system, Peschke Trade
GmbH). Riboflavin eyedrops were reapplied at
5-minute intervals throughout the period of irradiation.
Group 5: Accelerated 9 mW/cm2 CXL protocol (acceler-
ated CXL 9 mW) receiving riboflavin 0.1% eyedrops
in 20% dextran T-500 every 5 minutes for 30 minutes,
followed by a 10-minute exposure of the central 9.0 mm
region to UVA light with a fluence of 9 mW/cm2 and
reapplied riboflavin eyedrops at 5-minute intervals
during the exposure.
Group 6: Accelerated 18 mW/cm2 CXL protocol (acceler-
ated CXL 18 mW) receiving riboflavin 0.1% eyedrops
in 20% dextran T-500 every 5 minutes for 30 minutes,
followed by a 5-minute exposure of the central
9.0 mm region to UVA light with a fluence of
18 mW/cm2.
Immediately after treatment, the CCT was again
measured. The cornea with a 4.0 to 5.0 mm scleral rim was
then dissected from each globe, wrapped tightly in Clingfilm
(to prevent moisture loss), and refrigerated until all treat-
ments were complete. An 8.0 mm corneal button was tre-
phined from the center of each cornea using a disposable
skin biopsy punch (ref BP-80F, Kai Europe GmbH). The
corneal buttons were weighed, then placed in individual
plastic tubes, each containing 5 mL of pepsin solution, and
incubated in a water bath (VwB6, VWR International bvba)
at a temperature of 23C. The pepsin solution was made
of 1 g of 600 to 1200 U/mg pepsin from porcine gastric
mucosa (Sigma-Aldrich Co. LLC) in 10 mL 0.1 M hydrochlo-
ric acid at pH 1.4. Previous studies15 have shown that
changes in corneal disk thickness are not a reliable indicatorOL 41, SEPTEMBER 2015
1991LABORATORY SCIENCE: CORNEAL RESISTANCE TO ENZYMATIC DIGESTION AFTER CXLof the rate of enzymatic digestion because of the considerable
stromal swelling that occurs in the vertical direction within
24 hours of immersion in pepsin digest solution. Because
the diameter of the anterior surface of each corneal button
is unaffected by changes in stromal hydration,15 this param-
eter was used to monitor the rate of enzymatic digestion in 6
of the corneas from each treatment group. Measurements of
anterior surface diameter were made using an electronic dig-
ital caliper (model CM145 4500360, Clarke International) at
24 hourly intervals until complete digestion had occurred.
Because the diameter was found to vary slightly between
different meridians of an individual specimen, the average
of the major axis and minor axis diameter of each corneal
button was recorded at each time point and statistically eval-
uated. The definition of complete digestion was the point
at which the specimen could no longer be distinguished
from the surrounding pepsin solution, even under micro-
scopic examination.
To further assess the effect of each treatment on enzymatic
resistance, 5 corneal disks from each group were removed
from the pepsin digest solution after 12 days and placed in
a 60C oven until a constant dry weight was obtained. The
average corneal dry weight (which represents the mass of
undigested tissue) was calculated for each group.Statistical AnalysisMeasurements of corneal thickness (before and after treat-
ment), corneal disk diameter, dry weight, and complete
digestion time were statistically analyzed using a 1-way
analysis of variance test. Post hoc Bonferroni comparisons
were used to isolate significant interactions. All statistical an-
alyses were performed with Statistical Package for the
Social Sciences software (SPSS Statistics 20, International
Business Machines Corp.). A P value less than 0.01 was
considered to be significant. Data are presented in the results
as the mean G standard deviation. The observed power
computed using a equal to 0.05 was 1, demonstrating that
the sample size was sufficient.
RESULTS
Measurements of CCT before and after epithelial
removal and after each stage of treatment are shown
in Table 1. No statistically significant differences inTable 1. Central corneal thickness before and after epithelial removal a
Groups
Before Epithelial
Removal (mm)*
After Ep
Remova
Untreated 830G 46 739G
Dextran only 821G 41 721G
Riboflavin–dextran only 775G 45 676G
SCXL 3 mW 792G 48 694G
ACXL 9 mW 820G 38 716G
ACXL 18 mW 807G 32 706G
ACXLZ accelerated crosslinking; NAZ not applicable; SCXLZ standard crossl
*Data are given as meanG standard deviation.
†Percentage change from corneal thickness postepithelial removal to posttreatmen
J CATARACT REFRACT SURG - Vcorneal thickness were observed between the groups
either before or after epithelial removal. However,
there was a significant reduction in corneal thickness
after administration of dextran-containing solutions
in both group 2 (20% dextran) and group 3 (riboflavin
0.1%–dextran 20%) (P ! .0001). Application of the
riboflavin solution (containing dextran) to the deepi-
thelialized cornea (group 3) resulted in a significantly
greater reduction in corneal thickness than application
of the dextran-only solution (group 2) (P ! .001). A
significant reduction in corneal thickness was
observed after CXL in groups 4, 5, and 6 (P! .0001).
Because the post-treatment thickness of the irradiated
corneas (groups 4, 5, and 6) did not differ from that of
the nonirradiated riboflavin–treated corneas (group 3),
the corneal thinning in CXL may be attributed to the
application of riboflavin rather than to UVA exposure.
An approximately 10-fold increase in the thickness of
the corneal disk, as a result of stromal swelling in the
posterior–anterior direction,was observed in all corneal
buttons within 24 hours of submersion in pepsin digest
solution (Figure 1). After 1 week of digestion, the
anterior portion of each treated and untreated corneal
button had separated from the posterior portion.
Once detached, the posterior stroma was rapidly di-
gested (within 10 days); however, the anterior stromal
button persisted considerably longer and maintained
its form sufficiently to obtain reliable measurements
of its changing diameter during the digestion process.
Figure 2 shows the summed diameters of 6 corneal
disks within each treatment group as a function of
incubation time in pepsin solution. Statistical analysis
revealed no significant difference in either the mean
corneal button diameter of nonirradiated specimens
(groups 1, 2, and 3) at any timepoint during digestion
or in the time taken for complete digestion to occur
(Table 2). Similarly, in the irradiated specimens, no sig-
nificant difference in these parameters was detectednd after treatment.*
Central Corneal Thickness
ithelial
l (mm)* Posttreatment (mm)* Change (%)†
45 NA NA
39 602G 41 17
45 508G 39 24.9
50 494G 28 28.8
40 514G 31 28.1
34 495G 34 29.9
inking
t
OL 41, SEPTEMBER 2015
Figure 1. Corneal disks from left to right: untreated (U), riboflavin–dextran only (R), standard CXL 3 mW (S3), accelerated CXL 9 mW (A9), and
accelerated CXL 18mW (A18) before (a) and after 1 day (b), 2 days (c), and 12 days (d) of immersion in pepsin digest solution. All corneal buttons
are swollen after 1 day in pepsin digest solution (b). After 2 days of digestion, the anterior curvature has been lost in the untreated corneas but
remains intact in the crosslinked corneas (c). After 12 days, all nonirradiated buttons have been completely digested and only the anterior portion
of the crosslinked corneas remain.
1992 LABORATORY SCIENCE: CORNEAL RESISTANCE TO ENZYMATIC DIGESTION AFTER CXLbetween specimens treated with standard CXL (group
4) or acceleratedCXL (groups 5 and 6). The diameter of
the corneal disks in the CXL-treated groups (4, 5, and
6) was, however, significantly higher than that in the
nonirradiated specimens (groups 1, 2, and 3) at all
daily timepoints after 8 days (P ! .0001) (Figure 2),
and the time required for complete digestion to occur
was significantly longer (P ! .0001) (Table 2). By
12 days all nonirradiated corneas had been completely
digested, but the mean diameter of the CXL-treated
eyes (groups 4, 5, and 6) had decreased by only
27.2%, 27.0%, and 26.6% in the standard CXL 3mW,
accelerated CXL 9mW, and accelerated CXL 18 mW
groups, respectively.
At day 0, there was no significant difference be-
tween the mean wet weight of corneal disks in groupsFigure 2. The summed diameter of all corneal disks (n Z 8) in each trea
(ACXLZ accelerated crosslinking; SCXLZ standard crosslinking).
J CATARACT REFRACT SURG - V1, 3, 4, 5, and 6 (P O .14). However, the mean wet
weight of the dextran-only treated corneas (group 2)
was significantly higher than that of the 3 mW stan-
dard CXL (group 4) (P ! .03) and 9 mW accelerated
CXL treated corneas (group 5) (P! .03) (Table 3).
Measurements of corneal disk dry weight after 12
days of digestion showed a statically significant differ-
ence between irradiated and nonirradiated corneas
(P ! .0001) and between irradiated corneas treated
with 3 mW, 9 mW, or 18 mW accelerated CXL (P !
.0001) (Table 3). The standard CXL 3 mW-treated cor-
neas had a statistically higher mean dry weight than
the 9 mW and 18 mW accelerated CXL-treated corneas
(P! .0001) and the 9 mW accelerated CXL group had
a higher dry weight than the 18 mW accelerated CXL
group (P! .003) (Table 3).tment group shown as a function of time in pepsin digest solution
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Table 2. Time taken for the complete digestion of treated and
untreated corneal buttons.
Group
Time Taken for Complete Digestion (Days)
Minimum Maximum MeanG SD
Untreated 10 11 10.5G 0.55
Dextran only 10 11 10.5G 0.55
Riboflavin–
dextran only
9 11 9.83G 0.75
SCXL 3 mW 24 26 24.7G 1.03
ACXL 9 mW 23 26 24.7G 1.03
ACXL 18 mW 24 27 24.8G 0.98
ACXLZ accelerated crosslinking; SCXLZ standard crosslinking
Table 3. Corneal disk weight before and after 12 days of pepsin
digestion.
Group
Day 0
(Wet Weight) (g)*
Day 12
(Dry Weight) (g)*
Untreated 0.0540G 0.0050 0G 0
Dextran only 0.0563G 0.0055 0G 0
Riboflavin–dextran only 0.0477G 0.0047 0G 0
SCXL 3 mW 0.0438G 0.0032 0.0041G 0.0013
ACXL 9 mW 0.0440G 0.0038 0.0020G 0.0005
ACXL 18 mW 0.0445G 0.0018 0.0008G 0.0003
ACXLZ accelerated crosslinking; SCXLZ standard crosslinking
*Data are given as meanG standard deviation.
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Although the precise etiology of keratoconus is un-
known,22 an increased activity of proteinase enzymes
and a reduced activity of protease inhibitors have
been identified in keratoconic corneas.18 This
increased stromal protein digestion is thought to be
an important factor in the resultant corneal thinning
and biomechanical instability seen in keratoconic
eyes.19 Spoerl et al.15 demonstrated an increased resis-
tance of corneal stromal tissue to enzymatic digestion
after CXL, with irradiances of 2 mW/cm2 and
3 mW/cm2 UVA. This increased resistance to protein-
ase digestion after CXL has been replicated by
others16,17 and is likely to be an important factor in
preventing disease progression.15,19
In this study, the enzymatic resistance of
nonirradiated-treated porcine corneas was compared
with that of standard CXL- and accelerated CXL-
treated corneas. Similar to other clinical- and
laboratory-based studies,16,23,24 a significant reduction
in corneal thickness was observed after CXL using an
isotonic riboflavin solution. Because the posttreatment
thickness of the irradiated corneas did not differ from
that of the nonirradiated riboflavin-treated corneas,
the corneal thinning observed during CXL and acceler-
ated CXL may be attributed predominantly to the
application of riboflavin–dextran solution rather
than to the effect of CXL after UVA exposure. The
application of riboflavin solution (containing 20%
dextran) resulted in a significantly greater reduction
in corneal thickness than the application of the same
concentration of dextran in the absence of any ribo-
flavin. This finding may be the result of riboflavin
increasing the ionic strength of the applied solution,
because higher ionic strengths are known to be associ-
ated with lower corneal hydrations25 and reduced
corneal thickness.
As described previously,15,16 significant stromal
swelling occurred (predominantly in the posteriorJ CATARACT REFRACT SURG - Vstroma) in all corneal buttons during the first 24 hours
in pepsin solution. This observation can be attributed
to the negatively charged glycosaminoglycan compo-
nents of the proteoglycans within the extracellular ma-
trix, which result in the pepsin digest solution being
drawn into the tissue.26 The higher ratio of keratan sul-
fate to chondroitin sulfate in the posterior stroma
compared with the anterior27 may explain why most
of the swelling occurred in this region because keratan
sulfate has a higher water affinity than chondroitin
sulfate.28 Interestingly, the separation of the cornea
into anterior and posterior stromal regions during
the first week of digestion was observed in all treated
and untreated corneas. The separation of the corneal
buttons cannot, therefore, be attributed to CXL-
induced changes within the anterior stroma but must
instead be the result of naturally occurring structural
differences that exist between the anterior and poste-
rior regions. The diameter of the anterior portion of
the corneal button was unaffected by the changes
in corneal hydration and, therefore, formed a
much more reliable measure of the rate of enzymatic
digestion than measurements of corneal thickness.
However, calculations based on the sample size used
and the standard deviation of diameter measure-
ments confirmed that the sensitivity of the technique
was such that differences between groups (in terms
of the time taken for complete digestion) of less than
1 day could not be detected by this method. For this
reason, measurements of corneal disk dry weight
(which reflect the mass of undigested corneal tissue)
were recorded at day 12 of the digestion process to
allow more subtle differences in enzymatic resistance
between treatment groups to be identified.
Our results showed an increased resistance to pro-
teinase digestion after standard CXL that is in agree-
ment with the findings of other investigators.15–17
However, for the first time, we have shown that a
similar increase in enzymatic resistance can also beOL 41, SEPTEMBER 2015
1994 LABORATORY SCIENCE: CORNEAL RESISTANCE TO ENZYMATIC DIGESTION AFTER CXLachieved using higher fluences (up to 18 mW/cm2)
and shorter exposure times. Although the diameter
measurements detected no difference in enzymatic
resistance between the CXL protocols used in this
study, the mean dry weight of corneal tissue after 12
days of protein digestion was found to differ
significantly between groups (3 mW accelerated CXL
O 9 mW accelerated CXLO 18 mW accelerated CXL).
Measurements of corneal dry weight, which represent
the total mass of undigested tissue and negate the
complications associated with within-sample varia-
tions in corneal thickness and between-sample differ-
ences in hydration, provide a more accurate means
of assessing the relative efficacy of CXL procedures
at increasing corneal enzymatic resistance. Our find-
ings suggest that in protocols that use a higher fluence
and shorter exposure time, either the most anterior
layers of the corneal stroma may be crosslinked
equally and the effective depth of CXL is reduced or
the intensity of CXL (which is known to be depth
dependent29) decreases more rapidly as a function
of depth. One interesting observation in previous
studies is the presence of a shallower demarcation
line in accelerated CXL compared with standard
CXL,30,31 suggesting that this may represent a
reduced or shallower CXL effect. However, this as-
sumes that the depth of the demarcation line correlates
directly with the degree and depth of CXL, and
currently there is no direct evidence to support this.
The so-called stromal demarcation line, first described
by Seiler and Hafezi,32 has been shown to possibly be
shallower in older patients and thosewithmore severe
ectatic disease.33 It has been found to be thicker cen-
trally and thinner peripherally34 and possibly related
to an increased density of the extracellular matrix.35
Although a deeper demarcation line has been associ-
ated with a larger decrease in corneal thickness,36 its
depth has not been shown to be correlated to either
visual or keratometric changes 6 months postopera-
tively.33 It may simply represent natural wound-
healing responses rather than delineate the true area
between crosslinked and uncrosslinked tissue, and
more research is required to ascertain the true nature
of this demarcation line and its relationship to the
actual CXL process.
Other studies have concentrated on comparing the
biomechanical changes after CXL and accelerated
CXL using methods such as scanning acoustic micro-
scopy and extensiometry. Hammer et al.37 reported a
reduced corneal stiffening effect with increasing
UVA intensity (up to 18 mW); however, others have
shown similar biomechanical changes after both stan-
dard 3mW/cm2CXL and 9 to 10mW/cm2 accelerated
CXL,20,21 but a sudden decrease in efficacy with high
intensities (greater than 45 mW/cm2).38 The failureJ CATARACT REFRACT SURG - Vof the Bunsen-Roscoe law12 of reciprocity in cases of
high intensity and short illumination time is not yet
understood but may be related to rapid oxygen
consumption and subsequent reduced oxygen avail-
ability, which has been shown to limit the photochem-
ical CXL process.39 Oxygen and its vital role in free
radical production has been shown to be central in
driving the CXL process.39 Therefore, limitations in
availability because of reduced time to replenish suit-
able oxygen levels can theoretically inhibit the photo-
chemical CXL process.39 In our study, we found only
subtle differences in enzymatic resistance, with
increasing UVA intensity up to 18 mW/cm2. Further
studies with energies of 30 mW/cm2 and above are
indicated to seewhether the results of pepsin digestion
studies replicate those of extensometry and other me-
chanical methods.
Even though most laboratory results are supportive
of accelerated CXL, published clinical studies of the
technique are limited. A significant reduction in topo-
graphic keratometry and improvement in corrected
distance acuity, comparable to standard CXL, have
been reported at the 6-month follow-up.13 In a ran-
domized prospective study comparing a fluence of
7 mW/cm2 for 15 minutes with 3 mW/cm2 for 30 mi-
nutes,14 similar clinical results for ectasia stabilization
were reported after each treatment protocol, and
neither treatment resulted in any adverse effects. Simi-
larly, clinical studies using 9 mW/cm2 for 10 minutes
have shown a significant reduction in keratometry
after CXL, with no adverse effects in terms of endothe-
lial cell counts at 3 months.40 More recently, it was
shown that accelerated CXL with an irradiance of
30 mW/cm2 for 3 minutes resulted in a significant
improvement in uncorrected distance visual acuity
and a reduction in keratometry at 6 months.41 This
finding was supported by a nonrandomized study
comparing standard CXL with 30 mW/cm2 acceler-
ated CXL, which found no difference in visual, refrac-
tive, keratometric, or biomechanical parameters
between the 2 treatments at the 12-month follow-up.42
Although our studies have indicated that the
amount of CXL may be less with accelerated CXL,
the minimum effective amount of CXL needed for ec-
tasia stabilization has not yet been established. The
success of the clinical studies described previously in-
dicates that the amount of CXL produced by acceler-
ated CXL may be sufficient to prevent keratoconus
progression. Clearly, further clinical studies, especially
randomized prospective trials, will be necessary to
ascertain the clinical safety and efficacy of accelerated
CXL. But thus far, the accumulating clinical and labo-
ratory evidence demonstrates its similar efficacy to
standard CXL, and its clear benefits in terms of patient
and surgeon convenience support its use.OL 41, SEPTEMBER 2015
1995LABORATORY SCIENCE: CORNEAL RESISTANCE TO ENZYMATIC DIGESTION AFTER CXLWHAT WAS KNOWN
 Standard riboflavin–UVA CXL increases both the strength
of the cornea and its resistance to enzymatic digestion
and has proved to be successful in halting keratoconus
progression. The effect of accelerated CXL protocols on
corneal enzymatic resistance is currently unknown.WHAT THIS PAPER ADDS
 Both standard and accelerated riboflavin–UVA corneal
CXL protocols (up to 18 mW) resulted in an increase in
corneal enzymatic resistance.
 Differences in enzymatic resistance suggest that the
accelerated protocols result in less CXL than the standard
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The aim of this study was to investigate corneal enzymatic resistance following epithelium off and on
riboﬂavin/UVA cross-linking (CXL). One hundred and fourteen porcine eyes were divided into four non-
irradiated control groups and seven CXL groups. The latter comprised; (i) epithelium-off, 0.1% iso-
osmolar riboﬂavin, 9 mW UVA irradiation for 10 min, (ii) disrupted epithelium, 0.1% hypo-osmolar
riboﬂavin, 9 mW UVA for 10 min, (iii) epithelium-on, 0.25% hypo-osmolar riboﬂavin with 0.01% ben-
zylalkonium chloride (BACS), 9 mW UVA for 10 min, (iv) epithelium-on, 5 min iontophoresis at 0.1 mA
for 5 min with 0.1% riboﬂavin solution, 9 mW UVA for 10 min or (v) 12.5 min, (vi) epithelium-on, pro-
longed iontophoresis protocol of 25 min with 1.0 mA for 5 min and 0.5 mA for 5 min with 0.25% ribo-
ﬂavin with 0.01% BACS, 9 mW UVA for 10 min or (vii) 12.5 min. Enzymatic resistance was assessed by
daily measurement of a corneal button placed in pepsin solution and measurement of corneal button dry
weight after 11 days of digestion. This study revealed that the enzymatic resistance was greater in CXL
corneas than non-irradiated corneas (p < 0.0001). Epithelium-off CXL showed the greatest enzymatic
resistance (p < 0.0001). The prolonged iontophoresis protocol was found to be superior to all other trans-
epithelial protocols (p < 0.0001). A 25% increase in UVA radiance signiﬁcantly increased corneal enzy-
matic resistance (p < 0.0001). In conclusion, although epithelium-on CXL appears to be inferior to
epithelium-off CXL in terms of enzymatic resistance to pepsin digestion, the outcome of epithelium-on
CXL may be signiﬁcantly improved through the use of higher concentrations of riboﬂavin solution, a
longer duration of iontophoresis and an increase in UVA radiance.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Over the past decade, riboﬂavin/UVA corneal cross-linking (CXL)
has become an established treatment to halt the progression of
keratoconus and other corneal ectasias. Riboﬂavin is a hydrophilic
molecule, with a molecular weight of 340 Da, while, the corneal
epithelium is lipophyllic, with a decreasing permeability to mole-
cules over 180 Da (Huang et al., 1989). Therefore in the “gold-
standard” CXL protocol the epithelium is removed from the central
corneal to allow adequate stromal absorption of riboﬂavin prior to
UVA irradiation. Spoerl et al. conﬁrmed this need for epithelial
removal, reporting no changes in corneal biomechanics when CXLVision Sciences, Cardiff Uni-
).
r Ltd. This is an open access articlewas performed with the epithelium intact (Spoerl et al., 1998). On
this basis, the epithelium was removed in the ﬁrst published clin-
ical studies (Caporossi et al., 2006; Gkika et al., 2011; O'Brart et al.,
2011; Richoz et al., 2013; Wittig-Silva et al., 2014; Wollensak et al.,
2003). However, epithelial debridement is associated with a
number of adverse events, including severe ocular pain in the im-
mediate post-operative period, delayed visual rehabilitation and
the risks of scarring, infectious and non-infectious keratitis (Koller
et al., 2009).
As a result of such considerations, a number of trans-epithelial
CXL techniques have been postulated. The ﬁrst epithelium-on CXL
(epi-on-CXL) protocols included the use of multiple topical appli-
cations of tetracaine 1% to disrupt epithelial tight junctions (Boxer
Wachler et al., 2010; Chan et al., 2007) and partial epithelial
debridement in a grid pattern (Rechichi et al., 2013). More recently,
novel formulations of riboﬂavin have been developed to facilitateunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rations in which trometamol (Tris-hydroxymethyl-aminometane)
and sodium ethylenediaminetetraacetic acid (EDTA) have been
added facilitate stromal absorption when used in conjunction with
superﬁcial/grid pattern epithelial trauma (Alhamad et al., 2012).
Similarly, preparations without dextran but with sodium chloride
0.44% and benzalkonium chloride (BAC) have been shown to
facilitate trans-epithelial riboﬂavin stromal absorption (Kissner
et al., 2010; Raiskup et al., 2012). Clinical studies with such for-
mulations have demonstrated equivocal results with some sug-
gesting similar efﬁcacy to epithelium-off CXL (epi-off-CXL)
(Filippello et al., 2012; Magli et al., 2013), and others showing less
pronounced effects (Buzzonetti and Petrocelli, 2012; Kocak et al.,
2014; Koppen et al., 2012; Leccisotti and Islam, 2010). As ribo-
ﬂavin is negatively charged at physiological pH and soluble in
water, iontophoresis as a means of enhancing trans-epithelial ab-
sorption has also been postulated. In vitro studies of CXL using
iontophoresis-assisted delivery (Ion-CXL) of riboﬂavin 0.1% with a
current of 0.5e1 mA for 5e10 min have been encouraging,
demonstrating enhanced trans-epithelial riboﬂavin absorption and
corneal tissue biomechanics (Cassagne et al., 2016; Lombardo et al.,
2014; Mastropasqua et al., 2014; Touboul et al., 2014; Vinciguerra
et al., 2014a). Early clinical studies have reported cessation of pro-
gression and improvements in keratometric and visual parameters
(Bikbova and Bikbov, 2014; Buzzonetti et al., 2015; Vinciguerra
et al., 2014b).
In addition to the desire to keep the epithelium intact, the
current “gold-standard”, epi-off-CXL protocol, involves a 30 min
application of riboﬂavin followed by a 30 min irradiation with
370 nm UVA light, with an intensity of 3 mW/cm2, necessitating in
excess of one hour treatment time. In an attempt to reduce treat-
ment times, the use of accelerated CXL (A-CXL) procedures using
the same energy dose but higher UVA intensities and shorter
exposure times have been investigated. Published clinical studies of
A-CXL protocols are relatively few. However, those using 7 mW for
15 min or 9 mW for 10 min have reported improvements in cor-
rected distance acuity and a reduction in topographic keratometry
at up to 46 months follow-up with no adverse events associated
with the high ﬂuences used (Cinar et al., 2014; Cummings et al.,
2016; Kanellopoulos, 2012; Kymionis et al., 2014a; Shetty et al.,
2015). More recently, it has also been demonstrated that the efﬁ-
cacy of A-CXL may be further improved by increasing the UVA
exposure time and the overall cumulative dosage (Aldahlawi et al.,
2016; Kymionis et al., 2014b; Sherif, 2014).
Increased resistance of the corneal stroma to enzymatic diges-
tion following standard (Hayes et al., 2013; Spoerl et al., 2004) and
accelerated (Aldahlawi et al., 2015) epi-off-CXL has been demon-
strated by a number of investigators. It is likely that the improved
enzymatic resistance is an important factor in protection against
disease progression, since an increase in proteinase activity and a
reduction in proteinase inhibitor activity has been identiﬁed in
keratoconic corneas (Zhou et al., 1998). In order to investigate the
efﬁcacy of a number of different epi-on-CXL protocols, we
compared the enzymatic resistance of corneal tissue cross-linked
using epi-off-CXL with that of corneas treated with partially
disrupted-epithelium CXL (dis-CXL), existing epi-on-CXL protocols
(involving different riboﬂavin formulations and modes of delivery)
and a prolonged iontophoresis CXL protocol with 0.25% riboﬂavin
(TC-ion-CXL) that we have recently developed. In addition to this
we examined the effect of increasing the cumulative UVA dosage on
the enzymatic resistance of corneas treated with iontophoresis-
assisted epi-on-CXL. Pepsin was selected as the enzyme of choice
for this study in favour of collagenase, as it is a non-speciﬁc
endopeptidase that can break down both collagen and proteogly-
can core proteins, both of which are believed to be sites ofriboﬂavin/UVA induced cross-links (Hayes et al., 2013). Porcine eyes
were used as, unlike human cadaver eyes and rabbit eyes which are
of limited availability in the UK, they were readily available in the
fresh state and in the large numbers required for this study. How-
ever, due to the porcine cornea having a thicker epithelium than the
human cornea, the results presented herein should be regarded as a
conservative assessment of the effectiveness of trans-epithelial
CXL.
2. Materials and methods
2.1. Specimen preparation
A total of one hundred and fourteen fresh porcine cadaver eyes
with clear corneas and intact epithelium were retrieved from a
local European Community licensed abattoir within 6e8 h of death.
Due to the large number of eyes and treatment groups involved, it
was necessary to split the study into two runs. Run 1 examined the
effectiveness of dis-CXL and epi-on-CXL protocols at increasing
corneal enzymatic resistance to digestion with pepsin, whilst run 2
examined the effect on enzymatic resistance of increasing the UVA
dosage by 25% from 5.4 J/cm2 to 6.75 J/cm2 during iontophoretic
epi-on-CXL. In both runs, the effectiveness of the standard epi-off
CXL protocol at increasing enzymatic resistance was also exam-
ined for comparative purposes. The 11 treatment groups are
described below and summarised in Table 1.
Run 1:
Each treatment group consisted of six eyes.
i) Epi-off standard protocol (Group 1: Epi-off-ribo; Group 2:
Epi-off-CXL)
Complete corneal epithelial debridement was performed in
groups 1 and 2 using a single edged razor blade. These eyes then
received 0.1% riboﬂavin eye drops containing 20% dextran T-500
solution (Mediocross D®, Peschke Meditrade, Huenenberg,
Switzerland) every 5 min for 30 min. The central 9 mm region of
corneas in group 2 was then exposed to 365 nm UVA light with a
ﬂuence of CXL 9 mW/cm2 for 10min using a CCL-365 Vario™ cross-
linking system (Peschkmed, Huenenberg, Switzerland). During
irradiation, riboﬂavin was re-applied at 5 min intervals. Group 1
served as a non-irradiated control.
ii) Epi-disrupted protocol (Group 3: Dis-ribo; Group 4: Dis-
CXL)
Partial epithelial disruptionwas performed in groups 3 and 4, by
making 64 full-thickness epithelial punctures with a 25 gauge
needle in an 8  8 grid pattern. The corneas were then soaked in
riboﬂavin 0.1% dextran-free solution (Vitamin B2 Streuli, Uznach,
Switzerland) for 30 min and rinsed with phosphate-buffered saline
(PBS) for 5 min. Group 4 was then irradiated with 9 mW UVA for
10 min with PBS applied at 5 min intervals to keep the corneal
surface moist. Group 3 served as a non-irradiated control.
iii) Epi-on and high riboﬂavin concentration protocol (Group
5: Medio-ribo; Group 6: Medio-CXL)
Groups 5 and 6 received 0.25% riboﬂavin with 1.2% hydrox-
ypropylmethyl cellulose (HPMC) and 0.01% BAC (Mediocross TE®,
Peschketrade, Huenenberg, Switzerland) every 5 min for 30 min.
This was followed by a 5 min rinse with PBS. Group 6 was then
irradiated with 9 mW UVA for 10 min with PBS applied at 5 min
intervals. Group 5 served as a non-irradiated control.
iv) Epi-on, high riboﬂavin concentration and prolonged
iontophoresis (St. Thomas-Cardiff) protocol (Group 7: TC-ion-
ribo; Group 8: TC-ion-CXL)
Groups 7 and 8 received iontophoresis assisted delivery of 0.25%
riboﬂavin with 1.2% HPMC and 0.01% BAC (Mediocross TE®,
Peschketrade, Huenenberg, Switzerland) using a current of 1 mA
for 5 min. The corneas were then soaked with this riboﬂavin
Table 1
Treatment groups.
Group Abbreviation Epithelium Riboﬂavin formulation Ionto (1 mA) Ribo soak Ionto (0.5 mA) Ribo soak Saline rinse 9 mW UVA Applied during
irradiation
(1)Epithelium-off non-irradiated
control
Epi-off-ribo Off Mediocross D: 0.1% Riboﬂavin,
20% dextran
e 30 min e e e e e
(2) Epithelium-off standard CXL Epi-off-CXL 5.4 J/cm2 Off Mediocross D e 30 min e e e 10 min Mediocross D
(3) Disrupted epithelium non-
irradiated control
Dis-ribo Disrupted Vitamin B2 Streuli: 0.1%
riboﬂavin, saline
e 30 min e e 5 min e e
(4) Disrupted epithelium CXL Dis-CXL 5.4 J/cm2 Disrupted Vitamin B2 Streuli e 30 min e e 5 min 10 min PBS
(5) Epithelium intact non-irradiated
control
Medio-ribo On Mediocross TE: 0.25%
riboﬂavin, 1.2% HPMC, 0.01%
BACS, Pi-water
e 30 min e e 5 min e e
(6) Epithelium intact high riboﬂavin
concentration CXL
Medio-CXL 5.4 J/cm2 On Mediocross TE e 30 min e e 5 min 10 min PBS
(7) Epithelium intact, high riboﬂavin
concentration and prolonged
iontophoresis non-irradiated control
TC-ion-ribo On Mediocross TE 5 min 5 min 5 min 5 min 5 min e e
(8) Epithelium intact, high riboﬂavin
concentration and prolonged
iontophoresis CXL
TC-ion-CXL 5.4 J/cm2 On Mediocross TE 5 min 5 min 5 min 5 min 5 min 10 min PBS
(9) Epithelium intact, high riboﬂavin
concentration, prolonged
iontophoresis and high UVA energy
dose CXL
TC-ion-CXL 6.75 J/cm2 On Mediocross TE 5 min 5 min 5 min 5 min 3 min 12 min 30 s PBS
(10) Epithelium intact, basic
iontophoresis protocol
Ion-CXL 5.4 J/cm2 On Mediocross M: 0.1% riboﬂavin,
1.0% HPMC
5 min e e e 3 min 10 min PBS
(11) Epithelium intact, basic
iontophoresis protocol with high
UVA energy dose
Ion-CXL 6.75 J/cm2 On Mediocross M 5 min e e e 3 min 12 min 30 s PBS
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a power of 0.5 mA/min for 5 min and another 5 min riboﬂavin soak.
The iontophoresis delivery systemwas used to treat ex vivo eyes by
connecting the return electrode to a needle inserted into the vit-
reous chamber; the negative electrode was a steel grid contained in
a corneal well applicator which was adhered to the eye bymeans of
a vacuum well system (Fig. 1). The steel grid (negative electrode)
was completely covered with riboﬂavin and the power generator
set to the desired current and duration. The steel grid remained
covered with riboﬂavin solution for the entire procedure. After
treatment the applicator was removed from the cornea and the
corneas were washed with PBS for 5 min. Group 8 was then irra-
diated with 9 mW UVA for 10min with PBS applied at 5 min in-
tervals. Group 7 served as a non-irradiated control.
Run 2:
Each treatment group consisted of 11 eyes.
i) Epi-off standard protocol (Group 1: Epi-off-ribo; Group 2:
Epi-off-CXL 5.4 J/cm2)
Corneas were treated as described for groups 1 and 2 in run 1.
ii) Epi-on, high riboﬂavin concentration and prolonged
iontophoresis (St. Thomas-Cardiff) protocol (Group 8: TC-ion-
CXL 5.4 J/cm2; Group 9: TC-ion-CXL 6.75 J/cm2)
Groups 8 and 9 received iontophoresis assisted delivery of 0.25%
riboﬂavin with 1.2% HPMC and 0.01% BAC (Mediocross TE®,
Peschketrade, Huenenberg, Switzerland) using a current of 1 mA
for 5min. The corneas were then soaked with this riboﬂavin solu-
tion for 5 min before a further application of iontophoresis with a
power of 0.5 mA/min for 5 min and another 5 min riboﬂavin soak.
Following a 3 min wash with PBS, the corneas in Group 8 were
irradiated with 9 mW UVA for 10 min and those in Group 9 were
irradiated with 9 mW UVA for 12min and 30 s. During irradiation,
PBS was applied to all corneas at 5 min intervals.
iii) Epi-on basic iontophoresis protocol (Group 10: Ion-CXL
5.4 J/cm2; Group 11: Ion-CXL 6.75 J/cm2)
Groups 10 and 11 underwent iontophoresis assisted riboﬂavin
delivery using an isotonic 0.1% riboﬂavin solution (Vitamin B2)
containing 1.0% HPMC dextran-free solution (Mediocross M®,
Peschketrade, Huenenberg, Switzerland) and a 1 mA currentFig. 1. Iontophoresis riboﬂavin delivery sys(Iontophoresis device, Sooft Italia S.p.A, Italy). After treatment the
corneas were washed with PBS for 3 min. Group 10 was then
irradiated with 9 mW UVA for 10min and group 11 was irradiated
with 9 mW UVA for 12 min and 30 s. During irradiation, PBS was
applied to all corneas at 5 min intervals.
2.2. Measurements of corneal thickness
Using a Pachette2™ Ultrasonic Pachymeter (DGH Technology,
Exton, USA), the central corneal thickness was measured in all eyes
prior to treatment and where applicable after removal of the
epithelium, application of riboﬂavin and UVA irradiation.
2.3. Measurements of enzymatic digestion
A corneo-scleral ring was dissected from each eye immediately
following treatment, wrapped tightly in Clingﬁlm™ (to prevent
moisture loss) and refrigerated until all treatments were complete.
An 8 mm corneal button was trephined from the centre of each
cornea using a disposable skin biopsy punch. The corneal buttons
were then immersed into individual plastic tubes, each containing
5 ml of pepsin solution, and incubated in a water bath at a tem-
perature of 23 C. The pepsin solution was made up of 1 g of
>500 U/mg pepsin from porcine gastric mucosa (Sigma-Aldrich,
Dorset, UK) in 10 ml 0.1 M HCL at pH 1.2. The structural integrity of
the most anterior layers of the cornea was assessed by means of
daily measurements of corneal button diameter. The measure-
ments, which were made using an electronic digital caliper,
continued until the specimen could no longer be distinguished
from the surrounding pepsin solution. At this point the tissue was
considered to have undergone complete digestion.
As an additional means of assessing enzymatic resistance, 5
corneal buttons from each of the 6 treatment groups in run 2 were
removed after 11 days in pepsin digest solution and placed in a
60 C oven until a constant dry weight was obtained. The dry
weight of the tissue represents the total mass of undigested tissue
and can therefore be used as an indicator of the effective depth of
cross-linking.tem modiﬁed for use in ex-vivo eyes.
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Measurements of corneal thickness, complete digestion time
and tissue dry weight were statistically analysed using a one-way
analysis of variance (ANOVA) test. Post hoc Bonferroni compari-
sons were used to isolate signiﬁcant interactions. All statistical
analyses were performed with the Statistical Package for the Social
Sciences (IBM SPSS Statistics 20, New York, USA). P < 0.01 was
considered signiﬁcant. Data were presented in the results as
mean ± standard deviation (SD).
3. Results
3.1. Corneal thickness
Fig. 2 shows the average corneal thickness pre-treatment, post-
riboﬂavin application and post-irradiation for each treatment
group in runs 1 and 2. Statistical tests revealed that corneas treated
using the standard, epi-off protocol and an iso-osmolar riboﬂavin
solution (groups 1 and 2) were signiﬁcantly thinner than the cor-
neas in all other groups (p < 0.007).
3.2. Qualitative assessment of riboﬂavin uptake
As shown in Fig. 3, the distinctive yellow colouration of ribo-
ﬂavin was most clearly visible in the epi-off and TC-ion treated
corneas. Although riboﬂavin was also seen in corneas from
other treatment groups, the colour was notably less intense. Pho-
tographs recorded during the irradiation process in run 2 showed aFig. 2. Corneal thickness measurements are shown for each group in run 1 and run 2 before
*In groups 1 and 2 the corneal epithelium (measuring ~90 mm in thickness) was removednon-homogenous distribution of riboﬂavin in Ion-CXL treated
corneas and a more uniform distribution following epi-off CXL and
TC-Ion-CXL.3.3. Pepsin digestion of corneal buttons
Table 2 shows the number of days required for complete tissue
digestion to occur in each irradiated and non-irradiated treatment
group. Although the digestion times of equivalent non-irradiated
(group 1) and cross-linked treatment groups (group 2) were seen
to vary slightly between runs 1 and 2, possibly as a result of dif-
ferences in the breed and age of the pig eyes, the overall trends
were consistent between the two runs. For this reason the data
from each run was normalized against the total digestion time of
the standard epi-off CXL group to facilitate comparison between
the two runs (Figs. 4 and 5).
Figs. 4 and 5 show cumulative measurements of corneal disk
diameter for each irradiated and non-irradiated treatment group
throughout the digestion process. In both runs 1 and 2, the cross-
linked groups showed a signiﬁcantly greater resistance to enzy-
matic digestion than the non-irradiated groups (p < 0.0001). In run
1, complete digestion of all non-irradiated corneas had occurred by
day 13 (Table 2). At the same time point (normalized digestion time
of 0.33), the mean diameter of the epi-off-CXL, dis-CXL, medio-CXL
and TC-ion-CXL groups had only decreased by 39%, 62%, 74%, and
40% respectively (Fig. 4). No signiﬁcant difference was found be-
tween the non-irradiated groups in terms of either the average
corneal button diameter at any time point in the digestion process
or in the time required for complete digestion to occur (Fig. 4).treatment, after riboﬂavin application and where applicable, following UVA irradiation.
as part of the riboﬂavin application process.
Table 2
Time taken for the complete tissue digestion to occur.
Groups Time taken for complete digestion (in days)
Minimum Maximum Average (±SD)
RUN 1
(1) Epi-off-ribo 11 12 11.5 ± 0.55
(2) Epi-off-CXL 5.4 J/cm2 39 40 39.5 ± 0.55
(3) Dis-ribo 11 13 11.8 ± 0.75
(4) Dis-CXL 5.4 J/cm2 15 16 15.6 ± 0.52
(5) Medio-ribo 11 12 11.6 ± 0.51
(6) Medio-CXL 5.4 J/cm2 14 15 14.6 ± 0.52
(7) TC-ion-ribo 11 12 11.3 ± 0.52
(8) TC-ion-CXL 5.4 J/cm2 32 33 32.2 ± 0.41
RUN 2
(1) Epi-off-ribo 9 10 9.5 ± 0.55
(2) Epi-off-CXL 5.4 J/cm2 43 44 43.5 ± 0.55
(8) TC-ion-CXL 5.4 J/cm2 34 35 34.3 ± 0.52
(9) TC-ion-CXL 6.75 J/cm2 41 42 41.7 ± 0.52
(10) Ion-CXL 5.4 J/cm2 27 28 27.3 ± 0.52
(11) Ion-CXL 6.75 J/cm2 34 35 34.5 ± 0.55
Fig. 3. Corneal buttons from each group in run 1 and 2 are shown immediately post-treatment. The characteristic yellow colour of riboﬂavin can be seen most clearly in the
epithelium-removed, riboﬂavin treated corneas (epi-off) and in the corneas that received riboﬂavin via the St Thomas's/Cardiff modiﬁed iontophoresis protocol (TC-Ion). Photo-
graphs recorded during the irradiation process show a non-homogenous distribution of riboﬂavin in corneas treated with the basic iontophoresis protocol (Ion-CXL).
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linked groups in term of the time taken for complete digestion to
occur (Fig. 4). The conventionally treated, epi-off-CXL corneas
(group 2) took signiﬁcantly longer to digest than all other cross-
linked corneas (p < 0.0001). Although less resistant to enzyme
digestion than the epi-off-CXL corneas, the TC-ion-CXL treated
corneas (group 8) took signiﬁcantly longer to digest than corneas
treated with other disrupted epithelium (dis-CXL) or epi-on-CXL
protocols (p < 0.0001).
In run 2, the non-irradiated corneas were completely digested
by day 10 (Table 2). At this same time point, which corresponds to a
normalized digestion time of 0.25, the mean diameter of corneas in
the epi-off-CXL 5.4 J/cm2, TC-ion-CXL 5.4 J/cm2, TC-ion-CXL 6.75 J/
cm2, Ion-CXL 5.4 J/cm2 and Ion-CXL 6.75 J/cm2 treatment groups
had reduced by 21.4%, 16.2%, 13.4%, 26.7% and 19.4% respectively
(Fig. 5). Signiﬁcant differences in themean disk diameter of the CXL
treatment groups were only apparent after 24 days of digestion
(corresponding to a normalized digestion time of 0.6 in Fig. 5). The
epi-off-CXL group (group 2) took longer to undergo complete
digestion than all other cross-linked groups (p < 0.0001) butcorneas treated with the prolonged, high riboﬂavin concentration,
iontophoresis protocol (TC-ion-CXL) were found to persist in the
pepsin digest solution for signiﬁcantly longer than those treated
with the basic Ion-CXL protocol (Fig. 5). In both the Ion-CXL and TC-
ion-CXL treatment groups, an increase in UVA radiance from 5.4 J/
cm2 to 6.75 J/cm2 resulted in a signiﬁcant increase in the time
required for complete digestion to occur (P < 0.0001).
3.4. Undigested tissue mass
In run 2, only the cross-linked corneas remained after 11 days in
pepsin digest solution (Fig. 6). At this time point, the average
stromal dry weight of the epi-off-CXL 5.4 J/cm2 treated corneas
(group 2) was signiﬁcantly higher than that of all other treatment
groups (groups 8,10,11, P < 0.0001; group 9, P < 0.001). The stromal
dry weight did not differ signiﬁcantly between the Ion-CXL 5.4 J/
cm2 and Ion-CXL 6.75 J/cm2 treatment groups (p ¼ 0.32) or be-
tween the TC-ion-CXL 5.4 J/cm2 and TC-ion-CXL 6.75 J/cm2 groups
(p ¼ 0.038). However, corneas treated with the TC-Ion-CXL 6.75 J/
cm2 protocol had a higher stromal dry weight than corneas treated
with basic ion-CXL 5.4 J/cm2 protocol (p < 0.003).
4. Discussion
Attaining adequate stromal riboﬂavin concentration is essential
for CXL. Riboﬂavin acts as a photo-sensitizer for the production of
oxygen free radicals, which drive the CXL process (McCall et al.,
2010) and as a result insufﬁcient stromal absorption may result in
treatment failure (Wollensak et al., 2003; Wollensak and Iomdina,
2009). As riboﬂavin is a hydrophilic molecule which cannot pene-
trate epithelial cell membranes and tight junctions, the ﬁrst ribo-
ﬂavin/UVA CXL protocols required complete central corneal
epithelial debridement prior to riboﬂavin application (Spoerl et al.,
1998;Wollensak et al., 2003). Although epi-off-CXL is considered to
be the gold standard procedure, with multiple prospective and
randomized controlled studies demonstrating its efﬁcacy in terms
of cessation of keratoconus progression and improvements in
keratometric and visual parameters (Caporossi et al., 2006; Gkika
et al., 2011; O'Brart et al., 2011; Richoz et al., 2013; Wittig-Silva
et al., 2014; Wollensak et al., 2003), new methods of epi-on-CXL
Fig. 4. The summed diameter of all corneal disks within each treatment group (n ¼ 6) are shown for run 1 as a function of time in pepsin digest solution. The digestion time for each
treatment group has been normalized against the total digestion time of the standard epi-off CXL group.
Fig. 5. The summed diameter of all corneal disks within each treatment group (n ¼ 6) are shown for run 2 as a function of time in pepsin digest solution. The digestion time for each
treatment group has been normalized against the total digestion time of the standard epi-off CXL group.
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ment, thereby alleviating post-operative pain and potential risks of
infection (Koller et al., 2009). In addition, to reduce the longtreatment times associated with epi-off-CXL with 3mw/cm2 UVA
irradiation, the use of A-CXL protocols using the same energy dose
but higher UVA intensities and shorter exposure times have been
Fig. 6. Corneal button dry weight after 11 days of digestion. Error bars show standard deviation.
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protocols, multiple methodologies, including extensiometry
(Cassagne et al., 2016; Kissner et al., 2010; Vinciguerra et al., 2014a;
Wollensak and Iomdina, 2009), shear wave elastography (Touboul
et al., 2014), Brillouin microscopy (Scarcelli et al., 2013) and
Scheimpﬂug air pulse tonometry (Mastropasqua et al., 2014) have
been employed. However each of these methodologies have their
inherent inaccuracies and as yet there is no agreed best practice for
assessing biomechanical changes following CXL.
Although the precise aetiology of keratoconus is unknown
(Davidson et al., 2014), an increased activity of protease enzymes
and reduced activity of protease inhibitors has been identiﬁed
(Spoerl et al., 2004), with the resultant increase in stromal protein
digestion liable to be a factor in corneal thinning and secondary
biomechanical instability (Andreassen et al., 1980). Spoerl et al.
(2004) reported increased resistance of stromal tissue to enzy-
matic digestion following epi-off CXL with a dose response related
to the intensity of UVA irradiance. This increased resistance to
protease digestion following CXL has been replicated by others
(Hayes et al., 2013; Aldahlawi et al., 2016) and is thought to be an
important factor in preventing disease progression. In this studywe
utilized enzymatic resistance to pepsin digestion to evaluate the
effects of epi-off-CXL, dis-CXL and epi-on-CXL. Although minor
differences in the rate of enzymatic digestion were seen between
similarly treated corneas in runs 1 and 2, possibly due to variations
in the age and breed of the pig eyes in different batches of abattoir
tissue, each run showed an increased resistance in all of the cross-
linked groups compared to their non-irradiated controls. However,
in accordance with the ﬁndings of Wollensak and Iomdina (2009),
which reported corneal stiffness after epi-on-CXL to be only one
ﬁfth of that seen after epi-off-CXL (indicating a reduced cross-
linking effect), we found enzymatic resistance to be signiﬁcantly
greater with epi-off-CXL than with dis-CXL or epi-on-CXL. Whilst
dis-CXL showed a greater resistance to digestion than the non-
irradiated controls, it was not as effective as the other epi-on-CXLprotocols tested, possibly due to the non-homogeneous uptake of
riboﬂavin that we have documented previously (Alhamad et al.,
2012). Such observations are supported by a recently published,
randomized controlled study which showed better corneal ﬂat-
tening with epi-off-CXL than dis-CXL, although interestingly, dis-
CXL resulted in better improvement of corrected distance visual
acuity at 6 months (Razmjoo et al., 2014).
In this study we showed that corneas cross-linked using
Mediocross TE® (Medio-CXL protocol) showed a greater resistance
to enzymatic digestion than non-irradiated controls and dis-CXL
treated corneas. However, the enhanced enzymatic resistance
achieved with Medio-CXL was found to be inferior to that of the
epi-off and ion-CXL protocols. Mediocross TE® is a hypo-osmolar
riboﬂavin solution that contains 0.01% BAC, a cationic surfactant
that can disrupt epithelial tight junctions to increase corneal
permeability to riboﬂavin (Kissner et al., 2010; Raiskup et al., 2012).
Laboratory studies have shown that preparations with sodium
chloride and BAC can facilitate riboﬂavin transfer through an intact
epithelium albeit in a reduced concentration compared to the epi-
off-CXL (Touboul et al., 2014), and with signiﬁcant associated su-
perﬁcial epithelial damage (Uematsu et al., 2007). Published clinical
studies using enhanced riboﬂavin solutions with epithelial pene-
tration enhancers are limited and have produced equivocal results.
Some have reported similar efﬁcacy to epi-off-CXL (Filippello et al.,
2012; Magli et al., 2013), while others have demonstrated less
pronounced effects with high rates of treatment failure (Buzzonetti
and Petrocelli, 2012; Kocak et al., 2014; Koppen et al., 2012;
Leccisotti and Islam, 2010). There are currently only three pub-
lished randomized, controlled trials comparing epi-off and epi-on-
CXL. Two of the studies, with follow-up times of up to 12 months,
reported similar outcomes (Nawaz et al., 2015; Rossi et al., 2015).
However, the third study, showed epi-on-CXL to be safe but
demonstrated continued progression of keratoconus in 23% of cases
at 12 month follow-up (Soeters et al., 2015). The latter result is
consistent with the less pronounced biomechanical changes
N.H. Aldahlawi et al. / Experimental Eye Research 153 (2016) 141e151 149observed experimentally following epi-on-CXL (Wollensak and
Iomdina, 2009).
As riboﬂavin is negatively charged at physiological pH and sol-
uble in water, the use of iontophoresis has been postulated to
enhance trans-epithelial absorption. Commercially recommended
protocols for iontophoresis utilize 0.1% riboﬂavin solution and
electrical currents of 0.5e1 mA for 5e10 min. Treatment of rabbit
corneas by this means has been shown to reduce the stromal
riboﬂavin uptake achieved with epi-off-CXL by two thirds, but to
produce a similar improvement in corneal biomechanics (Cassagne
et al., 2016). Studies on rabbit and human cadaver corneas have
demonstrated similar ﬁndings, with better riboﬂavin penetration
and increased elastometry measurements obtained with Ion-CXL
than with epi-on-CXL (using Ricrolin TE) but less than epi-off-CXL
(Vinciguerra et al., 2014a). In a human donor eye model, Mas-
tropasqua et al. demonstrated a corneal stiffening effect following
Ion-CXL (Mastropasqua et al., 2014), with Lombardo et al. (2014)
reporting an almost comparable effect on corneal stiffness to that
with epi-off-CXL. These ﬁndings have been conﬁrmed by super-
sonic shear wave elastography (Touboul et al., 2014). Furthermore,
initial clinical studies in prospective case series have reported
cessation of keratoconus progression with up to 15 month follow-
up and some limited improvements in keratometric and visual
parameters (Bikbova and Bikbov, 2014; Buzzonetti et al., 2015;
Vinciguerra et al., 2014b). However, the relative efﬁcacy of this
technique compared to epi-off-CXL remains to be determined
especially over longer term follow-up.
Using spectrophotometry (Hayes et al., 2015) and two-photon
ﬂuorescence microscopy (Gore et al., 2014), we have found that
stromal riboﬂavin absorption in epithelium-intact corneas can be
improved by increasing riboﬂavin concentration, epithelial contact
time and iontophoresis dosage. Based on this work, we have
modiﬁed the basic Sooft italia Ion-CXL protocol (Sooft italia S.p.A,
Motegiorgio, Italy) and developed the St Thomas's/Cardiff modiﬁed
iontophoresis protocol (TC-ion-CXL) which uses Mediocross TE® as
the iontophoretic solution instead of Ricrolinþ®, as the riboﬂavin
concentration of the former is higher (0.25%) and the use of the
cationic surfactant BAC has been shown with percutaneous treat-
ment to have synergistic effect with iontophoresis on the transport
of anions (Fang et al., 1998). In addition to using this formulation,
the modiﬁed protocol employed a riboﬂavin-epithelial contact
period of 5 min after iontophoresis to allow time for the sub-
epithelial iontophoretically delivered riboﬂavin to diffuse homo-
geneously into the stroma, as well as an increased dosage of
iontophoresis with a second treatment 5 min after the ﬁrst. Results
from the present study demonstrated that both the basic Ion-CXL
and modiﬁed TC-ion-CXL protocols resulted in a greater resis-
tance to enzymatic digestion than all other dis-CXL and trans-
epithelial CXL protocols tested. Furthermore, as we have demon-
strated previously for epi-off CXL treated corneas (Aldahlawi et al.,
2016), we have now shown that the enzymatic resistance of Ion-
CXL and TC-ion-CXL treated corneas can also be enhanced by
increasing the cumulative energy dose and allowing additional
type I photochemical cross-linking to occur. The improvement in
enzymatic resistance was evidenced by the Ion-CXL and TC-ion-
CXL corneas treated with a total energy dose of 6.75 J/cm2 per-
sisting for longer in enzyme digest solution than those that
received a lower energy dose of 5.4 J/cm2. The absence of any dif-
ference in their dry weights after 11 days of digestion is likely
explained by the fact that at this stage of the digestion process, the
rate of digestion was similar for both the high and low energy
treatment groups and signiﬁcant differences in average corneal
disk diameter were not observed until day 24.
The enzymatic resistance achieved with the TC-ion-CXL 6.75 J/
cm2 protocol was closest to that of the standard epi-off-CXL 5.4 J/cm2 protocol, suggesting that this technique may be the best trans-
epithelial alternative for epi-off-CXL. Its slightly lower efﬁcacy
compared to epi-off-CXL, demonstrated by measurements of
corneal disk diameter and tissue dry weight, may be due to a
reduced riboﬂavin stromal absorption or due to other factors. These
might include absorption of UVA by riboﬂavin within the epithe-
lium, resulting in shielding of the underlying stroma and a reduced
UVA dosage to the stroma, although this is unlikely as a 3 min PBS
wash of the ocular surface was performed before UVA exposure.
Another possible cause of the reduced efﬁcacy might be the oxygen
consumption by the epithelium itself (Harvitt and Bonanno, 1998),
which could reduce the amount of oxygen available to the stroma to
drive the CXL process (McCall et al., 2010). Such problems may be
overcome by additional manipulation of the UVA dosage, in terms
of its intensity and duration and/or by increasing oxygen avail-
ability and require further investigation. One further explanation
may be the limitation of our porcine model. As the porcine cornea
has a much thicker corneal epithelium than the human cornea
(90 mm and 50 mm respectively), the results of the current study
should be regarded as a conservative assessment of the effective-
ness of trans-epithelial CXL. Unfortunately, human donor corneas
are unsuitable for examining the effects of CXL on enzymatic
resistance due to the fact that donors are typically over 60 years old,
and the naturally occurring cross-links which increase with age,
may mask the effects of the CXL treatment under investigation.
However, it would be interesting to repeat our methodology in the
rabbit model which has a thinner epithelium (40 mm) and is closer
in thickness to that of the human cornea. Such a study would
complement our current ﬁndings by providing a more liberal es-
timate of the effectiveness of trans-epithelial cross-linking.
This study, which shows our St Thomas'/Cardiff modiﬁed
iontophoresis protocol (TC-ion-CXL) to bemore effective than other
trans-epithelial CXL protocols at increasing the enzymatic resis-
tance of the cornea supports the concept that iontophoresis-
assisted CXL may, with modiﬁcations in terms of riboﬂavin con-
centration, duration of iontophoretic treatment, riboﬂavin soak-
time and UVA energy dose, be an effective technique to prevent
the progression of keratoconus and avoid the postoperative pain
associated with epithelial debridement. Such a technique is
envisaged to be especially useful for eyes that are not eligible for
treatment with epi-off-CXL due to minimum corneal thickness
values less than 400 mm. Further laboratory studies to optimize this
protocol and randomized, prospective clinical studies to compare
its efﬁcacy with epi-off CXL are indicated and are currently being
undertaken (O'Brart D, personal communication, International
Standard Randomized Controlled Trials Number: 04451470).
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PURPOSE. To investigate the effect of various riboflavin/ultraviolet light (UVA) crosslinking
(CXL) protocols on corneal enzymatic resistance.
METHODS. A total of 66 enucleated porcine eyes, with the corneal epithelium removed, were
divided into 6 groups. Group 1 remained untreated. Groups 2 to 6 received riboflavin/dextran
for 30 minutes. Group 3 underwent standard CXL (SCXL) with 3 mW/cm2 UVA for 30 minutes
(total energy dose 5.4 J/cm2). Groups 4 and 5 underwent high intensity CXL (HCXL) using 30
mW/cm2 UVA for 3 minutes (5.4 J/cm2) and 30 mW/cm2 for 4 minutes (7.2 J/cm2),
respectively. Group 6 was exposed to 8 minutes of 30 mW/cm2 UVA in a 10-second on/10-
second off pulsed-radiation mode (p-HCXL; 7.2 J/cm2). A central 8-mm disk from each cornea
was submerged in pepsin digest solution at 238C and measured daily. After 13 days, the dry
weight was recorded from 5 samples in each group.
RESULTS. The CXL-treated corneas took longer to digest than nonirradiated corneas (P <
0.0001). Differences in digestion time also were observed between CXL groups, such that,
HCXL (5.4 J/cm2) < SCXL (5.4 J/cm2) < HCXL (7.2 J/cm2) < p-HCXL (7.2 J/cm2; P < 0.0001).
The dry weight of the SCXL (5.4 J/cm2) group was higher than the HCXL (5.4 and 7.2 J/cm2; P
< 0.001) and p-HCXL 7.2 J/cm2 (P <0.05) groups. No difference was detected between the
HCXL and p-HCXL 7.2 J/cm2 groups.
CONCLUSIONS. The intensity and distribution of the crosslinks formed within the cornea vary
with different UVA protocols. The precise location and amount of crosslinking needed to
prevent disease progression is unknown.
Keywords: keratoconus, crosslinking, accelerated crosslinking, CXL, enzymatic digestion
Keratoconus is a degenerative corneal dystrophy, character-ized by progressive corneal thinning and subsequent
impairment of corneal biomechanics.1–3 The resultant conical
ectasia causes irregular astigmatism and associated reduction of
visual performance, which can be significant.4 It typically
presents in adolescence and is the most common of all corneal
dystrophies with a reported incidence of 1 in 1750.1–3 Its
precise pathophysiology is as yet undetermined, but it has been
shown to be associated with an upregulation of degradative
proteolytic enzymes.5 Riboflavin and ultraviolet A (UVA)
corneal crosslinking (CXL) was first postulated in 1998 as a
means of strengthening the corneal stroma, increasing its
resistance to enzymatic digestion and stabilizing cases of
progressive keratoconus.6 It has since been the subject of a
plethora of research articles investigating and confirming its
safety and efficacy.7–10
The standard CXL protocol (SCXL), first clinically tested by
Wollensak et al.,8 involves removing the central 9 mm of
corneal epithelium, soaking the exposed stromal surface with
0.1% riboflavin for 30 minutes, and irradiating the riboflavin-
laden stroma with 370 nm UVA light with an intensity of 3 mW/
cm2 (resulting in a cumulative dose of 5.4 J/cm2). This protocol
requires in excess of 1 hour of treatment time. Given its
frequency of occurrence, the potential numbers of patients
with progressive keratoconus requiring CXL is large and
represents a not inconsiderable burden to health services. In
an attempt to reduce the treatment time, a number of
modifications to the existing SCXL protocol have been
proposed. These changes are based primarily on current
understanding of the photochemical kinetics of UVA exposure
and the theoretical principles of the Bunsen–Roscoe law of
reciprocity,11 which states that a certain biological effect is
directly proportional to the total energy dose irrespective of the
administered regimen. However, as has been shown with other
photochemical reactions,12 this law may only be valid within a
certain dose range and this must be defined individually for
each reaction.
The precise photochemical mechanism involved in ribofla-
vin/UVA CXL currently is uncertain. What has been shown,
however, is that oxygen is essential to drive the process and in
the absence of oxygen, CXL is impaired.13 It has been suggested
that higher intensity UVA, or so-called ‘‘accelerated’’ CXL
protocols, result in more rapid oxygen depletion thereby
reducing efficacy.14,15 It has been shown that by ceasing UV
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irradiation, oxygen can be restored to its normal level within 3
to 4 minutes16 and, on this basis, it has been proposed that by
pulsing the UV light throughout the procedure, oxygen levels
may be replenished so that the CXL process is no longer
impaired.17,18 In addition to pulsing, it also has been suggested
that the efficacy of accelerated protocols may be improved by
increasing the exposure time by 30% to 40%.19,20
To further investigate these issues and compare the efficacy
of accelerated CXL, extended accelerated CXL and pulsed CXL
protocols with the ‘‘gold standard’’ SCXL protocol, we
analyzed the rate of enzymatic digestion after CXL in an ex
vivo porcine model.
METHODS
Study Design
A total of 66 fresh porcine eyes, with transparent corneas and
an intact corneal epithelium, were obtained from a local
European Community licensed abattoir and used within 6
hours of death. Following a complete debridement of the
corneal epithelium using a single-edged razor blade, the eyes
were divided randomly and equally into the 6 groups described
below (in which Groups 1 and 2 served as controls).
1. Untreated (U): no treatment performed.
2. Riboflavin only (R): a 0.1% riboflavin solution containing
20% dextran T-500 (Mediocross D; Peschke Meditrade,
Huenenberg, Switzerland) was applied to the anterior
corneal surface for 30 minutes using an annular suction
ring.
3. Standard low-intensity CXL (SCXL 5.4 J/cm2): a 0.1%
riboflavin solution containing 20% dextran T-500 was
applied to the anterior corneal surface for 30 minutes (as
above). The cornea then was exposed to 3 mW UVA for
30 minutes (total energy dose of 5.4 J/cm2) during
which time riboflavin was reapplied at 5-minute
intervals.
4. High intensity 30 mW/3 min CXL (HCXL 5.4 J/cm2): a
0.1% riboflavin solution containing 20% dextran T-500
was applied to the anterior corneal surface for 30
minutes. The cornea then was exposed to 30 mW UVA
for a period of 3 minutes (total energy dose of 5.4 J/cm2)
during which time riboflavin was reapplied once.
5. High intensity 30 mW/4 min CXL (HCXL 7.2J/cm2): a
0.1% riboflavin solution containing 20% dextran T-500
was applied to the anterior corneal surface for 30
minutes. The cornea then was exposed to 30 mW UVA
for a period of 4 minutes (total energy dose of 7.2 J/cm2)
during which time riboflavin was reapplied once.
6. High intensity 30 mW/8min pulsed CXL (p-HCXL7.2 J/
cm2): a 0.1% riboflavin solution containing 20% dextran
T-500 was applied to the anterior corneal surface for 30
minutes. The cornea then was exposed to 30 mW UVA
in a pulsed radiation mode of 10 seconds on and 10
seconds off for a period of 8 minutes (total energy dose
of 7.2 J/cm2). During irradiation the riboflavin solution
was reapplied twice.
All of the irradiation protocols were performed using the
Phoenix CXL System (Peschke Meditrade) with a wavelength of
365 nm, a 50 mm working distance, and a 9 mm aperture.
Central corneal thickness was measured via ultrasound
pachymetry (DGH Pachmate 55; DGH Technologies, Exton,
PA, USA) before treatment (after epithelial debridement), after
riboflavin application, and after UVA exposure.
Following treatment, an 8 mm full-tissue-thickness biopsy
was trephined from the center of each cornea. The corneal
disks were placed in individual sealed tubes containing 5 mL
pepsin digest solution (1 g 600 to 1200 U/mg pepsin from
porcine gastric mucosa [Sigma-Aldrich, Dorset, UK] in 10 mL
0.1 M HCL at pH 1.2) and incubated in a water bath at 238C. As
our previous studies suggest that CXL causes the formation of
crosslinks not only at the collagen fibril surface but also in the
protein network surrounding the collagen,21 pepsin was
selected in preference to collagenase as the enzyme of choice
for this study.
Using electronic digital calipers, the diameter of the anterior
surface of each corneal disk was recorded daily until the tissue
could no longer be distinguished from the surrounding pepsin
solution (even under microscopic examination). At this point
the tissue was considered to have undergone ‘‘complete
digestion.’’ We recorded the daily diameter of the trephined
corneal disks, rather than corneal thickness, as corneal disks
placed in pepsin are known to undergo significant stromal
swelling (predominantly in the posterior stroma) during the
first 24 hours.22
To assess further the effect of each treatment on enzymatic
resistance, 5 corneal disks from each group were removed
from the pepsin digest solution after 13 days and placed in a
608C oven until a constant dry weight was obtained. The
average corneal dry weight then was calculated for each group.
The corneal disk diameter measurements provide valuable
information about the structural integrity of the most anterior
layers of the cornea, while the dry weight measurements,
representing the total mass of undigested tissue, negate the
complications associated with within-sample variations in
corneal thickness and between sample differences in hydration
and provide information about the effective depth of CXL.
Data Analysis
Data are shown as mean measurements (6SD) for corneal
thickness, dry weight, and complete digestion time. Measure-
ments of corneal disk diameter are presented as a daily
cumulative measurement for each treatment group. Statistical
analysis was performed using a one-way ANOVA and Bonferro-
ni multiple comparisons in a depth-wise manner. All statistical
analyses were performed with the Statistical Package for the
Social Sciences (SPSS Statistics 20; IBM, Armonk, NY, USA). A
probability value of P < 0.05 was considered significant.
RESULTS
Corneal Thickness
The average stromal thickness at each stage of treatment is
shown in Figure 1. Before treatment, the average stromal
thickness did not differ significantly between groups. However,
a 30-minute application of riboflavin–dextran solution (groups
2–6) resulted in a significant decrease in stromal thickness (P <
0.0001). The subsequent irradiation of corneas in groups 3 to 6
produced no further changes in corneal thickness and the final
stromal thickness did not differ significantly between any of
the CXL groups.
Time Taken for Complete Digestion
Stromal swelling, in a posterior–anterior direction was
observed in all corneal disks within 1 day of submersion in
pepsin digest solution (Fig. 2). After 2 days of digestion, a loss
of structural integrity was seen in the untreated corneas but
the crosslinked corneas remained intact (Fig. 2). By day 7 of
the digestion process, the anterior portion of each treated and
untreated corneal button had separated from the posterior
portion and by day 10, the posterior portion had been
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completely digested in all cases. The anterior corneal disk
persisted considerably longer (particularly in the CXL-treated
corneas) and maintained its form sufficiently to allow reliable
measurements of corneal disk diameter to be recorded daily.
The time required for complete digestion of the crosslinked
corneas (groups 3–6) was significantly longer than that
required for the nonirradiated specimens (groups 1 and 2; P
< 0.0001; Fig. 3). After 13 days of digestion, all nonirradiated
corneas had undergone complete digestion and the average
diameter of all the crosslinked corneal disks had decreased in
diameter from their original value.
Corneas crosslinked with higher energy dose treatments
(7.2 J/cm2) using continuous (group 5) or pulsed (group 6)
light took significantly longer to digest than corneas cross-
linked using lower (5.4J/cm2) energy dose treatments (groups
3 and 4; P < 0.0001). A direct comparison between treatments
using the same energy dose revealed that corneas crosslinked
using the SCXL (5.4 J/cm2) procedure took longer to digest
than corneas crosslinked using the accelerated HCXL (5.4 J/
cm2) procedure (P < 0.0001), and corneas crosslinked using
the pulsed irradiation p-HCXL (7.2 J/cm2) procedure took
significantly longer to digest than those treated with the
continuous irradiation HCXL (7.2J/cm2) procedure (P <
0.0001).
Undigested Tissue Mass
After 13 days in pepsin digest solution, only the CXL-treated
corneas remained (Fig. 4). At this time point, the average
stromal dry weight of the SCXL (5.4 J/cm2)–treated corneas
was significantly higher than that of the HCXL 5.4 J/cm2– (P <
0.0001), HCXL 7.2 J/cm2– (P < 0.001), and p-HCXL 7.2J/cm2–
treated corneas (P < 0.05). The stromal dry weight did not
differ significantly between the two higher energy treatment
groups which used continuous (HCXL 7.2 J/cm2) and pulsed
(p-HCXL 7.2 J/cm2) irradiation, but the corneas treated with p-
HCXL 7.2 J/cm2 had a higher stromal dry weight than the
corneas treated with HCXL 5.4 J/cm2 (P < 0.0001).
DISCUSSION
Crosslinking has been shown to be a safe and effective
treatment for keratoconus7–10 and other corneal ectatic
disorders.23,24 The efficacy of CXL can be attributed, at least
in part, to its ability to increase the enzymatic resistance of
corneal tissue, as enzymatic digestion is known to be involved
in the pathogenesis of keratoconus.25
An increase in enzymatic resistance following CXL with
irradiances of 2 and 3 mW/cm2 UVA was first evidenced by
Spoerl et al.22 and later by others.21 It since has been shown
that the use of CXL with irradiances of 9 and 18 mW/cm2 also
results in enhanced enzymatic resistance.26 However measure-
ments of undigested tissue mass midway through the digestion
process revealed significant differences between treatment
groups that indicated that the amount of CXL may be less when
higher intensity ‘‘accelerated’’ protocols, with the same
cumulative dose as SCXL, are used.26 While some studies
show little differences between SCXL and accelerated CXL, a
possible reduction in efficacy with high-intensity UVA proto-
cols has been documented recently by some clinical investi-
gators. Ng et al.27 compared 9 mW/cm2 for 10 minutes to
SCXL and reported a statistically greater reduction in maximum
and mean keratometry and deeper demarcation lines in SCXL-
treated eyes.27 Similar results were reported in a retrospective
study by Brittingham et al.14
Oxygen is essential to drive the riboflavin/UVA CXL process
and in its absence crosslink formation is impaired.13 It has been
postulated that reduced efficacy with accelerated CXL
protocols is due to more rapid oxygen depletion compared
to the more prolonged but less intense UVA exposure in
SCXL.14,15 As oxygen can be restored to its normal tissue levels
FIGURE 1. Average corneal thickness measured before, during, and after treatment.
FIGURE 2. Photographs of a representative corneal disk from each
treatment group before immersion in pepsin digest solution (day 0) and
after 1 and 2 days of digestion.
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within 3 to 4 minutes of cessation of UVA radiation,16 it has
been postulated that by pulsing the UV light, oxygen levels
may be replenished so that the CXL process is no longer
impaired.17,18 In addition to pulsing, some investigators have
demonstrated that the efficacy of accelerated CXL protocols
may be improved by increasing the UVA exposure time, and,
hence, the overall cumulative dosage, by 30% to 40%.19,20 In
this present study, we tested a number of these newer
commercially available extended and pulsed accelerated
protocols by investigating their resistance to enzymatic
(pepsin) digestion.
All eyes treated in our study received an application of an
isoosmolar riboflavin solution (containing 20% dextran) to the
deepithelialized corneal surface. Consistent with previous
studies,21,28 this resulted in a significant decrease in corneal
thickness. The corneal thinning can be attributed primarily to
the deturgescent effect of the dextran but also, possibly, to the
presence of riboflavin,26 which has the effect of increasing the
ionic strength of the applied solution and presumably further
lowering the hydration of the cornea.29
Due to treatment-induced variations in corneal thickness
and the swelling of the trephined corneal disks (in the
posterior-anterior direction) during the first 24 hours of
immersion in pepsin digest solution,26 corneal thickness
measurements were considered to be an unreliable measure
of the rate of enzymatic digestion. Instead, in this current
study, daily measurement of the diameter of the anterior
corneal surface and the dry weight of the undigested tissue
after 13 days of digestion was performed. These measurements
provided a more accurate assessment of the structural integrity
of the anterior corneal stroma and the effective depth of CXL
following each treatment variation.
The discovery that corneas treated with HCXL (5.4 J/cm2)
had a lower residual mass after 13 days of digestion, and took
less time to undergo complete digestion than SCXL-treated
corneas, suggests a reduced CXL effect and a failure of the
Bunsen–Roscoe law of reciprocity at higher UVA intensities.
This supports the findings of biomechanical studies which
have reported a reduced corneal stiffening effect with
increasing UVA intensity up to 18mW,30 and a sudden decrease
in efficacy with very high intensities greater than 45 mW/
cm2.31 The failure of the Bunsen-Roscoe law of reciprocity in
cases of very high intensity and short illumination time is not
yet fully understood, but is thought to be caused, as discussed
above, by insufficient oxygen availability inhibiting the CXL
process.13 This hypothesis is supported by our findings of
increased enzymatic resistance in p-HCXL treated eyes, where
oxygen availability theoretically should be greater than in the
nonpulsed HCXL treatments.
The precise photochemical mechanisms involved in ribo-
flavin/UVA CXL are unknown. It has been postulated that the
process commences under aerobic conditions with a brief type
II photochemical reaction, in which sensitized photooxidation
of stromal proteins occurs, mainly by their reaction with
photochemically generated reactive oxygen species.16 As
oxygen becomes depleted, after the initial 15 seconds of
exposure to UVA, a type I photosensitizing mechanism then
may predominate, in which radical ions are produced that can
induce covalent CXL of stromal macromolecules.16 In SCXL,
where UVA exposure occurs over 30 minutes, the oxygen
FIGURE 3. The summed diameter of all corneal disks (n¼ 6) within each crosslinked and noncrosslinked treatment group is shown as a function of
time in pepsin digest solution. In addition, the average time (6SD) required for complete digestion of each treatment group has been added to the
time-line.
FIGURE 4. Corneal disk dry weight after 13 days of digestion.
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concentration in the cornea may slowly increase, during the
later stages of the treatment, to a level at which a type-II
mechanism may once again begin.16
The enhanced enzymatic resistance we observed when the
exposure time of the cornea to 30 mW UVA was increased
from 3 to 4 minutes may be attributed to the increase in the
total energy dose from 5.4 to 7.2 J/cm2, which allowed
additional type I photochemical CXL to occur. It is unlikely that
the increased CXL effect is due to the extended treatment
providing additional time for the oxygen levels to be
replenished to a level at which the type II CXL reaction could
be restarted as, even when SCXL is performed, the oxygen
concentration is thought only to reach sufficient levels in the
latter half of the 30-minute treatment.16
Although corneas treated with HCXL and p-HCXL and a
total energy dose of 7.2 J/cm2 persisted longer in enzyme
digest solution than SCXL (5.4J/cm2)–treated corneas, the dry
weight of the SCXL-treated corneas was higher when measured
midway through the digestion process. This suggested that
differences in the distribution of CXL may exist within the
tissue. It can be postulated that CXL using a higher UVA
intensity and a greater total energy dose results in superior CXL
efficacy within the most anterior stromal layers and/or the mid-
corneal region, resulting in longer overall digestion times.
However, the depth of CXL may be shallower or there may be a
more rapid decrease in the intensity of CXL as a function of
depth, compared to SCXL, resulting in a reduced overall mass
of crosslinked tissue. It is of interest that Brillouin microscopy
studies of SCXL-treated corneas have shown that the intensity
of CXL is depth-dependent, with the anterior stroma contrib-
uting the most to the increase in mechanical stiffness, and
examination of the effect of varying UVA exposure time (0–30
minutes) has shown a dose-dependent tissue stiffening in the
anterior third of the cornea.32
The clinical relevance of these findings is uncertain, as the
precise amount and location of crosslinked tissue required to
prevent keratoconic progression has yet to be determined.
Clinical studies comparing CXL with accelerated CXL proto-
cols are limited and somewhat conflicting. Tomita et al.,33 in a
study comparing SCXL with 30 mW/cm2 for 3 minutes, found
no differences in visual and topographic indices and similar
demarcation line depths at 6 months, while Shetty et al.,34 in a
randomized clinical study in 138 eyes with 12-month follow-
up, found poorer refractive and tomographic outcomes with
30 mW/cm2 for 3 minutes. A small clinical trial involving 20
patients treated with either pulsed or continuous light HCXL
showed keratoconus stability in both groups at 1 year follow-
up, although the pulsed light treatment produced better
functional outcomes and a deeper stromal penetration.17
Similarly, a retrospective assessment of 60 patients treated
with HCXL found the demarcation line to be significantly
deeper in patients treated with pulsed rather than continuous
light.35 Clearly further, comparative clinical studies are
required especially comparing the outcomes of p-HCXL with
standard CXL, both of which appeared on this basis of this
study to offer the best outcomes in terms of resistance to
enzyme digestion.
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PURPOSE. To investigate riboflavin concentration on enzymatic resistance following corneal
cross-linking (CXL).
METHODS. Ninety-six porcine eyes were divided into five groups in two treatment runs. Group
1 remained untreated. Group 2 received riboflavin 0.05%, group 3 riboflavin 0.1%, group 4
riboflavin 0.2%, and group 5 riboflavin 0.3%. Treated eyes underwent CXL with ultraviolet A
at 9 mW/cm2 for 10 minutes. Eight-millimeter discs from each cornea were submerged in
pepsin digest solution. In the first run, disc diameters were measured daily. After 10 days, dry
weights were recorded from five samples in each group. In the second run, dry weights were
recorded in five samples in each group at 10 and 20 days.
RESULTS. CXL-treated corneas took longer to digest than untreated (P < 0.001). Although eyes
treated with higher riboflavin concentrations generally took longer to digest, there were no
significant differences between groups (P ¼ 0.3). Dry weights at 10 days demonstrated, with
each increase in concentration, an increase in weight of residual undigested tissue (P <
0.001). In the second run, with each increase in riboflavin concentration there was an
increase in weight of residual tissue (P < 0.001) at 10 days. At 20 days, the dry weight was
lower with 0.05% riboflavin compared to 0.3% (P < 0.001) and 0.2% and 0.1% solutions (P <
0.05), with no other difference between groups.
CONCLUSIONS. There is a consistent dose-response curve with higher concentrations of
riboflavin achieving greater CXL efficacy, suggesting that manipulation of riboflavin dosage as
well as the UVA protocol can be used to optimize CXL.
Keywords: keratoconus, corneal cross-linking, riboflavin, enzymatic digestion
The current management of corneal ectatic diseases such askeratoconus depends on the severity and extent of the
degree of irregular astigmatism.1 Mild cases can be corrected
with spectacles and soft toric contact lenses.2 However, such
modalities are limited in their effectiveness as the cornea
becomes more irregular. In advanced disease, special soft, rigid
gas-permeable, and scleral contact lenses become a more
suitable solution to restore vision.3 Despite the use of such
special contact lenses, studies indicate that over 25% of patients
with keratoconus can progress to such an extent that they
require corneal transplantation,4 with this disease remaining
the most common indication for penetrating keratoplasty in
Europe, Australia, South America, Africa, and the Middle East.5
The introduction of cross-linking (CXL) has heralded a new
era in the treatment of corneal ectatic disorders. CXL utilizing
riboflavin/ultraviolet A (UVA) is now a widely established
intervention that has been shown to halt the progression of the
disease process in keratoconus, post-LASIK ectasia, and pellucid
marginal degeneration.6,7 The rationale of CXL is to enhance
the biomechanical rigidity of the cornea6,7 and its resistance to
enzymatic digestion8 by creating cross-links between both
collagen and proteoglycan molecules within the corneal
stroma.9–11 Not only does CXL appear to stabilize corneal
ectasia at a stage when contact lenses can still be utilized, it also
has been shown in many treated individuals to reduce
topographic steepness and corneal high-order aberrations,
resulting in improved vision.12 Indeed, a recent study in the
Netherlands demonstrated a significant reduction in the
number of corneal transplants for keratoconus following the
nationwide introduction of CXL.13
The standard CXL (SCXL) protocol, first described clinically
by Wollensak et al.7 in 2003, involves debridement of the
central 9 mm of corneal epithelium, followed by soaking the
exposed stromal surface with 0.1% riboflavin for 30 minutes
and irradiation with 370-nm UVA light with an intensity of 3.0
mW/cm2 for 30 minutes (a total dose of 5.4 J/cm2). This
protocol requires more than 1 hour of treatment time. To
shorten this procedure time, given the large potential numbers
of patients with progressive keratoconus requiring CXL and its
resultant burden to health service delivery, and to improve
patient and surgeon convenience alike, accelerated CXL (ACXL)
protocols have been introduced.14 These ACXL techniques are
based on the Bunsen-Roscoe law of photochemical reciprocity
and are modeled on the understanding that the same
photochemical effect can be achieved with a reduced
irradiation interval, provided that the total energy level is kept
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constant by a corresponding increase in irradiation intensity.15
However, as has been demonstrated with other photochemical
reactions, this law may be valid only within a certain dose
range and varies with different types of photochemical
processes.16 Certainly, while efficacy has been demonstrated,
it appears both in the laboratory17 and clinically18,19 that ACXL
may be less effective than SCXL, although the minimum
effective amount of CXL needed for stabilization of ectasia has
not yet been established.17,20
The precise reasons for the reduced efficacy of ACXL
protocols are unclear, and the exact mode of action of CXL at a
molecular level is undetermined.21 It is postulated that
riboflavin acts as a photosensitizer to produce both oxygen
singlets and riboflavin triplets,22 which then drive the CXL
process within the corneal stroma.23 What is understood is that
oxygen is essential to drive the process, and in the absence of
oxygen, CXL is impaired.24 It has been hypothesized that the
reduced efficacy associated with ACXL protocols might be the
result of more rapid oxygen depletion.25,26 Kameav et al.27
showed that, oxygen consumption occurs within seconds
during UVA irradiation and that following cessation of
irradiation, oxygen levels can take several minutes to be
restored. As such it has been hypothesized that by pulsing the
UVA light during irradiation, oxygen levels within the stroma
might be replenished/maintained so that the CXL process is
not compromised.28,29 Other investigators have advocated that
in addition to pulsing optimization of ACXL protocols can be
achieved by extending the UVA dosage by 30% to 40%.30,31
Indeed, in a laboratory study utilizing the same resistance to
enzymatic digestion methodology employed in this present
study, our group demonstrated increased efficacy with both
extended and pulsed UVA dosages with ACXL protocols,
although the results suggested that the distribution of cross-
links may be different compared to SCXL.23 As described
above, to date virtually all research directed at optimizing CXL
protocols has been targeted at manipulating the UVA irradia-
tion dosage of the treatment. Indeed, except for some
transepithelial CXL protocols,32 published CXL research,
including those with varying riboflavin formulations, has
almost universally maintained a riboflavin concentration of
0.1%. Almost 15 years after publication of the first clinical
paper,7 the optimal stromal riboflavin dosage for CXL is yet to
be determined.22 This present study aims to investigate this
issue by determining the efficacy of CXL using an enzymatic
(pepsin) resistance model in ex vivo porcine corneas with
varying concentrations of riboflavin (0.05%, 0.1%, 0.2%, and
0.3%).
METHODS
A total of 96 fresh porcine eyes were utilized in this study. All
had transparent corneas and an intact corneal epithelium on
inspection. They were obtained and transported on ice from a
local European Community licensed abattoir and used within
12 hours of death. The experiment was conducted using two
separate treatment runs to ensure the consistency of the
results. In the first run, 50 eyes were utilized, and in the
second, conducted 8 weeks later, 46 eyes were used.
Our pepsin digestion methodology has been published
previously.17,23 We chose this method as it facilitates relatively
slow digestion rates. This has allowed us in our past studies to
not only detect significant differences in the digestion rates in
terms of disc diameter measurements and time to complete
digestion but also to measure dry weights at 10 days, which has
highlighted significant differences between treatment proto-
cols that are not evident by just measuring disc diameters and
time to digestion alone.17,23 In addition, using this same
protocol we have repeatedly shown that there are no
differences in digestion times in nonirradiated corneas that
have not received riboflavin drops and those soaked in
riboflavin for 30 minutes.17,23 This allowed us in this study
to reduce the number of control groups and just use de-
epithelialized, nontreated, nonirradiated corneas as a sole
control group. In brief, following complete debridement of the
corneal epithelium using a single-edged razor blade, the eyes
were divided randomly into the five groups described in Table
1, in which group 1 (no riboflavin administered and no UVA
exposure) served as an untreated control and groups 2, 3, 4,
and 5 received varying concentrations of riboflavin solution
(0.05%, 0.1%, 0.2%, 0.3%, respectively) for a period of 30
minutes. All riboflavin solutions contained 20% dextran and
were identical in formulation except for the riboflavin
concentration. The riboflavin was applied using a 10-mm
suction ring/container (J2294; E. Janach srl, Como, Italy) that
was completely filled to its brim with the relevant riboflavin
solution concentration after being placed and suctioned over
the central cornea. Following the 30-minute riboflavin
diffusion period, all eyes in groups 2, 3, 4, and 5 underwent
irradiation using a CCL-VARIO corneal cross-linking UVA lamp
(Peschke Meditrade GmbH, Huenenberg, Switzerland) with a
wavelength of 365 nm and a 9.0-mm aperture, with an
intensity of 9 mW/cm2 for 10 minutes (total energy dose 5.4 J/
cm2). An accelerated treatment protocol was chosen, as we
needed to treat 44 eyes in each experimental run and wished
to use only one UVA irradiation device so that fluence levels
and UV beam profile were consistent between treatments. If
we had used the standard protocol of 3 mW/cm2 for 30
minutes, it would have taken 22 hours to complete the
treatments in radiation time alone. This would mean that the
eyes being treated last would be well over 24 hours old since
time from enucleation. Even though we treated one eye from
each group sequentially to minimize any effects of some eyes
being treated later than others, we did not want to include any
eyes in which treatment occurred after 24 hours. This was
undertaken to diminish any effects of natural decomposition,
endothelial and epithelial cell death with subsequent changes
in corneal hydration, and possible fungal/bacterial contamina-
tion. By using an accelerated treatment of 9 mW/cm2 for 10
minutes, we could reduce the total irradiation time to just over
7 hours and treat all eyes with 12 hours.
TABLE 1. Treatment Groups for the Two Separate Experimental Runs, Detailing the Differing Riboflavin Concentrations Utilized
Groups Riboflavin Soak Time CXL Time
No. of Eyes
Run 1 Run 2
1. Untreated corneas 30 minutes 9 mw/cm2 for 10 min 6 6
2. Riboflavin 0.05% 30 minutes 9 mw/cm2 for 10 min 11 10
3. Riboflavin 0.1% 30 minutes 9 mw/cm2 for 10 min 11 10
4. Riboflavin 0.2% 30 minutes 9 mw/cm2 for 10 min 11 10
5. Riboflavin 0.3% 30 minutes 9 mw/cm2 for 10 min 11 10
Riboflavin Solution Concentration and the Efficacy of CXL IOVS j February 2018 j Vol. 59 j No. 2 j 1059
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936739/ on 03/09/2018
Central corneal thickness measurements were taken man-
ually using a handheld ultrasonic pachymeter (Pachmate 55;
DGH Technology, Inc., Exton, PA, USA) after epithelial
removal, after riboflavin administration, and after UVA irradi-
ation in the treatment groups 2, 3, 4, and 5 in the first
experimental run (44 eyes).
On completion of the treatments, an 8-mm full-tissue-
thickness biopsy was trephined from the center of each
cornea. The corneal discs were placed in individual sealed
tubes containing 5 mL pepsin digest solution, 1 g ‡ 500 U/mg
pepsin from porcine gastric mucosa (Sigma-Aldrich Corp.,
Dorset, UK) in 10 mL 0.1 M hydrochloric acid at pH 1.2 and
incubated them in a water bath at 238C. As previous studies
have indicated that CXL results in cross-links not only at the
collagen fibril surface but also in the proteoglycan network
surrounding the collagen,11 we selected pepsin for enzymatic
digestion as it is a nonspecific endopeptidase that breaks down
both collagen and proteoglycan core proteins.
To reduce the risk of fungal/bacterial contamination,
sterility was maintained by undertaking the preparation of
the sample specimens with sterile instruments, which were
cleaned with an ethanol alcohol spray (Spiriclens DEB; Ecolab
Ltd., Leeds, UK) between specimen preparation. The sealed
tubes into which the corneal discs were placed were clean and
sterile prior to usage. To avoid contamination, from the water
bath, 30 mL chlorine-based disinfecting solution (Milton
sterilizing fluid; Milton Pharmaceutical Company, Bourne-
mouth, UK) was added to the bath water every 3 days and
the water replaced every 12 days. All instruments used when
handling samples for measurement were cleaned before and
between sample measurement and left to dry using ethanol
alcohol spray. At day 26, in the first experimental run the
pepsin digest solution in each sealed tube was replaced, both
to enhance further digestion and to attempt to maintain
sterility.
First Experimental Run
In the first experimental run (involving 50 eyes), electronic
digital calipers were used to perform daily measurements of
the longest diameter of the anterior surface of each corneal
disk. This was facilitated by microscopic examination at 103
magnification after the disk had been poured into a sterile petri
dish and separated from the pepsin digest solution using a
sterilized pipette. This magnified examination allowed the
longest diameter of the disc to be identified and precisely
measured with the electronic calipers. Measurements were
performed until the tissue could no longer be distinguished
from the surrounding pepsin solution, at which time point the
tissue was considered to have undergone complete digestion.
Measurements of anterior corneal disc diameter, rather than
stromal thickness, were used to assess the rate of enzymatic
digestion as the corneal discs underwent significant posterior
stromal swelling (in the vertical direction) during immersion in
pepsin digest solution, and the more-resistant anterior portion
of the cornea then separated from the posterior stroma after 4
to 6 days.17,23
To further evaluate the effect of different riboflavin
concentrations on corneal enzymatic resistance, five randomly
selected corneal discs from each CXL-treated group (groups 2,
3, 4, and 5) were removed from the pepsin digest solution after
10 days, placed in a 608C oven, and weighed daily until a
constant dry weight was obtained. The average dry weight was
then calculated for each group. There were no differences
between the groups in the mean times each of the groups were
in the oven (median 7 days). This methodology was
undertaken to ensure the samples were completely dehydrated
and the true dry tissue weight verified.
The remaining six discs in each of the CXL treatment
groups 2, 3, 4, and 5 remained in pepsin digest solution and
were measured daily, as described above, until digestion was
complete. At day 26 it appeared that the discs had stopped
digesting so the digest solution in each sealed tube was
replaced with freshly prepared pepsin digest solution (with the
same formulation as described previously), and the tempera-
ture of the water bath was increased to 268C to accelerate the
digestion process.
Second Experimental Run
To ensure the consistency of the results, a second experimen-
tal run of 50 eyes was conducted (Table 1). While previous
enzymatic digestion studies from our group17,23 have indicated
that the corneal disc diameter measurements appear to provide
information about the structural integrity of the most anterior
layers of the cornea, they can be subject to variation. This
occurs especially in the later stages of digestion when the
tissue tends to lose its circular shape and become irregular in
outline, making the longest diameter of the tissue difficult to
determine. As the dry weight measurements represent the total
mass of undigested tissue and negate any of the problems
associated with tissue shape and between-sample differences
in hydration, in the second experimental run we replaced
reliance on this more-reproducible methodology. In this run,
after being immersed in pepsin solution, the discs remained in
their sealed containers and were incubated at 238C until day
10, when five corneal discs from each CXL treatment group
(groups 2, 3, 4, and 5) were removed from the digest solution
and placed in the 608C oven until a constant dry weight was
obtained and the average corneal dry weight calculated for
each group. This process was repeated at 20 days, when the
remaining five corneal discs from each group were removed
from the pepsin digest, placed in the 608C oven, and their
constant dry weights recorded. The digest solution was not
renewed during this second run, and the water bath
temperature was maintained at 238C.
Statistical Analysis
Data are shown as average measurements (6 SD) for corneal
thickness, dry weight, and complete digestion time. Measure-
ments of corneal disk diameter are presented as a daily
cumulative measurement for each treatment group. Statistical
analysis was performed using a 1-way ANOVA and Bonferroni
multiple comparisons in a depth-wise manner. All statistical
analyses were performed with the Statistical Package for the
Social Sciences (SPSS Statistics 20; IBM, Armonk, NY, USA). A
probability value of P < 0.05 was considered significant.
RESULTS
Corneal Thickness
The average stromal thicknesses pretreatment (after epithelial
debridement), after riboflavin administration and after UVA
irradiation in the first experimental run are shown in Figure 1.
There was a significant decrease in thickness following CXL
(from pretreatment to after CXL) in all groups (P < 0.001), but
there were no differences in thicknesses between the groups
at any stage.
Time Taken for Complete Digestion
As previously reported,17,23 in all corneal discs significant
stromal swelling, in a posterior–anterior direction, was
documented within 24 hours of submersion in the pepsin
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digest solution. By 4 to 6 days, the anterior portion of each
corneal disc had separated from the posterior portion, and by
days 8 to 10 the posterior portion of each disc had undergone
complete digestion. The anterior portion of the corneal discs
persisted to allow daily measurements of diameter (Fig. 2;
Table 2).
The time required for complete digestion of the CXL-treated
corneal discs (groups 2, 3, 4, and 5) was significantly longer
than that required for the untreated specimens in group 1 (P <
0.001) (Fig. 2; Table 2). After 10 days, all untreated corneas
(group 1) had undergone complete digestion in both
experimental runs. Based on cumulative measurements of
corneal disc diameter for each treatment group, the irradiated
corneas treated with a higher concentration of riboflavin
appeared to take longer to undergo complete digestion than
those treated with lower concentrations of riboflavin. Howev-
er, this was largely due to the persistence of a minority of
samples within the higher riboflavin concentration groups
(Fig. 2), and the average time taken for complete digestion to
occur did not differ significantly between the CXL-treated
groups (P ¼ 0.3) (Table 2).
Dry Weight Measurements
After 10 days in the pepsin digest solution, only the CXL-
treated corneas remained, with all the untreated discs being
completely digested in both experimental runs (Fig. 2; Table
2).
First Experimental Run
In the first experimental run, there was a statistically significant
difference in dry weight measurements between all treated
groups (2, 3, 4, and 5) at 10 days (P < 0.001). For each group
with an increased riboflavin concentration, there was a
significant increase in the dry weight of residual undigested
corneal tissue, denoting an increased resistance of the tissue to
pepsin digestion (P < 0.001) (Fig. 3A; Table 3).
Second Experimental Run
Similarly, in the second experimental run, there was a
statistically significant difference in dry weight measurements
between all treated groups (groups 2, 3, 4, and 5) at 10 days (P
< 0.001). For each group with an increased riboflavin
concentration, there was a significant increase in the dry
weight of residual undigested corneal tissue, denoting an
increased resistance of the tissue to pepsin digestion (P <
0.001) (Fig. 3B; Table 3), with comparable average dry weights
for each of the treatment groups in the two experimental runs
(Table 3).
In the second experimental run at 20 days, measurement of
the average stromal dry weight was significantly lower in the
0.05% riboflavin treatment group (group 2) than in the 0.3% (P
< 0.001) and the 0.2% and 0.1% treatment groups (P < 0.05)
(groups 3, 4, and 5). There was no significant difference
between 0.1%, 0.2%, and 0.3% riboflavin/UVA treated groups
(groups 3, 4, and 5) at 20 days of digestion (Fig. 4; Table 4).
FIGURE 1. Corneal thickness measurements for each group in the first
experimental run are shown before treatment (after epithelial
debridement), following riboflavin administration for 30 minutes, and
after CXL (n¼ 11 per group). Data are shown as the mean value 6 SD.
FIGURE 2. The summed longest diameter of the corneal discs in each group in the first experimental run is shown as a function of time, which has
been normalized against the maximum time taken for corneas cross-linked using the standard 0.1% riboflavin formulation (42 days) to undergo
complete digestion. The discs appeared to stop digesting at approximately day 26 (normalized time of 0.62) so temperature was increased to 268C
and the digest solution renewed.
TABLE 2. Time in Days Taken for Complete Digest to Occur in All
Groups
Group
Time Taken for Complete Digestion to Occur
Minimum, d Maximum, d Average, d (6SD)
Untreated 6 10 8 (62)
0.05% Ribo/UVA 36 40 39 (62)
0.1% Ribo/UVA 36 42 39 (62)
0.2% Ribo/UVA 39 45 41 (62)
0.3% Ribo/UVA 38 46 41 (63)
Ribo/UVA, Riboflavin/UVA.
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DISCUSSION
SCXL has been shown to be efficient in arresting the
progression of corneal ectatic disease in most treated eyes
with up to 10 years follow-up.33,34 Although numerous
modifications of the epithelium-off CXL technique have been
postulated, these have almost universally focused on variation
in the UVA protocol and additives to the standard riboflavin
0.1% solution.21 Indeed, except for some epithelium-on CXL
formulations that utilize 0.25% riboflavin concentrations,32
virtually all currently used epithelium-off protocols use a
riboflavin concentration of 0.1%.21,22 Despite the passage of
almost two decades since the first human clinical CXL
treatments,7 the optimum riboflavin dosage for CXL is
undetermined,22 but to fully evaluate the efficacy and safety
of any drug, it is vital to determine its dose-response curve.35
There are multiple problems with determining this dose-
response curve, the not least of which is the difficulty in
measuring the biomechanical changes induced by CXL. As yet
there are no reliable ways to measure these changes in vivo,36 a
problem that compounded by the fact that any measurable
clinical changes take months to become evident and years to
stabilize.33,34 Even in vitro, the measurement of biomechanical
changes after CXL are beset with difficulty. Standard biome-
chanical measurement methodologies, such as stress-strain
extensiometry, have inherent deficiencies when applied to the
assessment of biological tissues such as the cornea.37 Such
biological tissues do not behave like metals and polymers with
homogeneous chemical/molecular bonds but rather have
nonhomogeneous chemical bonds and molecular interactions
that result in viscoelastic material properties. In addition, strip
specimens from corneas are originally part of a spherical
surface, so the length of the strip along its longitudinal
centerline is longer than its sides and there is variation in
thickness between the corneal center and its periphery.37 All
these factors can lead to poor measurement reliability, which
has led investigators to explore other potential methodologies
such as inflation techniques,38 scanning acoustic microsco-
py,39 and Brillouin microscopy,40 none of which have yet to
become a reliable gold standard measurement technique to
determine biomechanical changes after CXL.
An increase in activity of proteinase enzymes and reduction
of proteinase inhibitors have been identified in keratoconic
corneas41 and are liable to be important factors in the
pathophysiology of the condition and disease progression.
The main aim of corneal cross-linking is to halt the progression
of corneal ectasia. While cross-linking the macromolecules
within the corneal stroma undoubtedly augments its mechan-
ical strength, it also increases its resistance to enzymatic
FIGURE 3. (A) Average stromal dry weight of the untreated and treated
groups (n ¼ 5 samples per group) at day 10 in the first experimental
run. Error Bars: 61 SD. There was a statistically significant difference
in dry weights between all groups (P < 0.001) at 10 days. (B) Average
stromal dry weight of the untreated and CXL-treated groups (n ¼ 5
samples per group) at day 10 in the second experimental run. Error
Bars: 61 SD. There was a statistically significant difference in dry
weights between all groups (P < 0.001) at 10 days.
TABLE 3. Average Stromal Dry Weight of Control Group 1 and Treated
Groups 2, 3, 4, and 5 (n ¼ 5) at Day 10 in First and Second
Experimental Runs
Group
Mean Dry Weight After 10 Days
of Digestion, mg 61 SD
Run 1 Run 2
Untreated 0 0
0.05% Ribo/UVA 1.4 6 0.16 1.08 6 0.45
0.1% Ribo/UVA 2.5 6 0.16 2.68 6 0.19
0.2% Ribo/UVA 3.4 6 0.14 3.42 6 0.32
0.3% Ribo/UVA 4.04 6 0.18 3.86 6 0.54
FIGURE 4. Average stromal dry weight (milligrams) of control group 1
and treated groups 2, 3, 4, and 5 (n ¼ 5) at day 20 in a second
experimental run. Error Bars: 61 SD. The average stromal dry weight
was significantly lower in the 0.05% riboflavin treatment group (group
2) than in the 0.3% (P < 0.001) and the 0.2% and 0.1% treatment
groups (P < 0.05) (groups 3, 4, and 5).
TABLE 4. Average Stromal Dry Weight of the Untreated and CXL-
Treated Groups (n ¼ 5 samples per group) at Day 20 in the Second
Experimental Run
Group
Mean Dry Weight at 20 Days
in Second Experimental Run, mg 61 SD
Untreated 0
0.05% Ribo/UVA 0.68 6 0.33
0.1% Ribo/UVA 1.3 6 0.28
0.2% Ribo/UVA 1.3 6 0.25
0.3% Ribo/UVA 1.86 6 0.71
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digestion. Spoerl et al.42 were the first to demonstrate this
increased resistance of the corneal stroma to enzymatic
digestion after CXL. The ability of CXL to increase corneal
stromal resistance to enzymatic digestion can therefore be
expected to be a significant factor with regard to efficacy of the
procedure in halting disease progression. To what extend and
precisely how resistance to enzymatic digestion and increase in
biomechanical strength after CXL are responsible for and
contribute to its efficacy is yet undetermined, but both can
undoubtedly be used as a measure of CXL efficacy. It is for such
reasons, as well as poor measurement reliability of current
methods of corneal biomechanical assessment (which we
discussed above), that in this study we employed an enzymatic
digestion methodology. We have previously demonstrated the
efficacy of this methodology in determining differences in both
ACXL and epithelium-on CXL protocols compared to
SCXL.17,23
We employed two experimental runs in this study to ensure
consistency and verify our dry weight measurements, as well as
to simplify and improve our methodology. While daily
measurements of the disc diameters until digestion do provide
information about the structural integrity of the anterior layers
of the cornea to which CXL is directed,17,23 their measure-
ment, as well as being time-consuming, is subject to variation.
This is especially true in the later stages of digestion, when the
repeatability and hence reliability of the measurements are
reduced due to the smaller dimensions of the tissue and its
increasingly irregular outline. In addition, with time the pepsin
solution in which the discs are immersed loses its digestive
activity. Indeed, in the first experimental run we perceived that
the discs had stopped digesting at about day 26; therefore, in
order to complete the experiment, we had to renew the pepsin
solution. As dry weight measurements, which represent the
total mass of undigested tissue, were found to be highly
reproducible because they negate any problems associated
with within-sample variations in corneal thickness, shape, and
between-sample differences in hydration, in the second
experimental run we relied solely on this methodology and
collected dry weight measurements at day 10 and day 20 of
digestion.
All CXL-treated eyes in our study received an application of
an iso-osmolar riboflavin solution containing 20% dextran.
Consistent with previous studies,17,23,43 this resulted in a
significant decrease in corneal thickness (Fig. 1), probably
attributable to the deturgescent effect of the 20% dextran and
dehydration of the de-epithelialized cornea during cross-
linking. As might be expected, the concentration of riboflavin
over the ranges we used had no effect on corneal thickness.
In previous studies using an identical methodology, we have
shown that there are no differences at all between digestion
times in nonirradiated corneal controls that have not received
riboflavin drops and those soaked in riboflavin for 30
minutes.16,23 This allowed us, in this present study, to reduce
the number of control groups and use only completely de-
epithelialized, nontreated, nonirradiated corneas as a sole
control group. As we have documented previously,17,23 the
time required for complete digestion of the treated CXL
corneal discs was significantly longer than the untreated
controls, demonstrating the reproducibility of this technique
in detecting changes between CXL-treated and untreated
corneas. However, despite an evident trend for the higher-
concentration riboflavin-treated corneas to take longer to
digest completely, the differences between groups were not
significant. In contrast, the dry weight measurements after 10
days of digestion (Figs. 3A, 3B; Table 3) and to a lesser extent at
20 days (Fig. 4; Table 4), demonstrated significant differences
between the treatment groups, indicating that an increase in
riboflavin concentration from 0.05% to 3% results in a
progressive improvement in the resistance of cross-linked
corneas to enzymatic digestion. This suggests that measure-
ment of the time until digestion is complete is not sensitive
enough to detect subtle (but probably clinically important)
differences in CXL efficacy with differing protocols. Certainly,
in a previous study using this methodology to investigate SCXL
versus ACXL protocols,18 time to complete digestion showed
no differences, whereas dry weight measurements indicated
significant differences, with better results in SCXL.17 Clinical
investigations confirmed and supported such laboratory
findings of a reduced efficacy with ACXL.18,19
The similarity between runs 1 and 2 in terms of the average
dry weight measurements for each group after 10 days of
digestion confirmed our belief that the dry weight technique is
a less time-consuming and a more accurate and reproducible
technique for investigating CXL efficacy than are daily
measurements of corneal diameter (Fig. 3A, 3B; Table 3).
Over the ranges we tested, such outcomes support a dose-
response curve of riboflavin in CXL, with higher concentra-
tions, up to 0.3%, achieving greater efficacy. How these
results will transfer into clinical efficacy is undetermined until
clinical trials with higher concentrations are undertaken, but
they may have important implications. In this study, all
treatments were conducted using an ACXL technique of 9
mW/cm2 for 10 minutes (total energy dose 5.4 J/cm2), yet
manipulation of riboflavin dosage and hence stromal concen-
tration resulted in improved efficacy. This occurred without
oxygen supplementation or pulsing, which some authors,
both in laboratory23 and clinical studies,28,29 have hypothe-
sized may augment the CXL process, especially with ACXL
protocols. A riboflavin dose-response curve might suggest
that while oxygen and type II photochemical (aerobic)
reactions are undoubtedly important in the CXL process,24
type I photochemical (anaerobic) pathways, with direct
interaction between excited riboflavin triplets and stromal
proteins resulting in cross-linking, play a significant role and
may be augmented by increasing riboflavin concentrations
during CXL. As such, the efficacy of ACXL might be improved
not only by increasing the UVA dosage and perhaps the
addition of supplemental oxygen and/or pulsing but also by
simply increasing stromal riboflavin concentration. With
manipulation of such parameters, it might be possible with
ACXL to reduce the overall treatment time while maintaining
the same clinical efficacy as SCXL.
Such results may also have important implications for
epithelium-on CXL, where reports of reduced efficacy com-
pared to SCXL44 are likely to be related to limited riboflavin
absorption through the intact corneal epithelium and low
stromal riboflavin concentrations. A dose-response curve of
riboflavin with higher concentrations, at least up to 0.3%,
achieving greater efficacy would support such a hypothesis. It
is of note that by using two-photon fluorescence, we have
previously shown that stromal riboflavin concentrations with
currently commercially available protocols are only 10% to 30%
of that achieved with SCXL45 and that in laboratory studies,
manipulation of such epithelium-on protocols can result in
higher achieved stromal riboflavin concentrations46 and
resultant increased CXL efficacy.47
Finally, in the CXL process riboflavin has two basic
functions. As well as acting as a photosensitizer to produce
both oxygen singlets and riboflavin triplets to drive the CXL
process,22 it also absorbs the UVA photons within the anterior
corneal stromal to reduce UVA toxicity and potential damage to
internal ocular structures such as the endothelium.48 The use
of higher-strength riboflavin solutions resulting in increased
stromal riboflavin concentrations and therefore increased UVA
absorption within the anterior stroma, should theoretically
reduce the amount of UVA radiation reaching deeper layers of
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the cornea, reducing the risk of endothelial toxicity as well as
allowing for the possible treatment of thinner corneas.49 It is
interesting that while it might be supposed that increased
absorption of UVA photons within the anterior stroma by
higher riboflavin concentrations might result in an increased
but more superficial cross-linking effect, our dry weight results
of a significant increase in the mass of residual undigested
corneal tissue with increasing riboflavin concentration, while
there were no differences in disc diameter measurements,
suggest that this is probably not the case. We can postulate
from such results that more volume of tissue is being cross-
linked, including that in deeper stromal layers with higher
riboflavin concentrations, and that we are not merely getting a
more intense, but superficial effect, that one might expect not
to affect the dry weight measurements but to result in
differences in disc diameter measurements during the diges-
tion process.
CONCLUSIONS
Our results demonstrate a dose-response curve with increas-
ing riboflavin solution concentrations up to 0.3% achieving
greater CXL efficacy. This suggests that by simply increasing
the riboflavin concentration, at least within the limits we
tested, it may be possible to increase the efficacy of ACXL to
match that of SCXL. The use of higher concentrations of
riboflavin solution may also improve the outcomes of
epithelium-on CXL as well and allow the safe treatment of
thin corneas. Whether or not higher concentrations of
riboflavin in CXL may result in any adverse complications
(such as increased haze) is as yet undetermined, but this study
appears to support the commencement of clinical trials of
CXL with moderately increased higher riboflavin concentra-
tion solutions.
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Appendix C: Raw data of SAXS fibrillar parameter  
Group 
Ex/In 
Vivo 
Sample  
Interfibrillar 
Peak (nm) 
D Period 
(nm) 
Fibril 
Diameter 
(nm) 
BC Interfibrillar 
Peak (nm) 
C
o
n
tr
o
l 
In
 v
iv
o
 
C1 56.2 65.9 41.083 55.1 
C2 56.2 65.9 43 54 
C3 57.3 65.9 43.035 55.1 
C4 57.3 65.9 40.8 56.2 
C5 55.1 65.9 43.035 54 
C6 56.2 65.9 41.083 55.1 
Average  56.38 65.90 42.01 54.92 
SD 0.83 0.00 1.12 0.83 
E
x
 v
iv
o
 
E1C 63.9 65.9 39.09 59.8 
E2C 66.9 65.9 39.952 65.3 
E3C 62.4 65.9 38.74 59.8 
E4C 59.8 65.9 39.09 58.5 
E5C 59.8 65.9 40.471 58.5 
E6C 65.3 65.9 38.811 63.9 
E7C 59.8 65.9 38.811 58.5 
E8C 63.9 65.9 38.811 59.8 
E9C 59.8 65.9 39.952 58.5 
E10C 59.6 65.9 38.74 58.5 
E11C 59.8 65.9 39.877 57.3 
E12C 59.8 65.9 39.66 58.5 
Average  61.73 65.90 39.33 59.74 
SD 2.63 0.00 0.61 2.40 
T
re
a
te
d
 
In
 v
iv
o
 
T1 56.2 65.9 42.449 53 
T2 56.2 65.9 43.818 53 
T3 56.2 65.9 40.548 53 
T5 54 65.9 42.12 52 
T6 54 65.9 39.952 52 
Average  55.32 65.9 41.78 52.6 
SD 1.20 0.00 1.51 0.55 
E
x
 v
iv
o
 
E1T 65.3 65.9 39.261 63.9 
E2T 63.9 65.9 39.836 58.5 
E3T 58.5 65.9 39.373 55.1 
E4T 59.8 65.9 39.546 57.3 
E5T 59.8 65.9 39.373 58.5 
E6T 58.5 65.9 38.264 57.3 
E7T 62.4 65.9 39.546 58.5 
E8T 65.3 65.9 39.546 59.8 
E9T 65.3 65.9 38.701 63.9 
E10T 63.9 65.9 39.373 58.5 
E11T 59.8 65.9 40.548 58.5 
E12T 65.3 65.9 38.979 59.8 
Average  62.32 65.90 39.36 59.13 
SD 2.84 0.00 0.57 2.55 
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Appendix D: preliminary studies prior to corneal enzymatic 
resistance studies  
Prior to launching the main enzymatic resistance studies, the following two preliminary tests 
were performed to optimise the pepsin digest method used for assessing corneal resistance to 
enzymatic digestion.  
(i) Optimization of water bath temperature for enzyme digest studies 
Water baths were set at three different temperatures (23 ºC, 25 ºC and 28 ºC) in order to select 
the optimum water bath temperature for untreated and cross-linked 4-5 porcine corneal disks 
of 8 mm diameter with epithelial debridement (Table D.1.) to digest in a pepsin solution 
comprising 1 g of 600-1200 U/mg pepsin from porcine gastric mucosa (Sigma-Aldrich, Dorset, 
UK) in 10 ml 0.1M HCl at pH 1.2. As shown in Table D.1., the corneal disks placed in a 23 
ºC water bath temperature digested at a rate slow enough to allow differences between 
treatment groups to be detected but fast enough to ensure that the pepsin remained active 
throughout as it is continue digesting the disk. 
 
Table D.1. Three different temperatures set up (23 ºC, 25 ºC and 28ºC) in order to select the 
optimum water bath temperature for porcine corneal disks. 
Temperature Group n Time taken 
for 
complete 
digestion 
(days) 
Significantly 
difference 
from control 
groups 
28ºC Untreated 5 3.6 ± 0.5 
 
ACXL 9mW 4 4 ± 0 
 
25ºC Untreated 4 6.25 ± 0.5 
 
SCXL 3mW 4 9 ± 1.6 *(p < 0.018) 
ACXL 9mW 4 9.75 ± 0.5 *(p < 0.006) 
23ºC Untreated 4 9.5 ± 0.6 
 
SCXL 3mW 4 20.5 ± 3.7 *(p < 0.004) 
ACXL 9mW 4 19.75 ± 3.7 *(p < 0.006) 
 
(ii) Assessment of the effects of hydrochloric acid on corneal tissue 
digestion 
 
As hydrochloric acid is a component of the pepsin digest solution described above, it was 
necessary to ascertain the effects of the hydrochloric acid on the corneal tissue prior to 
beginning the pepsin digestion studies. Briefly, six 8 mm corneal disks (with epithelium 
removed) were immersed into 6 ml of 1 M HCl at pH 1.2. The diameter of the corneal disks 
was monitored at regular intervals for a period of four months. Our preliminary ex vivo data 
showed that HCl at the concentration used in the pepsin digest solution does not result in any 
changes in the diameter of the porcine eyes even after 126 days (Figure D.1.). Therefore, it 
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can be sure that during the pepsin digest studies any changes in corneal tissue diameter are due 
to enzymatic digestion.  
 
 
Figure D.1. Measurement of corneal disk diameter using digital calipers. The diameter of 
the porcine corneal disks remained unchanged after 126 days in HCl.  
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Appendix E: A preliminary study of corneal biomechanical 
properties 
 
(i) Optimising corneal hydration control during strip extensometry 
 
Previous studies confirmed that both hydration and collagen cross-linking treatment influence 
biomechanical properties of the cornea (Hatami-Marbini and Rahimi, 2015a, Hatami-Marbini 
and Rahimi, 2015b, Kling and Marcos, 2013). Thus, an accurate assessment of the stiffening 
effect of different CXL procedures by means of uniaxial tensile testing is only possible if the 
hydration of the samples is completely controlled. In this preliminary study the optimal method 
for maintaining the hydration of corneal strips during biomechanical testing. Ten corneal strips 
were positioned in a custom made sample holder that was compatible with a Lloyd 
extensometer and comprised metal clamps for securing the tissue strip and a detachable Perspex 
enclosure designed to minimise sample evaporation during biomechanical testing. The corneal 
strips were exposed to a variety of environmental conditions: (1) a cotton pad soaked with 
distilled water positioned within the sample enclosure beneath the tissue strip, (2) blue roll 
soaked with distilled water positioned within the sample enclosure beneath the tissue strip, (3) 
1.5 ml of distilled water within the sample enclosure beneath the tissue strip, (4) 4 ml of 
distilled water within the sample enclosure beneath the tissue strip, (5) one drop of distilled 
water applied to the corneal strip without use of the sample enclosure and (6) no hydration 
control method or sample enclosure used (Figure E.1). Wet weight measurements for each 
strip were performed before securing the specimen into the sample holder and again after 35 
minutes (the usual time required to perform a biomechanical testing measurement). All strips 
were then placed in a 60°C oven for three days, after which their dry weight was recorded. The 
percent of water content was calculated according to Equation 1. 
% water content = ((wet weight – dry weight) / wet weight) * 100              (1) 
 
Figure E.1. Preliminary study five various conditions of hydration control. These conditions 
were (a) cotton pad soaked in distilled water, (b) blue paper soaked in distilled water, (c) 1.5 
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ml distilled water, (d) 4 ml distilled water and (e) the application of one drop of distilled water 
to the corneal strip without use of the sample enclosure. 
 
Table E.1 Humidity chamber conditions showing that the cotton pad soaked in distilled 
water reduced the percent of water content by about 0.4% (indicated in bold). 
Control 
% 
decreased 
of water 
content 
Hydration conditions 
Hydration  
% 
decreased 
of water 
content 
% water content % water content 
start  
after 35 
min  
start  
after 35 
min  
81.1 75.1 6.0 
cotton pad soaked in 
distilled water  
80.1 79.7 0.4 
81.3 76.3 5.1 
blue paper soaked in 
distilled water 
81.5 79.7 1.8 
81.3 69.8 11.5 1.5 ml distilled water 81.5 79.6 1.8 
81.7 76.1 5.6 4 ml distilled water 80.4 77.9 2.5 
80.7 74.6 6.1 
apply one drop of 
distilled water 
81.1 80.1 1.1 
 
The results of this preliminary study indicated that the hydration of porcine corneal strips 
could be best maintained during biomechanical testing by placing a cotton pad soaked in 
distilled water directly beneath the sample within the sample enclosure (Table E.1). 
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Appendix F: The stress-strain data for accelerated cross-linking 
protocols  
 
The stress-strain data are presented here to support information in Chapter 3.  
 
 
Figure F.1. The stress-strain data was plotted for each sample within a single treatment 
group: (a) untreated; (b) riboflavin-only; (c) standard cross-linking with 3 mW UVA (S3); 
accelerated cross-linking using (d) 9 mW (A9) and (e) 18 mW (A18) UVA.  
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Appendix G: The stress-strain data for modified cross-linking 
protocols  
 
The stress-strain data are presented here to support information in Chapter 6.  
 
Figure G.1. The stress-strain data was plotted for each sample within a single treatment 
group: untreated (blue lines); SCXL (5.4 J/cm²) (standard cross-linking) (Green lines); p-
HCXL (7.56 J/cm²) (pulsed, high intensity and high energy UVA cross-linking) (Black lines) 
and p-TC-ion-HCXL (7.56 J/cm²) (pulsed, high intensity and high energy UVA cross-linking 
with iontophoretic riboflavin delivery) (Pink lines). 
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Appendix H: Supplementary Electron Microscopy Images  
Extra electron micrographs are presented here to support information in Chapter 7.  
Only representative images appeared in Chapter 7.  
 
 
Figure H.1 Electron microscopy images of the corneal epithelium of WST-D treatment 
showing a double basal lamina, fewer and more irregular basal epithelial cell 
hemidesmosomes than normal The scale bar for (a) is 2 µm (×2000), and the scale bar for (b) 
is 500 nm with higher magnification(×10K).  
 
 
Figure H.2a Montage electron microscopy images of anterior corneal stroma of the WST-
D/NIR treatment, showing an active keratocytes of an increased size, with a number of 
organelles and an altered morphology. Scale bar is 2 µm. 
a
. 
b
. 
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Figure H.2b Montage electron microscopy images of anterior corneal stroma of the WST-
D/NIR treatment, showing an active keratocytes of an increased size, with a larger number of 
organelles and an altered morphology. Scale bar is 1 µm.  
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Figure H.3 In the same cornea, (a) intra-cytoplasmic deposits of lipid material with vacuoles 
could be seen in the anterior stroma of WST-D/NIR corneas with few flat keratocytes (b). 
Scale bar is 2 µm. 
 
In the anterior stroma of WST-D/NIR corneas, activated keratocytes of an increased size, with 
a larger number of organelles and an altered morphology were observed (Figure 7.12 c, 
appendix, Figure H.2a and Figure H.2b). Moreover, intra-cytoplasmic deposits of lipid 
material with vacuoles could be seen in the anterior stroma of WST-D/NIR corneas with few 
flat keratocytes (appendix, Figure H.3). The posterior WST-D/NIR stroma had flat quiescent 
keratocytes (Figure 7.12 d). However, in the anterior stroma of riboflavin/UVA corneas, 
keratocytes were flattened (Figure 7.12 j). Meanwhile, the posterior stroma of riboflavin/UVA 
corneas showed some active keratocytes (Figure 7.12 h) with some flat keratocytes (appendix, 
Figure H.4). 
 
 
Figure H.4 The posterior stroma of riboflavin/UVA corneas showed (b) some active 
keratocytes (b) with some flat keratocytes. Scale bar is 1 µm. 
 
  
2 µm 
a
. 
b
. 
a
. 
b
. 
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Appendix I: Graphical Abstract 
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Pulsing UVA during high intensity/high energy procedures can increase 
the enzymatic resistance of the cornea by increasing oxygen availability. 
The optimised St Thomas’/Cardiff TE CXL protocol may be a 
promising, less painful, but equally effective alternative to SCXL. 
 
The intensity and distribution of the crosslinks formed within the 
cornea vary with different UVA protocols. 
High intensity protocols result in more CXL in the anterior-most stroma 
but the depth of CXL may be shallower. 
Develop epi-
on method 
that is equally 
effective to 
SCXL 
To examine the potential 
of a range of CXL 
therapies 
UVA intensity 
Increase concentrations 
UVA delivery 
mode (pulsed vs 
continuous) 
Combine all of the 
above 
epi-on CXL < epi-off CXL in terms of enzymatic resistance,  
the outcome of epi-on CXL may be significantly improved by:  
 
1. the use of higher concentrations of riboflavin solution. 
2. Increase riboflavin soakage time. 
3. a longer duration of iontophoresis. 
4. an increase in UVA radiance. 
 
30 mW for 4 min (p-HCXL 7.2) 
9 mW for 14 min (p-TC-ion-HCXL 7.56) 
9 mW/cm2 for 10 min 
18 mW/cm2 for 5 min 
 
Riboflavin 
solution 
 
UVA dosage 
Chapter 3 
Chapter 4 
Chapter 5 
Chapter 6 
By 
examining 
the impact 
of changes 
Increase by 25% 
from 5.4 to 6.75 J/cm2 
Chapter 7 
Assess the effect 
of another novel 
corneal stiffening 
treatment involve 
WST-D 
 The organisation of collagen within the corneal stroma as 
primary step to assessing its clinical potential. 
Slower healing processing of epithelium and anterior stromal in 
WST-D/NIR treatment compared to standard riboflavin/UVA 
treatment. 
 
No alterations in collagen structural parameters following 
treatment supports the idea that WST-D/NIR treatment is a 
suitable method for safely strengthening diseased or surgically 
weakened corneas. 
Compare the 
effectiveness 
of epi-on & 
epi-off 
